A Nano-Inspired Multifunctional POSS-PCU Covered Stent: Endothelial Progenitor Cell Capture with Stealth Liposomal Drug Release by Tan, AJK
	   1	  
A Nano-Inspired Multifunctional POSS-PCU 
Covered Stent: Endothelial Progenitor Cell 
Capture with Stealth Liposomal Drug 
Release 
 
by 
 
Aaron Jin Kiat Tan 
 
B.Sc. Surgical Sciences 
University College London, 2011 
 
 
A thesis submitted to the Division of Surgery and Interventional Science in partial 
fulfillment of the requirement for the degree of 
 
Doctor of Philosophy (Ph.D.) 
 
at  
 
University College London (UCL)    
 
 
 
 
 
Copyright © 2014 University College London (UCL)   
All Rights Reserved 
	   2	  
Declaration of Originality  
_______________________ 
 
I, Aaron Jin Kiat Tan, confirm that the work presented in this thesis is my own.  
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
 
 
 
________________ 
Signature 
 
 
________________	  
Date 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   3	  
Abstract 
_______________________ 
The 2 main unresolved issues inherent in coronary stents are in-stent restenosis (ISR) 
and late stent thrombosis (ST).  ISR is largely due to vascular smooth muscle cell 
(VSMC) proliferation, and ST is attributed to a lack of re-endothelialization.  This 
thesis describes the conceptualization and development of a biofunctionalized 
polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) 
platform, for the express purpose of circumventing ISR and ST.  A bare-metal stent is 
embedded between 3 layers of POSS-PCU facilitating endothelial progenitor cell 
(EPC) capture using antibodies, in tandem with sustained drug release using stealth 
liposomes.  The luminal area is impregnated with anti-CD34 antibodies, covalently 
bonded to a POSS-PCU base platform, for EPC capture to enhance re-
endothelialization.  Results indicated successful antibody immobilization, with an 
increased propensity for EPC capture compared to controls.  The abluminal area is 
integrated with paclitaxel-encapsulated stealth liposomes, with an ultrathin layer of 
POSS-PCU sprayed on top using an ultrasonic atomization spray system, for 
sustained drug release to inhibit VSMC proliferation.  Results in this aspect 
demonstrated sustained drug release with augmented cell kill in a 28-day in vitro cell 
culture. Mechanical engineering tests performed on the finished product demonstrated 
superior mechanical functionality as a covered stent.  Various sterilization techniques 
and a biodegradation model were also employed to robustly assess product viability, 
with results indicating that EPC capture potential and stealth liposomal drug elution 
were preserved.  Taken together, this novel POSS-PCU covered stent can enhance re-
endothelialization and inhibit VSMC proliferation, thereby addressing the issues of 
ST and ISR respectively. Furthermore, the covering membrane could also serve as a 
physical barrier against atherosclerotic plaque dislodgement to prevent 
thromboembolism. It is therefore hoped that the proof-of-principle demonstrated here 
in this thesis would serve as an impetus for further translational research, with the 
eventual goal of taking it from bench to bedside.              	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Overview of Thesis 
_______________________ 
Chapter 1 provides a brief introduction to the realm of nanotechnology and 
regenerative medicine, with particular reference to biomaterial applications.  It serves 
to set the scene of this rapidly advancing field in biomedicine, against the backdrop of 
an ageing population and the global burden of cardiovascular diseases.  
 
Chapter 2 discusses the nanocomposite polymer that was developed in our lab, 
polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU), 
and its applications in the development of next-generation smart biomaterials. 
 
Chapter 3 is a literature review on the current status of coronary stent technology, 
with particular emphasis on drug-eluting stents.  It also expounds on the possibilities 
of interfacing bioactive molecules and nanoscale drug delivery systems that can be 
incorporated onto stent platforms.  
 
Chapter 4 describes the various materials and methods used in this thesis.  It also 
explains the rationale for its use, and the basic principles behind them. 
 
Chapter 5 describes the attachment of endothelial progenitor cell (EPC)-specific 
antibodies (i.e. anti-CD34 antibodies) on POSS-PCU, and its ability for capturing 
EPCs, and supporting its growth and proliferation, in order to enhance re- 
endothelialization. 
 
Chapter 6 describes the encapsulation of drug molecules in stealth liposomes, for 
the purposes of protection against degradation, and a platform for sustained release.  
Tracking of drug elution over a year, and its propensity for inhibiting vascular smooth 
muscle cell (VSMC) proliferation is also described. 
 
Chapter 7 describes the construction of a tri-layered POSS-PCU covered stent, with 
EPC capture technology in the luminal area, and liposomal drug release in the 
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abluminal area.  Mechanical testing is done to assess polymer and polymer-stent 
stability. The functionality of EPC capturing and drug elution is also assessed in the 
finished product. 
 
Chapter 8 describes the various FDA-recommended sterilization techniques that are 
used in the medical device industry.  Various samples of finished product were 
subjected to sterilization, and their mechanical strength, EPC capture potential, and 
drug elution abilities were assessed.  
 
Chapter 9 summarizes and synthesizes the findings presented in this thesis, and how 
it relates to the overall picture of nanotechnology and regenerative medicine, as 
applied to stent technology.  It also discusses various limitations in the studies 
performed, and how it can be addressed in future work, before providing a 
conclusion. 
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Aims, Objectives, and Hypotheses  _______________________________	  
 
 
v To increase endothelial progenitor cell (EPC) capture on 
POSS-PCU via the attachment of anti-CD34 antibodies on its 
surface 
 
v To attain sustained drug release from the surfaces of POSS-
PCU using paclitaxel encapsulated in stealth liposomes 
 
v To integrate a tri-layered POSS-PCU membrane onto bare 
metal stents, for the construction of covered stents with EPC 
capture and liposomal drug release technology 
 
v To perform mechanical testing on POSS-PCU membranes, 
and POSS-PCU covered stents  
 
v To assess how sterilization on POSS-PCU would affect its 
mechanical engineering properties, EPC capture potential, and 
drug release profile   
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Chapter 1.  
_________________ 
 
 
 
 
 
A Prologue to  
Nanotechnology and  
Regenerative Medicine 	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1.1. Getting Smaller and Smarter 
 
In what was to become a seminal moment in the history of nanotechnology, the great 
physicist and Nobel laureate Richard Feynman delivered a lecture at the California 
Institute of Technology (Caltech) in 1959 entitled, There’s Plenty of Room at the 
Bottom[1]. In it, he described various thought experiments, such as the possibility of 
writing the entire Encyclopaedia Britannica on a pinhead, and the ability to probe and 
control matter in the nanoscale.  Since then, there has been significant advances in the 
field of nanotechnology: the invention of the scanning tunneling microscope (STM) in 
1981[2], the discovery of fullerenes in 1985[3], the discovery of graphene in 2004[4] 
– and for all of which their inventors received the Nobel Prize.   
 
The prefix ‘nano’ is derived from the Greek word for dwarf.  The term 
‘nanotechnology’ was not widely used within the scientific community until 1974, 
when Norio Taniguchi of the University of Tokyo used it to refer to the ability of 
engineering materials with precision at the nanoscale[5].  Interestingly enough, the 
conceptual underpinnings and primary driving force of nanotechnology came, not 
from academia per se, but from the electronics industry which had a vested interest in 
creating tools to manufacture smaller, faster, and more complex microprocessors and 
integrated circuits.  Indeed, by the early 1970s, International Business Machines 
Corporation (IBM) had already developed a technique called electron beam 
lithography, which could be used to engineer devices and nanostructures as small as 
40 to 70 nm[6].  
 
Given the potential of this field to revolutionize a wide range of industries from 
electronics to medicine, the UK Government commissioned the Royal Society and the 
Royal Academy of Engineering in 2003 to conduct an independent study on 
nanoscience and nanotechnology to assess its current status, future challenges, and its 
possible impact on society[7].  Considering the fact that the premise of 
nanotechnology and regenerative medicine presented in this thesis is inextricably 
linked, it is perhaps necessary to delineate these two terms from the outset, for the 
sake of clarity. 
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According to the Royal Society’s report, nanoscience is defined as the study and 
manipulation of matter at the atomic, molecular, and macromolecular scales, while 
nanotechnology is more concerned with the application of this system to a wide range 
of industries.  One nanometre (nm) is one billionth of a metre (i.e. 10-9 m).  To put 
this into perspective, a human hair is approximately 80,000 nm in width, and a red 
blood cell is about 7000 nm in diameter (Figure 1.1).  What makes nanotechnology 
particularly interesting is that at this scale, the properties of materials can behave very 
differently from that of a larger scale.  The reason for this unique phenomenon is two 
fold.  Firstly, nanomaterials have a large surface area-to-volume ratio, making them 
highly reactive, and this can consequently affect their mechanical strength and 
electrical properties.  Secondly, in the nanoscale, quantum effects begin to dominate 
the behavior of materials, which can give rise to interesting observations in their 
magnetic, optical, and electrical properties (Figure 1.2)[8]. 
 
Figure 1.1. Nanotechnology in perspective.  A scale showing various items in a nanoscale context.  
Image reproduced with permission from Dowling et al., 2003. Copyright © 2003 The Royal Society 
and The Royal Academy of Engineering.   
 
Although nanotechnology has been gaining significant traction and foothold in both 
academia and industry, in some ways, the concept of nanoscience and nanotechnology 
is not exactly new.  For many decades, chemists have been developing polymers, 
	   43	  
which are essentially made up of nanoscale subunits, and the electronics industry has 
been manufacturing smaller and more powerful silicon chips.  In fact, if we were to 
go back even further in time, the size-dependent properties of gold and silver 
nanoparticles have already been exploited since the 10th century AD.  These 
nanoparticles were mainly used as coloured pigments for ceramics and stained glass, 
due to the fact that gold particles can appear gold, blue, or red, depending on its 
size[9].   
 
 
Figure 1.2. The size-effect of quantum dot fluorescence. (a) CdSe quantum dots with a diameter of 
1.7 nm appear blue, while those with a diameter of 6 nm appear red.  (b) This size effect is due to the 
gap between the valence band (VB), and the conduction band (CB), and the absorption (up arrow) and 
fluorescence (down arrow).  Particles with a smaller diameter have a wider band gap.  Figure 
reproduced with permission from Roduner 2006.  Copyright © 2006 The Royal Society of Chemistry.   
 
However it is only with the recent advances in sophisticated instruments that enabled 
scientists to study molecules at the nanoscale with a high degree of precision, which 
had contributed considerably to our understanding of the nano-world.  A significant 
step forward was the invention of the STM in 1982, and the atomic force microscope 
(AFM) in 1986.  These instruments allowed the generation of images with atomic 
resolution, and the ability to manipulate atoms and molecules, for the purposes of 
building simple nanostructures.  In what is now considered a famous experiment, Don 
Eigler and Erhard Schweizer at IBM managed to assemble xenon atoms on a nickel 
surface to write the IBM company logo[10].  Consequently, the utilization of these 
powerful tools were not only used in electronics and engineering, but were also 
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widely adopted in fields like biology and chemistry.  For example, AFM is used to 
study proteins and the topography of various nanomaterials.     
 
Thereafter, the concept of nanotechnology found its way into fields relating to 
biomedicine. In contrast to nanotechnology, regenerative medicine is mainly 
concerned with using biological systems and material science to repair or indeed 
replace defective tissues and organs.  Within the field of regenerative medicine, 
biomaterials, stem cells, and nanoscale drug delivery systems have been considered 
most promising in terms of translating basic research into clinical practice.  Perhaps 
the best known pioneer of nanotechnology and regenerative medicine is Robert 
Langer of the Massachusetts Institute of Technology (MIT), who invented a plethora 
of devices and techniques pertaining to tissue engineering, biomaterials, and 
nanoscale drug delivery, and is often considered the most cited engineer in history[11, 
12].  Due to its multidisciplinary nature, this highly dynamic field of nanotechnology 
and regenerative medicine is a nexus for scientists, physicians, and surgeons.  Indeed, 
so prevalent is the realm of regenerative medicine that a recent New York Times 
article interviewed and featured various clinician-scientists around the world who are 
actively involved in creating tailor-made biomaterials and organs for patients[13] 
(Figure 1.3). 
 
  
Figure 1.3. Growing artificial organs: fact or fiction? Although simple tubular biomaterial scaffolds 
like tracheas can be made, the technology to manufacture more complex organs like kidneys and hearts 
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is still some time away.  Image reproduced with permission from Fountain 2012. Copyright © 2012 
Stefan Zimmerman. Copyright © 2012 The New York Times.                       
 
The development of biomaterials necessitates various strategies that are derived from 
the nanotechnology context.  For example, it has been well-documented that cells 
respond to a variety of environmental cues, and therefore the study of cell-material 
interaction is of particular relevance[14].  In terms of engineering a material 
specifically for an intended biomedical application, two broad categories are generally 
recognized: the top-down, and bottom-up approach (Figure 1.4).  The top-down 
approach mainly involves using a starting block material, and then creating grooves or 
patterns on the surface (e.g. using AFM lithography)[15].  In contrast, the bottom-up 
approach involves the manipulation of sub-units in order to make a larger structure 
(e.g. via molecular self-assembly)[16].   
 
The main difficulty for the top-down approach is the high degree of accuracy and 
dexterity required to create nano-patterns/structures on the surface, while in the 
bottom-up approach, the challenge is to manufacture structures large enough and of 
adequate quality in order for it to be a viable material.  A good analogy of top-down 
approach would be the sculpting of structures (e.g. ice or stone) using chisels.  In 
contrast, a bottom-up approach is akin to building a house, brick-by-brick.   
 
 
	   46	  
Figure 1.4. Top-down and bottom-up approaches in the macro and nano world. (A) The Great 
Wall of China was built, brick by brick, at around 700 BC. (B) An ice sculpture is skillfully crafted 
using chisels. (C) Peptide amphiphiles can self-assemble into larger cylindrical structures. (D) Nano-
patterns can be created on surfaces with high precision using AFM lithography.  Images adapted and 
reproduced with permissions from Hartgerink et al., 2001 and Martinez et al., 2007. Copyright © 2001 
American Association for the Advancement of Science. Copyright © 2007 American Chemical 
Society.       
 
Another noteworthy aspect of nanotechnology and regenerative medicine is the use of 
nanoparticles for drug delivery. Examples of nano-formulations of drugs include 
Doxil® (Janssen Products LP) and Abraxane® (Celgene Corporation) (Figure 1.5).  
Doxil® is a liposomal formulation of doxorubicin, and is approved by the United 
States Food and Drug Administration (FDA) (in 1995) for use in patients with ovarian 
cancer, AIDS-related Kaposi’s Sarcoma, and multiple myeloma[17].  The 
encapsulation of doxorubicin in PEGylated liposomes (liposomes with polyethylene 
glycol) serves to increase its blood circulation time, and protects the drug against pre-
mature degradation.  Abraxane® is an albumin-bound paclitaxel, and is approved by 
the FDA (in 2005) for use in metastatic breast cancer, non-small cell lung cancer, and 
adenocarcinoma of the pancreas[18].  The development of Abraxane® is an 
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interesting case study. Paclitaxel, sold under the trademark as Taxol® (Bristol-Myers 
Squibb), is insoluble in water and therefore had to be dissolved in an excipient 
(additive) before it could be delivered intravenously into patients.  In this case, the 
excipient used was a type of castor oil known as Cremophor EL (BASF Corp).  
However, there were reports of fatal anaphylaxis in patients, and it was found that the 
allergic reaction was not due to paclitaxel itself, but Cremophor EL[19, 20].  
Therefore, a technology was developed to bind paclitaxel to albumin nanoparticles as 
an alternative way to deliver paclitaxel safely and effectively into patients.   
 
 
Figure 1.5. Nanotechnology in drug delivery. (A) Doxil® consists of doxorubicin encapsulated in 
PEGylated liposomes. (B) Abraxane® consists of paclitaxel bound to albumin nanoparticles.  Images 
reproduced with permission from Janssen Products LP and Celgene Corporation. Copyright © 2013 
Janssen Products LP © 2013 Celgene Corporation. 
 
1.2. Cardiovascular Sciences: A Matter Close to Heart 
 
According to the World Health Organization (WHO), an estimated 17.3 million 
people died from cardiovascular disease in 2008, and it is projected to rise to 23.3 
million by 2030[21].  However, major advances in cardiovascular sciences has also 
contributed to a steady decline in the incidence (calculated as deaths per 100,000) of 
cardiovascular disease-related deaths[22].  Nevertheless, with the ageing population 
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in the UK, cardiovascular disease would continue to be a burden on the healthcare 
system in the foreseeable future.   
 
Atherosclerosis is a subset of cardiovascular disease, and is characterized by the 
thickening of the artery wall, and a corresponding narrowing of the luminal area of 
the artery.  Risk factors of atherosclerosis include tobacco smoking, diabetes, 
dyslipoproteinemia, and elevated serum C-reactive proteins.  Despite decades of 
research, the exact mechanism by with the progression of atherosclerosis happens is 
not completely understood.  Nevertheless, there are many published reports 
documenting the general events that occur in atherosclerosis which implicate a 
complex interplay of inflammatory molecules and cells[23-25] (Figure 1.6 and Figure 
1.7).  
 
 
Figure 1.6. Progression of Atherosclerosis. (a) The human artery in physiological conditions. (b) The 
progression of atherosclerosis starts with inflammatory cells stimulating the formation of foam cells. 
(c) Migration of SMCs occur from the media to the intima. Formation of plaque occurs, consisting of 
lipids, apoptotic bodies and cholesterol crystals. (d) Rupture of the fibrous cap causes a thrombus 
formation – the ultimate complication of atherosclerosis. Figure reproduced with permission from 
Libby et al., 2011.  Copyright © 2011 Nature Publishing Group.   
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Atherosclerotic lesions (atheromata) are thickened linings of the tunica intima in the 
artery, and it contains lipids, cellular debris, elements of connective tissue, and 
cells[26]. An accumulation of macrophages and T cells (collectively called fatty 
streak) beneath the endothelium precedes the formation of atherosclerotic lesions[27].  
Fatty streaks are present in healthy people, and can either disappear or progress to 
atherosclerotic lesions. Foam cells and extracellular lipid droplets form the core of the 
lesion, and is encapsulated by a collagen-rich matrix and smooth muscle cells.  There 
is an abundance of macrophages, T cells, and mast cells in the vicinity of the lesion, 
and they produce inflammatory cytokines[26, 28-32].   
 
A myocardial infarction (MI) occurs when the atherosclerotic lesion occludes the 
coronary artery and prevents the flow of blood to perfuse the myocardium.  It was 
previously thought that the main cause of MI was via the proliferation of smooth 
muscle cells in the plaque that narrowed the artery.  However, new studies using 
angiography suggests that it is the activation of plaque itself, rather than a progressive 
luminal narrowing that ultimately causes ischaemia and MI[33].  Although spasms in 
the coronary artery can contribute to MI, the most important culprit is the formation 
of a thrombus on the surface of the plaque[34].   
 
The 2 main causes of coronary thrombosis are plaque rupture and endothelial erosion.  
Plaque rupture is a potentially life-threatening condition as it exposes highly 
thrombogenic materials from the core (platelet-adhesive matrix molecules, tissue 
factor, and phospholipids) to the blood.  Plaque rupture (detectable in 60% of cases) 
predominantly occurs at sites where the fibrous cap is thin[35].  Incidentally, these 
areas also contain high levels of activated immune cells[31], which produce 
inflammatory molecules and proteolytic enzymes that weaken the fibrous cap, 
ultimately converting a stable plaque into a vulnerable one.     
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Figure 1.7. The complex interplay of inflammatory molecules and cells in atherosclerosis. (A) 
LDL infiltrates the artery, undergoes modification, and releases inflammatory lipids that causes 
endothelial cells to express leukocyte adhesion molecules.  LDL is then taken up by macrophages, and 
forms foam cells.  (B) Monocytes adhere to activated endothelial cells, and differentiate into 
macrophages. Molecules like endotoxin can activate macrophages, triggering the release of cytokines 
and inflammation. (C) T cells are activated by macrophages and releases Th1 cytokines and triggers 
inflammation and smooth muscle cell proliferation.  (D) The complex interplay of inflammatory factors 
release by T cells, macrophages and mast cells weakens the fibrous cap, and causes thrombosis.  Figure 
reproduced with permission from Hansson 2005. Copyright © 2005 Massachusetts Medical Society.  
 
Blocked coronary arteries can be treated by percutaneous coronary intervention (PCI, 
which consists of angioplasty and stenting), or coronary artery bypass graft surgery 
(CABG) (Figure 1.8).  Although PCI has become a ubiquitous and popular way of 
treating angina and blocked arteries, the recent SYNTAX Trial has shown that CABG 
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remains the gold standard in complex cases of coronary artery disease[36].  
Nevertheless, given the widespread usage of stents, much research has been dedicated 
to new and improved stent designs.   
 
Angioplasty was first described by Charles Dotter in 1964[37], and first balloon 
angioplasty was performed by Andreas Gruntzig in 1977[38].  Stenting, in tandem 
with balloon angioplasty, was performed by Ulrich Sigwart in 1986[39].  However, it 
was only after the BENESTENT trial[40], and STRESS trial[41] which demonstrated 
its safety and efficacy, that stenting became widely adopted.  By 1999, stenting had 
become synonymous with balloon angioplasty, accounting for 84.2% of all PCI 
procedures[42].  However, in-stent restenosis (ISR, a re-narrowing of the artery after 
stenting) was observed in around 20 to 30% of cases, due to vascular smooth muscle 
cell proliferation.   
 
To circumvent this problem, a new type of stent called drug-eluting stent (DES) was 
developed, and used in humans in 1999 by J. Eduardo Sousa[43-45].  A dramatic 
reduction in ISR was seen in DES compared to bare-metal stent (DES)[46-50], which 
consequently propelled the use of DES to the forefront of PCI.  Indeed, so popular 
was the use of DES, that by 2005, 80 to 90% of all PCI were done using a DES[51].   
 
However, in 2006, serious questions were raised pertaining to the use of DES due to a 
phenomenon called late stent thrombosis (ST)[52-54].  This potentially life-
threatening complication led to a significant reduction in their use.  Therefore, intense 
research and development (R&D) has been dedicated to DES technology to improve 
its safety prolife.  Although this contributed to the resurgence of DES use again, its 
current rate of use (about 75% of all PCI procedures) is still less than that of its peak 
in 2005[55].  
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Figure 1.8. PCI vs CABG.  (A) Balloon angioplasty (PCI) was first used as a less invasive way of 
treating blocked coronary arteries, compared to CABG.  (B) Metal stents were introduced in tandem 
with balloon angioplasty to prevent vessel collapse and maintain patency.  (C) However, CABG is still 
considered the gold standard for treating complex multivessel disease.  Figure adapted and reproduced 
with permission from Boston Scientific and Wikimedia Commons.  Copyright © 2013 Boston 
Scientific © 2013 Creative Commons. Key: PCI percutaneous coronary intervention; CABG coronary 
artery bypass graft surgery.     
 
1.3. In situ Endothelialization: Capturing Hearts and Minds? 
 
Endothelial cells are recognized to be important components of blood vessels as they 
maintain vessel homeostasis[56], and endothelial dysfunction is known to contribute 
to pathological behavior in vessels[57].  The endothelium, a one-cell thick layer lining 
the luminal area of blood vessels, is responsible for releasing vasoactive substances 
(Table 1.1) that regulate vessel tone, smooth muscle cell proliferation and coagulation 
cascade[58] (Figure 1.9).  In physiological conditions, endothelial cells produce 
soluble factors like tissue plasminogen activator (t-PA) and nitric oxide (NO) that 
prevents a thrombus from forming inside the vessel.  However, in times of endothelial 
injury (e.g. after stenting) or endothelial dysfunction (in patients with cardiovascular 
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disease), this physiological maintenance is impaired, thereby creating a pro-
thrombotic environment.    
         
 
Figure 1.9. The role of endothelial cells in balancing thrombosis and fibrinolysis. (A) Endothelial 
cells produce anti-thrombombotic factors like t-PA, NO, anti-inflammatory cytokines, and 
downregulate leukocyte adhesion molecules, to maintain low levels of thrombin (B) A pro-thrombotic 
environment is seen in times of endothelial cell injury, where there is increased levels of tissue factor, 
leading to higher levels of thrombin. (C) The complex interplay of factors which can 
upregulate/downregulate thrombosis.  Figure reproduced with permission from Bunte et al., 2008. 
Copyright © 2008 Nature Publishing Group.     
 
Given the important role of endothelial cells in blood vessels, and the observation of 
stent thrombosis due to impaired endothelialization in DES [59, 60], there has been a 
significant amount of R&D in search of biofunctionalized stent platforms that can 
enhance the level of endothelialization.  The Genous™ stent (OrbusNeich) contains 
endothelial progenitor cell (EPC)-specific antibodies (anti-CD34) on its surface.  It is 
postulated that this would enable the capture of circulating EPCs thereby increasing 
the level of endothelial cell proliferation in the stented vessel (Figure 1.10), and was 
first evaluated in a first-in-man study in 2005, demonstrating its safety and 
feasibility[61].  However, a subsequent randomized clinical trial comparing the 
Genous™ stent with conventional DES showed that its efficacy in inhibiting 
neointimal hyperplasia was not superior to conventional DES[62].  Nevertheless, this 
novel “pro-healing” approach remains a subject of much interest in intrigue within the 
regenerative medicine community, and there is evidence to suggest that various 
research groups are also attempting to utilize a variety of biomolecules (e.g. 
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antibodies and peptides) to enhance EPC capture to increase in situ 
endothelialization[63, 64].        
 
Table 1.1 Factors released by endothelial cells in physiological and pathological circumstances. 
Table adapted from Bunte et al., 2008. 
 Anti-Inflammatory Pro-Inflammatory 
Vasoactive Mediators • Nitric oxide 
• Endothelial-derived relaxant 
factors (EDRF) 
• Prostacyclin (PGI2) 
• Endothelin-1 
• Thromboxane A2 
Coagulation • Antithrombin 
• Heparan Sulfate 
• Dermatan Sulfate  
• Tissue factor pathway inhibitor 
(TFPI) 
• Thrombomodulin 
• Tissue factor 
• Thrombin 
Fibrinolysis & Fibrinogenesis • Tissue plasminogen activator (t-
PA) 
• Urokinase plasminogen activator 
(u-PA) 
• Plasmin 
• Thrombin activable fibrinolysis 
inhibitor (TAFI) 
• Plasminogen activator inhibitor-1 
(PAI-1) 
Cell adhesion & chemotaxis  • Cellular adhesion molecules 
(CAMs) 
• Selectins 
• von Willebrand factor (vWF) 
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Figure 1.10. Endothelial progenitor cell (EPC) capture technology in the Genous™ stent.  Anti-
CD34 antibodies are attached onto the surface of Genous™ stents, which would enable it to capture 
circulating EPCs to increase in situ endothelialization. Figure reproduced with permission from 
OrbusNeich.  Copyright © 2013 OrbusNeich. 
 
1.4. Drug Delivery using Liposomes: Less is More 
 
A closed phospholipid bilayer system was first described by Alec Bangham in 1965 
[65] at the Babraham Institute in Cambridge, thereby establishing a basis for model 
membrane systems[66, 67].  In the subsequent years, various types of closed 
phospholipid bilayer systems were described[68], first referred to as “bangosomes” 
(named after Alec Bangham), and then finally termed “liposomes”[69].  Early 
pioneers of liposomes include Gregory Gregoriadis of the MRC Clinical Research 
Centre, who found that liposomal drug formulation represented a novel way of drug 
delivery[70-74].          
 
Although Doxil® was the first liposomal “nano” drug formulation that was approved 
by the FDA in 1995, its chequered developmental history was an interesting case in 
point.  The precursor to Doxil® was the oligolamellar liposomal doxorubicin (OLV-
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DOX), which was developed in the 1980s.  However, although OLV-DOX displayed 
some potential in animal models, clinical tests in humans were a disappointment[75]. 
   
It was found that these early liposomes were of a relatively large size (around 200 to 
500 nm in diameter) and had no protective coating (nor sterically stabilized). It was 
therefore unable to avoid the mononuclear phagocyte system (MPS) 
(reticuloendothelial system (RES) being the older term), and was also unable to 
extravasate through the diseased tissue via the enhanced permeability and retention 
effect (EPR).  The MPS is part of the immune system, and it is responsible for 
detecting and destroying foreign bodies[76] (Figure 1.11).  The EPR is a phenomenon 
that relies on the fact that cancerous tissues have “leaky” blood vessels, and therefore, 
using nanoparticles as drug delivery agents would enable drugs to reach their target 
sites more efficiently[77] (Figure 1.12).     
 
 
Figure 1.11. The mononuclear phagocytic system (MPS).  The MPS is responsible for a variety of 
functions relating to the immune system, including the clearance of senescent cells as well as the 
destruction of foreign bodies.  Figure reproduced with permission from Murray and Wynn 2011.  
Copyright © 2011 Nature Publishing Group.   
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Figure 1.12. The enhanced permeability and retention effect (EPR).  Cancerous tissues often have 
“leaky” vasculature.  Therefore, having nano-drugs would enable a more efficient penetration into the 
tumour.  Figure reproduced with permission from Duncan 2003.  Copyright © 2003 Nature Publishing 
Group.   
 
Furthermore, scathing reports about the actual benefits of liposomal formulations 
further added to the general scientific negativity towards liposomes[78, 79].  Indeed, 
the 1980s saw an overall low expectation of liposomal drug formulation, so much so 
that it was difficult to obtain the necessary investment and funding required for its 
R&D.  It took some 10 years before the clinical success of liposomes entered the 
mainstream market and started to fuel interest in the scientific community about the 
potentials of nano-drug formulation.   
 
The development of Doxil® was a cross-continental academia-industry collaboration.  
This included Liposome Technology Inc. (LTI) at Menlo Park in California USA, 
Alberto Gabizon and Demetrios Papahadjopoulos at the University of California San 
Francisco (UCSF), Theresa Allen at the University of Alberta in Canada, and 
Yechezkel Barenholz at the Hebrew University-Hadassah Medical School in 
Jerusalem, Israel.  The developers also set out 4 basic requirements (and developed 
solutions) that must be met in order for a liposomal drug formulation to be successful 
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in humans, and is summarized in Table 1.2.  In summary, the scientists involved 
managed to create liposomes with a small diameter (around 100 nm), long-circulating 
time (via PEGylation on its surface), and with the drug payload fully encapsulated 
inside the aqueous core of the liposome, rather than within the phospholipid bilayer 
(Figure 1.13).  This enabled Doxil® to be far superior to OLV-DOX, and was able to 
effectively avoid the MPS, and exploit the EPR, leading to an increased therapeutic 
index compared to non-liposomal doxorubicin.  Indeed, the success of liposomal drug 
delivery has jumpstarted a whole new field of nanotechnology-based diagnostics and 
therapeutics, termed theranostics.  This involves integrating the dual modalities of 
therapy and diagnostics into a single platform, with liposomes functioning as a carrier 
system (Figure 1.14)[80].      
 
Table 1.2. The 4 basic requirements to achieve therapeutically efficacious liposomes. Table 
adapted from Barenholz 2012. 
Requirements Solutions 
Extended circulation time in in intact form in the human 
plasma 
Development of sterically stabilized liposomes (SSL) 
composed of high Tm phospholipids, cholesterol, and a 
lipopolymer e.g. 2000PEG-DSPE 
Sufficient levels and stable loading of drug in order for 
long circulating liposomes to reach disease site with 
liposomes loaded and with drug at a level needed to 
achieve therapeutic efficacy (t1/2 of drug release in blood 
should be longer than circulation t1/2) 
Use of pH or ammonium ion gradients for remote (active) 
loading of amphipathic weak bases or acids into 
liposomes 
Extravasation into diseased tissue Using liposomes of diameters of less than 120 nm, 
taking advantage of the EPR effect 
Getting active drug into target cells Releasing drug from liposome through selective drug 
leakage at diseased site by using: 
• Collapsible ion gradient  
• Heat 
• Radiofrequency 
• Ultrasound  
• Active targeting  
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Figure 1.13.  Schematic structure of Doxil®. Doxil is less than 100 nm in diameter so it can 
extravasate through diseased tissues via the enhanced permeability and retention effect (EPR).  It is a 
PEGylated “stealth” liposome and avoids detection by the mononuclear phagocyte system (MPS), and 
hence avoids pre-mature degradation.  Figure reproduced with permission from Barenholz 2012.  
Copyright © 2012 Elsevier B.V.   
 
 
Figure 1.14. Liposomes as theranostic platform.  Drugs (therapy) and quantum dots (diagnostic) can 
be integrating onto a single liposome, thereby achieving both spatial and temporal evaluation, as well 
as cell kill. Figure reproduced with permission from Al-Jamal and Kostarelos 2011.  Copyright © 2011 
American Chemical Society.  
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2.1. Material Science and Technology: A Perspective   
 
2.1.1. Polyurethane Chemistry   
 
Polyurethanes (PU) are polymers with carbamate (urethane) links (-NH-CO-O-)[1].  
Although PU has been used in a wide range of industries from textiles[2] to 
automotive[3], a particular category of PU is of relevance to the medical industry: 
segmented PU elastomers[4].  Segmented PU elastomers are block copolymers with 
an aliphatic polyol soft segment, and an aliphatic or aromatic PU hard segment.  
Examples of soft segments include: polyesters, silicones, polycarbonates, polyalkyl 
glycols, and hydroxyl-terminated polyethers.  They are termed “soft segments” due to 
their low glass transition temperatures (Tg) of around -70 °C to -30 °C.  Some 
examples of hard segments include: the aromatic hexamethylene diisocyanate (HDI), 
and the aliphatic 4,4’-methylene bisphenyl diisocyanate (MDI).  They are termed 
“hard segments” due to the relatively higher Tg compared to soft segments. 
 
The synthesis of segmented PU is generally a two-step process (Figure 2.1). 
 
Step 1:  1 mol of dihydroxy-terminated oligomer (HO-R-OH) is reacted with 2 
mols of diisocyanate, to yield a pre-polymer 
 
Step 2:  1 mol of the pre-polymer is reacted with 1 mol of diisocyanate, and 1 
mol of chain extender (X-R”-X).   
 
As their name suggests, chain extenders lengthen the hard segment and facilitate 
hydrogen bonding between the urethane and urea groups. Examples of chain 
extenders include diols and diamines[5-7].  The chemistry of hard segments is general 
influenced by three factors: the type of chain extender, the type of diisocyanate, and 
whether or not the diisocyanate is aliphatic or aromatic.  Generally, PU that are made 
up of aromatic diisocyanates (e.g. MDI) display greater mechanical strength, 
compared to PU that are made up of aliphatic diisocyanates (e.g. HDI).  Isocyanates 
with diol as chain extenders result in the production of urethane, while isocyanates 
with diamine chain extenders results in the production of urea.  PU-urea (produced 
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using diol as chain extenders) has a higher mechanical strength compared to PU, due 
to higher degree of hydrogen bonding between hard segments[8].                
 
 
Figure 2.1. Synthesis of segmented PU. This involves a 2-step process, using 3 main constituents: 
dihydroxy terminated oligomer, diisocyanate, and a chain extender. Figure adapted from Christenson et 
al., 2007. Copyright © 2007 Institute of Materials, Minerals and Mining.    
 
The microphase-separated characteristics of segmented PU are affected by various 
factors such as the ratio of hard segment to soft segment, the type of hard and soft 
segment, and the molecular weight of the soft segment.  For example, when there is a 
low ratio of hard-to-soft segment, the discrete hard segments would be distributed 
within the soft segment amorphous matrix, serving as crosslinks to reinforce the soft 
segment matrix.  In contrast, when there is high hard-to-soft segment ratio, the hard 
segments become continuous, rather than discrete[9].  This dual phase pattern of hard 
and soft segment contributes to the high degree of mechanical strength displayed in 
segmented PU.   
 
2.1.2. Nanocomposites: The Best of Both Worlds  
 
Composite materials are made up of two (or more) constituent entities that, when 
combined, display a synergistic effect, often resulting in an overall improvement in 
biophysical characteristics and performance of the final product.  In general, matrices 
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and reinforcements (or fillers) are the two main components of a composite material.  
Reinforcements can come in many shapes, such as layered (e.g. clay), spherical (e.g. 
metals), and fibrous (e.g. carbon nanotubes)[10].  The process by which the 
composite material is manufactured can have an effect on its biophysical 
characteristics, and a small change in the manufacturing technique can result in a 
large change in the final product.  A ubiquitous example of a high performance 
composite material would be carbon-fibre-reinforced polymer (simply termed carbon 
fibre).  In carbon fibre, the matrix is often epoxy, and the reinforcement is carbon 
fibre[11].  Its lightweight and superior mechanical properties (high tensile strength 
and rigidity) has seen it being used in a whole range of applications, from structural 
supports in civil engineering to high performance supercars.  Ironically (and perhaps 
understandably), lesser-known examples of composite materials are those that are 
seen in the natural world.  A recent article by Weaver et al., in Science studied the 
dactyl clubs of an aggressive marine crustacean, Odontodactylus scyllarus (peacock 
mantis shrimp)[12]. Indeed, so powerful are its dactyl clubs that the Odontodactylus 
scyllarus is able to fracture mollusk shell, crab exoskeleton, and even the glass in an 
aquarium tank, simply by using a series of repeated punches (Figure 2.2) (A YouTube 
video of Odontodactylus scyllarus in action can be found at: 
http://www.youtube.com/watch?v=i-ahuZEvWH8).                  
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Figure 2.2. Artificial vs. natural composite materials. (A) The monocoque of the Lamborghini 
Aventador is made of carbon fibre. (B) The peacock mantis shrimp has dactyl clubs made of 
nanocomposite materials that are capable of achieving acceleration similar to that of a .22 calibre 
handgun, and breaking glass aquarium tanks with a series of punches. (C) Due to its strength and 
rigidity, carbon fibre is seen in high performance supercars. (D) Backscattered electron micrograph 
(BSE) reconstruction revealing the nanostructures of the dactyl club. Panels A and C reproduced with 
permission from Automobili Lamborghini S.p.A.  Copyright © 2013 Automobili Lamborghini S.p.A. 
Panels B and D reproduced with permission from Weaver et al., 2012.  Copyright © 2012 American 
Association for the Advancement of Science.     
 
The term “nanocomposite” is used when one or more of the constituent components 
are in nanoscale ranges (often below 100 nm).  For all intents and purposes, matrices 
in nanocomposites can also be considered “hosts”, and reinforcements “guests”[13].  
Within the host matrix, the guest molecules can orientate themselves in distinct three 
ways: phase separated, intercalated, and exfoliated[14] (Figure 2.3).  Due to its 
nanoscale properties, the large surface area-to-volume ratio of the guest molecules 
would facilitate a higher probability for reactions to occur within the matrix, while 
simultaneously serving as a collection of nodes linking the polymer chains robustly 
together[15].  Nanocomposites tend to have superior mechanical strength, due to the 
fact that the matrix serves to transfer mechanical stresses to the guest molecules 
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(which are often “harder” than the matrix), which would then be responsible for the 
load bearing properties.   
 
 
Figure 2.3. Reinforcements and matrices in nanocomposites. Reinforcements can assemble in 3 
ways: phase separated, intercalated, and exfoliated.  Figure reproduced with permission from Yuan et 
al., 2007.  Copyright © 2007 Elsevier B.V.   
 
2.1.3. The Birth of POSS-PCU: A New Dawn? 
 
Polyhedral oligomeric silsesquioxane (POSS®, Hybrid Plastics Inc. USA), was 
developed by the Air Force Research Laboratory in the early 1990s as a new material 
for aerospace engineering applications[16, 17].  POSS has a three-dimensional nano-
caged structure with a stoichiometric formula of R8Si8O12.  Each POSS nanocage 
molecule measures 1.5 nm in diameter, and can be considered the smallest achievable 
silica particle[18] (Figure 2.4).   
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Figure 2.4. A three-dimensional structure of a POSS nanocage.  Since its development, POSS has 
been used in a wide range of industries from aerospace engineering to biomedical applications.  Figure 
reproduced with permission from Materials Digital Library Pathway.  Copyright © 2013 Creative 
Commons.   
 
Here at the Division of Surgery and Interventional Science at University College 
London (UCL), we selected PU as a model polymer for cardiovascular implants due 
to its strength and elasticity[19].  Specifically, poly(carbonate-urea) urethane (PCU) 
was used due to its resistance to hydrolytic and oxidative degradation[20, 21], and its 
viscoelastic behavior in blood vessels[22].  In our quest for a highly biocompatible 
material with superior mechanical engineering properties, we selected POSS as a 
reinforcement for the PCU matrix.  We further postulated that its chemical 
tunability[23] and reactive functionality[24] would render it an ideal candidate as a 
reinforcement, thereby creating a novel nanocomposite polymer[25-30].  Due to the 
dispersion of these nanoscale POSS reinforcements within the PCU matrix, the 
resultant nanocomposite would display unique structural and surface properties 
compared to conventional materials[31, 32].  Extending from this, we further 
hypothesized that incorporation of POSS into PCU would improve its 
haemocompatiblity due to mobile surface moieties[33] at the blood-material 
interface[34-36].  POSS can be incorporated into a polymer matrix as a cross-linking 
agent, as an end-group, or as a pendant chain attached to the polymer backbone[37-
39].  In this case, we reacted the silanol (-SiOH) groups of cyclohexanechlorohydrine-
functionalized POSS with isocyanate.  This resulted in POSS being incorporated in 
the polymer chain within the hard segment[30].  A linear organic-inorganic hybrid 
nanocomposite is thereby created, which reacts with a single (or double) 
polymerizable functional group upon covalent engraftment in PCU (Figure 2.5).       
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Figure 2.5. Chemical structure of POSS-PCU.  The main components are: the POSS nanocage, 
poly(hexamethylenecarbonate) soft segment, urethane group, and urea hard segment.   
 
2.2. POSS-PCU as a Platform for Nanotechnology and 
Regenerative Medicine 
 
2.2.1. Nano-Theranostics: Multifunctional Nanomaterials 
 
The concept of integrating therapy and diagnostic modalities in a single platform 
(known as theranostics) is a new and emerging field in biomedicine[40].  This usually 
involves the use of nanoparticles that can deliver drugs into cells, while 
simultaneously functioning as tracking beacons to indicate their location.  Examples 
of therapeutic agents can include anti-cancer drugs and siRNA; diagnostic agents 
include quantum dots (QD); carriers include liposomes and polymers; and targeting 
agents include antibodies and peptide motifs[41] (Figure 2.6).  Indeed, Bagalkot et al., 
developed drug-conjugated quantum dots that were specifically designed to fluoresce 
only after it had delivered its payload into the cell[42] (Figure 2.7). 
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Figure 2.6. Theranostic nanoparticles.  Therapeutic agents, diagnostic agents, targeting agents, and 
nano-carriers can be integrated into a single platform.  Figure reproduced with permission from Ho and 
Leong 2010.  Copyright © 2010 The Royal Society of Chemistry.      
 
 
Figure 2.7.  Tracking beacons. (a) Quantum dots (QD) can be loaded with doxorubicin (Dox).  (b) 
The QD would then fluoresce inside the cell, indicating that Dox has been successfully delivered and 
released.  Figure reproduced with permission from Bagalkot et al., 2007.  Copyright © 2007 American 
Chemical Society.     
 
One of the foremost concerns about nanoparticles is that it must be biocompatible.  To 
that end, we have explored the idea of using POSS-PCU as a coating for nanoparticles 
including QD[43-45] and carbon nanotubes (CNT)[46, 47].  We have demonstrated 
that coating QDs with POSS-PCU confers biocompatibility, while retaining its 
photostability, colloidal properties, ability to deliver therapeutic agents, and its 
fluorescence fidelity in vitro and in vivo[48].  CNTs have gained considerable interest 
in the biomedical field[49] due to its ability to function as novel photoacoustic 
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molecular imaging agents[50] as well as a nano-carrier to deliver drugs and small 
molecules into cells[51].  We have further shown that non-covalently functionalizing 
CNT with POSS-PCU confers biocompatibility while enhancing its thermal ablative 
effects on cancer cells when exposed to near-infrared light[46] (Figure 2.8).  In 
addition, we have also shown that it was possible for POSS-PCU coated CNT to 
function as nerve guidance channels with increased electric signals, thereby enabling 
it to function as novel cyborg tissue[52, 53]. 
 
Figure 2.8. Functionalization of CNT with POSS-PCU.  (A) CNT can be conjugated to doxorubicin 
via π-π interactions.  (B) Cell-specific antibodies can be attached to CNT with multi-colour in vitro 
cellular image rendered via deconvoluted confocal Raman spectroscopy. (C) CNT can be coated with 
POSS-PCU which confers biocompatibility and increases its thermal response when exposed to near-
infrared (NIR) light.  Panels A and B reproduced with permission from Liu et al., 2009.  Copyright © 
2009 Springer Science + Business Media.  Panel C reproduced with permission from Tan et al., 2012.  
Copyright © 2012 BioMed Central Ltd.                          
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2.2.2 Tissue Engineering: Driving the Future of Organ Development 
 
The impetus for the development of POSS-PCU was largely driven by the search for a 
next-generation vascular graft that would display haemocompatibility as well as 
viscoelasticity.  It was previously demonstrated that POSS-PCU has a higher degree 
of haemocompatibility[54] and viscoelasticity[55] compared to expanded 
polytetrafluoroethylene (ePTFE) and PCU controls.  To enhance in situ 
endothelialization and reduce the risk of thrombosis, we have also biofunctionalized 
POSS-PCU grafts with various bioactive molecules such as arginylglycylaspartic acid 
(RGD)[56], and nitric oxide (NO) donors such as diazeniumdiolate and S-
nitrosothiols[57] (Figure 2.9).  It has been shown that NO is vital in the 
cardiovascular system, and it plays in vital role in the regulation of vessel 
homeostasis, as well as having a cardioprotective role in myocardial ischaemia[58].  
Indeed, so crucial is NO as a signaling molecule in the cardiovascular system that its 
discoverer, Ferid Murad, was awarded the Nobel Prize in 1998[59].  
 
 
Figure 2.9. Biofunctionalized POSS-PCU vascular graft. (A) Diazeniumdiolate and (B) S-
nitrosothiols can be integrated into polymers and function as nitric oxide (NO) donors upon being 
catalyzed by light, copper, and ascorbate.  (C) Endogenous catalysis of NO by metal ions can occur 
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upon contact with plasma nitrosothiols.  (D) Diffusional barriers with respect to NO as applied to 
vascular haemodynamics. (E) In vitro assessment of NO-eluting POSS-PCU vascular graft in a 
bioreactor.  Figure reproduced with permission from de Mel et al., 2011.  Copyright © 2011 American 
Chemical Society.        
 
It is perhaps important to mention that since the initial development of POSS-PCU, 
this novel nanocomposite polymer has been used in three first-in-man implants; a 
bypass graft[60], lacrimal duct[61], and most notably, the world’s first bioartificial 
trachea[62] (Figure 2.10 and Figure 2.11).   
 
 
Figure 2.10. A tailor-made bioengineered trachea. (A) Preoperative volume rendered frontal plane 
image. Tumour shown in green, and tracheal and bronchial tree shown in blue.  (B) Measurements of 
trachea obtained via CT scan. (C) Schematics of the bioreactor. (D) Photograph of the bioreactor.  
Figure reproduced with permission from Jungebluth et al., 2011.  Copyright © 2011 Elsevier B.V.    
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Figure 2.11. POSS-PCU in 3 first-in-man studies.  (A) The world’s first bioartificial trachea 
transplanted into a patient was made of POSS-PCU. (B) A viscoelastic bypass graft made of POSS-
PCU. (C) A lacrimal duct made of POSS-PCU. Figure reproduced with permission from University 
College London.  Copyright © 2013 University College London.   
 
Compared to conventional materials, such as ePTFE, PU, and polyethylene 
terephthalate (PET) that are used in vascular grafts, POSS-PCU has demonstrated to 
be more viscoelastic, haemocompatible and biocompatible[60].  Viscoelasticity is 
defined as the ability of a material to respond mechanically to pressure changes.  This 
is of particular relevance, as the implanted graft has to match the biomechanics of 
native artery in order to achieve patency and reduce the risk of thrombosis.  The 
ability of POSS-PCU to function as small-diameter tubular structures was exemplified 
by using it as a material for a lacrimal duct, which measures less than 1 mm.  
Preliminary results indicate that biomechanical properties of POSS-PCU enables it to 
function as a lacrimal duct, and the technology of manufacturing it has also been 
patented by our lab[63].  It is without a doubt that the high point for POSS-PCU 
arrived with the trachea study, which garnered a significant amount of media 
attention, including the BBC[64] and the New York Times[65].  A patient with 
primary cancer of the distal trachea and main bronchi was given a bioengineered 
POSS-PCU trachea transplant, seeded with autologous bone marrow mononuclear 
cells in a bioreactor.  This procedure was carried out at the Karolinska Institute in 
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Stockholm, Sweden in 2011, with the patient still alive and well today (at time of 
writing).   
 
Given the considerable success of POSS-PCU in human studies, we sought to create 
other “human body parts” for the purpose of replacing those which have been ravaged 
by disease, trauma or congenital defects (Figure 2.12).   
 
 
Figure 2.12. Design, build, test.  (A) A digital reconstruction scan of a human ear. (B) A negative 
glass mold is constructed. (C) Additive layer manufacturing. (D) Solvent evaporation technique. (E) 
Phase separation technique. (F) Synthetic nose. (G) Synthetic heart valve.  Panels A-E reproduced with 
permission from Nayyer et al., 2013. Copyright © 2013 Elsevier B.V.  Panel F reproduced with 
permission from Seamus Murphy. Copyright © 2012 Seamus Murphy / VII / CNN. Panel G 
Reproduced with permission from Ghanbari et al., 2010.  Copyright © Elsevier B.V.        
 
An ideal biomaterial for tissue engineering applications should exhibit: 
biocompatibility, surface chemistry and topography to promote cell anchorage and 
extracellular matrix (ECM) production, a degradation rate that is matched with tissue 
regeneration and non-toxic by-products (if degradable polymers are used), a defined 
three-dimensional structure for cell and tissue growth, robust mechanical properties, 
and bioactive molecules on its surface to enhance its intended biological application.  
We have pursued organ tissue engineering, with synthetic nasal and auricular 
constructs, and bioartificial trachea as prime examples.  A 3-D digital reconstruction 
is rendered to suit the patient, and a negative mould is manufactured, before the 
POSS-PCU polymer is poured onto the negative mould to yield a positive mould.  
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Depending on the intended clinical application, the resultant POSS-PCU can either be 
in a casted state or a coagulated state.   In the casted state, liquid POSS-PCU in its 
mould is placed in a drying oven at 65 °C for 24 hours.  This yields a POSS-PCU film 
with a transparent/translucent appearance.  In the coagulated state, liquid POSS-PCU 
is placed in de-ionized water at room temperature for 24 hours.  The resultant POSS-
PCU would appear white in colour.  Casted POSS-PCU is non-porous and can 
therefore be used as coatings for medical devices, while coagulated POSS-PCU is 
porous and can be used as scaffolds for tissue engineering.  It should be noted, 
however, that although coagulated POSS-PCU encourages cell proliferation on its 
surface, it is at the expense of mechanical strength.  Depending on clinical need, the 
scaffold can be seeded with patient-specific cells and incubated in a bioreactor to 
allow for a confluent layer of cells to form on the scaffold, thereby further minimizing 
the risk of immunogenicity.  The possibility of using a degradable version of POSS-
PCU (POSS-PCL) has been explored in terms of using it as a nerve guidance channel 
/ conduit [66] (Figure 2.13).  In this study, Schwann cells were observed to proliferate 
within the luminal area of the POSS-PCL conduit, thereby facilitating nerve 
regeneration in tandem with the degradation kinetics of POSS-PCL.                                     
 
It has been recently shown that human adipose tissue-derived stem cells (hADSC) 
were able to proliferate and differentiate into cartilage, when seeded onto POSS-PCU 
scaffolds[67] (Figure 2.14).  Furthermore, grafting of chorioallantoic membrane 
(CAM) onto POSS-PCU significantly increased vascularization, and host erythrocyte 
were also detected within the scaffold, suggesting invasion of capillaries.  This 
therefore demonstrates the regenerative capacity of POSS-PCU, and its ability to 
function as a novel bio-nanoscaffold for cartilage tissue engineering applications, like 
craniofacial reconstructive surgery.   
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Figure 2.13. Manufacturing nerve conduits using POSS-PCL.  (A) AFM image of POSS-PCL. (B) 
SEM image of luminal area of POSS-PCL nerve conduit (C) Proliferation of Schwann cells on POSS-
PCL nerve conduit.  Figure reproduced with permission from Sedaghati et al., 2011.  Copyright © 2011 
John Wiley & Sons, Inc.     
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Figure 2.14. In vivo analysis of POSS-PCU scaffolds seeded with human adipose tissue-derived 
stem cells (hADSC) grafted with chorioallantoic membrane (CAM) grafting.  (A-C) In vivo 
images showing extensive vascularization from day 2 to 8.  (D) Staining with β3-tubulin, which cross-
reacts with both human and chick, and staining with nestin that reacts with human but not chick. (E) 
Erythrocyte and hADSC in scaffold.  (F) Higher magnification of panel E.  Scale bars in A-C represent 
500 µm, D and E represent 25 µm, F represent 10 µm.  Figure reproduced with permission from Guasti 
et al., 2013.  Copyright © 2013 Elsevier B.V.              
 
2.2.3. POSS-PCU as a Protective Coating    
 
With the recent health scare regarding the use of non-clinical grade Poly Implant 
Prothèse (PIP) breast implants[68], there has been a concerted effort to robustly assess 
the biomechanical properties and integrity of breast implants.  Indeed, we are 
currently assessing the feasibility of using POSS-PCU as breast implants, by 
collecting PIP explants and comparing its chemical and mechanical properties with 
POSS-PCU[69].  In recent years, there has been concern regarding the use of metal-
on-metal (MOM) hip implants due to their unacceptably high failure rates[70, 71].  
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Furthermore, there is evidence to suggest that toxic metal ion leaching of MOM hip 
implants could also lead to inflammation[72], and even cancer[73].  Consequently, 
there have been calls for the use of lubrication of even protective coatings on these 
implants to prevent failure and leaching.  Extending from a similar line of reasoning, 
we are advocating the development of a coronary stent that is covered with a POSS-
PCU membrane (thereby making a covered stent).  This highly biocompatible and 
haemocompatible membrane would prevent bare metal struts from being exposed to 
blood, thereby circumventing the possibility of stent thrombosis.         
 
2.3. Future Prospects and Conclusion  
 
With the advent of nanotechnology and regenerative medicine, it can be envisaged 
that the realm of biomaterials for medical applications would advance exponentially.  
The concept of 3D printing has recently gained traction, especially with widespread 
media reports documenting its potential applications in academia as well as industry.  
Much research has been dedicated to 3D printing tissues and organs (Figure 2.15 and 
Figure 2.16) [74, 75], and it is highly likely that many groups that have a vested 
interest in biomaterials for medical applications would pursue this line of research. 
Our research pertaining to POSS-PCU is currently geared towards the concept of 
manufacturing polymeric stents and cardiovascular grafts using 3D printing. This 
would enable a more precise and controlled fabrication solution, as opposed to 
traditional casting methods.  Furthermore, we are currently working towards Good 
Laboratory Practice (GLP) accreditation in order to prepare for large-scale production 
of POSS-PCU.  Several first-in-man studies for various applications of POSS-PCU 
(skin substitute, nerve conduit, coronary stent) are currently in the pipeline, with the 
next probable phase being clinical trials.          
 
Considering the rapid pace at which the biomedical engineering sector is progressing, 
coupled with the exponential increase in research output dedicated to biomaterials and 
nanotechnology, it is without a doubt that future breakthroughs in the multi-functional 
applications of POSS-PCU would hinge greatly on this niche area.   
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Figure 2.15. 3D printing of organs. Microfluidic channels can be printed, in tandem with tissue 
spheroids.  The printed construct can be connected to a bioreactor for perfusion. Figure reproduced 
with permission from Ozbolat and Yu 2013. Copyright © 2013 Institute of Electrical and Electronics 
Engineers (IEEE). 
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Figure 2.16. Fabricating tissues and organs using advanced technologies. (a) Cell sheets can be 
stacked to form complex tissues, scale bar = 200 µm. (b) Cell sheets can be rolled into cylindrical 
structures to form blood vessels, inner diameter = 4.2 mm. (c) Cell-laded hydrogel with lock-and-key 
shape increases complexity improves scalability, scale bar = 200 µm. (d) Cell-laden hydrogel can be 
extruded to form 3D structures, scale bar = 2.5 mm. (e) Cell aggregates can be manipulated to form 
vascular tubes, inner diameter = 0.9 mm. (f) Microscale patterning of cells using dielectrophoretic cell 
patterning. (g) Patterning and interfacing multiple cell types using laser-assisted bioprinting. (h) 
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Guided self-assembly of microvascular network using laser-assisted bioprinting. Figure reproduced 
with permission from Guillotin and Guillemot 2011.  Copyright © 2011 Cell Press.      
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3.1. Introduction 
 
Cardiovascular disease is one of the leading causes of mortality and morbidity in the 
world.  According to the World Health Organization (WHO), 17.3 million people died 
from cardiovascular-related diseases in 2008, and this number is projected to rise to 
an estimated 23.6 million by 2030[1].  Atherosclerosis is a subset of cardiovascular 
disease, and can be treated using percutaneous coronary intervention (PCI) as a less 
invasive alternative to coronary artery bypass graft (CABG) surgery[2].  
 
Early stents were made from stainless steel (previously referred to as wallstent), and 
were, for all intents and purposes, classified as bare metal stents (BMS).  As metal 
stents are perceived as foreign objects, the body mounts an immunological response 
with an upregulation of inflammatory mediators, ultimately causing neointimal 
hyperplasia, where the proliferation of vascular smooth muscle cells causes a re-
narrowing of the vessel[3] (in-stent restenosis). Drug-eluting stents (DES) were 
developed in response to the problems associated with BMS use.  The anti-
proliferative effects of DES resulted in lower rates of in-stent restenosis compared to 
BMS.  However, due to a distinct lack of endothelialization around the vessel wall, 
yet another problem arose with DES: late-stent thrombosis[4] (ST).  ST is a serious 
complication, with mortality rates of up to 30%.  Although the exact mechanism of 
ST is still unclear, it is postulated that polymer coatings on DES and the lack of 
endothelialization contribute to an increased risk of late ST.  This is further 
compounded by endothelial injury during stenting, and turbulent blood flow in the 
presence of stent struts in the luminal area of the vessel.  In the realm of fluid shear 
stress, evidence also suggests that laminar flow promotes a healthy endothelium, 
while turbulent flow is associated with atherosclerosis (Figure 3.1)[5, 6].   
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Figure 3.1.  Immunological responses after BMS and DES implantation. As BMS are perceived as 
foreign objects, the body mounts and immune response against it, resulting in intimal hyperplasia, 
vascular smooth muscle cell proliferation, and ultimately in-stent restenosis.  In the case of DES, anti-
proliferative drugs prevent in-stent restenosis.  However, polymer hypersensitivity and the lack of 
proper endothelialization result in late stent thrombosis, which is a potentially life-threatening event. 
BMS = bare metal stent; DES = drug-eluting stent; CRP = C-reactive protein; ECP = eosinophil 
cationic protein.  Copyright © 2010 American College of Cardiology Foundation.  Reproduced with 
permission from (Niccoli et al., 2010).   
 
Hence, there is an urgent need for a new breed of stents that would not inherit the 
problems seen with BMS and DES.  The advent of nanotechnology in medicine has 
witnessed a range of innovations tailored to addressing present-day clinical 
challenges.  For instance, the development of biologically-friendly polymers for 
artificial organs[7]; functionalized nanoparticles for targeted drug delivery[8] and the 
controlled release of drugs from polymers, exemplified by techniques like layer-by-
layer self-assembly[9].  Indeed, special nanocomposite polymers like polyhedral 
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oligomeric silsesquioxane poly (carbonate-urea) urethane (POSS-PCU, trade named 
UCL-Nano™) have been developed specifically to tailor to an unmet need for 
functional nanomaterials in clinical medicine.  The multi-faceted applicability of 
POSS-PCU has allowed it to be used as a scaffold in the world’s first artificial trachea 
transplant[7], synthetic bypass grafts[10], heart valves[11], and more recently, 
protective coatings for drugs and medical devices.          
 
Apart from appropriate polymer coatings, stents with novel features like endothelial 
progenitor cell (EPC)-specific antibodies for cell capture[12], and gene-eluting 
stents[13] have been developed, in hopes of achieving in situ endothelialization to 
circumvent problems of restenosis and thrombosis.  Furthermore, the biological 
significance of nitric oxide (NO) in the cardiovascular system is widely recognized, 
and has been hailed as a “guardian” for cardiovascular implants[14].  NO precursors 
can be integrated into nanocomposite polymers, optimizing them for regenerative 
cardiovascular applications[15].   
 
We envisage the future generation of cardiovascular stents would incorporate 
nanotechnology-based features like biofunctionalized polymers for enhanced 
biocompatibility, antibody/peptide conjugation for attracting endothelial progenitor 
cells, and multiple coating layers for controlled and sustained drug delivery[16] 
(Figure 3.2).  The journey of a coronary stent from bench to bedside entails not only 
developing a viable product, but it also has to pass a battery of industry-standard tests, 
animal studies and human clinical trials.  Therefore, this review focuses on new 
developments in stent coating technologies, and with a particular focus on various 
tests required before gaining regulatory approval for clinical use.   
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Figure 3.2.  Convergence of bio-functionalized polymers, controlled drug release, and EPC 
capture. To address the problems seen in BMS and DES, the next generation cardiovascular stent 
could involve coating with special nanocomposite polymers like POSS-PCU.  To enhance 
endothelialization, EPC-specific antibodies could be attached to the polymer.  NO is essential for 
maintaining a healthy endothelium and preventing thrombosis, and NO-eluting polymers could also be 
developed.  Multiple drugs could be incorporate using layer-by-layer coating technology.  POSS-PCU 
is non-biodegradable, and so is used as the base coat to prevent bare metal from coming into contact 
with blood.  POSS-PCL is biodegradable, and can be used together with drugs for controlled release. 
EPC = endothelial progenitor cell; NO = nitric oxide; POSS-PCU = polyhedral oligomeric 
silsesquioxane poly (carbonate-urea) urethane; POSS-PCL = polyhedral oligomeric silsesquioxane 
poly caprolactone. 
 
3.2. Percutaneous Coronary Intervention (PCI) for 
Atherosclerosis  
 
Atherosclerosis is a hallmark of cardiovascular disease, characterized by calcification 
and the build up of fatty deposits, cellular debris and cholesterol in arteries, resulting 
in stenosis (narrowing) of the vessels[17].  If this occurs in coronary arteries, 
insufficient delivery of oxygenated blood to the heart would result in cardiac 
ischemia, ultimately leading to myocardial infarction (a heart attack).  The 
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atherosclerotic plaque consists mainly of cellular debris and cholesterol, with a 
concomitant upregulation of pro-inflammatory mediators produced by immune 
cells[18].  While stable atherosclerotic lesions (plaque) may be relatively 
asymptomatic until complete vessel closure, unstable (or vulnerable) lesions are prone 
to rupture and thrombus formations, leading to life-threatening complications like 
thromboembolism.     
 
Blocked coronary arteries can be treated either by a coronary artery bypass graft 
(CABG) or a less invasive technique called percutaneous coronary intervention 
(PCI)[19].  PCI involves inserting a catheter with a guide wire to locate the site of the 
occluded vessel using real-time x-ray visualization.  A balloon angioplasty is then 
performed, whereby the inflation of the balloon encased within a metal stent “cage” 
unblocks the occluded vessel.  The deployed stent would then be a permanent fixture, 
eventually becoming part of the vessel wall. Balloon angioplasty was developed in 
1977 by Andreas Gruntzig in Switzerland[20], and was the mainstay of PCI. 
Although balloon angioplasty was a pioneering technique in the field of interventional 
cardiology, there were problems associated with it as well, like vessel closure due to 
elastic recoil and stenosis due to neointimal hyperplasia, which limited its use[21].  
The idea of introducing a more permanent structure in conjunction with the balloon 
during angioplasty to maintain patency in the blood vessel led to the development of 
stents in 1986 by Ulrich Sigwart[22].  These metal struts provided the necessary 
radial force on the vessel wall, circumventing the problem of vessel closure seen in 
balloon angioplasty.  The acceptance of stenting as a method of choice for PCI has 
seen a dramatic rise since the 1990s[23, 24].  By 1999, coronary stenting accounted 
for almost 80% of all PCI procedures[25]. 
   
In contrast to PCI, CABG is a surgical procedure, which involves harvesting a 
suitable autologous blood vessel (blood vessel from another part of the body) and 
grafting it onto the diseased area, to provide an alternative route for blood flow. 
Cardiac surgeons often perform CABG, while PCI is usually under the remit of 
interventional cardiologists/radiologists. A landmark randomized controlled trial of 
CABG versus PCI concluded that CABG remained the gold standard in patients with 
left main or 3 vessel coronary artery disease [26]. However, its exorbitant cost and 
long patient recovery time has led to a move towards adopting PCI as a first line 
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treatment for appropriate cases.  As opposed to CABG, which requires the patient be 
hospitalized a few days post-surgery, PCI allows the patient to go home often within a 
day.  Post PCI treatment normally involves dual anti-platelet therapy (aspirin and 
clopidogrel/prasugrel) to protect patients against stent thrombosis and major adverse 
cardiovascular and cerebrovascular events (MACE).  Although PCI may afford 
benefits similar to CABG[27], there are concerns that PCI is associated with a higher 
incidence of MACE, primarily caused by repeat revascularization[28].  However, 
with the rapid advancement of interventional cardiology, strong evidence suggests 
that endpoint results of PCI can match those of CABG[29].    
 
3.2.1. Bare Metal Stents (BMS) 
 
Early stents were mostly made of either stainless steel or cobalt chromium, and were 
for all intents and purposes, classified as bare-metal stents (BMS).  A common 
problem associated with BMS implantation is in-stent restenosis, which occurs due to 
inflammation and proliferation of vascular smooth muscle cell in the luminal area, 
collectively termed as neointimal hyperplasia[30], which occurs in around 30% of 
patients[31].  This then necessitates a repair procedure (revascularization), which 
could involve another round of PCI, or even CABG.  The ascension of BMS as an 
integral part of PCI saw the birth of a new breed of stents designed to solve its 
predecessor’s problems: the drug-eluting stent (DES).   
 
3.2.2. Drug-Eluting Stents (DES) 
 
As its name suggests, drug-eluting stents carry anti-proliferative agents on its surface 
with the purpose of inhibiting cell proliferation to prevent neointimal hyperplasia and 
restenosis.  At time of writing, there are currently 11 DES approved by the US Food 
and Drug Administration (FDA) for clinical use (Table 3.1).  Anti-proliferative drugs 
like sirolimus[32] and paclitaxel[33] were first used in DES, with newer versions 
featuring zotarolimus[34] and everolimus[35].  DES were first used in early 
2000s[36], and the CYPHER™ (Cordis) sirolimus-eluting stent gained FDA approval 
in 2003.  Early evidence demonstrating the safety and superiority of DES over BMS 
made DES the treatment of choice in PCI[37-39].  By 2005, use of DES accounted for 
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almost 90% of all PCI procedures[40].  Despite the initial fanfare and promise of 
DES, concerns about a potentially fatal phenomenon called late stent thrombosis (ST) 
were raised, possibly due to immunological response mounted against the polymer 
coating on DES, calling into question the actual long-term benefits of DES over BMS 
(Figure 3.3)[41-44].  Given the increased risk of late ST, patients implanted with DES 
often have to undergo dual antiplatelet therapy (a combination of aspirin and 
clopidogrel/prasugrel) for a longer time (6 to 12 months post-stenting) compared to 
patients implanted with BMS (1 month post-stenting)[45]_ENREF_34.   
 
Table 3.1. FDA-Approved Drug-Eluting Stents. 
Manufacturer Model Polymer Drug Date Approved Comments 
Cordis CYPHER • PEVA 
• PBMA  
Sirolimus 24 Apr 2003 • Manufacturing 
will stop by 
end of 2012 
due to quality 
control lapses 
Boston 
Scientific 
TAXUS 
Liberté Atom  
• SIBS Paclitaxel 21 May 2009 • Boston 
Scientific’s 
flagship 
model 
• Captures 
20% of US 
stent market 
Boston 
Scientific 
TAXUS Liberté 
Long 
• SIBS Paclitaxel  13 Jul 2009 • Boston 
Scientific’s 
flagship 
model 
• Captures 
20% of US 
stent market 
Boston 
Scientific 
ION • SIBS Paclitaxel  22 Apr 2011 • Platinum 
chromium 
stent struts 
promises 
increased 
strength, 
deliverability 
and visibility 
Boston 
Scientific 
PROMUS 
Element 
• PBMA 
• PVDF-HFP 
Everolimus 22 Nov 2011 • Utilizes same 
technology 
platform as 
Abbott’s 
Xience V 
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Medtronic Endeavor • PC Zotarolimus  1 Feb 2008 • Biomimetic 
PC coating is 
also found on 
outer 
membrane of 
red blood 
cells 
Abbott 
Vascular  
Xience V • PVDF-HFP 
• PBMA 
Everolimus  2 Jul 2008 • Abbott 
Vascular’s 
flagship 
model 
Abbott 
Vascular 
Xience Prime • PVDF-HFP 
• PBMA 
Everolimus  1 Nov 2011 • Abbott 
Vascular’s 
flagship 
model 
Abbott 
Vascular  
Xience Nano • PVDF-HFP 
• PBMA  
Everolimus  24 May 2011 • Abbott 
Vascular’s 
flagship 
model 
Boston 
Scientific 
TAXUS 
Express2 
• SIBS Paclitaxel 4 Mar 2004 • Boston 
Scientific’s 
flagship 
model 
• Captures 
20% of US 
stent market 
Medtronic  Resolute 
MicroTrac &  
Resolute 
Integrity  
• Hydrophobic C10 
(for drug release) 
• Hydrophilic C19 
(for bio-
compatibility) 
• PVP 
Zotarolimus 17 Feb 2012  • First DES to 
be approved 
by FDA for 
use in 
diabetic 
patients 
Key: PBMA = Poly-n-butyl methacrylate; PC = phosphorylcholine; PEVA = Polyethylene co-vinyl acetate; PVDF-HFP 
= Polyvinylidene fluoride co-hexafluoropropylene; SIBS = Poly (styrene-b-isobutylene-b-styrene); PVP = Polyvinyl 
pyrrolidone 
*Information compiled using data obtained from US FDA website on recently-approved devices:  
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-
ApprovedDevices/default.htm 
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Figure 3.3.  Late stent thrombosis in DES.  Stent thrombosis, a potentially fatal phenomenon, is seen 
on PES when implanted in various coronary arteries.  Stent thrombosis is virtually absent in BMS.  Cx 
= circumflex coronary artery; RCA = right coronary artery; LAD = left anterior descending artery; PES 
= paclitaxel-eluting stent; DES = drug-eluting stent; BMS = bare metal stent.  Copyright © 2009 
American College of Cardiology Foundation.  Reproduced with permission from (Chen et al., 2009).      
 
3.2.2.1. First Generation DES 
 
Sirolimus was the first drug incorporated onto DES seen in the FDA-approved 
CYPHER™ stent (Cordis). CYPHER™ was first evaluated in the RAVEL trial, 
which demonstrated superior anti-restenotic effects when compared to BMS[37] 
(0.0% vs 26.6%). The TAXUS® Express (Boston Scientific) and TAXUS® Liberté 
stent (Boston Scientific) contain paclitaxel, and gained FDA approval following 
studies which confirmed its safety and efficacy, which showed significantly less in-
stent restenosis compared to BMS[46, 47].  Meta-analyses comparing both sirolimus 
and paclitaxel DES with BMS revealed that DES afforded a reduction in restenosis 
and repeat revascularization, compared to BMS[31, 48-51].   
 
3.2.2.2. Second Generation DES 
 
Everolimus is a derivative of sirolimus, has similar mechanism of action, and is also 
used as an immunosuppressant for transplant patients.  The Xience V® stent (Abbott 
Vascular) is an everolimus-eluting stent (EES), and a multi-center randomized 
controlled trial demonstrated that everolimus-eluting stents (EES) had superior 
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outcomes compared to first generation paclitaxel-eluting stents (PES)[52].  
Zotarolimus is also a derivative of sirolimus, and the Endeavor® stent (Medtronic) is 
an FDA-approved zotarolimus-eluting stent (ZES).  The Endeavor® stent has been 
shown to be effective in treating coronary artery diseases, as shown by favorable 
results in various clinical trials and multi-center registries[53-55].  It has also been 
shown that both EES and ZES have comparable safety and efficacy outcomes[56].  
As second generation DES was only introduced recently, there is still no conclusive 
evidence as to whether they are superior to first generation DES (Figure 3.4)[57, 58].   
 
 
Figure 3.4.  Drug-Polymer Matrix Coatings.  The CYPHER stent consists of a PBMA topcoat, 
sirolimus, and a parylene C primer basecoat.  The TAXUS stent consists of a mixture of SIBS polymer 
and paclitaxel.  The Xience stent consists of a fluoropolymer mixed with everolimus and a basecoat.  
The Endeavor stent contains zotarolimus and uses a PC base coat.  However, problems like late stent 
thrombosis and impaired endothelial healing have been reported.  PBMA = Poly-n-butyl methacrylate; 
SIBS = Poly (styrene-b-isobutylene-b-styrene); LST = late stent thrombosis; PC = phosphorylcholine. 
DES = drug-eluting stent. Copyright © 2009 Informa UK Ltd.  Reproduced with permission from 
(Wykryzykowska et al., 2009). 
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3.3. Design Considerations in Stent Coating Technology 
 
3.3.1. Polymers for Coating Stents 
 
DES often utilize polymers as a foundation on which to incorporate pharmacologic 
agents[59].  Polymers can be broadly divided into two categories: biodegradable and 
non-biodegradable. Non-biodegradable (or durable) polymers were first used in DES.  
Due to the observation of late ST in DES, it was postulated that the prolonged 
presence of a non-biodegradable polymer contributed to late ST via an immunological 
response.  Thus, it was hypothesized that biodegradable polymers might serve as 
“second generation” polymers.  The idea was based on the premise that the 
degradation of the polymer in tandem with drug release would eventually leave 
behind a BMS, which could potentially mitigate late ST (as late ST was rarely seen in 
BMS).  Published reports indicate that biodegradable polymers were non-inferior to 
non-biodegradable polymers[60].  These studies largely demonstrated that 
biodegradable polymers share similar safety and efficacy as non-biodegradable 
polymers[61].  Hence, there is still a lack of conclusive evidence to show that 
biodegradable polymers are superior to non-biodegradable polymers[62].   
 
3.3.2. Non-Biodegradable Polymers  
 
The current range of FDA-approved DES employs non-biodegradable polymers. The 
Endeavor® stent (Medtronic) uses a phosphorylcholine (PC) polymer which is seen in 
biological membranes, for enhanced biocompatibility[60].  A newer version, the 
Endeavor® RESOLUTE (Medtronic) uses a proprietary BioLinx polymer system, 
which also mimics biological phospholipid bilayer membranes.  The BioLinx polymer 
system encompasses a combination of C10, C19 and polyvinyl pyrrolidone (PVP) for 
a controlled release of drug elution.  The C10 polymer is hydrophobic (contact angle 
= 118°) and aids in the control for drug release.  The C19 polymer is hydrophilic 
(contact angle = 91°), and is designed to confer biocompatibility.  The hydrophilic 
PVP increases the initial drug burst, enhancing the elution rate.   
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The CYPHER™ stent (Cordis) contains parylene C, polyethylene-co-vinyl acetate 
(PEVA), and poly n-butyl methacrylate (PBMA)[62].  Parylene C is used as a 
basecoat (primer) to the bare-metal stent as it is an excellent moisture barrier.  The 
parylene C-treated stent is then coated with a combination of PEVA and PBMA 
mixed with sirolimus (67%/33%).  A drug-free topcoat of PBMA is then applied for 
controlled release of sirolimus.   
 
The TAXUS® stent (Boston Scientific) is coated with poly(styrene-b-isobutylene-b-
styrene) (SIBS, trade name Translute), which is a hydrophobic elastomeric tri-block 
copolymer[63].  SIBS is composed of styrene and isobutylene units built on 1,3-di(2-
methoxy-2-propyl)-5-tert-butylbenzene.  It has a molecular weight of 80,000 to 
130,000 g/mol and a polydispersity index of 1.0 to 2.0.  A mixture of SIBS and 
paclitaxel is applied directly to the bare-metal stent without a basecoat (primer) or a 
topcoat layer.  The ION™ stent (Boston Scientific) uses the same drug and coating as 
the TAXUS stent, but uses platinum chromium instead of stainless steel for the stent 
strut.   
 
The Xience V® stent (Abbott Vascular) is coated with PBMA which adheres to the 
metal surface and drug coating, and polyvinylidene fluoride hexafluoropropylene 
(PVDF-HFP)[64].  Two variants, Xience Prime™  (Abbott Vascular) and Xience 
Nano™ (Abbott Vascular) are also available.   
 
The PROMUS™ Element™ (Boston Scientific) uses the same drug and polymer 
coating as the Xience stent. PVDF-HFP serves as a drug matrix layer containing 
everolimus, and no topcoat is used.  PVDF-HFP is a non-biodegradable semi-
crystalline random copolymer with a molecular weight of 254 to 293 kDa.  PVDF-
HFP is mixed with everolimus in a 83% /17% ratio and applied to the PBMA-treated 
metal surface, with a drug load of 100 µg/cm2. 
 
Non-biodegradable polymers are currently still the preferred coating of choice for 
stents.  This ensures that metal struts would not come into contact with blood, thus 
minimizing restenosis.  However, one issue that warrants attention is that of late stent 
thrombosis.  Considering that the FDA only approved the first DES in 2003, studies 
documenting long term follow up (more than 10 years) are few and far between.  
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Furthermore, since there are currently no FDA-approved DES with biodegradable 
polymers, an objective clinical comparison between non-biodegradable and 
biodegradable polymers cannot be definitively established.                            
 
3.3.3. Biodegradable Polymers  
 
DES with biodegradable polymers have been developed, based on the hypothesis that 
it may offer both the anti-restenotic effects of a standard DES, and the safety profile 
of a BMS.  The Supralimus® and Infinnium® stent (Sahajanand Medical 
Technologies) is a DES coated with biodegradable polymers consisting of poly-L-
lactide (PLA), poly vinyl pyrrolidone (PVP), poly lactide-co-caprolactone (PLC), and 
poly lactide-co-glycolide (PLGA)[57, 65].  The Excel stent (JW Medical System), is a 
sirolimus-eluting (SES) coated with poly-L-lactic acid (PLLA), which completely 
degrades after 6 to 9 months[66]. Abluminal coating is a way of minimizing exposure 
of polymers to the luminal area of the vessel.  This method of coating ensures that the 
drug and polymer matrix is in contact with the vessel wall, while retaining the bare-
metal strut in the luminal area.  Stents like BioMatrix™ (BioSensors International), 
Nobori® (Terumo), Axxess™ (Biosensors International), XTENT (Xtent), 
SYNERGY™ (Boston Scientific), DESyne™ BD (Elixir Medical), and JACTAX 
Liberté (Boston Scientific) utilizes the concept of abluminal coating with PLA[67-
73].   
 
However, the concept of biodegradable polymers in stents should be proceeded with 
caution, with evidence suggesting that they can cause more severe vessel 
inflammation compared to non-biodegradable polymers[74]. In order for a 
biodegradable polymer to be feasible, its breakdown products and monomers must be 
non-toxic and easily excreted from biological systems.  Currently, the use of 
biodegradable polymers are largely experimental and not approved by FDA, and the 
actual benefits of having a biodegradable polymer coating over a non-biodegradable 
one remains to be seen.                         
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3.4. Interfacing Advanced Pharmacologic Agents 
 
3.4.1. Achieving Anti-Thrombogenicity & Anti-Proliferation  
 
An ideal polymer coating would prevent thrombosis and smooth muscle cell 
proliferation, while simultaneously encouraging endothelial cell regeneration.  The 
current range of FDA-approved DES contains either sirolimus (and its derivatives) or 
paclitaxel dissolved in a polymer matrix, which is then used as a coating for the metal 
stent struts.  Sirolimus is an immunosuppressant normally used in renal transplant 
patients to prevent organ rejection.  A macrolide that inhibits mTOR (mammalian 
target of rapamycin), sirolimus causes cells to arrest in the G1 phase (Figure 3.5)[75].  
Paclitaxel is a microtubule inhibitor, normally used in the treatment of advanced 
ovarian cancer and metastatic breast cancer.  It binds to β-tubulin in the mitotic 
spindle, rendering them non-functional and thus prevents chromosome segregation, 
resulting in cell death.  Given that sirolimus and paclitaxel are anti-proliferative 
agents, the lack of endothelialization and polymer hypersensitivity contribute to late 
ST seen in DES.  Hence, while it is important to prevent in-stent restenosis by curbing 
vascular smooth muscle proliferation, it is also vital to ensure adequate 
endothelialization to prevent late ST.  
 
 
Figure 3.5. The disruption of cell cycle by anti-proliferative drugs.  Sirolimus is a cytostatic agent 
that causes the cell to arrest at G1 phase by inhibiting mTOR.  Paclitaxel is a cytotoxic agent that 
disrupts the G2 phase by binding to mitotic spindles and prevent chromosome segregation. mTOR = 
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mammalian target of rapamycin.  Copyright © 2006 Lippincott Williams & Wilkins.  Reproduced with 
permission from (Thanigaraj et al., 2006). 
 
3.4.2. Layer-by-layer (LbL) Self-Assembly for Controlled Release 
 
With the emergence of nanotechnology targeted for medical applications, a process 
for coating medical devices called layer-by-layer (LbL) self-assembly has emerged as 
a viable technique.  This method involves the “stacking” of thin films carrying an 
alternation of positive and negative polyelectrolyte charges.  LbL allows for 
controlled release of drug molecules, which could potentially be useful in developing 
the next generation of DES[76]. Multiple layers made up of drugs and polymers 
harbor the potential of achieving sustained and controlled release of pharmacologic 
agents (Figure 3.6).  For example, genistein which has anti-platelet and anti-
proliferative properties can be layered with sirolimus, preventing both smooth muscle 
cell proliferation and thrombosis [77].  Furthermore, various drug types can be 
incorporated into different layers corresponding to its therapeutic use in different 
phases in vessel healing.  The release of anti-proliferative[78] and anti-
thrombogenic[79] agents incorporated into multilayers can be fine-tuned to match the 
healing time and re-endothelialization of the vessel wall[80], circumventing problems 
like in-stent restenosis and late ST inherent in current ranges of BMS and DES 
respectively.  In addition, these multilayers can be functionalized with a plethora of 
bioactive molecules like nitric oxide (NO) donors to reduce platelet adhesion[81], 
DNA for gene therapy[82-84], and monoclonal antibodies to encourage 
endothelialization[85] and prevent platelet aggregation[86].  Coating via LbL self-
assembly is still currently in the experimental phase, and there are no large animal or 
human trials being conducted as yet.  Issues like maintaining batch-to-batch 
consistency and its advantage over conventional spray coating / dip coating still 
remains to be seen.                 
 
	   111	  
 
Figure 3.6.  Layer-by-layer (LbL) self-assembly for controlled release of multiple pharmacologic 
agents.  A combination of different drugs can be incorporated onto different layers to match healing 
times.  Initial high does of genistein release in top layer D will prevent platelet aggregation in the first 2 
days.  Release of genistein and sirolimus in middle layer C will prevent thrombus formation and 
intimal cell proliferation.  Slow release of genistein and sirolimus in middle layer B will prevent cell 
proliferation from day 10 to day 49.  Sustained release of genistein in base layer A will prevent late 
stent thrombosis.  Copyright © 2007 American Heart Association, Inc. Reproduced with permission 
from (Daemen and Serruys 2007). 
 
3.4.3. An Imperative for in situ Endothelialization  
 
3.4.3.1. Antibody Conjugation for Endothelial Progenitor Cell Capture 
 
The process of stent implantation in PCI damages the vessel wall and disrupts the 
endothelium.  Hence, it is imperative for re-endothelialization to occur in order to 
restore physiological vascular homeostasis[87].  Promoting re-endothelialization in 
the stented vessel wall by mobilizing endothelial progenitor cells (EPCs) is 
recognized as a measure to prevent both restenosis and thrombosis[88]. The notion of 
achieving in situ endothelialization via the capture of circulating EPCs is exemplified 
by the Genous™ stent (OrbusNeich).  The Genous™ stent is coated with anti-CD34 
antibodies, which capture circulating EPCs (Figure 3.7), and clinical follow-up 
reports indicated its safety even after 3 years implantation[89].  However, a study 
comparing the Genous™ stent with a TAXUS Liberté™ (Boston Scientific) DES 
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revealed that restenosis was observed in the Genous™ stent, while thrombosis was 
seen in the TAXUS stent[90].  This underscores the importance of combining both 
aspects of anti-proliferation and anti-thrombogenicity for stent technologies of the 
future.  Indeed, developments for stents combining anti-CD34 antibody and drug-
elution are currently underway[91].  Apart from anti-CD34, there is some evidence 
supporting the use of other EPC-specific antibodies like anti-CD133[92] and vascular 
endothelial growth factor receptor-2 (VEGFR-2)[93, 94].   
 
 
Figure 3.7. EPC capture using antibodies.  A Anti-CD34 antibodies are attached onto the stent to 
capture circulating EPCs to promote endothelialization.  B The Genous™ stent uses EPC capture 
technology.  EPC = endothelial progenitor cell.  Copyright © 2010 American College of Cardiology 
Foundation.  Reproduced with permission from (Garg and Serruys 2010).  
 
3.4.3.2. Functional Peptide Incorporation for Endothelialization  
 
Other molecules like synthetic functional peptides, arginine-glycine-aspartic acid 
(RGD) and peptide amphiphile (PA) nanofibers also harbor the potential to augment 
the rate of re-endothelialization on stent surfaces.  RGD is an integrin-binding motif, 
and binds to the αvβ3 integrin on endothelial cells[95, 96].  However, αvβ3 is also 
found on platelets, which could increase the risk of thrombosis.  Recently, a more 
specific ligand-binding sequence, RRETAWA, was propounded as an alternative to 
RGD as it binds to α5β1 integrin, which is present on endothelial cells but not 
platelets[97].  PA nanofibers were also evaluated as promising platforms on which to 
promote endothelial cell adhesion and proliferation by mimicking the extracellular 
matrix (Figure 3.8)[98].  PA nanofibers are self-assembling materials made up of 3 
domains: a hydrophobic alkyl chain covalently attached to a peptide segment, and a 
customizable bioactive epitope[99].  PA nanofibers can be functionalized with NO-
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releasing molecules[100] and VEGF[101] to promote and maintain endothelial cell 
growth and integrity.  The inhibition of platelet activation is also another way of 
achieving anti-thrombogenicity[86]. Glycoprotein (GP) IIb/IIIa is an integrin complex 
found on platelets, and plays a role in platelet activation[102].  It has been shown that 
incorporation of GP IIb/IIIa inhibitors onto stents can prevent platelet aggregation and 
thrombosis[103, 104], highlighting its potential use in stents.                     
 
 
Figure 3.8. Promoting endothelial cell adhesion and proliferation using a mixture of two PA 
nanofibers.  (a) Skeletal formula of Dopa-PA and REDV-PA.  TEM (b) and SEM (c) images of PA 
nanofibers.  (d) PA nanofiber coated on stainless steel promotes endothelial cell adhesion and 
proliferation.  Catechol groups of Dopa residues adsorb onto the metal surface, while the REDV 
bioactive epitope interact with endothelial cells.  (e) Circular dichroism spectroscopy of the PA 
nanofiber matrix.  (f) Rheology studies reveal gelation due to nanofibrous network formation by the 
mixture of REDV-PA and Dopa-PA at physiological pH.  PA = peptide amphiphile; Dopa = 3,4-
dihydroxyphenyl-L-alanine; TEM = transmission electron microscopy; SEM = scanning electron 
microscopy. Copyright © 2011 Elsevier Ltd.  Reproduced with permission from (Ceylan et al., 2011). 
 
3.4.4. Biofunctionalization via Nitric Oxide Integration   
 
Nitric oxide (NO) functions as a signaling molecule in biological organisms, and 
plays a significant role in maintaining homeostasis in the cardiovascular system.  NO 
is formed from l-arginine via NO synthase, which induces cyclic guanosine 
monophosphate (cGMP)-dependent vasodilation and inhibits vascular smooth muscle 
cell proliferation as well as preventing platelet adhesion and aggregation[105]. 
Conversely, a deficiency of NO is associated with in-stent restenosis and 
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thrombosis[106].  However, due to the short half-life of NO (2 to 5 seconds), NO 
precursors, donors and even gene encoding for NO production are often used to 
confer controlled and sustained release localized in a biofunctionalized polymer.  
Sodium nitroprusside (SNP), a NO donor, was incorporated into a polyurethane 
polymer, which was then subsequently coated onto a stent, and inhibited neointimal 
thickening in a porcine model[107].  Linsidomine (SIN-1) is a NO donor, and it was 
shown to inhibit platelet aggregation on metal stents[108].  Another NO donor, S-
nitrosoglutathione (GSNO) was similarly incorporated into a polymer and displayed 
anti-thrombogenic and anti-proliferative effects[109].  A therapeutic combination of 
NO donors and paclitaxel coated onto stents showed synergistic anti-restenotic 
effects[110].  NO-releasing polymers can also be developed by diazeniumdiolating 
fumed silica, and then incorporating it into a nanocomposite polymer.  These 
diazeniumdioated particles function as a reservoir for NO molecules, releasing it upon 
contact with physiological fluids[111].            
 
3.4.5. Localized Drug Delivery & Targeted Gene Therapy using 
Nanoparticles   
 
Using a novel cation electrodeposition coating technology, a bioabsorbable polymeric 
nanoparticle-eluting stent was developed to encapsulate therapeutic agents for the 
purpose of sustained intracytoplasmic release (Figure 3.9)[112].  It has also been 
reported that tagging endothelial cells with magnetic nanoparticles, and subsequently 
guiding them to stents using magnetic field gradients expedited the process of cell 
mobilization and re-endothelialization[113]. Furthermore, magnetic nanoparticles 
could also be loaded with paclitaxel and magnetically guided to the stented area for 
enhanced drug localization and delivery[114].           
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Figure 3.9.  Nanoparticle-eluting stents.  A Light and fluorescence microscopy of FITC encapsulated 
in nanoparticles via cationic electrodeposition coating technology. Scale bar = 1 mm.  B SEM of 
nanoparticle eluting stent. Low magnification on left, scale bar = 1 µm.  High magnification on right, 
scale bar = 100 nm.  C Release profile of nanoparticle-eluting stent.  FITC = fluorescein-
isothiocyanate; SEM = scanning electron microscopy.  Copyright © 2009 American College of 
Cardiology Foundation.  Reproduced with permission from (Nakano et al., 2009). 
 
It has been demonstrated that gene therapy holds potential promise for treating in-
stent restenosis. A study reported that local gene delivery was achieved using 
dodecylated chitosan-plasmid DNA nanoparticles coated onto stents[115]. Gene-
eluting stents have also been experimentally developed via the attachment of an 
adenovirus expressing inducible nitric oxide synthase (iNOS) on the stent surface to 
mitigate neointimal hyperplasia following stent injury (Figure 3.10)[116, 117]. iNOS 
is a potent inhibitor of smooth muscle cell proliferation and migration, platelet 
activation, and extracellular matrix production, and was shown to be effective in 
mitigating in-stent restenosis[118]. Furthermore, evidence suggests that a gene-
eluting stent with plasmid DNA encoding for human vascular endothelial growth 
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factor (VEGF-2) could reduce neointimal hyperplasia while simultaneously 
enhancing re-endothelialization[119].  Endothelial nitric oxide synthase (eNOS) 
catalyzes the production of NO from l-arginine.  Adenovirus-mediated gene delivery 
of eNOS to the vasculature was shown to inhibit restenosis and augment re-
endothelialization[120].  Lipopolyplexes with eNOS-expressing plasmid DNA were 
immobilized onto metal stent struts using a mixture of type B gelatin coating and 
PLGA, and this method was shown to prevent in-stent restenosis by inhibiting 
vascular smooth muscle cell proliferation[121].  An in vivo study using a non-viral 
method of encapsulating eNOS in liposomes also showed accelerated re-
endothelialization of the blood vessel wall[122]. In addition, liposomal formulations 
of eNOS were demonstrated to be effective against smooth muscle cell 
proliferation[123].  In terms of targeting drug delivery to specific cells, this aspect of 
nano-encapsulation of pharmacologic agents appear most promising in 
nanotechnology-based stent coatings.                   
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Figure 3.10.  Gene-eluting stents.  (A) PAA-BP synthesis with the corresponding peaks (B and C) 
using NMR spectroscopy to show chemical shifts, with peak changes indicating bisphosphonate 
addition.  XPS detection of phosphorus (D) and iron (E).  PAA-BP modified steel surface shows P(2p) 
and persistent Fe(2p) signals.  (F) Adenovirus containing iNOS gene tethered on PAA-BP modified 
metal surface. PAA-BP = polyallylamine bisphoaphonate; NMR = nuclear magnetic resonance; XPS = 
x-ray photoelectron spectroscopy; SPDP = N-succinimidyl 3-(2-pyridyldithio) propionate; iNOS = 
inducible nitric oxide synthase.  Copyright © 2005 The National Academy of Sciences of the USA.  
Reproduced with permission from (Fishbein at al., 2006). 
 
3.5. Inception to Actualization 
 
3.5.1. In Vitro Chemical & Engineering Tests 
 
After initial research and development (R&D), robust test have to be conducted prior 
to clinical use and FDA-approval.  The benchmark to use would be to closely adhere 
to tests that were conducted on FDA-approved devices.  For coronary stents, in vitro 
engineering tests comprises of 2 main parts: stent material specification conformance 
testing, and stent integrity / dimensional and functional attributes.  Stent material 
specification conformance testing encompasses: material characterization, surface 
contamination, mechanical properties (tensile strength and elongation), stent 
corrosion resistance, fretting corrosion, and galvanic corrosion.  Stent integrity testing 
includes: stent dimensional verification, percent surface area, length changes upon 
expansion (foreshortening), stent expansion uniformity, stent recoil, stent integrity / 
crack initiation, radial stiffness and radial strength, stent expansion / coating 
evaluation, coating stress analysis, finite element analysis, accelerated fatigue testing, 
magnetic resonance imaging (MRI) safety and compatibility, and radiopacity.  A 
summary and description of these tests can be found on Table 3.2. 
 
Table 3.2. In vitro engineering tests 
In Vitro Engineering Tests Description 
Stent Material Specification Conformance Testing 
Material Characterization  • Chemical analysis 
• Meet specifications for ASTM F-138 
Surface Contamination • SEM analysis to detect surface contaminants or 
impurities  
Mechanical Properties: Tensile Strength & 
Elongation  
• Determine yield strength, ultimate tensile strength, and 
percent elongation of tubing sizes used to fabricate 
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stent  
• Conform to ASTM F562 
Stent Corrosion Resistance  • Conform to ASTM F2129 “Standard Test Method for 
Conducting Cyclic Potentiodynamic Measurements to 
Determine the Corrosion Susceptibility of Small Implant 
Devices” 
• Test conducted to evaluate relative susceptibility to 
pitting/crevice corrosion using corrosion techniques 
outlined in ASTM F746 and using sample preparation 
techniques conforming to ASTM F2129 
Fretting Corrosion  • Post fatigue testing for overlapped stents to determine 
potential for fretting corrosion  
Galvanic Corrosion • Different stents are overlapped with one another to 
determine potential for galvanic corrosion   
Stent Integrity Testing / Dimensional & Functional Attributes 
Stent Dimensional Verification  • Measure and optically inspect stent dimensions 
correspond to product specifications  
Percent Surface Area  • Calculated using stent nominal dimensional values and 
is based on ratio of stent area to area of vessel  
Length Changes upon Expansion: Foreshortening  • Percentage change in stent length measured to 
determine amount of length reduction the stent may 
experience after expansion to the nominal inflation 
pressure 
• Foreshortening is calculated by subtracting expanded 
length from the length while crimped on catheter  
Stent Expansion Uniformity  • Units are inflated to nominal inflation pressure, balloon 
deflated, and measurements of stent diameter taken 
along expanded stent length 
• Product must be within 10% of the labeled diameter at 
nominal pressure along stent length  
Stent Recoil • To quantify the amount of stent diameter reduction 
experience after removal of inflated balloon to correlate 
this parameter to the recommended sizing procedures 
• System is inflated to rated burst pressure (RBP) and 
balloon removed 
• Recoil calculated by subtracting internal diameter after 
balloon deflation from internal stent diameter still 
mounted on inflated balloon   
Stent Integrity/Crack Initiation   • To determine if plastic deformation experienced by the 
stent when expanded from compressed profile to the 
final maximum deployed diameter can produce crack 
initiation of the stent  
• Stents are deployed to their largest possible diameters 
by inflating each delivery system to nominal plus 0.5 
mm 
• Stents are examined under magnification for potential 
cracks  
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Radial Stiffness & Radial Strength  • Determine stent resistance to radial load  
• Stents deployed to nominal stent diameter and placed 
in radial crush tester  
Stent Expansion/Coating Evaluation  • Qualitative comparison of coating in pre-deployed, 
deployed to nominal, and deployed to maximum 
diameter conditions using microscopy  
• Qualitative comparison of coating integrity is performed 
pre- and post tracking through a tortuous anatomy 
using microscopy and SEM    
Coating Stress Analysis  • Using finite element analysis (FEA)  
• Addition of coating to stent should not change critical 
location of stresses during expansion and during in 
vivo loading  
• Critical stress location within coating should be in the 
same location as found on bare (uncoated) stent  
Finite Element Analysis (FEA)  • Analysis of bare stent, when expanded beyond 
nominal maximum diameter, to ensure that stent would 
not fail due to fatigue (as determined by modified 
Goodman analysis) 
• FEA evaluated stent designs “deployed in a straight or 
bend configuration” when subjected to loading 
conditions expected in coronary arteries  
• Fatigue failure should not occur over 400 million cycles 
of loading  
Accelerated Fatigue Testing  • 500 million cycles conducted on stent, when expanded 
beyond nominal maximum diameter, to demonstrate 
ability of stent to maintain structural integrity  
• SEM used to assess surface of stent to check for 
fatigue-induced surface defects  
• Accelerated in vivo testing (up to 400 million cycles) 
when expanded beyond nominal diameter  
Magnetic Resonance Imaging (MRI) Safety & 
Compatibility  
• Static magnetic field of 3-Tesla  
• Spatial gradient field of 525 Guass/cm 
• Maximum whole-body averaged specific absorption 
rate (SAR) of 2 W/kg for 20 minutes of scanning  
• Stent temperature rise should be less than 0.5 °C at a 
maximum whole body averaged SAR of 2 W/kg for 20 
minutes of MR scanning in a 3-Tesla MR scanner  
• Stent should not move or migrate when exposed to MR 
scanning immediately post-implantation  
• Determine image artifact extension from device/lumen 
centerline when scanned in non-clinical testing using 3-
Tesla MR system with a send-receive RF body coil  
Radiopacity  • Addition of coating should not add or detract from the 
radiopacity of stent  
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If a DES is being developed, further tests regarding the polymer matrix coating and 
drug release kinetics would have to be ascertained as well.  Coating characterization 
test generally involves: material analysis of polymer, chemical analysis of polymer, 
chemical analysis of drug, total drug content, dose density, drug content along stent 
length, total drug-related substances, coating thickness, coating uniformity / 
reproducibility, in vitro drug elution, and particulates (Table 3.3).  Chemistry, 
manufacturing, and controls (CMC) testing would have to be done as well.  This 
involves: material analysis of polymer, drug identity, drug content / impurities, drug 
content uniformity, residual solvents, in vitro elution, and particulates (Table 3.4). 
 
Table 3.3. Coating characterization test 
Coating Characterization Tests Description  
Material Analysis – Polymer  • Testing of polymer components to ensure conformity to 
raw materials specifications and incoming inspection 
procedures  
Chemical Analysis – Polymer  • Appropriate assays conducted to determine Mw, Mn, 
polydispersity, monomer content, presence/formation 
of oligomers & free monomers  
Chemical Analysis – Drug  • Drug substance tested to ensure conformity to 
incoming Certificate of Analysis  
Total Drug Content • Quantitatively determine total amount of drug 
substance on stent  
Dose Density  • Dose per unit area is calculated  
Drug Content along Stent Length  • Characterize uniformity of distribution of drug along 
length of stent  
Total Drug Related Substances  • Quantitatively determine type and amount of impurities 
and degradation products on stent  
Coating Thickness • Measure thickness of coating on stent  
Coating Uniformity/Reproducibility  • Determine coating uniformity and reproducibility from 
stent to stent and from batch to batch  
In Vitro Elution  • Measure release kinetics of drug  
Particulates • Determine particulate levels after stent deployment  
• Must be within USP <788> specification for small 
volume injections  
 
Table 3.4. Chemistry, Manufacturing & Controls (CMC) Testing 
Chemistry, Manufacturing, & Controls (CMC) Testing  Description  
Material Analysis – Polymer  • Polymers tested to ensure conformity to specifications 
Drug Identity  • Verify identity of drug substance 
Drug Content/Impurities  • Quantitatively verify amount of drug and types of 
impurities on stent 
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Drug Content Uniformity  • Multiple stents are assayed to verify uniformity of drug 
content between individual stents 
Residual Solvents  • Verify that residual levels of solvents used in 
manufacturing process are below acceptable limits 
established for finished goods release   
In Vitro Elution  • Measure in vitro release profile of drug on stent  
• Specification based on elution characteristics of stents 
evaluated in clinical investigation  
Particulates  • Particulate levels are monitored to verify that they 
remain below acceptable levels as established in 
product specifications  
 
Perhaps the most important aspect for any medical devices before animal implantation 
studies would be to assess its biocompatibility.  In addition, it has to conform to the 
industry standard of ISO 10993.  A battery of tests have to be conducted, which 
include: cytotoxicity (L929 MEM elution)/part 5, cytotoxicity (direct contact)/part 5, 
sensitization (guinea pig maximization)/part 10, intracutaneous reactivity/part 10, 
acute systemic toxicity/part 11, material-mediated pyrogenicity (rabbit)/part 11, 13-
week systemic toxicity following subcutaneous implantation in rats/part 6 and 11, 
ames mutagenicity/part 3, in vitro mouse lymphoma/part 3, in vivo mouse 
micronucleus/part 3, hemolysis (direct contact)/part 4, hemolysis (extract 
method)/part 4, and complement activation (C3a and SC5b-9)/part 4.  Further 
supportive analytical chemistry tests include chemical characterization of extractables 
via ICP analysis, and residuals and leachables.  A description of these tests can be 
found on Table 3.5. 
 
Table 3.5. Biocompatibility Tests 
Test / ISO 10993 Part No. Description  
Cytotoxicity (L929 MEM Elution) / Part 5 • Determines cytotoxic effect of extracts of the test 
device using different extracting media and conditions 
• Extracts are transferred to cell layer and incubated  
• Malformation, degeneration and lysis of cells observed 
under microscope  
Cytotoxicity (Direct Contact) / Part 5 • Recommended for low density materials  
• Test material is placed directly onto cells and 
incubated in suitable condition  
• Leachable chemicals from test materials can diffuse 
into culture medium during incubation and make 
contact directly with cell layer  
• The chemicals released are concluded to be cytotoxic 
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if malformation, degeneration and lysis of cells are 
observed around the test material  
Sensitization (Guinea Pig Maximization) / Part 10 • Intradermal injection conducted on guinea pigs  
• This is to determine if device causes a delayed dermal 
contact sensitization reaction  
Intracutaneous Reactivity / Part 10 • To determine tissue reaction to extracts made from the 
device 
• Used when irritation tests are inappropriate for the 
device; e.g. devices having blood or compromised 
tissue contact  
Acute Systemic Toxicity / Part 11 • Evaluates potential adverse effects of medical device 
on the body’s organs and tissues that are remote from 
the site of contact  
• There are 4 categories: acute (24 hours), subacute (14 
to 28 days), subchronic (90 days or 10% of animal 
lifespan), and chronic (anything longer) 
Material-Mediated Pyrogenicity (Rabbit) / Part 11 • Comprises of administering extracts intravenously into 
rabbits and monitoring their rectal temperatures over 
the course of several hours  
• A significant rise in temperature indicates presence of 
pyrogens  
13-week Systemic Toxicity following Subcutaneous 
Implantation in Rats / Part 6 and 11 
• Determines the effects after implantation of 
biomaterials intended for use in medical devices 
Ames Mutagenicity / Part 3 • Determines the potential mutagenic activity of an 
extract from a medical devices/material/chemical  
• Test is performed as part of the genotoxicity battery of 
tests to determine if leacheables from a medical 
device/material or chemical are mutagenic   
In vitro Mouse Lymphoma / Part 3 • Detects mutations at the thymidine kinase locus 
caused by base pair changes, frameshift and small 
deletions  
In vivo Mouse Micronucleus / Part 3 • To test for genotoxic compounds 
• Increase in frequency of micronucleated polychromatic 
erythrocytes would indicate chromosomal damage  
Hemolysis (Direct Contact) Part 4 • Assesses thrombosis, coagulation, platelets and 
platelet functions, hematology and immunology  
Hemolysis (Extract Method) / Part 4 • Assesses thrombosis, coagulation, platelets and 
platelet functions, hematology and immunology 
Complement Activation (C3a and SC5b-9) / Part 4 • Exposure of serum to a test sample results in 
production of these fragments, which can be 
characterized quantitatively under standard conditions  
Supportive Analytical Chemistry Tests 
Chemical Characterization (Extractables – ICP 
Analysis) 
 
Chemical Characterization (Residuals and 
Leachables) 
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3.5.2. Animal Models 
 
Animal model studies are an integral part of the R&D process before the medical 
device in question can be brought to clinical trials (Figure 3.11).  The type of animal 
to be used largely depends on how similar its biology is to humans, and how 
accurately its data can be extrapolated to humans.  For coronary stents, the use of pigs 
is the most widely studied animal model, and all FDA-approved stents have used pigs 
as its definitive animal model (Table 3.6).  A plethora of animal studies pertaining to 
stents have been conducted, and they are generally classified into small animals 
studies, and large animal studies.  Small animal studies tend to be preliminary studies 
conducted to obtain the necessary data and endpoints before progressing into large 
animal studies.  Some examples of small animal studies include rats / mice, and 
rabbits.  Large animal studies include pigs, dogs, sheep, and non-human primates.  
Table 3.7 and Table 3.8 provide a comparison between the different biological 
characteristic and responses to stent implantation between various animal models. 
 
Table 3.6. Animal (porcine) studies in FDA-approved drug-eluting stents 
Manufacture
r 
Model Date 
Approved 
Animals Vesse
ls 
Stent 
Dimensions 
(mm) 
Time 
(days) 
Endpoints 
Cordis CYPHER 24 Apr 
2003 
• Yucatan 
Mini-
swine 
• Domesti
c swine  
• LAD 
• LCX 
• RCA 
Diameter: 
• 3 
Lengths: 
• 8, 18 
1, 3, 
30, 90, 
180 
• Drug release kinetics 
(evaluated in hours to 
a few weeks) 
• Arterial & systemic 
drug levels  
• Histological & histo-
morphometric 
evaluations coupled 
with angiography 
• Chronic vascular 
response & acute 
delivery  
• Evaluation of re-
endothelialization by 
SEM, TEM & 
immunohistochemistr
y 
• Dose response 
relationship for 
various SES 
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• Evaluation of high-
dose SES  
Medtronic 
Vascular 
Endeavor 1 Feb 
2008 
• Domesti
c swine  
• Juvenile 
Yorkshir
e swine  
• Yucatan 
Mini-
swine 
• LAD 
• LCX 
• RCA 
Diameters:  
• 2.25, 2.5, 
3.0, 3.5, 
4.0 
Lengths: 
• 8.0, 12.0, 
15, 18 
1, 2, 3, 
5, 7, 
10, 11, 
14, 28, 
90, 
180 
• Drug release kinetics 
(evaluated in hours to 
a few weeks)   
• Arterial & systemic 
drug levels  
• Histological & 
histomorphometric 
evaluation 
• Chronic vascular 
response and acute 
delivery  
• Subacute tissue 
reaction in vessel 
and myocardium  
• Thrombogenicity 
evaluation of stent at 
11 days  
• Angiographic patency  
• Cell proliferation  
Boston 
Scientific  
ION 22 Apr 
2011 
• Porcine 
• Rabbit 
(Iliac 
artery) 
• LAD 
• LCX 
• RCA 
• Iliac 
arter
y 
Diameters: 
• 2.5, 2.75, 
3.0, 4.0 
Lengths: 
• 8, 12 
10, 30, 
45, 60, 
90, 
180, 
270 
• Establish safety  
• Mortality, 
morphology, 
morphometry, 
myocardial effects  
• Drug release kinetics  
Boston 
Scientific  
PROMU
S 
22 Nov 
2011 
Swine  • LAD 
• LCX 
• RCA 
Diameters: 
• 3.0, 3.5,  
Lengths: 
• 8, 12 
28, 90, 
180, 2 
years 
• Drug release kinetics 
(evaluated in hours to 
a few weeks) 
• Arterial & systemic 
drug levels 
• Effects of high 
dosage drug on 
platelet function  
• Morbidity, mortality, 
stent thrombosis, MI 
• Angiographic vessel 
patency  
• Visual fracture 
analysis 
• Histological & 
histomorphometric 
evaluation  
• Acute device 
handling & 
deliverability  
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• Chronic vascular 
response 
• Angiography  
• Degree of re-
endothelialization 
using SEM 
Abbott 
Vascular  
XIENCE 
V 
2 Jul 2008 • Farm 
swine 
• New 
Zealand 
white 
rabbit 
(iliac 
artery) 
• Yucatan 
swine 
• LAD 
• LCX 
• RCA 
• Iliac 
arter
y 
Diameters: 
• 2.5, 3.0 
Lengths: 
• 8, 12  
28, 90, 
180, 
365 
• Drug release kinetics 
(evaluated in hours to 
a few weeks) 
• Arterial & systemic 
drug levels  
• Angiography 
• Histological & 
histomorphometric 
evaluation  
• Degree of 
endothelialization 
using SEM 
• Acute delivery 
• Chronic vascular 
response  
• Evaluation of polymer 
safety  
Abbott 
Vascular  
XIENCE 
PRIME  
1 Nov 
2011 
• Farm 
swine 
• Yucatan 
swine  
• LAD 
• LCX 
• RCA 
Diameters: 
• 3 
Lengths: 
• 12  
28, 
180, 
240, 
300 
• Drug release kinetics 
(evaluated in hours to 
a few weeks) 
• Chronic vascular 
response 
• Quantitative coronary 
angiography 
• Histological & 
histomorphometric 
evaluation  
• Degree of 
endothelialization 
using SEM  
Bio-
compatibles 
Cardiovascu
lar Inc. 
Bio-
divYsio 
29 Sep 
2000 
Not stated Not 
stated 
Diameters: 
• 3.0, 3.5, 
4.0 
Lengths: 
• 15.0  
Short 
term:  
1 – 5 
days 
Long 
term: 
1, 3, 6 
month
s 
 
• Early and late patency 
rates  
• Biological response of 
vessel to stent  
• Ability to deliver hand 
crimped stents using 
a variety of balloon 
catheters  
• Histological and 
pathological studies  
Boston TAXUS 13 July Not stated Not Diameters: Not Not stated 
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Scientific Liberté 
Long 
2009 stated • 2.75, 3.0, 
3.50, 4.0 
Lengths:  
• 38 
stated 
Boston 
Scientific 
TAXUS 
Liberté 
Atom 
21 May 
2009 
Not stated Not 
stated 
Diameters: 
• 2.5 
Lengths: 
• 8, 12, 16, 
20, 24, 28, 
32 
Not 
stated 
Not stated  
Abbott 
Vascular  
XIENCE 
nano 
24 May 
2011 
Not stated Not 
stated 
Diameters: 
• 2.25 
Lengths 
• 8, 12 
Not 
stated 
Not stated 
Medtronic Resolute 17 Feb 
2012 
• Domesti
c Farm 
Swine 
• Yucatan 
Mini 
Swine 
•  
Not 
stated 
Diameters: 
• 2.25, 2.5, 
2.75, 3, 
3.5, 
  
 
Table 3.7. Comparing pigs and humans.  
Stages  Pig Human 
Platelet aggregation, fibrin 
deposition, thrombus formation at 
injury site  
0 – 14 days  0 – 30 days  
Elastic and vasotonic recoil 0 – 3 days  0 – 3 days  
Inflammation  0 – 14 days  0 – 30 days  
Proliferation: re-
endothelialization, smooth 
muscle cell formation, 
extracellular matrix production  
3 – 28 days  14 days – 6 months  
Arterial remodeling  14 – 90 days  2 months – 3 years  
 
Table 3.8. Comparison of different animal models. 
Animal Model Animal Type  Vessel Advantages  Disadvantages  
Rat/Mouse Small Aorta  • Low cost 
• Availability  
• Reduced ethical 
concerns  
• Well-defined genetic 
characterization  
• Transgenic and gene 
knock-out mice   
• Lack efficacy in predicting 
restenosis in humans 
• Little thrombus formation  
• Neointimal hyperplasia 
bears little resemblance to 
human pathology 
specimens 
• Vessels less prone to 
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injury compared to 
humans 
• Only morphometric 
analysis can be 
conducted due to small 
size; no angiographic 
endpoints    
Rabbit  Small Iliac artery  • Low cost  
• First animal studies 
regarding DES were 
used in rabbits  
• Complete 
endothelialization occurs 
after 21 days 
• Flow dynamics of rabbit 
iliac artery similar to pig 
coronary artery 
• Readily susceptible to 
dietary-induced 
hypercholesterolemia; 
useful as atherosclerosis 
model    
• Different vessel 
physiology in iliac artery 
and coronary artery; 
hence not a good 
approximation 
• Elastic nature of iliac 
arteries less prone to 
injury compared to 
muscular coronary 
arteries   
Pig Large Coronary 
artery 
• Accepted as the most 
appropriate model for 
preclinical evaluation  
• Used for stent device 
approval by FDA  
• Coronary anatomy, 
physiology, 
pathophysiology mimics 
humans  
• High cost  
• Inconvenience due to 
large size  
• Highly susceptible to 
inflammation with 
implanted devices  
• Neointimal growth peaks 
at 1 month post-stenting, 
compared to 6 months in 
humans  
Dog Large  Coronary / 
peripheral 
arteries  
• Low cost 
• Availability  
• Ease of handling  
• Resistant to neointimal 
formation  
• High fibrinolytic activity 
and coagulation system 
distinctive from that of 
humans  
• Fails to predict thrombotic 
complications in humans  
Sheep Large  Coronary 
artery  
• Docile  
• Similar fibrinolytic and 
coagulation system to 
humans  
• Similar coronary anatomy 
to humans  
• Not many studies done  
Non-human Large  Coronary • Phylogenetic proximity  • Ethical considerations 
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primates  artery  • Very similar to humans  • High cost  
• Very few studies 
conducted  
 
Although not strictly a requirement prior to FDA-approval, small transgenic animal 
models can serve as useful tools in studying atherosclerosis.  For example, the 
Watanabe Heritable Hyperlipidaemic (WHHL) rabbit lack receptors for low density 
lipoprotein (LDL), and therefore have a high level of serum LDL, thus serving as a 
useful model for familial hypercholesterolaemia in humans[124].  Also, 
Apolipoprotein E (apoE) deficient mouse is a particularly useful model for studying 
atherosclerosis, as they are bred to spontaneously develop atherosclerotic 
lesions[125].        
 
 
Figure 3.11.  Inception to Actualization. Stents have to undergo rigorous testing before being 
approved for clinical use.  a Newly developed coronary stent. b Mechanical and in vitro engineering 
tests. c in vitro chemical tests. d in vivo animal studies. e clinical trials in humans                                                                 
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3.5.3. Clinical Trials in Humans  
 
A crucial step in bringing a product from bench to bedside is conducting clinical 
trials.  This is also where most products fail to gain regulatory approval for clinical 
use.  For stents, the main clinical endpoints to be evaluated are: target lesion 
revascularization (TLR), target vessel revascularization (TVR), target vessel failure 
(TVF), major adverse cardiac events (MACE), stent thrombosis, late thrombosis, 
subacute closure, cerebrovascular accident, major bleeding complications, major 
hemorrhagic vascular complication.  Table 3.9 shows the clinical trials of various 
FDA-approved stents.    
 
Table 3.9. Clinical trials in humans for FDA-approved drug-eluting stents 
Stent Trial Clinical Endpoints  
CYPHER • First-In-Man (Feasibility) 
(n=45) 
• RAVEL (Supportive) (n=238) 
• SIRIUS (Pivotal) (n=1058) 
Target lesion revascularization (TLR) 
Repeat percutaneous or surgical revascularization for a lesion 
anywhere within the stent or the  5 mm borders proximal or distal 
to the stent  
  
Target vessel revascularization (TVR) 
Revascularization when a patient experiences a recurrence of 
symptoms and the lesion is somewhere along the length of the 
previously treated vessel 
 
Target vessel failure (TVF) 
TVR, myocardial infarction (MI) or cardiac death that could not be 
clearly attributed to a vessel other than the target vessel. A 
combination of TVR and MACE   
 
Major adverse cardiac events (MACE) 
A composite endpoint comprised of death, Q-wave or WHO-
defined non Q-wave MI, or TVR 
 
Stent thrombosis 
A 30-day endpoint including subacute closure or unexplained 
death or Q-wave MI 
 
Late thrombosis 
MI occurring >30 days after the index procedure and attributable to 
the target vessel with angiographic documentation or thrombus or 
total occlusion at the target site freedom from an interim 
revascularization of the target vessel 
 
Endeavor • ENDEAVOR I (n=100) 
• ENDEAVOR II (n=1197) 
• ENDEAVOR III (n=436) 
• ENDEAVOR IV (n=1548) 
ION • PERSEUS Workhorse 
(n=1262) 
• PERSEUS Small Vessel 
(n=224) 
PROMUS • PLATINUM Workhorse 
(n=1530) 
• PLATINUM Small Vessel 
(n=94) 
• PLATINUM Pharmacokinetics 
(n=22) 
• PLATINUM Quantitative 
Coronary Angiography 
(n=100) 
TAXUS 
Liberté 
Long 
• TAXUS ATLAS Long (n=295) 
TAXUS 
Liberté 
Atom  
• TAXUS ATLAS Small Vessel 
(n=261) 
XIENCE V • SPIRIT FIRST (n=60) 
• SPIRIT II (n=300) 
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• SPIRIT III RCT (n=1002) 
• SPIRIT III Registries (n=168) 
Subacute closure 
Abrupt closure that occurs after the index procedure is completed 
and before the 30-day follow-up endpoint  
 
Cerebrovascular accident 
Sudden onset of vertigo, numbness, aphasia, or dysarthria due to 
vascular lesions of the brain such as hemorrhage, embolism, 
thrombosis, or rupturing aneurysm, that persists >24 hours 
 
Major bleeding complications 
Bleeding requiring transfusions or associated with hemoglobin 
drop >5 g 
 
Major hemorrhagic vascular complication 
Hematoma at access site >5 cm; false aneurysm; AV fistula; 
retroperitoneal bleed; peripheral ischemia/nerve injury; any 
transfusion required is reported as a vascular complication unless 
clinical indication clearly other than catheterization complication; 
and vascular surgical repair  
XIENCE 
PRIME  
• SPIRIT PRIME (n=529) 
XIENCE 
nano 
• SPIRIT Small Vessel (n=150) 
BiodivYsio • DISTINCT (n=686) 
Resolute 
Integrity 
• RESOLUTE US Trial (n=1402) 
• RESOLUTE AC (n=1140) 
• RESOLUTE Int (n=2349) 
• RESOLUTE FIM (n=139) 
• RESOLUTE Japan (n=100) 
 
3.6. Future Directions and Concluding Remarks   
 
Around one million stenting procedures are done each year in the USA, and a recent 
report by Global Industry Analysts, Inc. valued the coronary stent market to exceed 
US $13.0 billion by 2019[126].  Taking into account that considerable resources are 
needed for bringing stents from the experimental phase, to clinical trials and FDA-
approval, it is therefore hardly surprising that major industry players like Boston 
Scientific and Abbott Vascular continue to dominate the stent market.  Although the 
introduction of stents has revolutionized interventional cardiology, much still remains 
to be improved upon.   
 
The popularity of DES has largely overshadowed the use of BMS, due to its anti-
restenotic effects.  The BiodivYsio™ (Biocompatibles Cardiovascular Inc) is the only 
FDA-approved phosphorylcholine-coated stent, without any drug formulation[127].   
More clinical studies investigating the potential of coating BMS with a biocompatible 
polymer without any pharmacologic agents should be conducted.  This could well 
form a viable alternative “middle ground” for patients who might develop adverse 
reaction to drugs seen in DES.  Although the idea of having a plain polymer coating 
without any drug formulations is appealing, this concept has been largely neglected 
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due to the popularity of DES.  The question of using non-biodegradable or 
biodegradable polymers for coating medical devices or implants is still open to 
debate.  Interestingly, there is also evidence supporting the creation of 
nanotopograhpy or nanowires on the metal struts themselves, using radio frequency 
plasma surface texturing, which enhanced endothelialization[128, 129]. Recent 
toxicology studies of metal hip implants reported the leaching of metal nanoparticles 
into the bloodstream, causing inflammation and in some cases, cancer[130, 131].  
Hence, there are calls for metal hip implants to be coated with non-biodegradable 
polymers to prevent these potentially fatal complications.  Although there is no 
evidence to suggest that metal debris from BMS would cause inflammation or cancer, 
some form of non-biodegradable and biocompatible coating on bare metal should be 
advocated.            
 
Despite the anti-restenotic benefits of DES, the issue which still needs to be addressed 
is the problem of late ST.  The layer of polymer coating that remain even after the 
drug had completely eluted contributed to hypersensitivity and subsequent stent 
thrombosis.  Biodegradable polymer coatings on DES were thus designed to erode in 
tandem with the drug release, essentially leaving behind a BMS.  This was predicated 
on the hypothesis that the initial “DES phase” would prevent restenosis, while the 
subsequent “BMS phase” would circumvent the problem of late ST.  However, it still 
remains to be seen if this is indeed a viable method, as the current range of FDA-
approved DES are coated with non-biodegradable (durable) polymers.  Hence, it is of 
paramount importance to have a highly biocompatible polymer that would not only 
serve as a protective coating against the stent, but would not itself elicit an 
immunological response from the body. 
 
Apart from a biocompatible and haemocompatible polymer, the material itself has to 
be a favorable platform on which endothelial cells can adhere to and proliferate on.  
To increase the probability of capturing endothelial cells, specific antibodies and 
peptides can be incorporated into the polymer.  This would minimize the risk of 
proliferation of vascular smooth muscle cells that can cause restenosis.  The 
importance of NO for maintaining a healthy endothelium must be emphasized.  
Developing NO-eluting polymers could well pave the way for the next generation of 
stent coatings.  Furthermore, localized delivery of pharmacologic agents using 
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nanoparticles would mean a higher therapeutic index; achieving the maximum 
therapeutic benefit using the minimum dosage to minimize side effects. 
 
The topic of nanotechnology has gained considerable foothold in the basic sciences as 
well as applied and clinical medical research.  This is evident not only in the 
proliferation of various research journals dedicated to the subject of nanotechnology, 
but also the volume and rate at which they are published[132].  Taking a “nano” 
perspective allows one to delve deeper into the mechanisms of various problems in 
biology and medicine.  From targeted drug delivery, increased therapeutic index, and 
controlled/sustained drug release, the potential for nanotechnology in stent coatings 
appears promising.  The next challenge in this topic of stent technology would be to 
develop methods that would specifically target the elimination of smooth muscle cell 
proliferation, while encouraging the growth of endothelial cells.  This would perhaps 
involve some form of antibody / functional peptide targeting which would be specific 
for smooth muscle cells but not endothelial cells. Nano-encapsulation of cell-specific 
drugs would also aid in the targeted delivery of pharmacologic agents.  Finally, the 
polymer platform must be one that is highly compatible with biological systems while 
harboring the ability to interface with nanotechnology-based drug delivery systems.           
 
In conclusion, the convergence of biofunctionalized polymers, controlled drug release 
and endothelial progenitor cell capture technology would form the cornerstone of the 
next generation cardiovascular stent coatings, and would be well poised to address the 
current challenges faced today.    
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4.1. Pertaining to Material Preparation and Characterization 
 
4.1.1. Fourier Transform Infrared Spectroscopy (FTIR) 
 
Fourier transform infrared spectroscopy (FTIR) is a method of gathering data of an 
infrared spectrum of absorption of the bonds of atoms within a material[1].  FTIR 
gathers spectral data from a wide spectral range simultaneously, and has made the 
older method of dispersive infrared spectrometers obsolete.  Given the fact that 
different materials have different combinations of atoms, the obtain FTIR spectrum 
can be considered a “molecular fingerprint” unique to that particular material.  Hence, 
FTIR serves to identify unknown samples, and can also be used to detect changes / 
modifications of a sample (Figure 4.1).    
 
 
Figure 4.1. Fourier transform infrared spectroscopy (FTIR). The interferometer and beam splitter 
are the main components of FTIR. Figure reproduced with permission from Creative Commons. 
Copyright © 2013 Creative Commons. 
 
4.1.2. Raman Spectroscopy 
 
Raman spectroscopy is a technique that relies on inelastic scattering of 
monochromatic light, and measures the vibrational, rotational, and other low-
frequency modes in a system (Figure 4.2).  The shift in energy gives information on 
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the vibrational modes of the system, and can also be used to identify materials.  
Raman spectroscopy is a complementary technique to FTIR. If samples are in 
aqueous form, Raman would be a better technique, because in FTIR, water absorbs 
strongly in the IR region.     
 
 
Figure 4.2. Raman spectroscopy.  The main components of a Raman spectrometer system. Figure 
reproduced with permission from Horiba Ltd. Copyright © 2014 Horiba Ltd.  
  
4.1.3. X-Ray Photoelectron Spectroscopy (XPS) 
 
X-ray photoelectron spectroscopy (XPS) is a technique that is used to analyze the 
surface chemistry of materials.  It relies on x-rays that irradiate a surface, and then 
measures the kinetic energy and number of electrons that escape from the top of the 
surface (Figure 4.3).  XPS thus provides information about the elemental composition 
of a surface.  
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Figure 4.3. X-ray photoelectron spectroscopy.  XPS uses x-rays which irradiate a surface, and then 
analyzes information derived from electrons the escape from the surface.  Figure reproduced with 
permission from Creative Commons.  Copyright © 2013 Creative Commons.   
 
4.1.4. Ultraviolet-Visible (UV-Vis) Spectroscopy 
 
Ultraviolet-visible (UV-vis) spectroscopy is a technique that measures the optical 
absorbance of a compound (often in solution) in the UV, visible and near infrared 
(NIR) region (Figure 4.4).  UV-vis can be seen as an opposite to fluorescence 
spectroscopy, as fluorescence spectroscopy is mainly concerned with the transition 
from excited state to ground state, while UV-vis measures transitions from the excited 
state to ground state.  Thus, UV-vis gives complementary information to fluorescence 
spectroscopy.       
 
 
Figure 4.4.  Principles of UV-vis.  UV-vis uses a light beam that is split by a beam splitter that 
measures the optical absorbance of a compound.  Figure reproduced with permission from Creative 
Commons.  Copyright © 2013 Creative Commons.    
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4.1.5. Scanning Electron Microscopy (SEM) 
 
Scanning electron microscopy (SEM) is an imaging technique that utilizes a focused 
beam of electron that scans the surface of the sample to produce very high resolution 
images of a sample (Figure 4.5).  SEM has a large depth of field, and is useful 
producing images of the surfaces of materials.  Non-conductive samples must be 
coated with a thin layer of metal (e.g. gold) with a sputter-coater.  Environmental 
SEM is an alternative method, where sputter-coating is not required.  Field emission 
SEM provides high resolution images in high magnification, providing enhanced 
spatial resolution with minimal sample charging.      
 
 
Figure 4.5. Scanning electron microscopy (SEM). The main components in an SEM. Figure 
reproduced with permission from Creative Commons. Copyright © 2013 Creative Commons. 
 
4.1.6. Transmission Electron Microscopy (TEM) 
 
Transmission electron microscopy (TEM) is an imaging technique, where a beam of 
electron is transmitted through an ultrathin sample (Figure 4.6).  Although TEM can 
deliver a higher magnification level compared to SEM, it has a lower depth of field 
compared to SEM.  Due to the fact that electrons must be transmitted through the 
sample to obtain an image, samples must be microtomed using a diamond knife. 
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Figure 4.6. Transmission electron microscopy (TEM). The main components of a TEM. Figure 
reproduced with permission from Creative Commons. Copyright © 2013 Creative Commons.  
 
4.1.7. Atomic Force Microscopy (AFM) 
 
Atomic force microscopy (AFM) is a type of scanning probe microscopy, which 
provides information about the surface topography of a material (Figure 4.7). There 
are three main imaging modes with regards to the cantilever: contact mode, tapping 
mode, and non-contact mode.  Information obtained from the surface topography of 
the sample would then be constructed into an image by a computer.     
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Figure 4.7. Atomic force microscopy (AFM). Surface topography of a material can be assessed using 
AFM.  Figure reproduced with permission from Creative Commons Copyright © 2013 Creative 
Commons.   
 
4.1.8. Water Contact Angle 
 
The hydrophobicity or hydrophilicity of a material can be assessed by measuring its 
water contact angle (Figure 4.8).  The thermodynamic equilibrium between the three 
phases: liquid phase (L), solid phase (S), and gas phase (G) can be related according 
to the Young’s equation: 
0 = ϒSG – ϒSL – ϒLG cosθc 
 
Where ϒSG is the solid-gas interfacial energy, ϒSL is the solid-liquid interfacial energy, 
ϒLG is the liquid-gas interfacial energy, and cosθc is the equilibrium contact angle. 
Surfaces with a water contact angle greater than 90° is considered hydrophobic, while 
those with water contact angle less than 90° is considered hydrophilic.  In most cases, 
a static sessile drop method is used, and the contact angle is measured using a drop 
shape analyzer (also called a goniometer).      
    
 
Figure 4.8. Water contact angle. The angle at which a droplet of water makes with a surface can be 
used to measure its hydrophobicity or hydrophilicity.  Figure reproduced with permission from 
Creative Commons Copyright © 2013 Creative Commons. 
 
4.1.9. Thromboelastography (TEG) 
 
Thromboelastograpy (TEG) is a method where blood coagulation can be measured in 
real-time.  For testing biomaterials, it provides information on its haemocompatibility.  
4 main parameters are used: r-time, k-time, α-angle, and MA (Figure 4.9).  r-time is 
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reaction time, where it represents initial clot formation.  k-time is the time where a 
certain level of clot strength is achieved.  α-angle is the speed at which fibrin build-up 
occurs.  Maximum amplitude (MA) is the ultimate strength of fibrin clot.   
 
 
 
Figure 4.9. Thromboelastography. The main phases and parameters measured during blood 
coagulation in the TEG system.   
 
4.1.10. Phospholipids and Liposomes 
 
Liposomes are artificially-manufactured spherical particles that have a lipid bilayer.  
The starting block materials for liposome manufacture are often 
phosphatidylethanolamine (PE)- or phosphotidylcholine (PC)-enriched phospholipids.  
A simplified manufacturing procedure is as follows. Dry phospholipids are added to 
water, and placed in a bath sonicator.  This causes swelling of the phospholipid films, 
and the agitation causes it to spontaneously assemble into multilamellar vesicles 
(MLV)[2] (Figure 4.10).  However, in order for it to have therapeutic efficacy, 
unilamellar vesicles (ULV) must be produced. This can be done via an extrusion 
process, whereby the MLV are forced through a porous membrane (using a mini-
extruder) in order to obtain ULV[3] (Figure 4.11 and Figure 4.12).  The ULV would 
then be considered liposomes that can be used for drug delivery.          
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Figure 4.10. The manufacture of liposomes.  Dry phospholipids dissolved in water and sonicated to 
obtain multilamellar vesicles (MLV).  MLV is then extruded to yield unilamellar vesicles (ULV).  
Figure reproduced with permission from Patel S et al., 2006.  Copyright © 2006 Pharmainfo. 
 
 
Figure 4.11. A mini-extruder.  A porous polycarbonate membrane creates ULV from MLV, when a 
solution of MLV is forced through it.  Image courtesy of Avanti Polar Lipids, Inc.  Copyright © 2013 
Avanti Polar Lipids, Inc.    
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Figure 4.12.  The extrusion process.  MLVs are forced through a membrane, which would then create 
ULVs on the other side.  Figure reproduced with permission from Zhu et al., 2007.  Copyright © 2007 
Elsevier B.V. 
 
4.1.11. Zeta Potential 
 
Often used in colloidal systems, zeta potential (ζ) refers to the electric potential 
between the slipping plane and the point of the bulk away from the interface.  Hence, 
zeta potential measures the potential difference between the solvent in which the 
particle is dissolved in (dispersion medium), and the stationary layer of fluid attached 
to the particle (Figure 4.13).  In general, a higher numerical value of zeta potential 
(whether ±) indicates a higher stability of the colloidal system. This means that it has 
a lower tendency to aggregate or coagulate.     
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Figure 4.13. Zeta potential of a particle.  In simple terms, zeta potential measures the potential 
difference between the plane that is furthest away from the particle, to the plane nearest the particle.  
Figure reproduced with permission from Creative Commons.  Copyright © 2013 Creative Commons.   
 
4.1.12. Dynamic Light Scattering (DLS) 
 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy, is a 
method used to determine the size distribution of particles in a solution.  In general, 
smaller particle tend to have a greater fluctuation in its scattering intensity as a 
function of time, compared to larger particles, due to Brownian motion (Figure 4.14).     
 
 
Figure 4.14.  Dynamic light scattering (DLS).  DLS can be used to determine the size of particles, due 
to the phenomenon of Rayleigh scattering.  Figure reproduced with permission from Creative 
Commons.  Copyright © 2013 Creative Commons.       
 
4.1.13. Ellipsometry 
 
Ellipsometry is a method used for determining the thickness of thin films, down to the 
nanometer scale.  The main principles behind it is based on the phenomenon of 
polarized light, and therefore the change in polarization upon reflection would 
indicate its thickness (Figure 4.15).   
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Figure 4.15. Ellipsometry for determining thickness of thin films.  The main principles of 
ellipsometry relies on polarization and reflection.  Figure reproduced with permission from Creative 
Commons.  Copyright © 2013 Creative Commons.  
 
4.1.14. High Performance Liquid Chromatography (HPLC) 
 
High performance liquid chromatography (HPLC) is a method used to separate and 
identify different components of a sample (Figure 4.16 and Figure 4.17).  It relies on 
the principle that different components of the sample would interact differently with 
the adsorbent material in the HPLC system, thereby separating as they flow out of the 
column.  The individual components can then be detected using UV/vis or mass 
spectrometry.   
 
 
 
Figure 4.16. HPLC system. The main components in a HPLC system. Figure reproduced with 
permission from New Mexico State University. Copyright © 2014 New Mexico State University.  
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Figure 4.17. The separation of components.  Adsorbent materials are used in the HPLC system to 
separate individual components of the samples. Figure reproduced with permission from Creative 
Commons. Copyright © 2014 Creative Commons.   
 
 
4.1.15. Instron Tensile Tester  
 
To assess mechanical characteristics of materials, the Instron tensile tester is often 
employed as a multi-purpose machine (Figure 4.18).  Various mechanical engineering 
parameters like tensile strength and compression resistance can be measured. 
 
 
Figure 4.18. Instron Tensile Tester. Various mechanical engineering aspects of a material can be 
tested using this machine.  Figure reproduced with permission from Instron. Copyright © 2014 Instron.  
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4.1.16. Ultrasonic Atomization Spray System 
 
For coating stents with POSS-PCU, an ultrasonic atomization spray system was used 
(Figure 4.19 and Figure 4.20).  In-depth details of optimization and coating was 
described and developed by Farhatnia in our lab (unpublished results).   
 
 
Figure 4.19. Ultrasonic atomization spray system. Coronary stents were spray coated with POSS-
PCU using the system. 
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Figure 4.20. Computer-generated schematics of the spray system.  Multiple layers of ultrathin 
POSS-PCU films can be created using the ultrasonic spray system. 
 
4.2. Pertaining to in vitro Cell Culture 
 
4.2.1. Quantum Dot-Antibody Conjugates 
 
Quantum dots (QD) are semiconductor nanocrystals, and compared to conventional 
fluorophores, QDs are more resistant to photobleaching, and can be used in 
immunofluorescence under confocal microscopy (Figure 4.21).  Quantum dot-
antibody conjugates were manufactured in-house in our lab, and detailed description 
can be found elsewhere[4].  In brief, theses QF-antibody conjugates can be used to 
image cells under confocal microscopy.   
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Figure 4.21. Immunofluorescence. Quantum dots can be used as fluorophores, and cells can be 
imaged under confocal microscopy. Figure reproduced with permission from Leinco Technologies Inc. 
Copyright © 2014 Leinco Technologies Inc. 
 
4.2.2. AlamarBlue® Cell Viability Assay 
 
AlamarBlue is used to measure cell viability[5].  It relies on the reducing power of 
live cells to convert resazurin to resorufin (Figure 4.22).  Resorufin is highly 
fluorescent at 590 nm, and a fluorescence plate reader is used to measure its 
fluorescence, giving an indication of cell viability.   
 
 
Figure 4.22. Alamar Blue. Living cells reduces resazurin to resorufin, and fluorescence can be 
detected using a fluorescence plate reader. Figure reproduced with permission from Bio-Rad 
Laboratories Inc. Copyright © 2014 Bio-Rad Laboratories Inc.  
 
4.2.3. Fluorescence-Activated Cell Sorting (FACS) 
 
Fluorescence-activated cell sorting (FACS) is a type of flow cytometry that separates 
a heterogeneous population of cells based on fluorescence (Figure 4.23). It provides 
quantitative analysis of cell count and is especially useful in determining a sub-
population of cells.  For instance, a specific antibody with a fluorescent tag can be 
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used to label a cell population of interest within a heterogeneous population, and 
FACS analysis can provide quantitative analysis of that particular cell type.     
 
 
Figure 4.23. Fluorescence-activated cell sorting (FACS). A heterogeneous population of cells can be 
separated and quantitatively analyzed using FACS. Figure reproduced with permission from Abcam 
plc. Copyright © 2014 Abcam plc. 
 
4.2.4. Luciferin 
 
Luciferin is a type of light-emitting compound that is seen in bioluminescence.  One 
example of naturally-occurring luciferin is found in many firefly species.  In order to 
produced bioluminescence, luciferin has to be broken down by luciferase (an 
enzyme).  In this case, luciferase acts as a catalyst to allow oxygen to react with 
luciferin, and this reaction produces light (Figure 4.24).    
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Figure 4.24.  Luciferin and Luciferase.  Luciferin is broken down by luciferase, and this cases it to 
emit light.  Image courtesy of HowStuffWorks, Inc.  Copyright © 2013 HowStuffWorks, Inc.   
   
4.2.5. Luciferase Reporter Cell Line 
 
Reporter cell lines are cells that specially engineered to provide a qualitative and 
quantitative feedback, when exposed to a stimulus.  In this case, a luciferase reporter 
cell line is used.  This is because when it is exposed to luciferin, the reporter cell line 
would fluoresce, due to the fact that it has the luciferase gene encoded in it.  This 
would then be “reported back” to the operator, indicating that luciferin has indeed 
been taken up by the cell (Figure 4.25).     
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Figure 4.25.  Reporter cell line.  Specific reporter genes are encoded into the DNA of the cells, and 
would cause quantitative and qualitative event (e.g. luminescence) to indicate that it has been exposed 
to a certain stimuli.  Image courtesy of SABiosciences.  Copyright © 2013 SABiosciences.    
 
4.2.6. IVIS® Spectrum Imaging System 
 
The IVIS® Spectrum Imaging System is a proprietary technology from PerkinElmer 
Inc (Figure 4.26).  It can be used to determine fluorescence and bioluminescence from 
in vitro cell cultures and in vivo small animals.  The sample of interest is placed inside 
the system, and both digitally rendered images and spectral read-outs can be 
produced.      
 
 
Figure 4.26. The IVIS® Spectrum Imaging System.  Fluorescence and bioluminescence from cell 
cultures and even small animals (e.g. mice) can be measured using IVIS®.  Figure reproduced with 
permission from PerkinElmer Inc.  Copyright © 2013 PerkinElmer Inc.  
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4.2.7. Endocytosis Inhibitors 
 
In order to better understand how liposomes are taken up by cells, endocytosis 
inhibitors were employed to block various receptor-mediated endocytosis 
pathways[6] (Figure 4.27).  Three common endocytosis inhibitors were used here: 
amiloride, chlorpromazine (CPZ), and β-cyclodextrin (β-CD).  Amiloride is a 
potassium-sparing diuretic, used for treatment of hypertension and congestive heart 
failure.  It is an inhibitor of the sodium-proton exchange in cells, and is known to 
block macropinocytosis[7].  CPZ is a dopamine antagonist, and is a type of anti-
psychotic drug.  CPZ is known to inhibit clathrin-mediated endocytosis. β-CD is a 
type of cyclic oligosaccharide, and is an inhibitor of the lipid raft/caveolae-mediated 
endocytosis[8].        
 
 
Figure 4.27.  Cellular uptake of materials.  Particles can enter cells via phagocytosis, 
macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated endocytosis, and clathrin- 
caveolin- independent endocytosis.  Figure reproduced with permission from Conner and Schmid 2003.  
Copyright © 2003 Nature Publishing Group. 
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5.1. Introduction 
 
The advent of nanotechnology and regenerative medicine has engendered novel 
techniques to attain bio-mimicry.  Attaining functional attributes of biological systems 
are highly desired in the restoration of physiological homeostasis.  This is especially 
relevant in percutaneous coronary intervention (PCI), where the very act of stent 
deployment in an occluded vessel inadvertently causes trauma and damage to the 
implantation site.  Endothelial denudation and laceration of the internal elastic lamina 
triggers the accumulation and activation of platelets and the subsequent formation of a 
thrombus. This could also potentially mediate local and systemic inflammation, 
characterized by the influx of neutrophils and the migration of macrophages and 
monocytes to the injury site, causing vessel occlusion.  In general, the formation of a 
thrombus involves 2 events are inextricably linked: platelet adhesion and activation 
(Figure 5.1), and the blood coagulation cascade (Figure 5.2).     
 
Within the native blood vessel, aggregation of platelets occurs upon vessel injury via 
the adhesion of the exposed collagen matrix within the endothelial sub-layer.  This 
initial adhesion is mediated by glycoprotein VI, which is the membrane receptor that 
binds to collagen, and glycoprotein Ib, the membrane receptor that binds to collagen-
bound von Willebrand factor (vWF)[1-3].  The process of platelet adhesion is further 
mediated by integrin α2β1 which binds to collagen, and integrin αIIbβ3 which binds to 
fibrinogen and fibrin[4, 5].  Hence, it is hypothesized that adsorption of these proteins 
to blood-contacting devices causes the adhesion of platelets on biomaterial surfaces.   
 
With respect to biomaterial implants, a variety of factors are known to cause platelet 
activation[5-7], and the process of platelet adhesion alone can sometimes trigger 
platelet activation.  For example, the binding of integrin α2β1 and glycoprotein VI to 
collagen, and the binding of integrin αIIbβ3 to fibrinogen and fibrin itself can cause 
platelet activation.  Furthermore, the binding of soluble factors onto platelet receptors 
can also contribute to platelet activation.  For instance, activation of the tissue factor 
(TF) pathway causes the production of thrombin.  Both the cleavage of protease-
activated receptor 1 (Par-1) by thrombin on the surfaces of platelets, and the binding 
of thromboxane A2 and adenosine diphosphate (ADP) onto their respective receptors 
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on the surfaces of platelets lead to platelet activation[8-10].  Although it is generally 
accepted that both platelet adhesion and the binding of soluble factors can play largely 
independent roles in the activation of platelets, the exact interaction of their 
mechanism of action has not been elucidated[3, 10].  Activated platelets adopt a 
dramatic change in morphology[11], and releases chemicals that amplifies the 
activation process by recruiting and activating more platelets[6, 10, 12]. 
 
 
Figure 5.1. Platelet adhesion and activation.  Various stages can be observed, namely platelet 
adhesion, platelet activation, forming a procoagulant environment, platelet aggregation, and formation 
of a fibrin clot.  Figure reproduced with permission from Ibanez et al., 2006. Copyright © 2006 
European Society of Cardiology.       
 
The blood coagulation cascade is a series of events that generates thrombin and 
ultimately fibrin, which stabilizes the clot.  The coagulation cascade comprises of 2 
separate pathways: the intrinsic pathway (also known as the contact-activation 
pathway), and the extrinsic pathway.  Both pathways then converge into a common 
pathway to produce thrombin.  The intrinsic pathway occurs within 100 to 200 
seconds of initial contact with a foreign surface / material.  The main components of 
the intrinsic pathway include Factor XII, Factor XI, kallikrein, and high-molecular-
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weight kininogen[8, 13, 14].  However, it has been observed that patients deficient in 
Factor XII were still able to produce high levels of thrombin during vascular bypass 
surgery, which suggests that the intrinsic pathway might not play a significant role in 
thrombus formation on biomaterials[15].  
 
The extrinsic pathway is triggered by the exposure of TF to blood.  It has been 
traditionally believed that TF is contained within the tunica media and adventitia of 
blood vessels[16].  However, mounting evidence suggests that monocytes and 
neutrophils secrete TF, thereby supporting the notion that TF is present not only 
within the vessel layers, but in the circulation as well[10, 17, 18]. As such, it is 
postulated that TF might indeed play an important role in biomaterial-associated 
thrombosis[19, 20].  TF interacts with Factor VII to form the activated TF-Factor VIIa 
complex (the tenase complex).  Activated Factor X (Factor Xa) is produced via the 
cleavage of Factor X by the tenase complex.  Factor V is then activated by Factor Xa, 
which leads to the formation of Factor Xa-Factor Va complex (prothrombinase 
complex).  Prothrombinase complex then converts prothrombin to thrombin[8, 10, 
16].  Thrombin then converts soluble fibrinogen to insoluble fibrin, which stabilizes 
the blood clot.   
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Figure 5.2. The coagulation cascade.  The coagulation cascade is a complex mechanism, with the 
intrinsic and extrinsic pathway converging into the common pathway, to form a stable fibrin clot.  
Figure reproduced with permission from Creative Commons.  Copyright © 2014 Creative Commons.       
 
The endothelium (comprising of a confluent layer of endothelial cells) serves as a 
physical barrier between blood and pro-thrombotic elements (e.g. collagen) within the 
vessel wall.  More crucially, endothelial cells regulate blood coagulation, and platelet 
adhesion and activation.  Endothelial cells also synthesize molecules that can 
counteract blood coagulation.  HSPG on the surfaces of endothelial cells serve as a 
cofactor of anti-thrombin-III (AT-III) that inhibits thrombin[21, 22].  In addition, a 
thrombin receptor called thrombomodulin (TM) is expressed on the endothelial 
surface.  Upon binding to TM, thrombin converts the inactive form of protein C to 
activated protein C (APC), which inhibits Factor Va and Factor VIIa[23]. 
Furthermore, endothelial cells synthesize TF pathway inhibitor (TFPI), which binds to 
both Factor VIIa and Factor Xa, thereby impairing TF-induced activation of the 
extrinsic pathway[24, 25].   
 
Under physiological conditions, endothelial cells synthesize and produce nitric oxide 
(NO) and prostacyclin (PGI2), which inhibit platelet adhesion and activation[26, 27] 
(Figure 5.3).  NO and PGI2 are constitutively expressed by endothelial cells, with 
levels of expression being modulated in response to chemical stimuli and fluid shear 
stress[28, 29].  The surface of endothelial cells can bind ectonucleotidases, which can 
hydrolyze ADP (an agonist of platelet activation)[21, 30].  The brush-like glycocalyx 
layer on the surface of endothelial cells contains proteoglycans with 
glycosaminoglycan (GAG), and heparan sulphate proteoglycan (HSPG)[31].  These 
negatively-charged molecules on the surface are hydrophilic, thereby forming a layer 
of lubrication on the surface of endothelial cells, with evidence suggesting that they 
can inhibit platelet adhesion[32]. 
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Figure 5.3. The anti-thrombogenic effects of endothelial cells.  Endothelial cells regulate (a) 
coagulation, (b) platelet adhesion and activation, and (c) stimulation of fibrinolysis.  Figure reproduced 
with permission from Li et al., 2011.  Copyright © 2011 Annual Reviews.     
 
Given the salutary effects of endothelial cells, the concept of achieving and indeed 
augmenting the process of re-endothelialization on stented vessels is an area of 
intense research.  Evidence has shown that circulating endothelial progenitor cells 
(EPCs) are capable of mobilization, homing, and differentiation into endothelial 
cells[33].  An increasing body of work has been directed at functionalizing 
biomaterials with EPC-specific antibodies and peptide moieties that facilitate the 
capture of circulating EPCs[34-36]. 
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Considering that studies have shown that EPCs express CD34 on their surface, 
functionalizing stents with anti-CD34 antibodies have been proposed as an avenue for 
augmenting re-endothelialization via the capture of circulating EPCs[36] (Figure).  
The anti-CD34 antibody is of the IgG isotype with a molecular weight of around 150 
kDa.  It consists of 4 peptide chains; 2 identical heavy chains (molecular weight of 
about 50 kDa each) and 2 identical light chains (molecular weight of about 25 kDa 
each) linked by disulphide bonds, forming a tetrameric quaternary structure in a Y-
shaped configuration.  The upper part of the antibody is called the Fab region which 
binds to specific antigens, while the lower part of the antibody is called Fc region.   
 
In this chapter, anti-CD34 antibodies are covalently immobilized on the surfaces of 
POSS-PCU using an EDC/NHS crosslinker to facilitate the capture of EPCs (Figure 
5.4).  It is hypothesized that the presence of anti-CD34 antibodies on the surfaces on 
POSS-PCU would increase the propensity of endothelialization, compared to POSS-
PCU alone. 
 
Figure 5.4. Endothelial progenitor cell capture using anti-CD34 antibodies.  (A) Anti-CD34 
antibodies can be attached onto POSS-PCU surface, to capture EPCs.  (B) The structure of a typical 
antibody.                   
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5.2. Materials and Methods 
 
Standard laboratory reagents were obtained from Sigma-Aldrich UK unless otherwise 
stated.  Standard cell culture reagents were obtained from Life Technologies UK 
unless otherwise stated. For procedures that involved the use of human tissue, a 
signed informed consent document was obtained from healthy volunteers, and was 
approved by the Institutional Review Board (IRB) UCL.  All experimental procedures 
were done in triplicates (n=3) unless otherwise stated.  A tabulated description of 
samples is listed in Table 5.1. 
 
Table 5.1. Tabulated description of samples. 
 
Sample Description 
POSS-PCU Plain POSS-PCU films 
POSS-PCU-CD34 Anti-CD34 antibody (specific for CD34 antigen)  
immobilized onto POSS-PCU films 
POSS-PCU-IgG Isotype control IgG (non specific) immobilized onto 
POSS-PCU films 
     
 
5.2.1. Preparation of Biofunctionalized Nanocomposite Polymer  
 
5.2.1.1. POSS-PCU Synthesis 
 
In-depth discussion of the synthesis of POSS-PCU for peptide/antibody 
functionalization has been described elsewhere[37, 38].  Briefly a mixture of 
polycarbonate diol (Mw=2000) and transcyclohexanechlorohydrinisobutyl-
silsesquioxane (Hybrid Plastics Inc., USA) was placed in a custom-made home-built 
reaction flask equipped with a mechanical stirrer and nitrogen inlet, heated to 135 °C 
in order to dissolve the POSS nanocages in polycarbonate diol, and then cooled to 70 
°C.  4,4’-methylene-bis-(phenyl isocyanate) was then added to the mixture to form a 
pre-polymer.  Dimethylacetamide (DMAc) was subsequently added slowly to 
dissolve the pre-polymer, forming a solution that was then cooled to 40 °C.  
Following solvation, chain extension of the pre-polymer solution was achieved by 
drop-wise addition of a mixture of ethylenediamine and diethylamine (in DMAc) to 
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form a final polymer solution of POSS-modified polycarbonate urea-urethane (in 
DMAc).   
 
5.2.1.2. Incorporation of Fumed Silica  
 
1 g of Aerosil® A200 fumed silica (Evonik Industries, Germany) was mixed with 100 
ml of propan-2-ol, 5 ml of 3-aminopropyltriethoxysilane (APTES), and 5 ml of 
deionized water in a pre-silanized round-bottom flask.  This mixture was bath 
sonicated a bath sonicator (Grant Instruments, UK) for 45 min.  To prevent 
overheating, the flask containing the mixture was cooled in ice, and the water in the 
bath sonicator was changed every 15 min.  The resultant mixture was subsequently 
refluxed at 70 °C for 6 hr.  Following this, the mixture was centrifugated at 4000 rpm 
for 40 min.  The resultant supernatant was discarded, while the pellet was re-
suspended in propan-2-ol and centrifugated again at 4000 rpm for 40 min.  This step 
was repeated 5 times.  Finally, the pellet was placed in a heating oven (Binder, 
GmBH) at 65 °C for 24 hr. 
 
Fumed silica incorporation into POSS-PCU has been described in detail 
elsewhere[37]. Briefly, 36 mg of fumed silica prepared above was dissolved in 1 ml 
of DMAc in a glass scintillation vial.  The vial was placed in a bath sonicator (Grant 
Instruments, UK) for 30 minutes at room temperature.  The water in the bath was 
changed every 15 minutes, and the vial placed in ice, to prevent overheating. The 
contents in the vial were added to 10 g of POSS-PCU in a 50 ml conical tube.  The 
resultant mixture was subjected to further mixing using an Ultrasonic Processor (Cole 
Parmer) for 3 cycles of 20 s each.  The respective mixtures were left to stand for 1 
hour for air bubbles to dissolve.  The mixtures were then poured onto metal plates and 
placed in a heating oven (Binder, GmbH) for 24 hours, at 65 °C.  Polymer films were 
sterilized via autoclaving at 121 °C and 975 Torr (Rodwell Scientific Instruments, 
UK).  
 
5.2.1.3. Surface Immobilization of Anti-CD34 Antibody  
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0.008 g of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) 
(0.4 mg / ml), 0.0115 g of N-Hydroxysuccinimide (NHS) (0.575 mg/ml), and 0.05 g 
of succinic acid (2.5 mg/ml) were placed in a 50 ml conical tube.  To this, 20 ml of 
phosphate-buffered solution (PBS) was added.  The mixture was placed on a roller 
mixer (Stuart Equipment, UK) for 1 hour, to allow activation.  NHS is an activator of 
carboxylic acids, while EDC is a coupling agent.     
 
Circular-cut discs of polymer sheets were placed in a 24-well plate.  500 µl of the 
above-mentioned EDC-NHS-PBS mixture was pipetted onto each polymer sheet in 
the wells.  The well plate was wrapped in aluminium foil to avoid light, and placed on 
a Luckham R100 rotatest shaker (Richmond Scientific Ltd., UK) for 24 h.    
 
500 µl of PBS, and 5 µl of mouse anti-CD34 concentrate (Life Technologies, UK) 
were pipetted into an Eppendorf tube giving a concentration of 2 µg/ml.  The sample 
was passed through a sterilizing-grade 0.22 µm filter (Millipore Corporation, USA) to 
remove contaminating particles. Equal amounts of the antibody solution were pipetted 
onto the well plates, which gives a surface coating density of 0.5 µg/cm2 per cm2 of 
polymer disc.  The well plate was wrapped in aluminium foil and placed on a shaker 
for 30 minutes.  It was then transferred to a 4 °C fridge and left for 24 hours.  After 24 
hours, the polymer discs were washed with PBS. 
 
5.2.2. Biophysical Characterization  
 
5.2.2.1. Fourier Transform Infrared Spectroscopy (FTIR) 
 
Chemical groups were detected using attenuated total reflectance (ATR)-FTIR with a 
Jasco FT/IR 4200 Spectrometer (JASCO Inc., USA).  Parameters were set at 20 scans 
at a 4 cm-1 resolution with a wavenumber range of 600 cm-1 to 4000 cm-1.  
 
5.2.2.2. Atomic Force Microscopy (AFM) 
 
AFM was done using a Nanoscope V (7.0) controlled Dimension V Scanning Probe 
Microscope with a XYZ Hybrid Scanner (Vecco Instruments Inc., Germany).  
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Aluminum-coated silicon probes were used, at a resonant frequency at 190 kHz 
(Nanoscience Instruments Inc., USA).  The system was operated in the tapping mode 
with a VT-103K Acoustic/ Vibration Isolation System, and the VT-102 Vibration 
Isolation Table at room temperature in air.   
 
5.2.2.3. Scanning Probe AFM Confocal Raman Spectroscopy  
 
Raman spectroscopy integrated with atomic force microscopy (AFM) was performed 
using an NT-MDT NTEGRA Spectra® System (Nano Technology Instruments 
Europe B.V., The Netherlands) with an upright Raman microscope and a universal 
head.  AFM scanning was done in semi-contact mode with commercial rounded 
cantilevers for large scans, obtained from MicroMasch (R ∼ 40 nm, k = 5.7 N/m).  
Raman scanning was done in backscattering geometry with a Mitutoyo long-working 
distance objective (100 ×, 0.7 NA).  The excitation source was 473 nm solid state 
Cobalt Blues® laser with power at the sample being 2 mW.  Acquisition time per step 
was 10 s and step size was 0.5 µm.  Optical images of the area were captured using 
the same objective. 
 
5.2.2.4. Water Contact Angle 
 
Water contact angle measurements were measured using a KRÜSS DSA 100, and 
Easy Drop DSA20E Drop Shape Analysis software (KRÜSS GmBH, Germany).  The 
sessile drop method was used, with droplet volume and dispensing rate kept constant 
at 5 µl and 195.1 µl/min respectively. A total of 6 measurements were taken randomly 
at different spots of each sample (n=6), each within 10 s of dispensing.  Surfaces with 
a water contact angle of > 90° were considered hydrophobic, while those with a water 
contact angle of < 90° were considered hydrophilic.    
 
5.2.2.5. X-Ray Photoelectron Spectroscopy (XPS)  
 
The analysis of the samples was carried out using a Thermo Scientific Theta Probe 
XPS (Thermo Fisher Scientific Inc., UK). Monochromatic Al Kα X-ray 
(hν=1486.6eV) was employed with an incident angle of 30° with respect to surface 
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normal. Photoelectrons were collected at a take-off angle of 50° with respect to 
surface normal. The analysis area was approximately 400µm in diameter while the 
maximum analysis depth lies in the range of 4 - 10nm. Survey spectra and high-
resolution spectra were acquired for surface elemental identification and for chemical 
state identification, respectively. For chemical state analysis, a spectral deconvolution 
was performed by a curve-fitting procedure based on a Lorentzian function, and 
broadened by a Gaussian function. 
 
5.2.2.6. Thromboelastography (TEG)  
 
The effect of polymer material on blood coagulation kinetics was assessed using a 
TEG® 5000 Thromboelastograph® Hemostasis Analyzer System (Haemonetics 
Corporation, USA).  Cuvettes were coated with POSS-PCU and further conjugated 
with anti-CD34 antibodies in the protocol mentioned above.  Uncoated cuvettes 
served as controls.  Whole blood was obtained from healthy volunteers and 320 µl of 
whole blood were pipetted into each cuvette.  For each round of analysis, the TEG 
system was calibrated to 37 °C before mounting POSS-PCU-CD34 coated TEG cups 
in the TEG analyser. 20 µl of 0.2M calcium chloride solution, a known initiator of 
blood coagulation, was added to each cup, followed by 340 µl of citrated blood. 
Similar TEG analyses were performed on POSS-PCU-coated cups for comparison. 
Standard TEG cups with citrated whole blood (340 µl) were used as positive controls, 
whereas standard cups containing citrated blood (300 µl) mixed with 0.01M L-
arginine (40 µl) were used as negative controls, as L-arginine is known to have anti-
coagulant effects on native whole blood. To reduce variability due to blood samples, 
each test was repeated three times with blood drawn from the same volunteer at the 
same time. 
 
5.2.2.7. Scanning Electron Microscopy (SEM) 
 
Samples were mounted on an aluminium stub and sputter-coated with a 20 nm layer 
of gold via vapour deposition using a SC500 sputter coater (EM Scope, UK), and 
imaged using a Philips 501 SEM (Philips, UK)  
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5.2.2.8. C3a & SC5b-9 Complement Activation 
 
Enzyme immunoassay to quantify C3a fragment of the complement protein C3 in 
human plasma and serum was done using MicroVue™ C3a kit (Quidel Corporation, 
USA).  The assay was done in accordance to manufacturer’s protocol.  Whole blood 
was obtained from healthy volunteers with informed consent.  50 µg/ml of test 
samples (POSS-PCU, POSS-PCU-CD34, CD34) were added to whole blood and 
incubated at 37°C for 30 minutes.  Blood plasma was extracted via density gradient 
centrifugation at 400 g for 30 min. Blood plasma was diluted in a dilution ratio of 
1:200.  For each test specimen, 90 µl of specimen diluent for dilution 1, and 475 µl for 
dilution 2 were pipetted into 2 separate dilution tubes.  Dilution 1 was prepared by the 
addition of 10 µl of test specimen to 90 µl specimen diluent, and mixed gently. 25 µl 
of plasma in dilution 1 was then mixed with 475 µl of plasma in dilution 2. 100 µl of 
specimen diluent (blanks), standards, controls, and test specimens were pipetted into 
assay wells and incubated for 60 minutes at 20 °C.  Wells were washed 4 times with 
the wash solution provided in the assay kit.  100 µl of horseradish peroxidase (HRP)-
conjugated anti-C3a (as provided in the assay kit) was added in the wells, and further 
incubated for 60 minutes at 20 °C.  Wells were washed 4 times with wash solution.  
100 µl of 3,3’,5,5’ tetramethylbenzidine (TMB) chromogenic substrate solution (as 
provided in the assay kit) was then pipetted into the wells, and incubated for 15 
minutes at 20 °C.  100 µl of stop solution (as provided in the assay kit) was added to 
terminate the reaction process.  The well plate was then placed in an xMark™ 
Microplate Absorbance Spectrophotometer (Bio-Rad Laboratories Inc., UK), and an 
absorbance wavelength of 450 nm was selected.  All experimental procedures were 
done in triplicates (n=3). 
 
The quantification of SC5b-9 complex was done using a MicroVue™ SC5b-9 Plus 
Enzyme Immunoassay kit (Quidel Corporation, USA).  The experiment was done in 
accordance to manufacturer’s protocol, and the procedure was similar to the 
quantification of C3a mentioned in the above paragraph.  Briefly, blood plasma was 
diluted in a dilution ratio of 1:10.  300 µl of wash solution was added into assay well 
and incubated for 2 minutes at 20 °C.  Liquid was aspirated from each well and 
blotted dry.  100 µl of specimen diluent (blank), standards, controls, and test samples 
were added into assay wells, and incubated for 60 minutes at 20 °C and washed 5 
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times.  50 µl of SC5b-9 plus conjugate was added and incubated for 30 minutes at 20 
°C, and washed 5 times. 100 µl of substrate was added and incubated for 15 minutes 
at 20 °C.  100 µl of stop solution was added, and an absorbance wavelength of 450 
nm was selected.     
 
5.2.2.9. Erythrocyte Compatibility and Haemolysis Assay 
 
Isolation of erythrocytes (red blood cells) was done via the collection of whole blood 
from healthy volunteers.  Informed consent was obtained from volunteers, and the 
Institutional Review Board (IRB) at UCL approved the procedure.  Briefly, 800 µl of 
freshly collected whole blood was centrifuged at 10,000 g using a MiniSpin® 
(Eppendorf AG., Germany) for 5 minutes at room temperature. It was then washed 5 
times using sterile isotonic PBS.  Erythrocytes were re-suspended in 7.5 ml of PBS.  
50 µg/ml of test samples (POSS-PCU, POSS-PCU-CD34, CD34) were added to 
erythrocytes.  PBS was used as negative control, and sterile water was used as 
positive control.  The samples were then vortexed for 5 seconds and left to stand at 
room temperature for 3 hours.  It was then centrifuged at 10,000 g for 5 minutes at 
room temperature. 200 µl of the supernatant was aliquoted into a 96 well plate and 
placed in a Mircoplate Absorbance Reader (Bio-Rad Laboratories, Inc. USA).  The 
absorbance wavelength was set at 577 nm (the absorbance of haemoglobin), and was 
measured with a reference wavelength of 655 nm.  The percentage of haemolysis was 
calculated using the formula: 
 
% Haemolysis = (Absample – Abneg ctrl ) / (Abpos ctrl – Abneg ctrl) 
 
 
Where Ab is the absorbance value, neg ctrl is the negative control, and pos ctrl is the 
positive control.   
 
Erythrocyte compatibility assay was conducted as follows.  Whole human blood from 
healthy volunteers was centrifuged at 1500 g at 4 °C for 10 min.  The supernatant was 
discarded, and the pellet was washed with PBS.  This centrifuging and washing step 
was repeated 3 times.  The pellet (which contain erythrocytes) were mixed with saline 
at 4% (v/v).  300 µl of erythrocytes were cultured on POSS-PCU and POSS-PCU-
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CD34 membranes, and incubated at 37 °C for 4h.  Positive control was untreated 
erythrocytes, and negative control was polyamidoamine (PMAM), an agent that is 
known to be toxic to erythrocytes[39].  After incubation, erythrocytes were washed 
twice with PBS.  After each washing step, erythrocytes were centrifuged at 1500 g for 
3 min.  Samples were then placed in 2.5% SEM-grade glutaraldehyde in PBS at pH 
7.4 at 2 °C for 24 h.  Thereafter, the sample was washed 3 times with PBS.  The 
erythrocytes were then fixed with 1% osmium tetroxide dissolved in PBS at pH 7.4 at 
2 °C for 1 h. Samples were then washed with PBS, and serially diluted in 30%, 50%, 
70%, 90% and 3 times with 100% ethanol.  Erythrocytes were then re-suspended in 
hexamethyldisilazane (HMDS) and spread on a glass slide.  After evaporation of 
HMDS, platinum deposition was performed and SEM images were acquired using a 
JEOL JSM-6701F (JEOL, Japan) field emission scanning electron microscope.         
 
5.2.2.10. Antibody Stability and Orientation 
 
To assess the orientation of anti-CD34 antibodies on POSS-PCU, a control was set up 
whereby antibodies were added onto POSS-PCU without the EDC/NHS crosslinker.  
Secondary antibodies (IgG) conjugated to quantum dots (10 µg/ml) were then added, 
and their fluorescence measured using a Fluoroskan Ascent Microplate Fluorometer 
(Thermo Scientific Inc., UK).  The dissociation constant between immobilized anti-
CD34 antibodies and secondary antibodies was measured using a response curve 
(captured secondary antibodies vs. fed secondary antibodies), and the amount of 
surface-immobilized primary antibodies.  The amount of primary antibody and 
captured secondary antibodies were measured by quantifying its fluorescence. The 
response curve was converted with the Hill equation to estimate the Hill coefficient 
(n) and the dissociation constant (Kd).  
 
5.2.3. In vitro Cell Culture  
 
5.2.3.1. Human Endothelial Progenitor Cell (EPC) Isolation 
 
20 ml blood samples were collected with informed consent from healthy adult human 
volunteers by venepuncture in ethylenediaminetetraacetic acid (EDTA) BD 
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Vacutainers (BD Biosciences, UK). Samples were mixed thoroughly with the EDTA 
to prevent coagulation.  
EPC isolation was carried out within an hour of blood sample collection, using a 
method that has been reported previously[40] to produce EPC colonies that are able to 
differentiate into cells with endothelial cell markers and characteristics. First, density 
gradient centrifugation was carried out by layering the blood sample over Histopaque-
1077, and centrifuging in a MSE Mistral 3000i centrifuge (MSE UK) at 400 g for 30 
min at room temperature. The buffy coat layer containing the mononuclear fraction of 
peripheral blood, including EPCs, was carefully harvested and washed with Hank’s 
Balanced Salt Solution (HBSS) (Life Technologies, UK) by centrifuging at 250 g for 
10min, discarding the supernatant, and re-suspending the pellet in HBSS. After 2 
rounds of washing, isolated peripheral blood mononuclear cells (PBMCs) were re-
suspended in cell culture media (CCM), which comprised Medium 199 supplemented 
with 20% FBS, 1% glutamine, and 1% penicillin/streptomycin (all from Life 
Technologies). PBMCs were then enumerated using a haemocytometer and Trypan 
Blue exclusion dye, and then diluted in CCM to a final concentration of 1.0 × 106 
PBMCs/ml.  
For EPC characterization, 2–3 x 106 PBMCs/well were seeded in 6-well plates. After 
3 days of culture, non-adherent cells were removed by gentle washing with PBS, 
while adherent cells were kept in culture for further cultivation. On days 5 and 7 post-
seeding, half of the media in each well was carefully replaced with fresh CCM. The 
cell cultures were visualised every 2-3 days under light microscopy, and any eventful 
changes in cell morphology were recorded. After 7 days, cells were fixed and directly 
immunostained with quantum dot (QD)-antibody conjugates, for the expression of 
CD34, VEGFR-2, CD31 (or PECAM-1, platelet endothelial cell adhesion molecule-
1), and von Willebrand factor (vWF).  
For the EPC capture assay, sterile POSS-PCU-CD34, POSS-PCU-IgG (isotype 
control), as well as pristine POSS-PCU, were placed in a 24-well plate and 
equilibrated in sterile CCM in a 37oC, 5% CO2 incubator overnight. The next day, the 
CCM in each well was replaced by 1ml of 1x106 PBMCs/mL PBMC suspension, and 
the plate was returned to the 37 °C, 5% CO2 incubator. For positive controls, PBMCs 
were seeded in empty wells, whereas POSS-PCU discs with no cells seeded were 
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used as negative controls. After 3 days of culture, non-adherent cells were removed 
by gentle washing with PBS, while adherent cells were kept in culture for further 
cultivation. On days 5 and 7 post-seeding, half of the media in each well was carefully 
replaced with fresh CCM. At day 7, cells were fixed and double-stained for EPC 
markers (CD34 and VEGFR-2) as well as endothelial cell markers (CD31 and vWF). 
In addition, the total number of EPC colonies formed per 106 PBMCs seeded in each 
well was enumerated manually. EPC colonies were defined morphologically as 
central clusters of rounded cells with spindle-shaped cells emanating from the centre, 
which also stained positive for both CD34 and VEGFR-2 under a laser scanning 
confocal microscope.  
5.2.3.2. HT29 Colorectal Cell Line 
 
As a negative control to EPCs, a HT29 colorectal cell line (Sigma-Aldrich, UK) was 
used.  Standard cell culture techniques were used for proliferation and expansion.  
Briefly, HT29 cells (passage 2) were cultured in Dulbecco’s Modified Eagle Medium 
(D-MEM), supplemented with 10% Fetal Bovine Serum (FBS), and 1% penicillin 
(collectively called the growth medium).  All standard cell culture reagents were 
purchased from Invitrogen.   
 
Resuscitation of frozen cells were performed as follows.  The frozen ampoule 
containing cells were left at room temperature for 1 min, and then transferred to a 
water bath (Fisher Scientific, UK) at 37 °C for 4 min.  The thawed cells were then 
centrifuged at 200 g for 5 min.  The supernatant was removed and discarded, and 1 ml 
of growth medium was pipetted to the pellet and mixed thoroughly by repeated 
pipetting.  The cell suspension was then transferred to a cell culture flask (Corning, 
USA) and incubated at 37 °C and 5% CO2, until they attained 75% confluency.     
 
When cells had attained 75% confluency, sub-culture of adherent cells were 
conducted as follows.  The growth medium in the cell culture flask was aspirated and 
discarded. Washing of the cells were done via the addition of 5 ml of PBS, and this 
washing step was repeated 3 times.  PBS was aspirated and discarded after the final 
washing step.  3 ml of trypsin was then added and incubated for 4 min at 37 °C and 
5% CO2, and was observed under a light microscope to ensure that cells had been 
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detached.  The trypsinized cell culture was then transferred to a 15 ml centrifuge tube. 
7 ml of growth medium was added, making up the total volume to 10 ml.  This was 
then centrifuged at 200 g for 5 min, and the supernatant was aspirated and discarded. 
3 ml of fresh growth medium was pipetted to the pellet and mixed thoroughly by 
repeated pipetting.   
 
Cell counting was done using standard established protocols.  Briefly, 10 µl of Trypan 
Blue (Sigma-Aldrich, UK) was mixed with 10 µl of cell suspension (making a 
dilution factor of 2).  10 µl of the mixture was then pipetted into a chamber of a 
haemocytometer counting chamber (Camlab, UK).  Cells in the 4 large squares were 
counted and divided by 4 to obtain the average number of cells.  The number of viable 
cells per ml was determined using the formula:  
 
no. of cells/ml = avg no. of cells per 0.1 cm2 × 104 (correction factor for volume of 
area indicated by brace) × 2 (dilution factor) 
 
 
5.2.3.3. Immunofluorescence using Quantum Dot-Antibody Conjugates  
 
Prior to direct immunostaining with QD-antibody conjugates, cells cultured on the 
various surfaces were first washed twice with 0.1% PBST, fixed with 2% 
paraformaldehyde (PFA, in 0.1% PBST) for 20 min, then washed 3 times with 0.1% 
PBS-Tween 20 (PBST) at room temperature. Cells were subsequently permeabilised 
in 0.5% Tween-20 (in PBS) for 15min, then washed thrice with 0.1% PBST.  
The fixed cells were first blocked with 1% bovine serum albumin (BSA, in 0.1% 
PBST) for 30 min at 4 °C in the dark, and then washed with 0.1% PBST before 
incubation with QD-antibody conjugates for 2hrs at 4 °C in the dark. Samples were 
subsequently washed with 0.1 % PBST, incubated with 4',6-diamidino-2-
phenylindole (DAPI, 5 µg/ml) for 5 min at room temperature, washed with 0.1 % 
PBST, and left in 0.1 % PBST for imaging.  Images were captured by a Nikon Eclipse 
TE300 inverted microscope equipped with an EZ-C1 confocal microscopy system 
(Nikon Europe B.V.). A 488nm He-Ne excitation laser was used, and images were 
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acquired using either a 515-530 nm emission range channel (for green and blue 
fluorescence detection), or a 650LP channel (for red fluorescence detection).  
Anti-CD34 (250µg/ml), anti-VEGFR-2 (250 µg/ml), anti-vWF (250 µg/ml), and anti-
CD31 (250 µg/ml) antibodies were conjugated with either red or green quantum dots 
and diluted in 1% BSA to make up 0.25µg/ml QD-antibody working solutions.  
Quantum dots were manufactured in-house, and has been extensively described 
elsewhere[41]. The conjugation protocol was similar to the conjugation protocol of 
anti-CD34 immobilization onto POSS-PCU using the EDC/NHS crosslinker. 
VEGFR-2 and CD34 are EPC markers, whereas vWF and CD31 are endothelial cell 
markers. Hence, the following pairings of QD-antibodies were used: QD-anti-
VEGFR-2 (red, emission maximum 640nm) and QD-anti-CD34 (green, emission 
maximum 555nm); QD-anti-vWF (red) and anti-CD31 (green). Additionally, cells 
were stained with blue DAPI nuclei counterstain.  
Quantitative analysis of fluorescence intensity was also conducted using a Fluorsokan 
Ascent Microplate Fluorometer (Thermo Scientific Inc., UK), with an excitation 
wavelength set at 488 nm, and emission wavelength set at 640 nm (for red quantum 
dots).  Normalized fluorescence intensity was calculated as follows: 
Normalized fluorescence = (FLsample – FLneg ctrl) / (FLpos ctrl – FLneg ctrl) 
 
Where FL is the fluorescence intensity, neg ctrl is the negative control, and pos ctrl is 
the positive control.    
 
5.2.3.4. Platelet Adhesion and Activation Assay  
 
Sterile samples of POSS-PCU and POSS-PCU-CD34 were equilibrated overnight in 
sterile PBS in a 24-well plate placed in a 37 °C, 5% CO2 incubator. For the isolation 
of platelet-rich plasma (PRP) by density centrifugation, a 20 ml blood sample was 
first collected from healthy volunteers using BD Vacutainers containing 0.109 M 
buffered sodium citrate, and mixed gently. The citrated blood was carefully layered 
onto 20 ml of Histopaque-1077 and centrifuged at 200 g for 30 min. The topmost 
clear yellow layer making up the PRP was carefully harvested. Average platelet 
number was determined by making 3 reference counts with a haemocytometer, 
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following which, the harvested PRP was diluted in sterile PBS to give a final working 
concentration of 1x106 platelets/ml.  
PBS in each well was replaced with 1 ml of diluted PRP (1 × 106 platelets/ml), and 
incubated for 1 hour in a 37 °C, 5% CO2 incubator. After 1 hour, the supernatant in 
each well was gently transferred to separate eppendorf tubes, and the number of 
platelets enumerated immediately using a haemocytometer.  
The degree of platelet adhesion to each sample was expressed quantitatively as a 
Platelet Adhesion Index (PAI), which was calculated as follows: 
 
PAI = 100 (Pi – Ps) / Pi 
 
Where Pi is the initial number of platelets seeded on each sample (106), and Ps is the 
number remaining in the supernatant after the 1-hour incubation.  
For morphometric analysis of the surface-activated platelets, the polymer discs were 
retained following removal of the supernatant, and prepared for SEM. This was done 
by gently washing the discs with PBS, and then fixing any adhered platelets with 4% 
PFA for 20 min, followed by dehydration with ascending concentrations of ethanol 
(20, 40, 60, 80, 100% w/v), with 20 min of incubation for each step. This method of 
fixation and dehydration protects platelets from desiccation while concurrently 
reducing unwanted artefacts, thereby preserving platelet integrity for high-resolution 
morphological analysis under SEM. The samples were air-dried in the laminar 
flow hood for 16-24 h prior to SEM imaging. 
5.2.3.5. Alamar Blue® Cell Viability Assay  
 
Cell viability was measured using Alamar Blue® (Life Technologies, UK).  An initial 
cell density of 10,000 cells per well was seeded on a 96-well plate, and Alamar Blue 
was added to cell aliquots in a volumetric ratio of 1:10.  After incubating for 2 hours, 
it was placed in a Fluoroskan Ascent Microplate Fluorometer (Thermo Scientific Inc., 
UK).  In accordance with manufacturer’s protocol, excitation wavelength was set at 
560 nm, and an emission wavelength was set at 590 nm.  Normalized cell viability 
was calculated using the equation:  
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Normalized cell viability = (FLsample – FLneg ctrl) / (FLpos ctrl – FLneg ctrl) 
 
Where FL is the fluorescence intensity, neg ctrl is the negative control, and pos ctrl is 
the positive control.    
 
5.2.3.6. Fluorescence-Activated Cell Sorting (FACS)  
 
Cell count data was obtained via fluorescence-activated cell sorting (FACS).  A BD 
FACSAria™ Fusion Flow Cytometry (BD Biosciences, UK) was used, and 10,000 
events per sample were acquired.  Data analysis was done using its proprietary BD 
FACSDiva software (BD Biosciences, UK).  Cells were stained with: 4’6-diamidino-
2-phenylindole (DAPI) for cell nucleus/DNA, anti-CD34 antibodies are conjugated to 
QDs, and anti-VEGFR-2 that are conjugated to QDs. Cell density was calculated 
simply by dividing the number of cells by the area of the well plate.  A normalized 
cell density was then calculated for data analysis using the formula: 
 
Normalized cell density = (Dsample avg – Dneg ctrl) / (Dpos ctrl – Dneg ctrl) 
 
Where D is the cell density, sample avg is the sample that is being measured, neg ctrl 
is the negative control, and pos ctrl is the positive control.   
 
5.2.4. Statistical Analyses 
 
Parametric data is presented as ± standard deviation (SD) of the mean, and all 
experiments were performed in triplicates (n = 3), unless otherwise stated.  Curve 
fitting and statistical analysis was done using GraphPad Prism® (GraphPad Software 
Inc., USA).  One-way analysis of variance (ANOVA) with post-hoc Tukey’s range 
test was performed at a 95% confidence interval.  p < 0.05 was considered statistically 
significant.    
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5.3. Results 
 
5.3.1. Biophysical Characterization 
 
5.3.1.1. Detection of Surface-Immobilized Anti-CD34 antibodies using 
Quantum Dots-IgG Secondary Antibody Conjugates 
 
A high level of fluorescence was seen on POSS-PCU-CD34 under confocal 
microscopy, using quantum dot-IgG secondary antibodies (Figure 5.5).  This was in 
stark contrast to POSS-PCU, whereby no fluorescence was detected.  This qualitative 
data was further backed up using quantitative analysis via a fluorescence plate reader, 
which showed a statistically significantly (p < 0.05) higher level of fluorescence on 
POSS-PCU-CD34 (0.8 ± 0.1) compared to POSS-PCU (0.07 ± 0.01) (Figure 5.6).  
This therefore clearly indicates the presence of anti-CD34 antibodies on the surface of 
POSS-PCU-CD34.         
 
 
Figure 5.5.  Immunofluorescence using QDs.  No fluorescence was detected on POSS-PCU surface.  
POSS-PCU-CD34 displayed high fluorescence when QD-IgG secondary antibodies were used for 
primary antibody detection.  Scale bar represents 20 µm.   
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Figure 5.6. Detection of anti-CD34 antibodies on surfaces of POSS-PCU via fluorescence.  POSS-
PCU-CD34 displayed a high level of fluorescence, indicating the presence of anti-CD34 on its surface.  
Results were statistically significant (p < 0.05) from POSS-PCU and negative control.  
 
5.3.1.2. Detection of Chemical Groups via FTIR 
 
The peak at 1100 cm-1 represents the Si-OR functional group in the POSS molecule, 
as POSS has a chemical formula of (RSiO1.5)n.  The peak at 1700 cm-1 represents the 
carbonyl group, C=O, in the urea hard segment and polycarbonate soft segment of the 
POSS-PCU molecule.  The peak at 1200 cm-1 represents the C-O group in urea hard 
segment and polycarbonate soft segment of the POSS-PCU molecule.  FTIR studies 
were consistent with previous studies on POSS-PCU[38], which showed that these 
surface modifications did not alter the chemical integrity of POSS-PCU (Figure 5.7).  
However, due to the fact that the antibodies attached on the surface would only be 
bioactive under physiological solutions (aqueous solutions), we used Raman 
spectroscopy to give complementary information, because in FTIR, water absorbs 
strongly in the IR spectrum. 
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Figure 5.7.  FTIR spectra of POSS-PCU and its biofunctionalized counterparts.  Antibody 
conjugation did not significantly alter the FTIR spectra of POSS-PCU.  The amide I band 
(characteristic of antibodies) was detected on POSS-PCU-CD34, but it was masked be the stronger 
POSS-PCU signal.       
 
5.3.1.3. Detection of Surface Modification via Raman Spectroscopy 
 
All Raman spectra obtained generally had very similar intensities, however they were 
normalized to the intensity of their C-C peak at 1619 cm-1, which comes primarily 
from the PCU part of the material, and thus should not change between the different 
compositions (Figure 5.8). The spectra were offset vertically for easier viewing. The 
positions of the characteristic peaks were calibrated by crystalline Si peak and were 
not seen to drift during the measurement.  The assignments were done using 
established methods and references therein.  The Si-O vibrations are clearly 
discernible from the spectrum, which results after the subtraction of the PCU-rich 
domain spectrum from a POSS-rich one.  The most prominent peaks have also been 
marked in Figure 5.8.  The Si-O cage vibration has been assigned to the peak at 996 
cm-1, while Si-O-H bending vibration has been assigned to 404 cm-1.  The amine 
functionality of the silica particles is too weak to be distinguished from the control 
material, since it is located right next to the very strong C-C band at 1619 cm-1.  It is 
important to note here that no peak can be observed in the vicinity of 2050 cm-1, 
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which would correspond to Si-H vibration.  This means that all of the silsesquioxane 
has been bound to PCU polymer.  Other bands could be assigned as antisymmetric 
(713 and 782 cm-1) and symmetric (1340 and 1464 cm-1) Si-C-H bending vibrations. 
POSS-PCU-CD34 and POSS-PCU-CD34-QD samples did not show any significant 
differences in their Raman spectra, however the former appeared to degrade faster 
under laser beam than the control sample (POSS-PCU). This was not observed (or at 
least to a much lesser extent) with the latter sample (CD34-QD).  There was a 
minimal gain, if any, of the intensity of those bands in the QD sample. 
  
 
 
 
Figure 5.8.  Raman spectra of POSS-PCU and its POSS-PCU-CD34.  (A) Consistent with FTIR 
results, conjugation of anti-CD34 antibodies did not significantly alter the Raman spectra.  (B) 
Attachment of quantum dot-IgG complex onto POSS-PCU-CD34 resulted in an amplification of the 
Raman signal at 1041 cm-1 and 1139 cm-1.  (C) A spectral difference was obtained after subtraction of 
PCU-rich domain from the POSS-rich domain.      
 
Raman integration maps were also constructed to assess the POSS-rich and PCU-rich 
regions (Figure 5.9).  After antibody attachment, optical images showed that the 
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polymer displayed a cobblestone-like pattern. This is in agreement with SEM and 3D 
AFM images which showed a ridge-like pattern.  Both the POSS-rich and PCU-rich 
regions can also be seen to be more dispersed after antibody attachment.  More in-
depth Raman integrated studies were done on POSS-PCU-CD34 with QD attached to 
its surface.  We hoped that tethered QDs, which we used for fluorescent detection of 
antibodies would amplify the Raman signals at 1041 and 1139 cm-1 and result in an 
integration map with higher contrast.  Raman AFM images also showed a 
cobblestone-like appearance, in agreement with optical images.  Phase AFM images 
also showed the stiffness variability on the surface, and had a similar pattern to 
Raman AFM and optical scans. Antibody-QDs were also mapped using Raman 
according to their characteristic peaks, and it could be seen that the antibodies were 
well-dispersed throughout the surface of the polymer (Figure 5.10). 
 
 
Figure 5.9.  Raman integration maps of POSS-PCU and POSS-PCU-CD34.  Raman integration 
maps show that surface modifications occur after antibody conjugation, revealing a ridge-like pattern 
and cobblestone appearance on the surfaces of POSS-PCU.  Scale bar represents 5 µm.   
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Figure 5.10.  Raman integration maps of POSS-PCU-CD34-QD.  QDs were tethered onto POSS-
PCU-CD34 for signal amplification, and results clearly show a change in surface characteristics after 
antibody conjugation, with a characteristic ridge-like pattern and cobblestone appearance.  Scale bar 
represents 5 µm.  
 
 
5.3.1.4. Reduction in Water Contact Angle after Antibody Immobilization 
 
POSS-PCU was observed to be hydrophobic, with a water contact angle of 100° (± 
2°) (Figure 5.11).  Antibody conjugation rendered it statistically significantly more 
hydrophilic (p < 0.05), with POSS-PCU-CD34 displaying a contact angle of 80° (± 
3°).  In order to assess that antibodies in general would create a more hydrophilic 
surface, a non-specific antibody isotype (IgG) was conjugated to POSS-PCU (POSS-
PCU-IgG), with results being non-statistically significant (p > 0.05) to POSS-PCU-
CD34.  To function as controls (and contrasts), contact angles of materials that were 
extremely hydrophobic (lotus leaf) and extremely hydrophilic (contact lens) were 
measured.       
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Figure 5.11.  POSS-PCU-CD34 is more hydrophilic compared to POSS-PCU.  Antibody 
immobilization onto POSS-PCU renders it more hydrophilic (p < 0.05), possibly due to the 
amphiphilic nature of proteins.  Positive control (lotus leaf) and negative control (contact lens) showed 
high degrees of hydrophobicity and hydrophilicity respectively.        
 
5.3.1.5. Assessment of Surface Topography using AFM 
 
AFM revealed characteristic bulbous structures on the surface of POSS-PCU, which 
were possibly POSS nanoparticles that had migrated to the surface during solvent 
evaporation (Figure 5.12).  After antibody immobilization, the surface appeared to 
have a more granite-like and ridge-like morphology, possibly due to protein 
aggregates.     
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Figure 5.12. Surface topography of POSS-PCU after antibody immobilization.  Consistent with 
Raman integration maps, AFM images reveal a ridge-like pattern and cobblestone appearance of 
POSS-PCU-CD34.  Scale bar represents 1 µm. 
 
 
5.3.1.6. Assessment of Surface Morphology using SEM 
 
SEM results were largely consistent with AFM results, with a bulbous surface 
observed on POSS-PCU, and a ridge-like and granite-like surface observed on POSS-
PCU-CD34 (Figure 5.13).  The bulbous surface on POSS-PCU can be attributed to 
the presence on POSS nanoparticles that have migrated to the surface during solvent 
evaporation, while the ride-like cobblestone pattern on POSS-PCU-CD34 could be 
due to the presence of antibodies that altered the surface topography.     
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Figure 5.13.  Effect of antibody immobilization on POSS-PCU as seen on SEM. Similar to AFM 
images, SEM images show POSS-PCU having bulbous structures on its surface, while POSS-PCU-
CD34 had a ridge-like cobblestone appearance.  Scale bar represents 1 µm.  
 
5.3.1.7. Detection of Antibody Grafting using XPS 
 
C, O, Si, Cl and N were detected on the surface of POSS-PCU sample (Figure 5.14).  
Part of the O and Si atoms were from POSS, while C, part of O and N were from 
PCU. N is likely to be present in H-N-C=O environment based on the binding energy 
(BE) of N1s.  C, O, Si, N, Cl and Na were detected on the surface of POSS-PCU-
CD34 sample. Part of O and Si are from POSS, while C, part of O and a small part of 
N were from PCU. A large portion of N was from the antibody and was present in 
H2-N-C environment. The higher N% detected in POSS-PCU-CD34 (2.3%) than that 
in POSS-PCU (0.5%) suggests successful grafting of antibody on the surface of 
POSS-PCU (Table 5.2 and Table 5.3). Na and Cl were likely to be present as NaCl, 
which were present in the anti-CD34 concentrate.  Literature has shown that XPS is a 
viable technique for detecting the attachment of antibodies on surfaces.  Taken 
together, results from XPS analysis suggests the successful attachment of antibodies 
on the surface of POSS-PCU.   
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Figure 5.14. Detection of antibody grafting via XPS.  (A) XPS wide survey spectra of POSS-PCU 
and POSS-PCU-CD34 revealed peaks in nitrogen after antibody conjugation.  (B) The binding energy 
level of H2N-C, and N-H-C=O.  (C) Binding energy level of C-C/C-H, and C-O/C-N.    
 
 
Table 5.2. Atomic percentage of the composition of measured samples.  POSS-PCU-CD34 had a 
higher percentage composition of N compared to POSS-PCU, indicating the presence of antibodies on 
its surface.   
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Table 5.3. Peak binding energy and its associated atomic percentage composition of measured 
samples.  POSS-PCU-CD34 showed a higher percentage of C-N, possibly due to the effects of 
antibody grafting on the surface.   
 
5.3.2. Haemocompatibility and Immunogenicity 
 
5.3.2.1. Normal Blood Coagulation Kinetics 
 
The measurement of blood coagulation kinetics in thromboelastography (TEG) is 
divided into 4 parameters: r-time, k-time, α-angle, and maximum amplitude (MA).  In 
this experiment, collagen was used as a positive control as it induces blood 
coagulation, while l-arginine was used as a negative control, as it delays blood 
coagulation.  Untreated samples were blood without any sample treatment. 
 
r-time denotes the time taken from the start of the experiment until the first sign of 
fibrin formation.  The reference range for r-time in blood is between 5 to 7 minutes. 
An r-time lower than this range indicates possible thrombogenicity, while an r-time 
higher than this range indicates possible impairment in blood coagulation.  POSS-
PCU and POSS-PCU-CD34 all displayed r-time that was within the normal range 
(Figure 5.15). 
 
k-time represents the time taken (from the end of r-time) to the time when the clot 
reaches 20 mm.  The reference range for k-time in blood is between 1 to 3 minutes.  A 
k-time that is lower than this range indicates possible thrombogenicity, while a k-time 
that is higher than this range indicates a possible impairment in blood coagulation 
kinetics.  POSS-PCU and POSS-PCU-CD34 all displayed k-time that was within the 
normal range (Figure 5.16).   
 
α-angle measures the rate of clot formation.  The reference range for α-angle in blood 
is between 53° to 67°.  A high α-angle outside the normal range indicates a high rate 
of clot formation (hence thrombogenicity), while a low α-angle outside the normal 
range indicates an impairment of blood coagulation. POSS-PCU and POSS-PCU-
CD34 all displayed α-angles that were within the normal range (Figure 5.17). 
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Maximum amplitude (MA) measures the final clot size, and the reference range for 
MA in blood is between 59 to 68 mm.  A high MA outside the reference range 
indicates possible thrombogenicity, while a low MA outside the reference range 
indicates possible impairment in clotting kinetics.  POSS-PCU and POSS-PCU-CD34 
all displayed MA values that were within the normal range (Figure 5.18). 
 
Hence, it could be seen that immobilization of anti-CD34 antibodies onto POSS-PCU 
does not adversely affect its haemocompatibility.   
   
 
Figure 5.15. r-time on TEG.  POSS-PCU and POSS-PCU-CD34 displayed r-time that was not 
statistically significantly different (p > 0.05) from untreated samples, indicating they were 
haemocompatible.  Collagen was used as positive control, which showed thrombogenicity, while l-
arginine was used as a negative control, which prevented normal clotting from taking place.   
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Figure 5.16. k-time on TEG.  POSS-PCU and POSS-PCU-CD34 displayed k-time that was not 
statistically significantly different (p > 0.05) from untreated samples, indicating they were 
haemocompatible.  Collagen was used as positive control, which showed thrombogenicity, while l-
arginine was used as a negative control, which prevented normal clotting from taking place.   
 
 
 
Figure 5.17. α-angle on TEG.  POSS-PCU and POSS-PCU-CD34 displayed α-angles that were not 
statistically significantly different (p > 0.05) from untreated samples, indicating they were 
haemocompatible.  Collagen was used as positive control, which showed thrombogenicity, while l-
arginine was used as a negative control, which prevented normal clotting from taking place.   
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Figure 5.18. MA on TEG. POSS-PCU and POSS-PCU-CD34 displayed MA values that were not 
statistically significantly different (p > 0.05) from untreated samples, indicating they were 
haemocompatible.  Collagen was used as positive control, which showed thrombogenicity, while l-
arginine was used as a negative control, which prevented normal clotting from taking place.    
 
5.3.2.2. Decrease in Platelet Adhesion and Activation 
 
Under SEM, it was observed that platelet adhesion was greatest on collagen (control) 
(Figure 5.19). POSS-PCU had less platelet adhesion compared to collagen, and 
POSS-PCU-CD34 had an even lower amount of platelet adhesion.  This observation 
under SEM was correlated to the normalized platelet density, whereby collagen 
demonstrated the highest levels of platelet adhesion (Figure 5.20).  POSS-PCU and 
POSS-PCU-CD34 had a statistically significantly lower (p < 0.05) amount of platelet 
adhesion compared to collagen.  Interestingly, POSS-PCU and POSS-PCU-CD34 also 
displayed a statistically significantly lower (p < 0.05) amount of platelet adhesion 
compared to tissue culture plate (TCP), which served as a control as well. 
 
The degree of platelet activation was observed under SEM (Figure 5.21).  Non-
activated platelets have a small spherical appearance, whereas activated platelets 
adopt a drastic change in morphology, with extended pseudopodia.  This was 
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observed under SEM as well, whereby collagen displayed a high degree of platelet 
activation, while POSS-PCU-CD34 had platelets that were non-activated.   
 
 
Figure 5.19. SEM of platelet attachment. (A) The greatest level of platelet adhesion can be observed 
on collagen.  (B) POSS-PCU displayed a lower amount of platelet adhesion compared to collagen.  (C) 
POSS-PCU-CD34 displayed a lower amount of platelet adhesion than POSS-PCU. Scale bar represents 
10 µm.      
 
 
 
Figure 5.20.  Reduction in platelet adhesion after antibody conjugation.  Collagen served as a 
positive control, and displayed the highest levels of platelet adhesion.  POSS-PCU had a statistically 
significantly lower level of platelet adhesion compared to collagen.  POSS-PCU-CD34 had a 
statistically significantly lower level of platelet adhesion compared to POSS-PCU.  TCP (tissue culture 
plate) served as a control, and it had a higher level of platelet adhesion compared to POSS-PCU.    
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Figure 5.21. SEM of platelet activation.  POSS-PCU and POSS-PCU-CD34 displayed platelets that 
were not activated.  In contrast, collagen displayed activated platelets on its surface. Scale bar 
represents 1 µm. 
   
5.3.2.3. Erythrocyte Compatibility and Haemolysis Assay 
 
Erythrocytes that were cultured on POSS-PCU and POSS-PCU-CD34 showed normal 
morphology, with its characteristic biconcave disc shape, similar to positive controls 
(Figure 5.22).  This indicates that both POSS-PCU and POSS-PCU-CD34 are 
haemocompatible to the extent that they do not have any adverse effects erythrocytes.  
In contrast, erythrocytes cultured on polyamidoamine (PAMAM), a known toxic 
agent to erythrocytes, displayed abnormal morphology, losing its biconcave disc 
shape and adopting a flattened structure.      
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Figure 5.22. SEM images of erythrocyte compatibility. Erythrocytes cultured on POSS-PCU and 
POSS-PCU-CD34 appeared normal with its characteristic biconcave disc shape, comparable to positive 
control.  In contrast, erythrocytes cultured on negative control (polyamidoamine, PMAM) displayed 
abnormal morphology, losing its characteristic biconcave disc shape.  Scale bar represents 10 µm.   
 
 
Haemolysis assay was also performed, with results showing that blood exposed to 
POSS-PCU and POSS-PCU-CD34 had a statistically significantly lower (p < 0.05) 
percentage of haemolysis compared to positive control (water) (Figure 5.23).  
Furthermore, percentage haemolysis was not statistically significantly (p > 0.05) 
different from negative control (PBS), indicating that the very low levels of 
haemolysis observed could in fact be attributed to experimental sensitivities, rather 
than actual haemolysis.  This further re-confirms the haemocompatible nature of both 
POSS-PCU and POSS-PCU-CD34, making it suitable as a blood-contacting device.       
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Figure 5.23. Haemolysis assay.  POSS-PCU and POSS-PCU-CD34 did not induce haemolysis on 
erythrocytes, indicating its haemocompatibility.  As a control, water was used to haemolyse 
erythrocytes.  
 
5.3.2.4. POSS-PCU-CD34 is Non-Immunogenic  
 
C3a is a fragment in the complement component 3 (C3) in the complement system.  
High levels of C3a is often associated with inflammation and immunogenicity.  Using 
the C3a complement activation assay kit, the absorbance of known amounts of C3a 
were measured, and a standard curve was plotted.  A characteristic sigmoidal curve of 
C3a was obtained, which was in accordance to manufacturer’s guidelines (Figure 
5.24).  Results demonstrated that POSS-PCU and POSS-PCU-CD34 had levels of 
C3a that were not statistically significant (p > 0.05) from negative control, indicating 
that these samples did not elicit an appreciable amount of immune response (Figure 
5.25).  In contrast, positive control had a significantly higher (p < 0.05) level of C3a 
level compared to POSS-PCU and POSS-PCU-CD34. 
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Figure 5.24. Standard curve of C3a complement activation assay.  A sigmoidal curve of the 
absorbance of C3a was plotted using known concentrations of C3a that was provided in the assay kit.   
 
 
Figure 5.25. Levels of C3a detected in samples.  POSS-PCU, POSS-PCU-CD34 and CD34 all 
displayed C3a levels that were not statistically significantly (p > 0.05) different from negative control, 
indicating that they were non-immunogenic.  Positive control (provided in the assay kit) showed high 
levels of C3a levels, indicating immunogenicity.   
 
SC5b-9 is a terminal complement complex that is generated by the activation of the 
complement system.  Measuring levels of SC5b-9 provides an idea of 
immunogenicity.  Using known concentrations of SC5b-9 provided in the assay kit, 
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absorbance was measured, and a standard curve was plotted.  A linear plot was 
generated, and this was in agreement with manufacturer’s guidelines (Figure 5.26).  
POSS-PCU and POSS-PCU-CD34 demonstrated low levels of SC5b-9, similar to that 
of negative control (p > 0.05) (Figure 5.27).  In contrast, positive control showed a 
high level of SC5b-9 levels, with the difference being statistically significant (p < 
0.05) to POSS-PCU and POSS-PCU-CD34. 
 
Taken together, it can be seen that both C3a and SC5b-9 complement activation 
assays indicate that POSS-PCU and POSS-PCU-CD34 is not immunogenic, thereby 
underscoring an aspect of biocompatibility.   
                
 
Figure 5.26. Standard curve of SC5b-9.  A linear plot of the absorbance of SC5b-9 was obtained 
using known concentrations of SC5b-9 that was provided in the assay kit.   
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Figure 5.27. SC5b-9 levels in test samples.  POSS-PCU, POSS-PCU-CD34, and CD34 had SC5b-9 
levels that were not statistically significantly different (p > 0.05) from negative controls, indicating that 
they were non-immunogenic.  Positive control (provided in the assay kit) displayed high levels of 
SC5b-9, indicating immunogenicity.  
 
5.3.3. Efficacy of EPC Capture 
 
5.3.3.1. Significance of Antibody Orientation  
 
Anti-CD34 antibodies were covalently immobilized onto POSS-PCU, via and 
EDC/NHS crosslinker (Figure 5.28). As a control, we have also simply added the 
anti-CD34 antibodies, without EDC/NHS crosslinker.  Therefore, comparison 
between the samples with and without EDC/NHS crosslinker would provide 
information on the role of EDC/NHS crosslinker in maintaining antibodies in their 
correct orientation for optimal antigen capture.   
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Figure 5.28. Illustration of correctly oriented antibodies on POSS-PCU.  Anti-CD34 antibodies 
were covalently attached to the surfaces of POSS-PCU using an EDC/NHS crosslinker.   
 
It was observed that there was a statistically significantly higher (p < 0.05) amount of 
antigens captured on anti-CD34 antibodies that were covalently immobilized using 
EDC/NHS crosslinker, compared to those without EDC/NHS thereby sole relying on 
non-covalent hydrophobic interactions (Figure 5.29).  Indeed, calculations revealed 
that there were almost 2 antigens captured per primary antibody when EDC/NHS was 
used, compared to only 0.5 antigen captured per primary antibody when EDC/NHS 
was not used.  The Hill equation was used to plot a standard curve, relating the 
fractional occupancy against the amount of fed antigens.  Results showed that a linear 
calibration curve was obtained, with coefficient of determination (R2) value close to 
unity, indicating that the data points fit well on the line (Figures 5.30 and Figures 
5.31).  Using the Hill plot, the cooperative index (n) was also established, with results 
showing that with EDC/NHS, n was greater than 1, indicating that the second antigen 
is kinetically encouraged to bind to the antigen-bound antibody (meaning that it each 
antibody has the potential to capture 2 antigens) (Figure 5.32).  Indeed, this 
observation was in agreement with the mol ratio of the captured antigen per antibody, 
where it was shown that around 2 antigens were captured per antibody.  In contrast, 
	   214	  
for samples without EDC/NHS, n was less than 1, which means that the subsequent 
antigens are not kinetically encouraged to bind to the antigen-antibody complex, 
which also correlated well with the mol ratio results.           
 
Figure 5.29. Ratio of captured antigens per immobilized primary antibody, standardized by their 
molarities.  There was a statistically significantly higher (p < 0.05) mol ratio of captured antigens 
when anti-CD34 antibodies were covalently immobilized using EDC/NHS crosslinker, compared to 
samples without EDC/NHS crosslinker.  
    
 
Figure 5.30. Hill plot of sample without EDC/NHS crosslinker.  θ represents the fractional 
occupancy , and [Ag] represents the amount fed antigens.   
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Figure 5.31. Hill plot of sample with EDC/NHS crosslinker.  θ represents the fractional occupancy , 
and [Ag] represents the amount fed antigens.   
 
 
Figure 5.32. Comparison of the cooperative index of samples with and without EDC/NHS 
crosslinker.  Samples with EDC/NHS crosslinker displayed a statistically significantly higher (p < 
0.05) cooperative index, compared to samples without EDC/NHS crosslinker.  
 
5.3.3.2. Successful Isolation of EPCs from Peripheral Blood 
 
6.32 × 107 ± 2.94 × 106 PBMCs were isolated from 20 ml of venous blood in with a 
protocol that was described previously[37, 42, 43] (Figure 5.33).  This method allows 
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the extraction of putative EPCs that would differentiate into cells with characteristic 
EC markers.  Cells were fixed after 7 days, and were assessed to see if they had 
attained an EC-like phenotype.  EPCs displayed elongated spindle-shaped 
morphology after 24 hours.  At day 5, cell clusters began forming.  At day 7, EPC 
clusters were seen as clusters of round cells surrounded by spindle-shaped cells along 
the periphery (Figure 5.34).  Growth of isolated PBMCs on the various polymer 
samples was monitored over a period of 7 days.  Colonies were identified by QD-
immunostaining for EPC markers (CD34/VEGFR-2) (Figure 5.35).  The ability of 
these EPCs to proliferate and differentiate into an EC phenotype was further 
investigated by QD-immunostaining for EC markers (CD32/vWF). 
 
 
 
Figure 5.33. Photograph of buffy coat layer after density gradient centrifugation.  The buffy coat 
contains EPCs.   
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Figure 5.34. Morphological changes of human endothelial progenitor cells (EPCs) isolated from 
peripheral blood, and cultured for 7 days.  (A) Peripheral blood mononuclear cells (PBMCs) 
containing a heterogenous population of EPCs, monocytes, and granulophages, plated on normal 
uncoated tissue culture plate on day 1 (40x magnification).  (B) White arrows point towards EPC 
colonies observed at day 7 (10x magnification).  (C) An EPC colony at day 7, defined morphologically 
as central cluster of rounded cells surrounded by multiple spindle-shaped cells (20x magnification). 
Inset: Black arrows point to multipotent stem cells; white arrows point to EPCs (40x magnification). 
Scale bar represents 20 µm. 
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Figure 5.35. EPCs under light and confocal microscopy. (A) An EPC colony, defined 
morphologically as a central cluster of rounded cells surrounded by multiple spindle-shaped cells (20x 
magnification). (B-D) Expression of VEGFR-2 (red) and CD34 (green) was assessed under laser 
scanning confocal microscopy (10x magnification). Double-positive colonies (yellow) were identified 
as EPC colonies. Scale bar represents 20 µm.   
 
5.3.3.3. Increased EPC Capture with POSS-PCU-CD34 
 
It was observed that POSS-PCU-CD34 was able to capture a higher proportion of 
cells that were positive for both CD34 and VEGFR-2.   This was quantitatively 
represented by FACS, whereby flow cytometry results revealed that 88.9% of cells 
captured on POSS-PCU-CD34 were CD34+VEGFR-2+, whereas only 15.1% of cells 
were CD34+ when cultured on POSS-PCU (Figure 5.36).  Thus it can be seen that 
although we have established a protocol for isolating EPCs, POSS-PCU-CD34 had 
the ability of increasing the efficacy of EPC capture. Furthermore, EPC proliferation 
assay showed that POSS-PCU-CD34 had the ability of maintaining cell growth over a 
period of 28 days, achieving the highest normalized cell density (with statistical 
significance, p < 0.05), compared to POSS-PCU and controls (Figure 5.37).  It was 
also observed that POSS-PCU, POSS-PCU-IgG (negative isotype control), and tissue 
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culture plate (TCP) had a cell proliferation curve that was almost similar in trend over 
the 28 day period.        
 
Figure 5.36. Fluorescence-Activated Cell Sorting (FACS) of EPCs.  Detection and enumeration of 
CD34+ and VEGFR-2+ EPCs was done using flow cytometry.  Results indicate that a high percentage 
(89.8%) of cells grown on POSS-PCU-CD34 were double positive for CD34 and VEGFR-2, compared 
to cells grown on POSS-PCU.   
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Figure 5.37. EPC proliferation assay over 28 days.  POSS-PCU-CD34 displayed the highest rate of 
EPC proliferation, compared to POSS-PCU and controls.  Cell density on POSS-PCU-CD34 was 
statistically significantly higher (p < 0.05) compared to POSS-PCU and controls.   
 
5.3.3.4. Immunofluorescence of EPCs Grown on POSS-PCU-CD34 
 
EPCs were seeded onto various samples, and grown over a period of 28 days.  
Immunofluorescence was performed at day 7, to detect the presence of specific 
surface markers which would identify them as EPCs.  Confocal microscopy revealed 
that only POSS-PCU-CD34 was capable of capturing and maintaining the growth of 
EPCs that were positive for CD34, VEGFR-2, CD31, and vWF; surface markers that 
would identify them as EPCs (Figure 5.38 and Figure 5.39).  In contrast, POSS-PCU-
IgG (control antibody isotype), and POSS-PCU did not display any detectable 
fluorescence of specific cell markers under confocal microscopy, indicating that they 
were unable to capture and maintain the growth of EPCs.  A control cell line (HT-29 
colorectal cell) was used in order to show the specificity and cell-capturing efficacy of 
POSS-PCU-CD34    
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Figure 5.38. Immunofluorescence of EPCs grown on various samples.  Confocal microscopy 
revealed that of all polymer samples, cells that were double positive for CD34 and VEGFR-2 were 
only present on POSS-PCU-CD34.  A control cell line (HT-29 colorectal cell) was used as a negative 
control against EPCs.  Scale bar represents 40 µm.   
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Figure 5.39. Immunofluorescence of EPCs grown on various samples.  Confocal microscopy 
revealed that of all polymer samples, cells that were double positive for CD31 and vWF were only 
present on POSS-PCU-CD34.  A control cell line (HT-29 colorectal cell) was used as a negative 
control against EPCs.  Scale bar represents 40 µm.   
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5.4. Discussion 
 
Re-endothelialization is an essential aspect of restoring vascular homeostasis after 
stenting.  Although it was previously thought that the process of re-endothelialization 
happens with the migration and proliferation of mature endothelial cells that are near 
to the denudated regions[44], recent research has focused on a novel mechanism of 
vascular repair involving bone marrow-derived precursor / stem cell: the endothelial 
progenitor cell (EPC).  It has been suggested that mobilization of EPCs occur after 
vessel injury, and are able to home in to sites of endothelial denudation[45] for the 
purposes of re-endothelialization[46].  The placement of stent struts within a vessel 
would cause laceration of the internal elastic lamina, which may even extend through 
to the tunica media and into the external elastic lamina[47].  Aggregation and 
activation of platelets, and a subsequent thrombus formation occur after vessel injury, 
which would ultimately lead to acute / sub-acute stent occlusion[48].  Vessel injury 
also causes local[47] and systemic[49] inflammation, characterized by a rapid influx 
of monocytes and macrophages into the vessel wall. Migration and proliferation of 
vascular smooth muscle cell (VSMCs), fibroblasts, and the recruitment of adventitial 
myofibroblasts occur due to cytokine and growth factors release, and collectively 
contribute to neointimal hyperplasia and in-stent restenosis[50].  Using scanning 
electron microscopy (SEM), Grewe et al has demonstrated how stent integration 
occurs within a vessel over a period of time[51].  A thin multi-layered thrombus can 
be detected between the vessel lumen and arterial wall within the first 6 weeks after 
stent placement.  As time progresses, the amount of VSMCs and extracellular matrix 
increases.  From week 6 to 12, a resolution of thrombus happens, and endothelial cells 
begin to populate the stented area.  Completion of re-endothelialization occurs after 
around 3 months post-stenting.  This time frame also coincides with the decrease in 
the amount of VSMC.  In summary, it is evident that the endothelium plays a 
prominent role not only in endogenous fibrinolysis and vasomotor function, but also 
functioning as a protective barrier against VSMC by secreting inhibitory factors.              
 
Although Asahara et al first used the term “EPC” in 1997[45], the exact definition of 
what constitutes a “true” EPC remains contentious.  In general, 2 methods can be 
employed in the identification of EPCs: 1. Identification of cell markers that indicate 
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cellular naïveté and endothelial origin. 2. Looking for the presence of endothelial 
precursors within a cell population by identifying mature endothelial cell 
characteristics.  In terms of surface markers, EPCs can be defined by the expression 
of CD34 (to denote cellular naïveté) and vascular endothelial growth factor receptor-2 
(VEGFR-2) (to denote a vascular phenotype)[45].  Similar to the importance of 
endothelial cells in regulation of vessel homeostasis, EPCs are postulated to play a 
significant role in vascular biology as well.  Indeed, it has been shown that levels of 
CD34+VEGFR-2+ are decreased in patients with cardiovascular risk factors such as 
diabetes mellitus[52], hypertension[53], and elevated levels of low-density lipoprotein 
(LDL)[54].  Conversely, a strong association has been linked between high levels of 
circulating CD34+VEGFR-2+ concentration, and freedom from myocardial infarction, 
revascularization, and mortality.  Furthermore, evidence suggests that levels of 
CD34+VEGFR-2+ cells in patients decrease with age[55].  A genetic component has 
also been demonstrated, whereby offsprings of individuals with coronary heart 
disease have reduced levels of CD34+VEGFR-2+ cells, compared to healthy 
individuals[56].  Due to the fact that expression of CD34 and VEGFR-2 are also 
present on mature endothelial cells[57], it has been suggested that CD133 could also 
function as a marker of cell naïveté for EPC identification.  However, there are also 
conflicting reports, with studies showing that CD133 is more appropriate for 
identifying haematopoietic cell lines which are not capable of forming true EPCs[58, 
59].   
 
Enumeration of EPCs can be done via functional assays, the most common of which 
is called the endothelial cell colony-forming unit (EC-CFU), which was first 
described by Hill et al[60].  Characterization and generation of EC-CFU is done from 
a non-adherent population of mononuclear cells that are grow on fibronectin, and 
display endothelial expressions such as CD31, von Willebrand Factor (vWF), CD34, 
CD31, CD105, CD141, CD146, Tie-2, KDR, and E-selectin, and the ability to bind 
lectins and take up acetylated LDL.  This lends credence to the notion that EC-CFUs 
are endothelial cells that are formed from circulating progenitor cells.  However, there 
are also contradictory reports showing that surface antigens used to identify mature 
endothelial cells are non-specific, and are in fact common to peripheral blood 
monocytes[61].  Other reports have further supported this finding, to show that EC-
CFUs are made up of monocytes and angiogenic lymphocytes[62, 63], thereby having 
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little potential of forming vessel-like structures[64].  Interestingly enough, EC-CFUs 
actively secrete angiogenic factors like matrix metalloproteinase-9 (MMP-9), stromal 
derived factor-1 (SDF-1), interleukin-8 (IL-8), vascular endothelial growth factor 
(VEGF), hepatic-like growth factor, granulocyte-macrophage colony-stimulating 
factor, and granulocyte colony-stimulating factor (G-CSF).  These factors are 
associated with the mobilization of progenitor cells from bone marrow to enhance 
angiogenesis[63, 65].  Indeed, research has shown that patients with diabetes 
mellitus[66], coronary artery disease[67], and hypertension[68] have reduced levels of 
EC-CFUs.  On the other hand, high levels of EC-CFUs are linked to enhanced 
vascular function[60].  It has also been observed that EC-CFUs are mobilized in 
response to cardiovascular stresses and percutaneous coronary interventions[69-72].  
Hence, it is evident that EC-CFU could function as a marker for cardiovascular heath, 
and could also serve as an approximation for EPC characterization.    
 
The main premise of developing a biofuntionalized polymer for cardiovascular 
applications is to circumvent restenosis and thrombosis in order to sustain long-term 
patency and viability.  Furthermore, adopting a “pro-healing” approach such as 
mobilizing endothelial progenitor cells to form a confluent layer of endothelium is 
one way to restore vessel homeostasis.  POSS-PCU has been previously shown to 
function as a viable material for cardiovascular applications due to its superior 
biocompatibility and mechanical properties[38, 73].  In this chapter, we have sought 
to increase the EPC capture potential of a POSS-PCU nanocomposite polymer via the 
immobilization of anti-CD34 antibodies on the surface.  The native vascular 
endothelium normally provides an efficient anti-thrombotic and anti-coagulant barrier 
against thrombus formation, lipid uptake, and inflammatory cell migration[74].  It 
also regulates VSMC growth by acting as a physical barrier separating VSMCs from 
circulating growth factors, and by secreting inhibitory factors that limit VSMC 
proliferation and migration[75].  It is hence not surprising that inevitable endothelial 
injury during PCI and the absence of an endothelial layer on stents are implicated in 
the restenotic and thrombotic events occurring post-PCI. The formation of a 
functional, competent endothelium on stent surfaces is therefore crucial to preventing 
both thrombosis and restenosis.   
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Early studies focused on cultivating patient-isolated ECs to confluence on implant 
surfaces in vitro, before implanting the autologous endothelium back into the 
patient[76-78].  However, this strategy has several disadvantages that render it 
clinically unfeasible: firstly, an initial surgery is required for a vessel biopsy; 
secondly, retention of ECs on the implant surface under exposure to blood flow has 
proven to be a challenge; and thirdly, in vitro endothelialization is time-consuming 
and expensive, with a high risk of contamination[75, 79].  An alternative strategy that 
has garnered much research attention in recent years involves capturing circulating 
endothelial progenitor cells (EPCs) onto the stent surface, thereby generating an 
autologous endothelium in situ[80, 81].  EPCs have been widely investigated for 
tissue engineering applications for a number of reasons: firstly, their relative ease of 
isolation; secondly, their high capacity for proliferation in vitro; thirdly, their ability 
to retain a capacity for differentiation; and fourthly, their ability to migrate to sites of 
vascular injury.  
 
Numerous in vitro and in vivo studies have successfully demonstrated induction of 
EPC mobilization, homing, incorporation to target sites, and/or differentiation into an 
EC monolayer. Notably, a substantial number of these studies employed surfaces 
biofunctionalized with the EPC-specific anti-CD34 antibody to capture circulating 
EPCs[37, 42, 80, 82-88].  Encouraging results have been achieved with the anti-
CD34-coated GenousTM Stent (GS) (OrbusNeich), which follow-up studies have 
shown to be safe even after 3 years post-implantation[75, 80, 86, 87, 89, 90].  The 
results of 3 clinical studies provide substantive evidence of significantly accelerated 
re-endothelialization of the stent surface and decreased thrombogenicity with the use 
of GS over BMS[87, 90-93].  Anti-CD34-mediated EPC adhesion appeared to protect 
against the blood-implant interactions leading up to thrombosis and restenosis, such 
as the adhesion of platelets, fibrin, and inflammatory cells. Additional in vitro and in 
vivo experiments by Larsen et al provide further support for anti-CD34 
immobilization as a viable strategy for EPC capture[87].  An in vitro EPC-capture 
assay demonstrated a preferential adhesion of human peripheral blood-derived CD34+ 
cells to GS over BMS. An in vivo baboon AV shunt model showed that GS inhibits 
in-stent thrombosis, as indicated by a significantly lowered platelet deposition 
compared to BMS, while in a rabbit endothelial denudation model, analysis of EC 
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markers expression after 7 days indicated that GS significantly promotes re-
endothelialization[87].   
 
Despite the large amount of literature on the EPC capture efficacy of anti-CD34-
coated surfaces, much less work has been done on the hemocompatibility of these 
modified surfaces. While these surfaces aim to increase EPC adhesion, they 
inadvertently run the risk of increasing clotting tendencies by encouraging non-
specific platelet or leukocyte adhesion[7].  It is therefore important for the anti-CD34-
coated stent surface to be anti-thrombogenic and anti-inflammatory itself, so as not to 
activate pro-coagulatory cascades that jeopardize stent patency, and in the process, 
effectively address both issues of restenosis and thrombosis through rapid surface 
endothelialization in situ.  Results in this chapter clearly indicate that POSS-PCU-
CD34 is non-thrombogenic, when compared to controls.  Considering that POSS-
PCU is known to be non-thrombogenic, that observation that POSS-PCU-CD34 is 
even less thrombogenic (less platelet adhesion) than POSS-PCU itself lends credence 
to the concept that biofunctionalizing polymers with appropriate antibodies on its 
surface can confer haemocompatiblity.       
 
Literature on in vitro and in vivo studies indicate that CD34+ cells have the potential 
to differentiate into mature EC and VSMCs.  Furthermore, EPCs can release growth 
factors such as VEGF, which can upregulate mobilization and proliferation of 
VSMCs[79, 94].  Another important factor to consider is that EPCs make up a very 
small proportion of PBMCs; flow cytometry has indicated that only 0.002% of 
PBMCs are positive for CD34, and only 0.4 ± 0.2 % of this percentage are EPCs, 
defined by being positive for VEGFR-2 and CD133[94].  Evidence has shown that 
anti-CD34 antibodies can attract other cells such as granulocytes, monocytes, and 
plasma proteins like fibrinogen.  Hence, there is a will be a possible scenario that 
these cells would also compete with CD34 positive EPCs for binding on anti-CD34 
antibodies.  Interestingly enough, a study propounded the use of granulocyte colony 
stimulating factor (G-CSF) could mobilize EPC for the repair of injured arteries[95].  
However, more in vivo studies would be needed to ascertain if the application of G-
CSF in tandem with EPC-capturing stents could increase its endothelialization 
efficacy.  It was previously reported that despite accelerated endothelialization on 
CD34-coated ePTFE grafts and stents, there was also a higher degree of intimal 
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hyperplasia[96].  Hence, solely relying on anti-CD34 as a strategy to achieve 
endothelialization might not be sufficient, considering that there is a probability of 
indiscriminate binding of other cells to anti-CD34 antibodies.  Indeed, there is a risk 
of intimal hyperplasia and increased cell proliferation index if cell capture technology 
is not sufficiently optimized for accuracy and specificity[75, 81, 86, 97]. 
 
It is important to note that one limitation of this study is that the static culture was not 
representative of cells within the luminal area of blood vessels, which are in 3D and 
exposed to flow conditions.  Evidence suggests that cells grown in 3D perfused 
reactors might be more representative of physiological conditions compared to 2D 
static conditions.  Furthermore, it has been shown that fluid shear stress can influence 
the differentiation of progenitor cells into endothelial cells[98].  Therefore, a dynamic 
flow circuit calibrated to physiological conditions might serve as a better 
approximation in studying the growth and proliferation of EPCs into ECs. 
 
In material science, surface modifications (chemical or physical) can often be 
detected by measuring its water contact angle.  In terms of thermodynamics, water 
contact angle is governed by the Young’s equation: 
 
ϒLG cosθc = ϒSG − ϒSL 
 
Where ϒLG is the liquid-gas interfacial energy, θc is the equilibrium contact angle, ϒSG 
is the solid-gas interfacial energy, and ϒSL is the solid-liquid interfacial energy.  
However, if we consider other factors like the roughness of a surface, the Wenzel 
equation comes into play, where it describes how a hydrophobic surface can become 
more hydrophobic, and a hydrophilic surface becomes more hydrophilic when 
roughness is increased.  The Wenzel equation is written as: 
 
cosθapp = Rroughcosθ 
 
Where Rrough is the ratio of the actual and projected surface area, θapp is the apparent 
contact angle which corresponds to the equilibrium state, and θ is the Young contact 
angle for an ideal surface.  From this equation, it can be inferred that for hydrophobic 
surfaces (when θ > 90°), θ would increase with increasing roughness, since Rrough is 
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always > 1.  However, one limitation of the Wenzel model is that it cannot adequately 
describe chemically heterogenous surfaces.  In this scenario, the Cassie model is more 
appropriate, where it is written as: 
 
cosθA = f1cosθ1 + f2cosθ2 
 
Where f1 and f2 are the areas of the material expressed as a fraction of each other (i.e. 
f1 + f2 = 1), and θ1 and θ2 are the contact angles of the pure materials of 1 and 2 
respectively.   
 
In this chapter, it was shown that immobilization of antibodies onto the surface of 
POSS-PCU resulted in a reduction in water contact angle.  This alterations in surface 
chemistry was also seen via Raman spectroscopy (and to a lesser extent, FTIR).  
Raman integration maps clearly show detectable changes visually, and this also 
correlated well with SEM and AFM images.  It was generally seen that the bulbous 
surface of POSS-PCU adopted a more ridge-like cobblestone pattern, with an increase 
in surface roughness as well.  The surface modification also manifested itself in terms 
of its interaction with platelets, whereby there was a lower level of platelet adhesion 
on POSS-PCU-CD34, compared to POSS-PCU alone.  An attempt was therefore 
made to correlate water contact angle to haemocompatibility.  The relationship 
between surface wettability and thrombogenicity, however, is contentious.  While 
there is evidence suggesting that hydrophobic materials such as ePTFE are 
thrombogenic due to its affinity for plasma proteins such as fibrinogen[7], others have 
argued the converse.  It has also been postulated that due to the adsorption of different 
proteins on hydrophobic surfaces, there is increased competition between proteins and 
clotting factors, thereby reducing surface-induced activation of pro-coagulating 
factors[99].  Therefore, it seems likely that thrombogencity of a material is often 
dictated by the type of proteins that are preferentially adsorbed onto the surface.  For 
instance, fibrinogen would increase thrombogenicity, while albumin would decrease 
it.  More in-depth studies on the interaction of various proteins and soluble factors on 
POSS-PCU and POSS-PCU-CD34 would therefore be crucial for understanding its 
haemocompatiblity. 
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A crucial aspect that needs to be explored is the functionality of antibodies, after it 
has been immobilized onto a surface.  It has been suggested that, once immobilized, 
proteins invariably lose their high bioactivity[100-104]. Reports have shown that, 
with antigen-antibody reactions as prime examples, the dissociation constant (Kd) of 
immobilized antibodies to antigens range from 10-7 to 10-5 mol/l, while their non-
immobilized (soluble) counterparts display binding affinities that are around a 
thousand-fold greater in magnitude, with Kd of around 10-10 to 10-9 mol/l[105-107].  
This tremendous loss of bioactivity is well-known, and is thought to be due to the 
denaturation of the three-dimensional globular structure of the protein[108-111], and 
possible steric hindrance at the antigen-binding sites[103, 104]. Molecular orientation 
of immobilized antibodies is an important area of research due to its implications in 
immunoassay sensitivities.  Ideally, in order to preserve functionality, the 
immobilized proteins should not be denatured due to the fact that bioactivity relies on 
both the orientation (accessibility and capacity of the binding site) and conformation 
(reactivity of the binding site).  Protein denaturation happens when hydrogen bonds 
are cleaved due to external stimuli, thereby resulting in a three-dimensional structure 
that can no longer retain its native configuration.  The loss of bioactivity can also be 
due to the type of immobilization process employed, as well as the type of material 
(substrate) on which it is immobilized onto.  The most common technique of 
attaching antibodies onto surfaces is via hydrophobic interactions, because it is 
versatile and simple to perform.  However, although a relatively convenient way of 
immobilization, this method usually results in denaturation.  It has shown that, at 
extreme cases, more than 90% of antibody bioactivity can be lost when this 
hydrophobic interaction technique is used[101].  Denaturation occurs in this case due 
to a thermodynamic driving force that alters the protein’s native three-dimensional 
configuration to facilitate the hydrophobic portion of the protein to bind with the 
substrate surface[112]. Interestingly, it has been reported that, in contrast to 
hydrophobic surfaces, hydrophilic surfaces tend to reduce the consequent 
denaturation of the antibody[113-118].  Indeed, this was consistent with our results 
whereby POSS-PCU was rendered more hydrophilic after EDC/NHS crosslinking and 
antibody conjugation.     
 
In our study, the dissociation constant (Kd) of antigen-antibody reaction was 
calculated using the Hill equation for multivalent binding analysis. Various analytical 
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methods for antibody-antigen binding for immunological applications have been 
reported[116, 119-123].  For instance, for monovalent binding in antibody-antigen 
reactions, the conventional Scatchard plot is relevant as long as Langmuir adsorption 
is assumed.  For our application, the vast majority of immobilized antibodies were 
considered bivalent, and hence, their reactivity can be assessed using the Hill 
equation[124, 125].  The Hill equation is as follows: 
 
θ = [Ag]n / (Kd + [Ag]n) 
 
Where θ is the fractional occupancy defined by the ratio of the amount of captured 
antigen to the amount of surface-immobilized antibody, [Ag] is the amount of fed 
antigens, and n is the Hill coefficient.  Rearranging this equation gives us the Hill 
plot, which is written as: 
 
log [θ / (1− θ)] = nlog [Ag] – log Kd 
 
In order to estimate the Kd of antigen-antibody reaction as applied to antibody 
orientation, the amounts of surface-captured antigens were quantified in response to 
different concentrations of IgG solutions, and a linear response curve was obtained.  
We were then able to derive the dissociation constant and Hill coefficient from the 
linear response curve.  Our results indicate that covalent bonding via EDC/NHS 
crosslinking was superior to random hydrophobic interactions, as it had a higher 
binding constant, and their Kd value did not decline compared to those of native 
antibodies.  Therefore, it can be inferred that our results clearly indicate the 
importance of antibody orientation.  Antibodies that are correctly oriented are able to 
capture more antigens, display more stable binding, possibly due to the increased 
spatial capacity around their binding sites.  In contrast, antibodies which are 
orientated in a random fashion display weak binding capabilities.   
 
The Hill coefficient, n, represents the cooperativity of antigen binding[123].  If n > 1, 
(i.e. a positive cooperativity), there will be a kinetic driving force for the second 
antigen to bind to the antigen-bound antibody.  This increases the probability of 
observing antibodies that are able to capture two antigens.  On the other hand, if n < 
1, (i.e. a negative cooperativity), there is a very low probability of a second antigen to 
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bind to an antibody that is already bound to the first antigen. If n = 0, no cooperativity 
will be observed, which means that each binding site functions independently of each 
other.  Consistent with this principle, our results reveal that the Hill coefficient for 
randomly oriented antibodies (no EDC/NHS crosslinker) is approximately equal to 1, 
while properly oriented antibodies (with EDC/NHS crosslinker) had a Hill coefficient 
that is greater than 1.  Indeed, we estimate that our immobilized antibody captured an 
average of 1.8 ± 0.2 antigens.  Therefore, we hypothesize that controlling the 
orientation of anti-CD34 antibodies allowed more spatial configuration for antigen 
binding, giving rise to stable complexes with a high antigen/antibody ratio.  In 
summary, our observation of positive cooperativity largely supports this hypothesis.           
 
5.5. Conclusion 
 
In conclusion, we have demonstrated a proof-of-principle and viable technique to 
immobilize anti-CD34 antibodies onto the surfaces of POSS-PCU, for the express 
purpose of capturing EPCs.  Various biophysical techniques were used to characterize 
the resultant surface modifications, and functional assays were also performed to 
track its in vitro efficacy.  Taken together, it can be seen that anti-CD34 antibodies 
were correctly oriented on the surface of POSS-PCU for optimized EPC capture.  
Furthermore, we have also established that POSS-PCU-CD34 is haemocompatible 
and biocompatible, and harbours the ability to capture a higher amount of EPCs 
compared to controls, with greater specificity.  
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6.1. Introduction 
 
The advent of drug-eluting stents (DES) was a considered revolutionary method of 
utilizing a permanent scaffold to maintain vessel patency (as seen in bare-metal stents 
(BMS)), while simultaneously serving as a sustained and controlled platform for 
localized drug release.  Drugs used in DES are anti-cancer agents, such as sirolimus 
(and its derivatives), and paclitaxel.  The development of paclitaxel was led by the 
United States National Cancer Institute, in its quest to find anti-cancer drugs from 
natural sources.  Paclitaxel was derived from the leaves, roots, and barks of several 
types of Pacific yew tree species, namely Taxus brevifolia. The United States Food 
and Drug Administration (FDA) approved paclitaxel in 1992, for the treatment of 
metastatic ovarian cancer.  Schiff et al first described the mechanism of action of 
paclitaxel, as a promoter of microtubule assembly[1].  In contrast to other vinca 
alkaloids which trigger the disassembly of microtubules, paclitaxel induces the 
polymerization of β-tubulin into stable microtubules (Figure 6.1).  This overly-stable 
configuration of microtubules prevents anaphase, thereby stopping cell division[2, 3].  
In addition to its function as forming mitotic spindle fibres during cell division, 
microtubules are also involved in a wide range of cellular functions such as 
intracellular transport, signal transduction, cell motility, and maintenance of cell 
shape[2].  Therefore, paclitaxel’s action on stabilizing microtubule assembly 
interrupts a plethora of cellular activity, such as cell division, migration, cytoskeletal 
processes, and transport of membrane proteins (Figure 6.2).  More importantly, 
studies have found that paclitaxel can effectively inhibit neointimal hyperplasia (IH), 
thereby circumventing in-stent restenosis (ISR)[4-7]. 
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Figure 6.1. The mechanism of action of paclitaxel. Figure reproduced with permission from 
Lippincott Williams & Wilkins. Copyright © 2008 Lippincott Williams & Wilkins.   
 
 
Figure 6.2. The interaction of paclitaxel on the cell cycle.  Figure reproduced with permission from 
Eurocor GmbH.  Copyright © 2013 Eurocor GmbH.   
 
Paclitaxel has a molecular formula of C47H51NO15, and a molecular mass of 853.91.  
Its molecular structure consists of a tetracyclic core, and an ester-linked side chain at 
the carbon 13 position of the tetracyclic core (Figure 6.3).  It has a melting point of 
between 209.3 to 216.2 °C, and an octanol/water coefficient range of 600 to 800 in 
various buffer and octanol concentrations[8-10].  Paclitaxel has a limited solubility in 
water, with values ranging from 0.3 to 30 µg /ml.  This wide range of solubility is 
attributed to the existence of paclitaxel hydrates, which possess a lower aqueous 
solubility compared to the anhydrous form[11].  The chemistry of paclitaxel is well-
documented, and there are published reports describing its crystallographic data, mass 
spectra, nuclear magnetic resonance (NMR) data, and molecular interactions[3, 11-
16].           
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Figure 6.3. The chemical structure of paclitaxel.  Figure reproduced with permission from Creative 
Commons. Copyright © 2013 Creative Commons. 
 
Due to the fact that paclitaxel has poor solubility in water, an excipient was necessary 
to confer solubility for clinical use.  In this respect, paclitaxel (trade name Taxol®) 
was initially dissolved a type of castor oil, Cremophor EL (BASF SE, Germany).  
However, the inherent toxicity of Cremophor EL (rather than paclitaxel itself), which 
included the leaching of plastic intravenous tubing and hypersensitivity reactions 
which led to deaths in patients, meant that a new excipient had to be found[17].  To 
this end, a nanoparticle formulation of paclitaxel that is bound to albumin (trade name 
Abraxane®) was developed.  Indeed, research into nanotechnology-based delivery 
agents has engendered various polymeric nano-formulations of paclitaxel, such as 
poly(lactic-co-glycolic) acid (PLGA)[18], and lipid-based formulations such as 
liposomes[19]. The concept of drug delivery using liposomes as a nanoscale drug 
delivery vehicle has been recognized as an attractive means of increasing efficacy 
while reducing toxicity, thereby enhancing its therapeutic index[20, 21].  Various 
forms of liposomal drug formulations are currently in clinical use for the treatment of 
cancer.  For example, Doxil®, a PEGylated liposomal formulation of doxorubicin, 
was the first FDA-approved liposomal drug[22] for use in recurrent ovarian 
cancer[23] and refractory multiple myeloma[24].  For this reason, it has been 
proposed that liposomal formulations of paclitaxel could also be developed[19], as a 
way of increasing its efficacy.  In contrast to hydrophilic drugs (e.g. doxorubicin), 
hydrophobic paclitaxel would be confined within the phospholipid bilayer of the 
liposome due to hydrophobic interactions with the hydrocarbon tail (Figure 6.4).  The 
attachment of polyethylene glycol (PEG) to the surface of liposomes increases its 
circulation time in the body, as it is able to avoid the mononuclear phagocytic system 
(MPS).  The presence of PEG on the surface of liposomes confers steric repulsion of 
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proteins, thereby preventing opsonization and destruction by phagocytes[25] (Figure 
6.5).  Furthermore, it has been shown that PEGylation increases biocompatibility and 
reduces thrombogenicity[26-29]. 
 
 
 
Figure 6.4. Schematic of a liposome. (A) Liposomes are spherical vesicles of phospholipids, and 
consists of a hydrophilic phosphate head and a hydrophobic hydrocarbon tail. (B) Hydrophilic drugs 
(e.g. doxorubicin) can be encapsulated within the aqueous core of the liposome, while hydrophobic 
drugs (e.g. paclitaxel) are confined within the lipid bilayer membrane.  Figure reproduced with 
permission from NeoPharm, Inc.  Copyright © 2007 NeoPharm Inc.         
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Figure 6.5. PEGylated phospholipids for generating stealth liposomes. Figure reproduced with 
permissions from NOF Corporation.  Copyright © 2013 NOF Corporation.   
 
 
The main premise of a drug-eluting platform on a stent is to inhibit the proliferation of 
vascular smooth muscle cell (VSMC).  In physiological conditions, VSMC maintain a 
quiescent and contractile phenotype that is responsible for the regulation of vessel 
tone.  However, in pathological conditions or injury (e.g. during stenting), VSMCs 
lose their quiescence and become activated, adopting a proliferative phenotype, 
ultimately causing in-stent restenosis (ISR) due to intimal hyperplasia[30, 31].  
Current standards in FDA-approved DES (e.g. TAXUS stent, Boston Scientific) 
consist of a polymer matrix that is mixed with paclitaxel.  Paclitaxel would then be 
eluted from the polymer matrix to inhibit VSMC.  However, there is evidence to 
suggest that paclitaxel can upregulate tissue factor (TF) and mediate thrombosis[32, 
33].  Therefore, rather than directly dissolving paclitaxel within the polymer matrix, 
we postulate that using PEGylated liposomal paclitaxel within the polymer would 
confer haemocompatibility, and fucntion as a sustained and controlled release 
platform for the inhibition of VSMC.           
 
In this chapter, PEGylated (stealth) liposomes are used as nano-carriers as well as an 
excipient for the delivery of paclitaxel.  The liposomal paclitaxel is then sprayed on 
the surface of a POSS-PCU polymer, with an additional ultra-thin topcoat of POSS-
PCU layer to function as a sustained and controlled release reservoir.  It is thus 
hypothesized that liposomal paclitaxel on a POSS-PCU base platform could serve as a 
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more effective means of delivering therapeutic agents, compared to non-liposomal 
paclitaxel.       
 
6.2. Materials and Methods 
 
Standard laboratory reagents and chemicals were obtained from Sigma-Aldrich UK, 
while standard cell culture reagents were obtained from Life Technologies UK, unless 
otherwise stated.  Informed consent and approval from the Institutional Review Board 
were obtained for procedures involving human tissue. All experiments were done in 
triplicates (n=3) unless otherwise stated. A tabulated description of samples is listed 
in Table 6.1. 
 
Table 6.1. Tabulated description of samples. 
 
Sample Description 
Pacli Paclitaxel that has been integrated into POSS-PCU 
polymer film 
Pacli-Lipo Liposomal paclitaxel that has been integrated into 
POSS-PCU polymer film 
Lipo Empty liposomes (no paclitaxel payload) that has been 
integrated into POSS-PCU films 
POSS-PCU Plain POSS-PCU films 
 
 
6.2.1. Generation of Stealth Liposomes 
 
PEGylated phospholipids, N-(carbonyl-methoxypolyethyleneglycol 2000)-1,2-
distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-020CN) were obtained from 
NOF Corporation, Japan.  Liposome mini-extruder was obtained from Avanti Polar 
Lipids Inc, USA.  Due to the hydrophobic nature of paclitaxel, loading of paclitaxel 
into liposomes would largely be confined to within the phospholipid bilayer, rather 
than being strictly encapsulated in the aqueous interior.  The pH of all working 
solutions were maintained at 7.4 (where appropriate), and monitored using a FE20 
Desktop pH Meter (Mettler-Toledo International Inc, USA). 
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3 types of drug payload were each separately incorporated into liposomes, depending 
on experimental needs (Figure 6.6).  Paclitaxel (Sigma-Aldrich, UK) was used for 
general experimental procedures. Oregon Green® paclitaxel (Life Technologies, UK) 
was used for UV-Vis analysis.  D-luciferin (Sigma-Aldrich, UK) was used for 
luciferase reporter cell line assay. 
 
 
Figure 6.6. 3 different types of liposomal payload.  Depending on experimental needs, 3 different 
types of payloads were separately incorporated into liposomes.  
 
6.2.1.1. Lipid Preparation 
 
Generation of PEGylated (stealth) liposomes was carried out in accordance with 
manufacturer’s guidelines, and in-depth discussion regarding liposomal formulations 
of paclitaxel is extensively described elsewhere[19, 34-36].  Briefly, 100 mg of 
DSPE-020CN (NOF Corporation, Japan), and 1 mg of paclitaxel / D-luciferin was 
dissolved in 10 ml of chloroform in a 100 ml round-bottom flask. The solution was 
mixed thoroughly by swirling it manually, and placed on a Vortex Mixer (Cole-
Parmer Instrument Co. Ltd., UK) at every 1-minute interval.  This process was carried 
out for 5 minutes.  To remove the solvent (chloroform), the round-bottom flask was 
placed in an R-210 Buchi Rotary Evaporator (Sigma-Aldrich, UK).  The motor was 
set at 8 revolutions per minute (rpm), and temperature of the water bath was set at 
60.5 °C (the boiling point of chloroform).  This was carried out in a fume hood, and 
the set-up was left for 24 hours.  This step is to ensure that a homogenous lipid-drug 
composition is obtained.  A 3M™ Full Facepiece Respirator 6800DIN (3M Company, 
USA) was used while handling chloroform.   
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After 24 hours, a thin lipid-drug film will be formed on the sides of the round-bottom 
flask. 10 ml of chloroform is again added to this thin lipid-drug film in the round-
bottom flask.  This lipid-drug solution is then placed in a container of dry ice for 24 
hours, to allow for complete freezing of the lipid-drug solution, to yield a frozen lipid-
drug cake.  The frozen lipid-drug cake is then placed in a vacuum chamber and 
lyophilized for 48 hours, using a Benchtop Manifold Freeze-Dryer (Millrock 
Technology, USA), and was set at 0.01 Torr.  After 48 hours, the round-bottom flask 
containing the dried lipid-drug cake is tightly sealed, and stored frozen at – 20 °C.  
 
6.2.1.2. Hydration of Lipids 
 
Hydration of the dry lipid-drug cake involves adding 2.4 ml of a buffer stock solution 
per 1 mg of lipid-drug cake. The buffer stock solution was prepared as follows.  2.4 
ml of TES buffer (0.001 mol/dm3, pH = 7.4) was prepared with 0.1 mol/dm3 of NaCl, 
and 0.01 mol/dm3 of EDTA.  This buffer stock solution was heated to 70 °C, as 
hydration of lipids must be performed above the gel-liquid crystal transition 
temperature (Tc) of the lipids[37].  It has been previously determined that the Tc of 
DSPE is 61.85 °C[38], and therefore 70 °C was arbitrarily chosen, as too high a 
temperature would damage the lipids due to hydrolysis[36]. 2.4 ml of the heated 
buffer stock solution was added to 1 mg of the lipid cake, in a 6 ml glass scintillation 
vial.  This was bath sonicated in a CAMSONIX C-Series Heated Ultrasonic Cleaning 
Bath (Camlab, UK) for 10 minutes at 70 °C.  This bath sonication process creates 
large multilamellar vesicles (MLV).  In order to remove free paclitaxel and excess 
lipids, samples were placed in an Amicon® Ultra-4 Centrifugal Filter Unit with a 
molecular weight cutoff (MWCO) of 3kDa, and centrifuged for 10 minutes at 4000 g 
at room temperature.  The filter was washed 5 times by adding buffer and repeating 
the centrifugation step in order to completely remove free paclitaxel and excess lipids.       
 
6.2.1.3. Lipid Extrusion              
 
Lipid extrusion, the process in which large MLV are forced through a polycarbonate 
filter to yield small unilamellar vesicles (ULV), is a vital part of liposomal generation.  
Pre-filtering extrusion is normally done to prevent membrane fouling and improves 
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the size distribution and homogeneity of the final colloidal system.  2.4 ml of 
hydrated lipids was aspirated using a syringe from the Avanti® Mini-Extruder system 
(Avanti Polar Lipids, Inc.).  A polycarbonate membrane (Avanti Polar Lipids, Inc.) 
with pore size of 1.0 µm was selected, and 11 extrusion cycles (1 extrusion cycle is 
defined as forcing the contents of the filled syringe through the polycarbonate 
membrane, to the empty syringe on the other side) were performed, with the system 
placed on a SD500 hot plate (Bibby Scientific Limited, UK) maintained at 70 °C.  
This is because extrusion has to be done at a temperature above Tc of the lipids.  For 
the main extrusion process a smaller pore size than the pre-filtering step is needed.  
Therefore, the 1.0 µm polycarbonate membrane was replaced with a 0.1 µm 
polycarbonate membrane (Avanti Polar Lipids, Inc.), and 11 extrusion cycles were 
again performed at 70 °C.  The final mixture after the final extrusion should appear 
less cloudy than the starting mixture.  This final liposome suspension can be stored 4 
°C.           
 
6.2.1.4. Integration of Liposomes on POSS-PCU 
 
Surface integration of liposomes onto POSS-PCU membrane (circular discs of 15.6 
mm in diameter) was done using the MediCoat DES 1000 Ultrasonic Spray System 
(Sono-Tek Corporation, USA).  However, the piezoelectric transducer was turned off 
during the liposome spraying process, as ultrasonic waves can disrupt liposome 
membranes and trigger drug release (prematurely, for our intended application)[39-
41].  1 ml of liposome suspension was fed into the system, and spray rate was set at 
0.01 ml / min, and each disc was sprayed for a period of 1 min.  Nitrogen gas pressure 
(BOC Industrial Gases, UK) was set at 4.5 psi.  For control, non-liposomal paclitaxel 
was sprayed on POSS-PCU using the same parameters as above.  A thin layer of 
POSS-PCU was then sprayed on top of the liposome layer.  For this, the piezoelectric 
transducer was turned on, and set at 0.24 W, and a burst spray was performed, for 1 
sec.  This thin layer of POSS-PCU porous topcoat serves as a membrane in which 
liposomes can be eluted from.  To determine the mass of paclitaxel that was present, 
samples were sprayed into a glass vial, and reconstituted in 3 ml of phosphate 
buffered saline (PBS), and analyzed using HPLC.        
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6.2.2. Biophysical Characterization 
 
6.2.2.1. Ellipsometry 
 
Film thickness was determined using a UVISEL 2 Scientific Spectroscopic 
Ellipsometer (Horiba Ltd, Japan).  Ellipsometric measurements were done in 
accordance with manufacturer’s guidelines at an incidence angle of 70°, with a 
spectral range of 248-826 nm (1.5-5 eV), and beam size was set at 1 mm.      
 
6.2.2.2. Transmission Electron Microscopy (TEM) 
 
Transmission electron microscopy (TEM) was conducted using a Zeiss EM 920A 
Transmission Electron Microscope (Carl Zeiss Inc., Germany).  Samples were 
prepared at 25 °C, and images were captured in zero-loss bright field mode, with an 
80 kV acceleration voltage.    
 
6.2.2.3. Atomic Force Microscopy (AFM) 
 
As described in Chapter 5. 
 
6.2.2.4. Field Emission Scanning Electron Microscopy (FESEM) 
 
Field emission scanning electron microscopy (FESEM) was performed using a JSM-
6390 Scanning Electron Microscope (JEOL Limited, Japan).  Samples were coated 
with platinum for 60 sec, with current set at 20 mA (JFC1600, Japan) prior to loading 
in the FESEM chamber. A high vacuum was created inside the chamber, and an 
acceleration voltage of 5 kV was applied.     
 
6.2.2.5. Zeta Potential 
 
Zeta potential and dynamic light scattering (DLS) was measured using a Zetasizer 
Nano Series (Malvern Instruments Ltd, UK).  Calibration against a polystyrene 
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standard was carried out prior to measurement, in which 1 ml of sample was loaded 
into the cell.  DLS and zeta potential were measured separately, in triplicates (n=3).   
 
6.2.2.6. Dynamic Light Scattering (DLS) 
 
As described above. 
 
6.2.2.7. Polarized Light Microscopy (PLM) 
 
Polarized light microscopy (PLM) was done using an Eclipse LV100 POL Polarizing 
Microscope (Nikon Instruments Europe B.V.).  Samples were placed between 2 glass 
slides and viewed under 400 × magnification.     
 
6.2.2.8. Ultraviolet-Visible (UV-Vis) Spectroscopy 
 
Ultraviolet-visible (UV-Vis) absorbance spectra were determined using a V-630 
UV/VIS/NIR Spectrophotomer (JASCO, Inc., USA).  The spectra of Oregon Green® 
paclitaxel loaded into liposomes was measured by the absorbance peak at 524 nm 
with a molar extinction coefficient of 68000 M-1cm-1 (characteristic of Oregon 
Green® paclitaxel[42, 43]) after subtracting the absorbance of unloaded liposomes at 
that wavelength.   
 
6.2.3. Drug Elution Kinetics 
 
6.2.3.1. High Performance Liquid Chromatography (HPLC) 
 
For leakage assessment, liposomes were centrifuged at 10,000 g for 30 min[44].  The 
pellet was then re-constituted in methanol and subjected to HPLC. POSS-PCU 
polymer samples integrated with liposomes were immersed in phosphate buffered 
saline (PBS) (Life Technologies, UK), at pH 7.4, placed on a roller mixer (Cypress 
Diagnostics) at 20 rpm, and maintained at a temperature of 37 °C in an incubator 
(Thermo Scientific) for 91 days.  Controls were POSS-PCU polymer samples with 
paclitaxel but without liposomes.  The release study of samples was conducted using 
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a tightly capped glass scintillation vial (Sigma-Aldrich, UK), with samples immersed 
in 3 ml of PBS.  The receptor media (PBS) was completely removed periodically at 
specific sampling time points, and an equal amount (3 ml) of fresh media was 
introduced.  The amount of paclitaxel present in the receptor media was determined 
using a Flexar HPLC (PerkinElmer Inc, UK).  The reverse phase column (internal 
diameter = 4 mm, length = 250 mm, pore size = 5 µm) was maintained at 25 °C.  The 
mobile phase consists of a mixture of distilled water, acetonitrile, and methanol 
(44:30:30, v/v), with a flow rate at 0.8 ml/min with a pump gradient of t = 0, 50/50, t 
= 15, 50/50, t = 21, 0/100, with a 10-minute post process.  20 µl of sample was 
injected into the system using an autosampler.  Calibration standards were conducted 
in the range of 1.0 to 250 µg/ml.  UV detection was set at a wavelength of 227 nm for 
paclitaxel. Peak integration and analysis was performed using Chromera® 
Chromatography Data Systems, the proprietary software as provided in the HPLC 
system.  Experimental procedures on samples were performed in triplicates (n=3).  
 
6.2.4. In vitro Cell Culture 
 
6.2.4.1. Luciferase Reporter Cell Line 
 
The luciferase reporter cell line, GloResponse™ NK-κB-RE-luc2P HEK293 
(Promega Corporation), is a clonal derivative of Human Embryonic Kidney 293 cells, 
which are specifically designed to fluoresce when exposed to D-luciferin.  Hence, this 
could be used to determine the efficacy of liposomal D-luciferin against control (non-
liposomal) D-luciferin.  Propagation of cells were done using standard cell culture 
protocols, and in accordance with manufacturer’s guidelines[45].  Briefly, frozen cells 
in the vial were thawed by placing them in a 37 °C water bath (Thermo Fisher 
Scientific Inc., UK) with gentle agitation for 2 min.  The vial was wiped with 70% 
ethanol, before opening in a Class II biological safety cabinet for the maintenance of a 
sterile environment.  Cells in the vial were pipetted into a 15 ml conical tube (BD 
Biosciences, UK) containing 10 ml Growth Medium.  The Growth Medium was made 
up of 90% DMEM (Life Technologies, UK), and 10% fetal bovine serum (FBS) (Life 
Technologies).  Cells were centrifuged at 500 g for 5 minutes at 18 °C.  The 
supernatant was aspirated, and the cell pellet was re-suspended in 12 ml of Growth 
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Medium at 37 °C.  The re-suspended cells were transferred to a T75 tissue culture 
flask (Sigma-Aldrich, UK).  This was placed in a tissue culture incubator (Thermo 
Fisher Scientific Inc.) at 37 °C and 5% CO2.  Cells were checked every day under a 
light microscope (Nikon Europe B.V.) and passaged twice a week, for it to reach 90% 
confluency.  The medium was then aspirated from the flask, and cells were washed 
with 2 ml of phosphate-buffered saline (PBS) (Life Technologies, UK).  2 ml of 
0.05% trypsin (Life Technologies, UK) was then added to evenly coat the surface of 
the cells, for 2 min.  The flask was placed under a light microscope (Nikon Europe 
B.V.) to confirm cell detachment and clump dispersion.  10 ml of Growth Medium 
was added. The cell suspension was transferred to a 15 ml conical tube (BD 
Biosciences, UK).  The number of cells was determined using a haemocytometer 
(Camlab, UK).  Cells were seeded onto 24-well plate (Corning Inc., USA), at an 
initial density of 20,000 cells per well.                         
 
6.2.4.2. IVIS® Spectrum Imaging System 
 
Qualitative and quantitative analysis of bioluminescence was done using an IVIS® 50 
Imaging System (PerkinElmer Inc., USA).  The system consists of an integrated 
charge-coupled device (CCD) camera mounted on a dark specimen chamber, and is 
able to detect bioluminescence caused by the interaction of luciferase with luciferin.  
In accordance to manufacturer’s guidelines, fluorescence excitation wavelength was 
set at 328 nm, and emission wavelength was set at 523 nm.       
 
6.2.4.3. Human Vascular Smooth Muscle Cell 
 
Human vascular smooth muscle cells (VSMC) (Lonza Group Ltd., Switzerland) were 
used as a model cell line for cell growth inhibition assay. Cell culturing protocol was 
similar to the luciferase reporter cell line mentioned above.  VSMC were used to 
assess the efficacy of stealth liposomal paclitaxel, over a 28-day period.  Cells were 
seeded onto 24-well plate (Corning Inc.), at an initial density of 20,000 cells per well.  
For AlamarBlue® cell viability assay, VSMCs were aliquoted onto a 96-well plate, 
with an initial seeding density of 10,000 cells per well.        
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6.2.4.4. Endocytosis Inhibition 
 
VSMCs were seeded on a 24 well plate, at an initial seeding density of 20,000 cells 
per well.  After 24 hours, the cell culture medium was replaced with 0.5 ml of fresh 
medium with either: 5 mM β-cyclodextrin (Sigma-Aldrich, UK), 20 µg/ml 
chlorpromazine (Sigma-Aldrich, UK), or 2 mM amiloride (Sigma-Aldrich, UK).  
Amiloride is an inhibitor of macropinocytosis, chlorpromazine is an inhibitor of 
clathrin-mediated endocytosis, and β-cyclodextrin is an inhibitor of caveolae-
mediated endocytosis.  After 30 minutes, 50 mM of liposomal Oregon Green® 
paclitaxel were added into the medium and incubated for 2 hours at 37 °C. For 
control, luciferase reporter cell line were cultured without any endocytosis inhibitors.  
The 24 well plate was then placed in a MicroMax 384 Microwell-Plate Reader 
(HORIBA Ltd), with a fluorescence excitation wavelength was set at 496 nm, and 
emission wavelength was set at 524 nm. Normalized fluorescence intensity was 
calculated according to the equation:  
 
Normalized Fluorescence Intensity  = (FLsample – FLblank) / (FLctrl – FLblank) 
          
Where FL is the fluorescence intensity, and ctrl is the control well plate. 
 
6.2.4.5. AlamarBlue® Cell Viability Assay 
 
AlamarBlue® (Life Technologies, UK) was used to assess cell viability (and hence 
cell kill efficacy). Briefly, a cell density of 10,000 cells per well were seeded on the 
96 well plate, alamarBlue® was added to cell aliquots in a volumetric ratio of 1:10.    
After incubating for 2 hours, it was placed in a Fluoroskan Ascent Microplate 
Fluorometer (Thermo Fisher Scientific Inc., UK).  In accordance with manufacturer’s 
protocol, excitation wavelength was set at 560 nm, and an emission wavelength of 
590 nm. Normalized cell viability was calculated using the equation: 
 
Normalized cell viability = (FLsample – FLneg ctrl) / (FLpos ctrl – FLneg ctrl) 
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Where FL is the fluorescence intensity, neg ctrl is the negative control, and pos ctrl is 
the positive control. 
 
6.2.4.6. C3a And SC5b-9 Complement Activation Assay 
 
Enzyme immunoassay to quantify C3a fragment of the complement protein C3 in 
human plasma and serum was done using MicroVue™ C3a kit (Quidel Corporation, 
USA).  The assay was done in accordance to manufacturer’s protocol[46].  Whole 
blood was obtained from healthy volunteers with informed consent.  50 µg/ml of test 
samples (liposomal paclitaxel or paclitaxel alone) were added to whole blood and 
incubated at 37°C for 30 minutes.  Blood plasma was extracted via density gradient 
centrifugation in a protocol that was described in Chapter 5. Blood plasma was 
diluted in a dilution ratio of 1:200.  For each test specimen, 90 µl of specimen diluent 
for dilution 1, and 475 µl for dilution 2 were pipetted into 2 separate dilution tubes.  
Dilution 1 was prepared by the addition of 10 µl of test specimen to 90 µl specimen 
diluent, and mixed gently. 25 µl of plasma in dilution 1 was then mixed with 475 µl of 
plasma in dilution 2. 100 µl of specimen diluent (blanks), standards, controls, and test 
specimens were pipetted into assay wells and incubated for 60 minutes at 20 °C.  
Wells were washed 4 times with the wash solution provided in the assay kit.  100 µl 
of horseradish peroxidase (HRP)-conjugated anti-C3a (as provided in the assay kit) 
was added in the wells, and further incubated for 60 minutes at 20 °C.  Wells were 
washed 4 times with wash solution.  100 µl of 3,3’,5,5’ tetramethylbenzidine (TMB) 
chromogenic substrate solution (as provided in the assay kit) was then pipetted into 
the wells, and incubated for 15 minutes at 20 °C.  100 µl of stop solution (as provided 
in the assay kit) was added to terminate the reaction process.  The well plate was then 
placed in an xMark™ Microplate Absorbance Spectrophotometer (Bio-Rad 
Laboratories Inc., UK), and an absorbance wavelength of 450 nm was selected.  All 
experimental procedures were done in triplicates (n=3). 
 
The quantification of SC5b-9 complex was done using a MicroVue™ SC5b-9 Plus 
Enzyme Immunoassay kit (Quidel Corporation, USA).  The experiment was done in 
accordance to manufacturer’s protocol[47], and the procedure was similar to the 
quantification of C3a mentioned in the above paragraph.  Briefly, blood plasma was 
diluted in a dilution ratio of 1:10.  300 µl of wash solution was added into assay well 
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and incubated for 2 minutes at 20 °C.  Liquid was aspirated from each well and 
blotted dry.  100 µl of specimen diluent (blank), standards, controls, and test samples 
were added into assay wells, and incubated for 60 minutes at 20 °C and washed 5 
times.  50 µl of SC5b-9 plus conjugate was added and incubated for 30 minutes at 20 
°C, and washed 5 times. 100 µl of substrate was added and incubated for 15 minutes 
at 20 °C.  100 µl of stop solution was added, and an absorbance wavelength of 450 
nm was selected.     
 
6.2.4.7. Erythrocyte Isolation and Haemolysis Assay 
 
Isolation of erythrocytes (red blood cells) was done via the collection of whole blood 
from healthy volunteers.  Informed consent was obtained from volunteers, and the 
Institutional Review Board (IRB) at UCL approved the procedure.  Briefly, 800 µl of 
freshly collected whole blood was centrifuged at 10,000 g using a MiniSpin® 
(Eppendorf AG., Germany) for 5 minutes at room temperature. It was then washed 5 
times using sterile isotonic PBS.  Erythrocytes were re-suspended in 7.5 ml of PBS.  
0.5 ml of test samples (paclitaxel, liposomal paclitaxel, liposomes) were added to 
erythrocytes.  PBS was used as negative control, and sterile water was used as 
positive control.  The samples were then vortexed for 5 seconds and left to stand at 
room temperature for 3 hours.  It was then centrifuged at 10,000 g for 5 minutes at 
room temperature. 200 µl of the supernatant was aliquoted into a 96 well plate and 
placed in a Mircoplate Absorbance Reader (Bio-Rad Laboratories, Inc. USA).  The 
absorbance wavelength was set at 577 nm (the absorbance of haemoglobin), and was 
measured with a reference wavelength of 655 nm.  The percentage of haemolysis was 
calculated using the formula: 
 
% Haemolysis = (Absample – Abneg ctrl ) / (Abpos ctrl – Abneg ctrl) 
 
 
Where Ab is the absorbance value, neg ctrl is the negative control, and pos ctrl is the 
positive control.   
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Scanning electron microscopy (SEM) was also performed on erythrocytes, and 
erythrocytes in a state of crenation were also obtained by using a concentrated 
solution of 10% NaCl.  The protocol for SEM was described in the previous chapter.   
 
6.2.4.8. Fluorescence-Activated Cell Sorting (FACS) 
 
Cell count data was obtained via fluorescence-activated cell sorting (FACS).  A BD 
FACSAria™ Fusion Flow Cytometry (BD Biosciences, UK) was used, and 10,000 
events per sample were acquired.  Data analysis was done using its proprietary BD 
FACSDiva software (BD Biosciences, UK).  Cells were stained with: Annexin V to 
determine apoptosis, 4’6-diamidino-2-phenylindole (DAPI) for cell nucleus/DNA, 
and Alexa Fluor® 488 Phalloidin (Life Technologies, UK) for F-actin. The protocol 
for cell staining was described in Chapter 5. Cell density was calculated simply by 
dividing the number of cells by the area of the well plate.  A normalized cell density 
was then calculated for data analysis using the formula: 
 
Normalized cell density = (Dsample avg – Dneg ctrl) / (Dpos ctrl – Dneg ctrl) 
 
Where D is the cell density, sample avg is the sample that is being measured, neg ctrl 
is the negative control, and pos ctrl is the positive control.   
  
6.2.5. Statistical Analyses 
 
Parametric data is presented as ± standard deviation (SD) of the mean, and all 
experiments were performed in triplicates (n = 3), unless otherwise stated.  Curve 
fitting and statistical analysis was done using GraphPad Prism® (GraphPad Software 
Inc., USA).  One-way analysis of variance (ANOVA) with post-hoc Tukey’s range 
test was performed at a 95% confidence interval.  p < 0.05 was considered statistically 
significant.    
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6.3. Results 
 
6.3.1. Biophysical Characterization  
 
6.3.1.1. Confirmation of Unilamellar Vesicular Structure via TEM  
 
Transmission electron microscopy (TEM) revealed that unilamellar vesicles (ULV) of 
liposomes were generated, with a consistent diameter of 100 nm (Figure 6.7).  The 
phospholipid bilayer that forms the circumferential area of the liposomes can clearly 
be seen under TEM, indicating that the preparation process was successful in creating 
liposomes of defined architecture.  Due to the hydrophobic nature of paclitaxel, its 
encapsulation would be restricted to within the lipid bilayer membrane, rather than 
inside its aqueous core.  Indeed, TEM has clearly revealed the presence of paclitaxel 
within the phospholipid bilayer membrane, making it characteristically darker in 
colour, compared to unloaded liposomes, which have a bilayer that is lighter in colour 
(Figure 6.8).   
      
 
Figure 6.7. Transmission electron microscopy (TEM) of liposomes. Unilamellar vesicles of 
liposomal paclitaxel were obtained with a consistent size of 100 nm in diameter.  Scale bar represents 
25 nm.  
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Figure 6.8. Loading of paclitaxel within the phospholipid bilayer.  TEM reveals that unloaded 
liposomes have a clear phospholipid bilayer, whereas liposomal paclitaxel had a phospholipid bilayer 
that was darker in colour, indicating the presence of paclitaxel.  Scale bar represents 25 nm. 
 
6.3.1.2. Detection of Liposomes on POSS-PCU Film via AFM and PLM 
 
Liposomes were then sprayed onto POSS-PCU films, with an ultra-thin topcoat of 
POSS-PCU added subsequently, functioning as a sustained release layer.  The 
integrated liposomes were imaged using AFM, revealing that the circular morphology 
of the liposomes was retained even after spraying (Figure 6.9).  Furthermore, it can 
also be seen that a consistent size of 100 nm was retained in liposomes on the POSS-
PCU layer.  The orange background depicts POSS-PCU film, while the yellow spots 
depict liposomes that had been integrated into it. Polarized light microscopy (PLM) 
was also used to assess the change in surface morphology of liposome integrated-
POSS-PCU.  PLM images clearly show the difference between pristine POSS-PCU 
surface, and POSS-PCU-Liposome surface (Figure 6.10).  Results also suggests that 
the presence of liposomes within POSS-PCU changes its ability in its reflectance of 
polarized light as it had a distinctly different colour and pattern.      
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Figure 6.9. AFM of Liposomes on POSS-PCU films. AFM images reveal liposomes on POSS-PCU, 
depicted by yellow bright spots.     
 
 
Figure 6.10. Polarized Light Microcopy of POSS-PCU with Liposomes. (A) PLM image of pristine 
POSS-PCU surface.  (B) PLM image of POSS-PCU surface integrated with liposomes. Scale bar 
represents 1 µm. 
 
6.3.1.3. Generation of Liposomes with 100 nm Diameter  
 
In order to obtain small unilamellar vesicles (ULV) of defined and consistent sizes, 
rather than large multilamellar vesicles (MLV), extrusion cycles through porous 
polycarbonate membrane must be performed.  The final size of ULV is often defined 
by the pore sizes on the polycarbonate membrane.  Hence, a pore size of 100 nm 
would yield liposomes of 100 nm in diameter.  It can thus be seen from the results 
that before extrusion, a multitude of MLVs of non-uniform sizes were present, within 
ranges of around 290 nm (20%), 375 nm (10%), and 450 nm (40%), displaying a 
largely tri-modal distribution (Figure 6.11).  MLVs of such inconsistently large sizes 
are of little therapeutic value.  After extrusion, a high percentage yield (85%) of ULV 
with a consistent size of 100 nm was obtained.       
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Figure 6.11. Size distribution of liposomes before and after extrusion using dynamic light 
scattering (DLS).  A high percentage (87.5%) of 100 nm-sized liposomes were obtained after 
extrusion, while non-consistent larger sized multilamellar vesicles were seen before extrusion.   
 
In colloidal systems, zeta potential represents the potential difference that exists 
between the dispersion medium (in this case, PBS), and the layer of fluid at the 
surface of the dispersed particle (in this case, liposomes). In general, a high numerical 
zeta potential (negative or positive) value indicates that the dispersed particles are 
stable in the colloidal system. In contrast, a low numerical zeta potential (negative or 
positive) value indicates particle instability, and therefore a propensity for coagulation 
or flocculation.  Results revealed that pure paclitaxel had a zeta potential of -10 mV, 
while liposomal paclitaxel had a zeta potential of -50 mV (Figure 6.12).  This 
indicates that loading paclitaxel into liposomes significantly increases its colloidal 
stability, demonstrating that they are well dispersed and are able to resist aggregation.      
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Figure 6.12. Zeta potential of liposomal paclitaxel versus paclitaxel alone.  A low zeta potential (-10 
mV) was seen in paclitaxel alone indicating colloidal instability, while a high zeta potential (-50 mV) 
was seen in liposomal paclitaxel, indicating colloidal stability.  
 
6.3.1.4. Detection of Oregon Green® Paclitaxel Loading using UV-Vis  
 
Paclitaxel with a fluorescent tag (Oregon Green®) was used a payload in liposome, in 
order for detection under UV-Vis.  Oregon Green® paclitaxel absorbs at 524 nm, and 
this was clearly discernable under UV-Vis spectroscopy.  Results indicated the 
characteristic absorbance peak at 524 nm for Oregon Green® paclitaxel (Figure 6.13).  
Liposomal Oregon Green® paclitaxel retained its signature absorbance peak at 524 
nm, with increasing magnitude as concentration increases.  Thus, this shows 
successful loading of drug payload into liposomes that was quantifiable using UV-
Vis.     
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Figure 6.13. UV-Vis spectra of liposomes loaded with Oregon Green® paclitaxel.  The 
characteristic absorbance of Oregon Green® at 524 nm was detected in liposomes loaded with them. 
Increasing the concentration of liposomes resulted in an increase in the characteristic absorbance 
spectra. Lipo: liposome; Ptx: paclitaxel; Lipo Ptx: liposomal paclitaxel.       
 
6.3.1.5. Increase of POSS-PCU Film Thickness after Liposomal 
Integration  
 
A freeze fracture technique followed by FESEM was employed to reveal a reservoir 
of liposomes under the ultra-thin topcoat of POSS-PCU (Figure 6.14).  Spherical 
structures were clearly seen under FESEM, indicating that liposomes retained their 
spherical morphology of a consistent diameter of 100 nm, even after spraying and 
being integrated within POSS-PCU films (Figure 6.15).  Ellipsometry was used to 
measure film thickness, which showed a step-wise increase in thickness after spraying 
liposomes and the top-coat respectively.  Pure POSS-PCU films had a thickness of 
18.1 µm ± 0.4 µm, POSS-PCU-liposome had a thickness of 19.3 µm ± 0.2 µm, and 
POSS-PCU-liposome-POSS-PCU had a thickness of 20.1 µm ± 0.3 µm (Figure 6.16).  
All results were statistically significant (p < 0.05) from each other.    
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Figure 6.14. FESEM of liposomes on POSS-PCU film.  FESEM revealed numerous liposomes on 
POSS-PCU film.  Scale bar represents 100 nm. 
 
 
Figure 6.15. FESEM of a single liposome on a POSS-PCU film.  The spherical morphology of a 
liposome can be clearly seen on the surface of a POSS-PCU film.  The line across the picture should be 
treated as an artifact, as it was due to an interruption of the scanning process.  Scale bar represents 20 
nm.  
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Figure 6.16. Increase in POSS-PCU film thickness after liposomal integration.  There was a 
detectable and statistically significant increase (p < 0.05) in film thickness after liposomal integration 
and an ultra-thin topcoat spray.  
 
6.3.2. Drug Elution Kinetics 
 
6.3.2.1. Achievement of a High Encapsulation Efficiency 
 
In the process of drug encapsulation (loading) in a liposome, a certain amount of drug 
loss has to be anticipated.  The amount of paclitaxel that was present before and after 
loading was determined using HPLC.  Results indicate that a high level (86.3% ± 
0.03%) of paclitaxel loading efficiency was achieved, demonstrating minimal drug 
loss (Figure 6.17).  
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Figure 6.17. A high paclitaxel encapsulation efficiency.  High levels of paclitaxel loading (86.3 % ± 
0.03%) was achieved, indicating a low level of drug loss.   
 
6.3.2.2. Determination of Drug-Liposome Stability via Leakage 
Assessment  
 
Drug-liposome stability is an important parameter that has to be assessed, in order to 
ascertain that the drug payload does not leach out from the liposome, thereby 
undermining its use in the first place.  HPLC was used to determine that amount of 
paclitaxel leakage, and results were normalized against pure paclitaxel (control).  As a 
separate control study, ultrasound was applied to liposomes to rupture its 
phospholipid membrane and to cause drug release.  Results indicate that ultrasound 
application caused a high level of drug leakage almost similar to that of control, with 
statistical significance (p < 0.05). In contrast, liposomal paclitaxel (without ultrasound 
treatment) had no detectable drug leakage over 7 days (Figure 6.18), and the same 
stability was displayed even after 1 year (p < 0.05) (Figure 6.19).        
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Figure 6.18. Percentage leakage over 1 week.  No detectable paclitaxel leakage (p < 0.05) was 
observed after 1 week.  Ultrasound was delivered to liposomal paclitaxel to trigger drug release, and 
was used as a comparison to samples without ultrasound treatment.     
 
   
 
Figure 6.19. Percentage leakage over 1 year.  No detectable paclitaxel leakage (p < 0.05) was 
observed after 1 year. Pure paclitaxel was used as a positive control.  Ultrasound was delivered to 
liposomal paclitaxel to trigger drug release, and was used as a comparison to samples without 
ultrasound treatment.     
 
 
6.3.2.3. Sustained and Controlled Elution  
 
Drug elution was measured over defined time points, and data was represented as 
percentage paclitaxel released.  It must be noted both samples (paclitaxel and 
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liposomal paclitaxel) were integrated into POSS-PCU films.  Positive control was 
simply paclitaxel without POSS-PCU film (hence 100% elution was detected even at 
month 0).  Negative control was POSS-PCU film without any drug included (hence 
0% elution throughout).  In a drug release study measured over 28 days, both 
liposomal paclitaxel and paclitaxel displayed a similar release profile, although the 
percentage of drug release from paclitaxel was statistically significantly higher (p < 
0.05), compared to liposomal paclitaxel (Figure 6.20).  In the 1-year release profile, 
results showed that liposomal paclitaxel had a sustained drug release over 1 year, with 
100% of drug released only from month 12 to month 13 (Figure 6.21).  In contrast, it 
can be seen that paclitaxel alone had a statistically significantly higher (p < 0.05) level 
of percentage drug release, with 100% eluted by month 4 (Figure 6.22).  Furthermore, 
visual analysis of POSS-PCU films using SEM confirms that liposomes were 
successfully eluted from the surface of POSS-PCU, leaving behind characteristic 
holes / pores (Figure 6.23).   
 
 
Figure 6.20. Paclitaxel elution over 28 days.  Liposomal paclitaxel and paclitaxel had a similar drug 
release profile, although paclitaxel had a statistically significantly higher (p < 0.05) percentage of 
release. Positive control was pure paclitaxel without any POSS-PCU film, while negative control was 
pure POSS-PCU film without any drug.   
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Figure 6.21. Sustained paclitaxel elution over 1 year.  Liposomal paclitaxel displayed a sustained and 
controlled release over 1 year, achieving 100% elution only after 12 months.  Non-liposomal paclitaxel 
had near 100% release by month 4. Positive control was pure paclitaxel without any POSS-PCU film, 
while negative control was pure POSS-PCU film without any drug.   
 
Figure 6.22. Percentage paclitaxel release at month 4.  By month 4, films with non-liposomal 
paclitaxel had a near 100% release, while liposomal paclitaxel had 64% release. Positive control was 
pure paclitaxel without any POSS-PCU film, while negative control was pure POSS-PCU film.     
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Figure 6.23.  SEM of POSS-PCU film surface before and after liposomal elution.  It can be seen 
visually that liposomes were successfully eluted from the POSS-PCU surface, leaving behind pores. 
Scale bar represents 1µm. 
 
6.3.3. Haemocompatibility and Immunogenicity 
 
6.3.3.1. Normal Blood Coagulation Kinetics 
 
The measurement of blood coagulation kinetics in thromboelastography (TEG) is 
divided into 4 parameters: r-time, k-time, α-angle, and maximum amplitude (MA).  In 
this experiment, collagen was used as a positive control as it induces blood 
coagulation, while l-arginine was used as a negative control, as it delays blood 
coagulation.  Untreated samples were blood without any sample treatment. 
    
r-time denotes the time taken from the start of the experiment until the first sign of 
fibrin formation.  The reference range for r-time in blood is between 5 to 7 minutes. 
An r-time lower than this range indicates possible thrombogenicity, while an r-time 
higher than this range indicates possible impairment in blood coagulation.  Liposomal 
paclitaxel, liposome, and POSS-PCU all displayed r-time that was within the normal 
range (Figure 6.24).  In contrast, paclitaxel had a low r-time that was outside the 
normal range, indicating a level of thrombogenicity.  
 
k-time represents the time taken (from the end of r-time) to the time when the clot 
reaches 20 mm.  The reference range for k-time in blood is between 1 to 3 minutes.  A 
k-time that is lower than this range indicates possible thrombogenicity, while a k-time 
that is higher than this range indicates a possible impairment in blood coagulation 
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kinetics.  Liposomal paclitaxel, liposome, and POSS-PCU all displayed k-time that 
was within the normal range (Figure 6.25).  In contrast, paclitaxel had a very low k-
time, similar to that of positive control, indicating a level of thrombogenicity. 
 
α-angle measures the rate of clot formation.  The reference range for α-angle in blood 
is between 53° to 67°.  A high α-angle outside the normal range indicates a high rate 
of clot formation (hence thrombogenicity), while a low α-angle outside the normal 
range indicates an impairment of blood coagulation. Liposomal paclitaxel, liposome, 
and POSS-PCU all displayed α-angles that were within the normal range (Figure 
6.26).  Paclitaxel displayed a high α-angle, similar to that of positive control, 
indicating a level of thrombogencity.   
 
Maximum amplitude (MA) measures the final clot size, and the reference range for 
MA in blood is between 59 to 68 mm.  A high MA outside the reference range 
indicates possible thrombogenicity, while a low MA outside the reference range 
indicates possible impairment in clotting kinetics.  Liposomal paclitaxel, liposome, 
and POSS-PCU all displayed MA values that were within the normal range (Figure 
6.27).  Paclitaxel displayed a high MA value, almost similar to that of positive 
control, indicating a level of thrombogenicity.   
 
Hence, it could be concluded that liposomal paclitaxel appears to have lower level of 
thrombogenicity, compared to paclitaxel alone. This would have possible implications 
in terms of using liposomes not only as a delivery vehicle, but also to confer 
haemocompatibility.                             
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Figure 6.24. r-time on TEG. Liposomal paclitaxel, liposome, and POSS-PCU films displayed r-time 
within normal ranges.  Paclitaxel displayed a low r-time outside the normal range, indicating a level of 
thrombogenicity.  Collagen was used as a positive control as it induces blood coagulation, while l-
arginine was used as a negative control, as it delays blood coagulation.  Untreated samples were blood 
without any sample treatment. 
   
 
Figure 6.25. k-time on TEG. Liposomal paclitaxel, liposome, and POSS-PCU films displayed k-time 
within normal ranges.  Paclitaxel displayed low k-time outside the normal range, indicating a level of 
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thrombogenicity.  Collagen was used as a positive control as it induces blood coagulation, while l-
arginine was used as a negative control, as it delays blood coagulation.  Untreated samples were blood 
without any sample treatment. 
   
 
Figure 6.26. α-angle on TEG. Liposomal paclitaxel, liposome, and POSS-PCU films displayed α-
angles within normal ranges.  Paclitaxel displayed a high α-angle outside the normal range, indicating a 
level of thrombogenicity.  Collagen was used as a positive control as it induces blood coagulation, 
while l-arginine was used as a negative control, as it delays blood coagulation.  Untreated samples were 
blood without any sample treatment. 
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Figure 6.27. Maximum amplitude (MA) on TEG. Liposomal paclitaxel, liposome, and POSS-PCU 
films displayed MA values within normal ranges.  Paclitaxel displayed a high MA value outside the 
normal range, indicating a level of thrombogenicity.  Collagen was used as a positive control as it 
induces blood coagulation, while l-arginine was used as a negative control, as it delays blood 
coagulation.  Untreated samples were blood without any sample treatment. 
     
 
6.3.3.2. Non-Significant Levels of Haemolysis  
 
Haemolysis assay measures the percentage of haemolysed erythrocytes after exposure 
to various treatment samples.  PBS was used as a negative control, as it is isotonic to 
erythrocytes, while water was used as a positive control, as it is hypertonic to  
erythrocytes, causing them to rupture.  Results of the haemolysis assay revealed that 
liposomal paclitaxel and liposomes did not cause an appreciable level of haemolysis, 
as their percentage haemolysis was not statistically significant from the PBS control 
(p > 0.05) (Figure 6.28).  In contrast, paclitaxel elicited a high level of haemolysis 
measuring 51.3% ± 8.1%, and with the difference being statistically significant (p < 
0.05) to liposomal paclitaxel and liposomes.  This could also be seen visually, as 
samples that caused haemolysis appeared pink.  It must be noted that samples appear 
transparent (rather than cloudy), as there were no cells in the suspension to scatter 
light. 
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Erythrocytes were also imaged using SEM (Figure 6.29).  For normal erythrocytes, 
SEM showed their characteristic biconcave shape.  Samples that underwent crenation 
displayed characteristic spikes on their surfaces, while samples that underwent 
haemolysis appeared withered due to the rupture of the cell membrane.       
 
Figure 6.28. Haemolysis assay. Percentage haemolysis of liposomal paclitaxel and liposomes were not 
statistically significant (p > 0.05) from the negative control, PBS.  A statistically significant (p < 0.05) 
level of haemolysis was seen in paclitaxel.  Water was used as a positive control.    
  
 
Figure 6.29. Scanning electron microscopy (SEM) of erythrocytes.  Normal erythrocytes display 
their characteristic biconcave shape.  When exposed to a hypotonic solution, erythrocytes undergo 
	   282	  
crenation as it loses water, and spikes can be seen on its surface.  When exposed to a hypertonic 
solution (pure water), haemolysis occurs as erythrocytes are ruptured.  Scale bar represents 1 µm.  
 
6.3.3.3. Non-Immunogenic Response in C3a and SC5b-9 Complement 
Activation Assay 
 
C3a is a fragment in the complement component 3 (C3) in the complement system.  
High levels of C3a is often associated with inflammation and immunogenicity.  Using 
the C3a complement activation assay kit, the absorbance of known amounts of C3a 
were measured, and a standard curve was plotted.  A characteristic sigmoidal curve of 
C3a was obtained, which was in accordance to manufacturer’s guidelines (Figure 
6.30).  Results demonstrated that liposomal paclitaxel, liposomes, and POSS-PCU 
had levels of C3a that were not statistically significant (p > 0.05) from negative 
control, indicating that these samples did not elicit an appreciable amount of immune 
response (Figure 6.31).  In contrast, paclitaxel showed a statistically significantly 
higher (p < 0.05) level of C3a level compared to liposomal paclitaxel, indicating its 
immunogenicity. 
 
 
 
Figure 6.30. Standard curve of C3a complement activation assay.  A sigmoidal standard curve of 
the absorbance of C3a was plotted using known concentrations of C3a. Note that Beer-Lambert Law 
dictates that the absorbance read-out should stop at 1; however the absorbance read-out was plotted 
until 3 to display the sigmoidal shape. 
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Figure 6.31. C3a complement activation assay.  Liposomal paclitaxel, liposomes, and POSS-PCU 
displayed low levels of C3a, not statistically significant (p > 0.05) to negative control. Paclitaxel 
displayed statistically significantly higher (p < 0.05) levels of C3a. Positive and negative controls were 
standards that were provided in the assay kit.      
 
SC5b-9 is a terminal complement complex that is generated by the activation of the 
complement system.  Measuring levels of SC5b-9 provides an idea of 
immunogenicity.  Using known concentrations of SC5b-9 provided in the assay kit, 
absorbance was measured, and a standard curve was plotted.  A linear plot was 
generated, and this was in agreement with manufacturer’s guidelines (Figure 6.32).  
Liposomal paclitaxel, liposomes, and POSS-PCU all demonstrated low levels of 
SC5b-9, similar to that of negative control (p > 0.05) (Figure 6.33).  In contrast, 
paclitaxel showed a high level of SC5b-9 levels, with the difference being statistically 
significant (p < 0.05) to liposomal paclitaxel. 
 
Taken together, it can be seen that both C3a and SC5b-9 complement activation 
assays displayed a similar trend, whereby the encapsulation of paclitaxel into 
liposomes effectively circumvents immunogenicity.  Furthermore, both POSS-PCU 
and liposomes are not immunogenic, furthering underscoring the fact that using 
	   284	  
liposomes as both a delivery vehicle and an excipient for paclitaxel could confer 
biocompatibility to an otherwise immunogenic substance.                  
 
 
Figure 6.32. Standard curve of SC5b-9.  A linear plot of the absorbance of SC5b-9 can be obtained 
by using known concentrations of SC5b-9. Note that Beer-Lambert Law dictates that the absorbance 
read-out should stop at 1; however the absorbance read-out was plotted until 3 to correlate with the 
range of concentration tested. 
   
 
 
Figure 6.33. SC5b-9 complement activation assay. Liposomal paclitaxel, liposomes, and POSS-PCU 
displayed low levels of SC5b-9, not statistically significant (p > 0.05) to negative control. Paclitaxel 
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displayed statistically significantly higher (p < 0.05) levels of SC5b-9. Positive and negative controls 
were standards that were provided in the assay kit.      
   
 
6.3.4. Enhanced Cell Kill with Stealth Liposomes 
 
6.3.4.1. Tracking Cell Metabolic Activity using Alamar Blue 
 
Alamar Blue was used as a measure of cell metabolic activity.  In this case, metabolic 
activity of VSMCs was tracked after being exposed to various treatment samples.  
Fluorescence intensity of known amounts of VSMCs was measured, and a standard 
curve was plotted (Figure 6.34).  The metabolic activity of VSMCs was measured at 
defined time points over 28 days.  Results revealed that in general, VSMCs that were 
exposed to liposomal paclitaxel had the lowest metabolic activity of 0.21 ± 0.02 
(normalized against control) compared to all other samples (p < 0.05) (Figure 6.35).  
In contrast, it was observed that VSMCs exposed to paclitaxel had a slightly higher 
metabolic activity at 0.53 ± 0.03, which was statistically significant (p < 0.05) to both 
liposomal paclitaxel and control.  VSMCs exposed to both POSS-PCU and liposomes 
had a high metabolic activity at 0.89 ± 0.02, and 0.83 ± 0.03 respectively. This 
indicates that POSS-PCU and liposomes were biocompatible and does not impair cell 
viability.  Therefore, it can be seen that liposomal paclitaxel was able to significantly 
reduce VSMC metabolic activity more effectively compared to paclitaxel alone.  
Normalized metabolic activity measured over 1 week (7 days) and 1 month (28 days) 
displayed a similar trend whereby POSS-PCU and liposomes displayed high 
metabolic activity, whereas paclitaxel and liposomal paclitaxel displayed significantly 
lower levels (Figures 6.36 and Figures 6.37).  Indeed, VSMCs exposed to liposomal 
paclitaxel had the lowest metabolic compared to all other treatment samples at all 
time points measured throughout 28 days, with statistical significance (p < 0.05).  
Therefore, this indicates that liposomal paclitaxel had a higher efficacy in the 
inhibition of VSMC metabolic activity (and hence an indirect measure of viability and 
proliferation) compared to paclitaxel alone.                 
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Figure 6.34. Standard curve of Alamar Blue in vascular smooth muscle cell (VSMC).  A standard 
curve can be plotted when fluorescence intensity is plotted against known amounts of VSMCs.  
 
 
Figure 6.35. Averaged normalized metabolic activity of VSMC over 28 days.  Liposomal paclitaxel 
displayed the greatest ability of suppressing cell metabolic activity to around one-fifth, compared to 
control.  Paclitaxel reduced metabolic activity to around half compared to control. VSMCs exposed to 
POSS-PCU and liposomes retained a high level of metabolic activity, indicating their biocompatibility.           
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Figure 6.36. Normalized VSMC metabolic activity tracked over 7 days.  Liposomal paclitaxel was 
able to reduce cell metabolic activity to the greatest extent among samples.  Paclitaxel was able to 
reduce metabolic activity to around half compared to control.  Cells exposed to POSS-PCU and 
liposomes retained high levels of metabolic activity, indicating their biocompatibility. All samples 
displayed the same general trend over 7 days.        
 
Figure 6.37. Normalized VSMC metabolic activity tracked over 28 days.  Liposomal paclitaxel was 
able to reduce cell metabolic activity to the greatest extent among samples.  Paclitaxel was able to 
reduce metabolic activity to around half compared to control.  Cells exposed to POSS-PCU and 
liposomes retained high levels of metabolic activity, indicating their biocompatibility. All samples 
displayed the same general trend over 28 days.        
 
6.3.4.2. Determination of Cell Proliferation using FACS 
 
Whilst Alamar Blue provides information about cell metabolic activity (which 
technically could also function as an indirect measure of cell proliferation), a more 
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precise way of calculating cell proliferation numbers is the use of a flow cytometry 
method called fluorescence-activated cell sorting (FACS).  Annexin V is a marker for 
cell death, and FACS analysis revealed that liposomal paclitaxel caused the greatest 
amount of cell death (97.3%) compared to paclitaxel alone (46.5%) (Figure 6.38).  
This trend was also confirmed when cells were stained for DNA (DAPI), and F-actin 
(phalloidin), where 50.2% of cells remained viable when exposed to paclitaxel alone, 
while only 3.1% of cells remained viable when exposed to liposomal paclitaxel.   
 
A cell proliferation assay was also conducted to track VSMC growth in terms of cell 
density on culture plates, normalized against control (untreated cells).  In the 7-day 
proliferation assay, it was observed that cells exposed to liposomal paclitaxel had a 
statistically significantly (p < 0.05) lower density compared to paclitaxel alone 
(Figure 6.39).  Both POSS-PCU and liposomes had a statistically significantly (p < 
0.05) higher cell density compared to paclitaxel and liposomal paclitaxel, which 
indicates their biocompatibility.  When cell growth was tracked over 28 days, a 
similar trend could be observed whereby liposomal paclitaxel had a statistically 
significantly (p < 0.05) lower cell density compared to paclitaxel alone, across all 
time points (Figure 6.40).  Indeed, it could be seen that when cells were exposed to 
liposomal paclitaxel, they were effectively inhibited from proliferating, as their cell 
densities remained relatively constant (and low) throughout 28 days.  In contrast, 
although paclitaxel was seen to be able to inhibit cell growth, its inhibition was less 
effective compared to liposomal paclitaxel, as there was still an appreciable amount of 
cell growth over 28 days. 
 
Control VSMCs observed under light microscopy demonstrated their characteristic 
elongated morphology, indicating normal growth and proliferation.  Control VSMCs 
were also stained with phalloidin (for F-actin) and DAPI (for nucleus), and observed 
under confocal microscopy (Figure 6.41).  Rounded cell nucleus (blue) and actin 
fibres (green) were clearly seen under confocal microscopy. In contrast to control 
samples, VSMCs exposed to paclitaxel adopted a less elongated morphology with a 
lower cell density, indicating possible apoptosis.  Similarly, VSMCs that were 
exposed to liposomal paclitaxel appeared to be non-adhered with an even lower cell 
density compared to that of the paclitaxel sample.                       
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Figure 6.38.  Determination of cell numbers using FACS.  Liposomal paclitaxel elicited the highest 
amount of cell death, with 97.3% staining positive for annexin V.  Paclitaxel elicited 46.5% of cell 
death.  3.1% of cells stained positive for both DAPI and phalloidin when exposed to liposomal 
paclitaxel, while 50.2% of cells exposed to paclitaxel was double positive for DAPI and phalloidin.  
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Figure 6.39. 7 day cell proliferation assay.  Cell proliferation was lowest when exposed to liposomal 
paclitaxel.  A higher degree of cell proliferation was observed when exposed to paclitaxel, indicating 
that it had a lower efficacy in inhibiting VSMC growth. Cells that were not exposed to any treatment 
were used as positive controls, and blank well plates (with only tissue culture medium) were used as 
negative controls.    
   
 
Figure 6.40. 28 day cell proliferation assay.  Cell proliferation was lowest when exposed to liposomal 
paclitaxel.  A higher degree of cell proliferation was observed when exposed to paclitaxel, indicating 
that it had a lower efficacy in inhibiting VSMC growth. Cells that were not exposed to any treatment 
were used as positive controls, and blank well plates (with only tissue culture medium) were used as 
negative controls.   
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Figure 6.41. Light and confocal microscopy images of VMSCs at day 28.  (A) Control samples had 
a high cell density. (B) Cells exposed to paclitaxel had a lower cell density. (C) Cells exposed to 
liposomal paclitaxel had the lowest cell density.  (D) Confocal microscopy image of control VSMC 
stained with phalloidin and DAPI. Scale bar represents 5 µm. 
 
 
6.3.5. Liposomes Preserve Payload Integrity 
 
A luciferase reporter cell line (GloResponse™ NK-κB-RE-luc2P HEK293) assay was 
used to ascertain the ability of liposomes in preserving payload integrity.  In this 
experiment, luciferin was loaded into liposomes.  Upon entering the cell, luciferin 
would be oxidized by luciferase, which results in bioluminescence.  Results revealed 
that liposomal luciferin was able to elicit a statistically significantly (p < 0.05) higher 
amount of bioluminescence (11.0 ± 1.0) compared to luciferin (7.7 ± 0.7) that was 
detectable even at day 0 (Figure 6.42).  This trend was observed all throughout the 28-
day time frame, whereby liposomal luciferin demonstrated a statistically significantly 
higher (p < 0.05) level of bioluminescence compared to luciferin alone.  It can be seen 
that bioluminescence generally decreased throughout the 28-day period, possibly due 
to the degradation of luciferin (Figure 6.43).  However, it is evident that liposomes 
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effectively preserves the integrity of luciferin, retaining a higher level of 
bioluminescence compared to luciferin alone at every time point throughout the 28 
days (Figure 6.44).          
 
 
Figure 6.42.  Bioluminescence of luciferase reporter cell line assay at day 0.  Cells that were 
exposed to liposomal luciferin had the highest bioluminescence detected.  Cells that were exposed to 
luciferin had a lower bioluminescence with statistical significance (p < 0.05). Cells without any 
treatment were used as controls. The units for bioluminescence is average radiance, measured in 
photons per second per centimeter squared per steradian (p/s/cm2/sr).   
 
 
Figure 6.43. Bioluminescence of luciferase reporter cell line assay over 28 days.  Liposomal 
luciferin retained the greatest ability of eliciting bioluminescence compared to luciferin, with statistical 
significance (p < 0.05). Cells without any treatment were used as controls. The units for 
bioluminescence is average radiance, measured in photons per second per centimeter squared per 
steradian (p/s/cm2/sr).     
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Figure 6.44.  Bioluminescence of luciferase reporter cell line detected via IVIS®. Bioluminescence 
gradually reduced over 28 days. However, liposomal luciferin was able to preserve bioluminescence to 
a statistically significantly greater (p < 0.05) extent compared to luciferin. Cells without any treatment 
were used as controls. The units for bioluminescence is average radiance, measured in photons per 
second per centimeter squared per steradian (p/s/cm2/sr).  
 
6.3.6. Liposomal Uptake is via Caveolae-Mediated Endocytosis 
 
3 types of endocytosis inhibitors were added into the cell culture in order to ascertain 
the route of liposomal uptake into cells.  Fluorescence was detected in controls as well 
as samples with amiloride (0.85 ± 0.06) and chlorpromazine (0.81 ± 0.09).  However, 
a statistically significantly lower level (p < 0.05) of fluorescence was detected in 
samples that were exposed to β-cyclodextrin (0.1 ± 0.05) (Figure 6.45).  This 
indicates that liposomal uptake via caveolae-mediated endocytosis.  Confocal 
microscopy was also done on samples, and images showed high levels of fluorescence 
in controls, as well as samples exposed to amiloride and chlorpromazine (Figure 
6.46).  In contrast, samples exposed to β-cyclodextrin did not show fluorescence that 
was visually detectable under confocal microscopy.       
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Figure 6.45. Fluorescence intensity in endocytosis inhibition assay.  Samples exposed to amiloride 
and chlorpromazine displayed a high level of fluorescence intensity, similar to that of control.  Samples 
exposed to β-cyclodextrin displayed a statistically significantly lower level (p < 0.05) of fluorescence, 
indicating liposomal uptake is via caveolae-mediated endocytosis.      
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Figure 6.46. Confocal microscopy of VSMC in endocytosis inhibition assay. β-cyclodextrin 
effectively inhibits the uptake of liposomes. Amiloride and chlorpromazine does not inhibit liposomal 
uptake, similar to control, which demonstrated cellular fluorescence.   Scale bar represents 10 µm. 
 
6.4. Discussion 
 
The introduction of drug-eluting stents (DES) as a means of circumventing in-stent 
restenosis seen in bare-metal stents (BMS) was considered a revolutionary idea in the 
realm of interventional cardiology.  However, one major problem that is encountered 
with the use of DES is stent thrombosis (ST).  Although its exact mechanism has yet 
to be elucidated, it has been postulated that polymer-drug matrix hypersensitivity and 
impaired endothelialization are major contributing factors.  Currently, all FDA-
approved DES utilize a non-biodegradable polymer coating, in which the drug is 
directly mixed in. 
 
At time of writing, the concept of nanoscale drug delivery localized on stent platforms 
is largely experimental, and there are no FDA-approved DES utilizing nanoparticles 
for drug delivery.  This chapter describes, for the first time, a technique of using 
PEGylated liposomes as both an excipient and a delivery vehicle for paclitaxel, 
integrated on a POSS-PCU nanocomposite polymer for sustained and controlled drug 
release.  Results revealed that paclitaxel was successfully loaded into liposomes with 
high fidelity and stability.  In terms of biological interactions, POSS-PCU and 
liposomes were highly biocompatible and haemocompatible. Encapsulation of 
paclitaxel into liposomes with the subsequent integration onto POSS-PCU films 
demonstrated a synergistic effect of inhibiting VSMC proliferation, with a statistically 
significantly higher efficacy than paclitaxel alone.  Interestingly, using liposomes as 
an excipient and delivery vehicle for paclitaxel conferred haemocompatibility, and 
also making it less immunogenic.  
 
Ever since the approval of the first liposomal drug formulation by the FDA in 1995, 
there has been considerable interest in the utilization of liposomes for drug 
delivery[22].  The most basic aspect of creating liposomal drug formulations is to 
ensure that successful drug loading has indeed occurred.  To visually assess this, TEM 
has been utilized for the imaging for Doxil®, which showed the accumulation of 
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doxorubicin within the aqueous core of liposomes, characterized by darker and denser 
regions in loaded liposomes compared to unloaded liposomes[22].  The location in 
which the drug resides is dependent on the hydrophobicity or hydrophilicity of the 
drug.  Due to the fact that doxorubicin is hydrophilic, it would be largely confined to 
within the aqueous core of the liposome.  In contrast, as paclitaxel is hydrophobic, it 
would be expected to reside within the phospholipid membrane layer due to 
hydrophobic interactions with the hydrocarbon tail of the phospholipid.  Indeed, using 
TEM, our results have confirmed the presence of paclitaxel within the phospholipid 
bilayer. 
 
The hydrophobic nature of paclitaxel makes it poorly soluble in water, and it has been 
shown that its solubility is in the range of 0.3 µg/ml to 30 µg/ml[11].  Furthermore, 
research has demonstrated that paclitaxel can exist in an amorphous, hydrate, or 
crystalline form[11, 48, 49].  The solubility of paclitaxel in its amorphous state is 
higher than its hydrate state, and is understood to dimerize in solution[16], and has a 
high adsorption affinity on many surfaces such as plastic, glass, and proteins[50, 51].  
The inherent hydrophobicity of paclitaxel also necessitates a high volume of medium 
for the maintenance of non-saturation sink condition[52].  Taking these factors into 
consideration, it is evident that paclitaxel requires an excipient and / delivery vehicle 
in order for it fulfill its therapeutic functions.  In colloidal systems, one method of 
assessing the solubility of a substance is to measure its zeta potential.  It is generally 
accepted that a colloidal system with a higher zeta potential is more stable and less 
likely to coagulate or flocculate, when compared to a system with a lower zeta 
potential[53].  Furthermore, it has been shown that liposomes with a high zeta 
potential have a higher therapeutic efficacy[54].  Results in this chapter revealed that 
liposomal paclitaxel had a higher numerical zeta potential value, compared to 
paclitaxel alone.  This provides verification that using liposome as an excipient 
increases the stability of the colloidal system, making it less prone to coagulation and 
flocculation, as is expected when the particle in question (paclitaxel) is largely 
hydrophobic.  Furthermore, our results are also supported by a previous study which 
demonstrated that the use of PEGylated liposomes increased the solubility and 
stability of paclitaxel[55].                             
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In order for liposomes to be efficacious, it has been proposed that it needs to have a 
size around 100 nm in order for it to exploit the enhanced permeability and retention 
(EPR) effect in diseased tissues[56-58].  This is because diseased tissues have a 
network of abnormal blood capillaries that are “leaky”, thereby making it permeable 
to particles that are 100 nm or smaller[59].  Furthermore, impaired lymphatic 
drainage within diseased tissues would facilitate accumulation of liposomes in the 
diseased site, thereby increasing the likelihood of cellular uptake.  The production of 
liposomes as small unilamellar vesicles (ULV) of 100 nm in diameter with 
consistency via extrusion though a polycarbonate filter was considered a significant 
advance in liposome production technology[60, 61].  In this chapter, we employed 
established lipid extrusion techniques to obtain liposomes of 100 nm, with a very high 
level of consistency. Using dynamic light scattering (DLS), our results show that 
before extrusion, there was a multitude of liposomes with varying sizes from 300 nm 
to 500 nm.  However, after extrusion, we were able to obtain a homogenous 
population of paclitaxel-loaded liposomes that were 100 nm in diameter, with high 
efficiency.  Generating liposomes of small (100 nm) consistent sizes is a highly 
important factor in the case of nanoscale drug delivery.  Indeed, the premise of 
packaging drugs into discrete nanoparticles would be effectively nullified if the 
process of generating consistently small sizes cannot be controlled to a high degree of 
fidelity.  In addition to manufacturing liposomes of a consistent diameter of 100 nm, 
we were also able to demonstrate that a high level of encapsulation efficiency (86.3 ± 
0.03%) was also achieved.  Although a certain amount of drug loss has to be 
anticipated during the encapsulation process, our results revealed that we were able to 
package a very high amount of paclitaxel into liposomes, with minimal drug loss.  
Literature has shown that, depending on the type of phospholipids used and protocols 
adopted, encapsulation efficiency can range from 50% to 95%[19, 55].  Given this 
wide and variable range, it can thus be inferred that our method has proven to be 
viable in terms of achieving relatively high levels of encapsulation.       
 
Results in this chapter revealed that paclitaxel itself was observed to be thrombogenic 
in the TEG assay.  This was supported by a study by Eisenreich et al[32] which 
demonstrated that paclitaxel upregulated the expression of tissue factor (TF) mRNA 
5-fold, as well as TF activity 6-fold in smooth muscle cells. Furthermore, Wang et 
al[62] also showed the same effect of paclitaxel enhancing mRNA expression of TF, 
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and the activity of TF protein.  It was also suggested that, due to the observation that 
TF mRNA production was increased before TF protein activity, paclitaxel upregulates 
TF via transcriptional control. It was also previously shown by Stahli et al[33] that 
paclitaxel increases thrombin-induced endothelial TF expression via c-Jun N-terminal 
kinase (JNK) activation, mainly due to the stabilization of microtubules in endothelial 
cells.  TF expression is induced by thrombin at the transcriptional level by the 
activation of mitogen-activated protein (MAP) kinases such as extracellular signal-
regulated kinase (ERK), p38, and JNK[63, 64].  It was observed that while paclitaxel 
increased thrombin-mediated JNK phosphorylation, p38 and ERK was not affected in 
terms of activation patterns.  This suggests that JNK activation by paclitaxel is a 
highly selective process.  Paclitaxel was previously shown to activate both activator 
protein 1 (AP-1) pathway, and nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) pathways[65-67].  It is also known that paclitaxel activates the 
interleukin 8 (IL-8) promoter via NF-κB and AP-1 pathways[65].  It has been 
postulated that since IL-8 also shares the same non-consensus κB-like site that binds 
c-Rel/P65 heterodimers like TF promoter, it is not surprising that NF-κB and AP-1 
pathways can be activated by paclitaxel, resulting in TF up-regulation[62, 68].  TF is 
an important trigger of the extrinsic pathway in the blood coagulation cascade. In 
vivo, TF pathway (extrinsic pathway) is often considered the predominant blood 
coagulation pathway[69].  Indeed, it has been shown that severity of the thrombotic 
process on stented arteries is highly dependent on TF activity[70].  In addition, 
atherosclerotic plaques contain high levels of TF mRNA and antigen, which are 
associated with the activation of VSMCs and macrophages within the plaque[71].  TF 
binds to factor VIIa, and the resulting TF-factor VIIa complex activates factor IX or 
factor X[72].  Fibrin formation is then initiated via the conversion of prothrombin to 
thrombin by factor Xa.  This finally results in the formation of a thrombus on stented 
arteries, especially in DES[32, 73, 74]. 
 
Terry (Theresa) Allen, who was part of the team that developed the world’s first 
clinically functional PEGylated liposomes for Doxil®, once said, “If you want to be 
invisible, look like water”[75].  Set against this backdrop, an important observation 
was further noted in our results, whereby the encapsulation of paclitaxel in PEGylated 
liposomes statistically significantly mitigated its thrombogenic effects (p < 0.05).  
This effect was further seen in the complement activation assay, where the use of 
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PEGylated liposomes also reduced the immunogenicity of paclitaxel with statistical 
significance (p < 0.05).  In terms of blood coagulation, it has been shown that the 
adsorption of plasma proteins on surfaces can mediate thrombogenicity[76-78].  In 
terms of immunogenicity, it has been shown that adsorption of soluble factors and 
opsonization on the surface of nanoparticles can mediate complement activation[78, 
79].  Therefore, it can be reasonably argued that if a nanoparticle is able to resist 
adsorption of soluble factors and proteins on its surface, the problems of 
thrombogenicity and immunogenicity could be circumvented.  It has been proposed 
that protein adsorption is dependent on the hydrophobicity/hydrophilicity of a 
surface[80, 81].  In other words, the more hydrophobic a material is, the more likely 
that protein adsorption would occur on the surface due to hydrophobic 
interactions[82-84].  Among hydrophilic polymers, PEG is widely used due to the 
face that it is approved by the FDA for use in humans[85].  Furthermore, PEG chains 
have been observed to capture water molecules, creating a water cloud which 
minimizes interfacial free energy, resulting in a lower attractive force between 
proteins and the surface of the liposome[86].  PEGylated liposomes are often called 
“stealth liposomes” due to their ability to evade the mononuclear phagocytic system 
(MPS)[25], and there is also evidence that they also confer haemocompatibility[87].  
It is generally an accepted view that PEGylation improves the biosafety profile while 
concomitantly increases therapeutic index of nanoparticles for drug delivery[88, 89].  
It has been proposed that the main reason of why PEGylation improves the overall 
performance of a nanoparticle is due to the physiochemical alterations it makes on the 
molecule on which it is attached to.  These alterations include changes in 
conformation, level of hydration, electrostatic binding, and the balance of 
hydrophobicity/hydrophilicity.  Increasing levels of hydration leads to structural 
changes, and increases the bulkiness and volume of PEG moieties[90, 91].  This 
results in steric stabilization, which reduces non-specific protein-protein binding, and 
non-specific protein-cell binding.  This could also influence the binding affinity of 
cell receptors, thereby altering the patterns of absorption and distribution within 
biological systems.       
   
2 main mechanisms[92] have been proposed regarding the ability of PEGylated 
liposomes in being non-thrombogenic and non-immunogenic: Steric repulsion and 
steric obstruction.  Steric repulsion occurs when an incoming molecule (e.g. opsonin 
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or plasma proteins) collides with a segment of the PEG brush, which then redirects 
the molecule away from the liposome surface.  In essence, the PEG brush behaves 
like a shock absorber, letting the incoming molecule bounce away from the liposome, 
thus preventing direct contact.  A probabilistic model has been proposed, describing 
random movement of the PEG brush and would fulfill its repelling function when 
there are acts of collision between a substrate (the incoming molecule) and the surface 
(of the liposome).  The decrease in substrate-surface collision rate can be described 
as: 
 
F = (P0 – Pp)/P0 
 
Where F is the factor by which the rate is decreased, P0 is the probability a collision 
between an incoming molecule and PEG or the surface of the liposome, and Pp is the 
probability of collision of the incoming molecule with PEG only.  F can also be 
described as the ratio of between the kinetic constants of substrate-surface rates. 
 
Steric obstruction[93] occurs when the PEG brush on the liposome surface is 
positioned in such a way that contact between the incoming molecule and the 
liposome surface becomes almost impossible, especially at high brush densities.  For 
this mechanism to work, the size of the incoming molecule must be smaller than the 
size of the gap between individual PEG brush bristle.  Steric obstruction is effective 
against non-specific multi-point interactions, especially in situations where the 
establishment a cooperative bond system requires continuous contact between the 
liposome surface and in the incoming molecule.  The stability of this cooperative 
system can be defined as: 
 
Kn = e−ΔG/RT = eΣΔGi/RT 
 
Where Kn is the association constant, n is the number of bonds, ΔG is the Gibbs free 
energy of the system, ΔGi is the free energy of the ith bond, and Σ is the energy 
summation over all n bonds.  For a cooperative system of n equal bonds, the total 
association constant depends on the number of bonds exponentially:  
 
Kn = e−(nΔG)/RT = en(−ΔG/RT) 
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Where ΔG is the free energy of a single bond.  Hence if there is an absence of 
continuous contact between the surface and substrate, the cooperative association 
constant would decrease sharply as: (1) the maximal allowed number of associations 
nmax decreases, and (2) some intermediate states (with n < nmax) becomes impossible, 
as the experimentally determined association constant includes all states of adsorption 
with 1 < n < nmax. Therefore, a situation of decreased association rate and increased 
dissociation rate can be expected in a model of steric obstruction, thereby rendering 
all reactive surfaces to be inaccessible for a given substrate.  Considering then that 
both thrombosis and complement activation requires some type of particle adsorption 
on the surface, the mechanisms explained above could explain the observed effects of 
reduced thrombogenicity and immunogenicity of paclitaxel when it was encapsulated 
in PEGylated liposomes.      
 
In this chapter, drug release of liposomal paclitaxel was observed to be more 
sustained and controlled over a period of 1 year, compared to paclitaxel alone.  The 
drug release profile of liposomal paclitaxel was seen as a smooth curve, releasing 
100% of paclitaxel only after 1 year.  In contrast, a burst release could be seen in 
paclitaxel alone, and 100% of drug was eluted after 4 months.  It could thus be 
inferred that using liposomes as an excipient and delivery vehicle conferred a 
sustained and controlled release.      
 
POSS-PCU is a polyurethane-based nanocomposite polymer, characterized by 
urethane linkages in the backbone.  Polyurethane nanocomposite polymers comprise 
of alternating hard and soft segments, and its unique physiochemical properties are 
mainly determined by its 2-phase domain structures[94].  This phenomenon of phase 
separation is largely due to strong hydrogen bonds between urethane and urea-type 
hard segments, and/or hard segment crystallization.  It has been suggested that drug 
loading into polyurethane-based polymers can be conducted after polymerization by 
means of equilibrium absorption[95].  For drug-loaded polyurethanes, it has been 
previously observed that its drug release profile is linear, with an initial burst release, 
and it has been suggested that diffusion is the main driving force for it[96-99].  This 
observation was largely in agreement with results presented in this chapter, whereby 
there was an initial burst release seen in POSS-PCU-paclitaxel membranes.  However, 
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interestingly enough, POSS-PCU-liposomal paclitaxel did not display an initial burst 
release, and its release profile was seen to be more sustained and controlled over a 
longer period of time.  The main issue in burst release models is its unpredictability, 
and even if burst release is salutary, the amount of burst cannot be precisely 
controlled.  Research has been geared towards to avoidance of burst release, due to 
the fact that the initial high release rate would result in drug concentrations near or 
above the toxic level in vivo[100, 101].  Furthermore, any drug released in the burst 
stage might be metabolized and excreted without exerting its intended therapeutic 
effects.  Thus, even if no negative effect is exerted during the initial burst release, this 
portion of drug is essentially wasted, and this inefficiency in drug use may have both 
negative therapeutic effects for the patient, and even negative economic effects for the 
manufacturer.  Considering that paclitaxel was directly sprayed onto POSS-PCU, with 
a final ultra-thin top coat of POSS-PCU sprayed on top, this can be described as a 
reservoir system.  These systems are good at achieving zero-order or constant drug 
delivery, although there is a risk of dose dumping with too much burst release without 
conferring any therapeutic effect.  Burst release seen in this reservoir system is 
attributed to its storage effect[102].  This occurs when reservoir systems are stored for 
some time prior to use, and the pharmacological agent saturates the entire membrane, 
thereby enclosing the drug reservoir.  Thus, when immersed in a release medium, the 
drug particles that have diffused to the surface of the membrane is release 
immediately, resulting in a burst effect.  The amount of drug release with an initial 
burst can be defined as: 
 
Mt = DCo/l [t + (l2/6D)] 
 
Where Mt is the amount of drug released with an initial burst, D is the drug diffusion 
coefficient, Co is the drug concentration within the membrane, l is the thickness of the 
membrane, and t is the time.  Using this equation, it has been experimentally 
determined that the release profile during burst stage (t > 0) did not occur in a 
predictable manner[102].      
 
In order to circumvent initial burst release, we postulated that encapsulation of 
paclitaxel in liposomes (thereby increasing its solubility and colloidal stability) would 
confer sustained and controlled release.  It is known that the solubility of the drug, as 
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well as their partition coefficient has a bearing on the driving forces of release due to 
thermodynamic imbalances.  This effect has been explored by Narasimhan and 
Langer[103] who developed a model that was able to predict burst release based on 
solute solubility differences and diffusivities.  Although burst released can be 
considered favorable in limited circumstances, in most scenarios however, burst 
release is considered a negative effect.  In this chapter, we have developed a 
controlled release system that comprises of high drug loading (into liposomes) and 
was seen to not have a burst release.  Indeed, it has been showed that sustained release 
with a lower burst release effect is observed when molecular weight substances were 
used as a carrier for the drug, which was possibly due to greater hindrance to pore 
diffusion due to the solute molecular size[104].  It has also been reported that polymer 
microstructure and hydrophilic/hydrophobic interactions can also determine drug 
distribution profiles and release characteristics[105].  Furthermore, it has been 
observed that burst release was decreased with increasing molecular weight of the 
drug formulation, possibly due to change in relative size between the polymer pores 
and the decreasing mobility of the drug and the polymers[106].  This is consistent 
with our results, whereby the larger molecular weight liposomal paclitaxel had less 
burst release and more controlled and sustained release compared to paclitaxel alone.  
Using liposomes as an excipient, paclitaxel acquired an additional liquid-crystalline 
phase, producing and overall intact surface morphology, resulting in more controlled 
and sustained release. This mechanism is possibly due to the adsorption or diffusion 
into the polymer matrix via π-π aromatic stacking between the PEGylated liposomes 
and POSS-PCU. 
 
Within the context of a matrix-based drug release system, the release profile of a drug 
as a solid in an inert matrix has been described by Higuchi[107, 108] via the 
following equation: 
 !(!)!!  = 4(!"!!!)1/2  = 𝑘𝑡!/! 
 
Where M(t)/M0 is the fraction of released drug, D is the diffusion coefficient, l is the 
thickness of the polymer matrix, k is the release rate, and t is the release time.  This is 
considered a first-order release, and obeys Fick’s second law of diffusion (which 
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predicts how diffusion causes the concentration to change with time).  The major 
assumption in this model is that the diffusion takes place in only 1 dimension, the 
drug diffusion coefficient is held as a constant, and there is no matrix swelling or 
degradation.  The Higuchi model describes that in the first instance, the drug first 
dissolves from the surface of the polymer membrane.  When this layer becomes 
depleted of drug (in this case, liposomal paclitaxel), the next layer begins to be 
depleted by the dissolution of the drug and diffusion to the external solution via the 
inert carrier matrix (in this case, POSS-PCU).  In this way, the interface between the 
layer containing the dissolved drug and the layer containing the solid dispersed drug 
moves into the interior of the matrix as a boundary front.  This could explain the 
apparent sustained and controlled release profile of liposomal paclitaxel in POSS-
PCU membranes observed in this chapter. 
 
Apart from having a more controlled release compared to paclitaxel alone, it was also 
noteworthy that in the 28-day cell proliferation assay, liposomal paclitaxel was able to 
inhibit VSMC proliferation to a greater extent than paclitaxel alone, even without an 
initial burst release.  This further supports the notion that burst release does not 
necessarily equate to a higher efficacy in the first instance, as most of the drug is 
“wasted” (does not enter the cell / undergoes premature breakdown in the medium) 
rather than fulfilling its intended function.  Hence, it is plausible that the efficacy of 
liposomal paclitaxel over paclitaxel alone could be due to the cellular uptake process, 
rather than the initial amount of released paclitaxel from POSS-PCU films.  To this 
end, we have investigated the uptake process by performing an endocytosis inhibition 
assay. Results indicated that β-cyclodextrin effectively inhibited liposomal uptake 
into cells (VSMCs).  Due to the fact that β-cyclodextrin is an inhibitor of caveolae-
mediated endocytosis, we postulate that liposomal uptake into cells is via caveolae-
mediated endocytosis.  Caveolae are a subset of lipid rafts, which are cholesterol-rich 
plasma membrane regions that are also involved in signal transduction[109].  The 
defining feature of caveolae is the presence of hairpin-like membrane protein, 
caveolin-1, which is responsible for the production of caveolae.  Caveolae adopt a 
flask-shaped structure (about 70 nm), and can engulf cargo molecules which bind to 
the surface of caveolae.  Apart from caveolin-1, there are also other isoforms such as 
caveolin-2 and caveolin-3[110].  Other components of the caveolae system include 
dynamin (which enables vesicle scission), cavin (which induces membrane 
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curvature), synaptosome-associated protein (SNAP), and vesicle-associated 
membrane protein (VAMP2) which facilitates membrane fusion[111, 112].  
Subsequent to the budding of plasma membrane, the caveolae vesicles transport and 
fuse with multivesicular bodies and caveosomes. This pathway effectively bypasses 
lysosomes, thereby preventing degradation by lysozymes.  Hence, this could be an 
explanation for the increased efficacy of liposomal paclitaxel, compared to paclitaxel 
alone.  Indeed, our results are in agreement with other studies which show that 
Doxil® (doxorubicin in PEGylated liposomes) is taken up by cells via caveolae-
mediated endocytosis[113].  Furthermore, it has been reported[114] that caveolae-
mediated endocytosis only occurs with particles that are 100 nm or smaller, thereby 
providing indirect confirmation that our liposomes were no larger than 100 nm.                          
 
6.5. Conclusion 
 
In this chapter we have demonstrated, for the first time, a facile method of using 
PEGylated (stealth) liposomes both as an excipient and delivery vehicle for the 
sustained and controlled release of paclitaxel from POSS-PCU films.  We were able 
to synthesize liposomal paclitaxel of consistent and defined sizes of 100 nm in 
diameter, with high loading efficiency, and almost negligible leakage.  A sustained 
and controlled release over 1 year was observed, with a high efficacy of inhibiting 
VSMC proliferation in a 28-day assay.  Furthermore, this formulation was also non-
thrombogenic and non-immunogenic.  Finally, we have also shown that uptake of 
liposomes were via a caveolae-mediated endocytotic process.  Taken together, our 
results conclusively prove that liposomal paclitaxel integrated on POSS-PCU films 
could serve as a novel drug release platform.     
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7.1. Introduction 
 
The development of covered stents was originally intended for the treatment of 
aneurysms and to seal perforated and ruptured arteries to attenuate internal 
haemorrhage as a less invasive alternative to surgery.  The membrane on the stent 
reduces radial pressure experienced by the stent, and reduces the risk of in-stent 
restenosis and re-embolization by sealing the endoluminal layer. This is achieved via 
a physical barrier (the covering membrane) between the vessel wall and bloodstream, 
thereby limiting tissue in-growth, and preventing the release of thromboemboli[1-3].  
Covered stents can also function as enhanced localized drug delivery platform, by the 
provision of a uniform coverage and increase surface area throughout the artery wall.  
 
For all intents and purposes, a covered stent can be considered a hybrid stent-graft 
with both a metallic scaffold and a polymeric membrane.  Current models of covered 
stents have their metallic stent struts exposed.  We view this is a major design flaw, as 
the exposed metallic stent struts can cause both intimal hyperplasia and stent 
thrombosis.  Furthermore, the haemodynamics of blood flow can be affected by the 
presence of non-uniform of stent struts protruding within the luminal area.  This can 
further exacerbate the pathology of an already diseased vessel, as turbulent flow can 
occur in the non-uniform luminal area[4] (Figure 7.1).  In addition, at time of writing, 
there are no biofunctionalized polymer covered stents in the market[5].  To this end, 
we have developed a dual-functional nanocomposite polymer that is able to both 
capture endothelial progenitor cell (EPC) in the luminal area and inhibit vascular 
smooth muscle cell (VSMC) proliferation in the abluminal area.  Furthermore, we 
have ensured that the metallic stent struts are sandwiched in between the two polymer 
layers to prevent the metal struts from coming into contact with blood.  In addition, a 
smooth and uniform luminal area is maintained for the purpose of re-establishing 
laminar flow. 
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Figure 7.1. The effects of stent struts on vascular haemodynamics.  (a) Under physiological 
conditions, laminar flow is observed, with healthy endothelium intact. (b) The presence of stent struts 
would cause turbulent flow, and lead to platelet activation. (c) Having a covering membrane would 
smoothen the effects of the non-uniformity of stent struts, re-establishing laminar flow.  (c) 
Endothelialization and vessel healing can occur with a uniform covering membrane in the luminal area. 
Reproduced with permission from Jimenez and Davies 2009. Copyright © 2009 Biomedical 
Engineering Society. 
 
Apart from fulfilling its intended function of EPC capture and controlled drug release, 
a polymer that is integrated onto a metallic stent platform must also be robust in terms 
of its mechanical engineering aspects.  Indeed, if a polymer is unable to withstand 
sufficient in vitro mechanical testing parameters, it can be said to be of little value in 
functioning as a covering membrane for a stent.  Various established mechanical tests 
are commonly performed for polymers, including tensile test, tear resistance, and 
puncture resistance.  These are done on flat sheets of polymer, and can provide 
information on how robust the polymer is under mechanical stress.  Tubular samples 
can also be fabricated from the polymer, and tests like viscoelasticity/compliance and 
burst pressure can be performed.  These tests would provide information on how the 
polymer would behave under flow conditions. In addition, mechanical characteristics 
of the finished product of the entire covered stent system (metal stent strut with 
polymer membrane) must be assessed.  Tests would include radial strength, 
viscoelasticity/compliance, and bending test. 
 
It is important to note that the significance of optimal mechanical engineering 
characteristics is two-fold.  Firstly, the polymer-stent system must be able to 
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withstand sufficient stresses and forces both during the implantation procedure, and 
the subsequent time in the body.  Secondly, mechanical characteristics of the product 
must not adversely affect vessel mechanics, as stent-vessel mismatch can cause 
further complications.  Indeed, evidence has shown that stent-vessel mismatch has 
negative effect on long-term patency, with problems including disturbed flow 
patterns[6, 7], thrombosis[8], and restenosis[9].               
 
Subsequent to the development of a two-dimensional (2D) flat sheet of 
biofunctionalized POSS-PCU polymer with endothelial progenitor cell capturing 
potential and sustained liposomal drug release, the construction of a three-
dimensional (3D) tubular structure that can be integrated onto a metal stent platform 
is of paramount importance.  Since optimization technique of POSS-PCU integration 
onto a metallic stent platform has been extensively investigated by Farhatnia in our 
lab, this chapter focuses mainly on a biofunctionalized version of POSS-PCU, and its 
difference in mechanical performance (if any) compared to plain POSS-PCU.    
 
7.2. Materials and Methods 
 
All standard laboratory reagents were obtained from Sigma-Aldrich UK, unless 
otherwise stated.  All experimental procedures were done in triplicates (n = 3) unless 
otherwise stated.  Polymer films were maintained at 20 µm for all tests, as this was 
the optimum thickness for POSS-PCU covered stents (Farhatnia, unpublished results). 
A tabulated description of the samples can be found in Table 7.1.   
 
Table 7.1. Tabulated description of samples. 
 
Sample Description 
POSS-PCU Film Flat sheets of POSS-PCU 
POSS-PCU Tube Tubes of POSS-PCU 
POSS-PCU Covered Stent Metal stent sandwiched between POSS-PCU membrane 
POSS-PCU-Lipo-Ab Film Flat sheets of POSS-PCU with anti-CD34 antibodies on 
one side, and liposomes on the other side 
POSS-PCU-Lipo-Ab Tube Tubes of POSS-PCU with anti-CD34 antibodies in the 
luminal area, and liposomes on the abluminal area 
POSS-PCU-Lipo-Ab Covered Stent Metal stent sandwiched between POSS-PCU 
membrane, containing anti-CD34 antibodies in the 
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luminal area, and liposomes on the abluminal area 
 
 
7.2.1. POSS-PCU Nanocomposite Polymer Synthesis 
 
Detailed explanation of POSS-PCU synthesis was described in previous chapters. 
Briefly, POSS-PCU polymer solutions were diluted in tetrahydrofuran (THF) to 
obtain a w/w concentration of 2.5%.  This optimization technique was developed in 
our lab by Farhatnia (unpublished results).  0.05% of Tween-20 was then added to the 
sample.  The resultant solution was left on a roller mixer (Stuart Equipment) for 24 h 
at room temperature.       
 
7.2.2. POSS-PCU Nanocomposite Pre-Polymer Synthesis 
 
Poly(hexamethylenecarbonate)diol (Bayer Material Science AG, Germany), and 
trans-cyclohexane chlorohydrin isobutyl polyhedral oligomeric silsesquioxane 
(POSS) (Hybrid Plastics Inc., USA) was placed in a custom-made home-built reaction 
flask equipped with a mechanical stirrer and nitrogen inlet.  The reaction mix was 
heated to dissolve POSS into the polyol, and then cooled. 4,4’-methylenebis(phenyl 
isocyanate) (MDI) was then added into the mixture and reacted under nitrogen to 
form a pre-polymer solution.  Dry THF was slowly added to form a 20% (w/w) pre-
polymer solution.  The resultant pre-polymer was then diluted in THF to form a 5% 
(w/w) solution for enhanced atomization during the ultrasonic spray coating process.  
The purpose of a pre-polymer is to function as an adhesive to ensure a high fidelity 
bonding with the actual polymer.      
 
7.2.3. Metal Stents 
 
Omega™ platinum chromium coronary stents (2.5 mm diameter) were purchased 
from Boston Scientific.  Prior to experiments, stents were placed inside a glass 
scintillation vial with 95% (v/v) ethanol and bath sonicated in a bath sonicator for 15 
min.  This bath sonication step was repeated with 100% (v/v) acetone.    
  
7.2.4. Fabrication of Polymer Films (Flat Sheets) 
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POSS-PCU polymer solutions were casted onto specially manufactured 20 × 20 cm2 
stainless steel plates (Bibby Scientific, UK), yielding a thickness of 20 µm.  This was 
then placed in an oven at 65 °C for 24 h. Preparation of POSS-PCU-CD34 and POSS-
PCU-liposome were described in previous chapters.  
  
7.2.5. Fabrication of Polymer Tubes (Tubular Structures) 
 
Polymer tubes were fabricated using a custom-made home-built mechanical dip 
coating machine, developed by Farhatnia in our lab (unpublished results).  Briefly, dip 
coating was done using a 3 mm diameter stainless steel mandrel (Bibby Scientific, 
UK), which was dipped into a solution of POSS-PCU.  The polymer-coated mandrel 
was then left on the drying oven (Binder GmBH, Germany) at 65 °C for 24 h.     
 
7.2.6. Construction of a Nano-Inspired Multifunctional POSS-PCU 
Covered Stent 
 
There are 8 main stages in the construction of the nano-inspired multifunctional 
POSS-PCU covered stent (Figure 7.2 and Figure 7.3).   
 
Stage 1 is the silanization of the bare-metal stent (BMS), details of which have been 
extensively described elsewhere[10], and is considered proprietary information.  
Briefly, 3-aminopropyltriethoxysilane (APS) was applied to the surface of BMS to 
function as a cross-linking agent to facilitate adhesion between the bare metal surface 
and the POSS-PCU polymer coating.  BMS were cleaned with acetone and ethanol, 
and immersed in 0.5 M NaOH at 60 °C for 15 min.  It was then rinsed with distilled 
water and dried in air at room temperature.  Silane solution was made up of 2% APS 
solution (v/v) and 95% ethanol solution (v/v).  The pH of the silane solution was 
maintained at pH 4.0 by adding acetic acid. The APS solution was activated and 
hydrolysed for 15 min at room temperature.  BMS were immersed in the silane 
solution, and dried in air for 15 min, and cured at 110 °C for 20 min to allow cross-
linking of the organosilane film to the metal surface. 
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Stage 2 is the amino-functional silicone coating that would be found on the surface of 
BMS after the silanization process described in Stage 1. 
 
Stage 3 involves the spraying of POSS-PCU pre-polymer on BMS, using a MediCoat 
DES 1000 ultrasonic atomization spray system (Sono-Tek Corp, USA).  BMS was 
placed on a mandrel, with translational speed set at 2.5 mm/sec, and rotational speed 
set at 115 rpm.  Spray parameters were as follows: flow rate at 0.1 ml/min, and 
focusing gas pressure at 4.4 psi. The coated stent was then placed in a drying oven for 
1 h at 65 °C. During this stage, the amine group on the silane-treated surface would 
react with the isocyanate groups on the pre-polymer via covalent bonding. This pre-
polymer on the metal surface serves as an adhesive for enhanced bonding when the 
actual polymer is sprayed in the next stage.  
 
Stage 4 involves spraying of POSS-PCU polymer, with the same parameters as above. 
 
Stage 5 is the fabrication of a POSS-PCU covering membrane on the POSS-PCU 
coated stent.  Dip coating was done using a custom-made home-built mechanical dip 
coating machine. The mandrel (with the coated stent crimped onto it) was dipped into 
a solution of POSS-PCU.  This was the placed in a drying oven at 65 °C for 1 h.  
 
Stage 6 is the spraying of liposome onto the POSS-PCU covered stent. The protocol 
for spraying is described in Chapter 6. 
 
Stage 7 is the immobilization of anti-CD34 antibodies on the luminal area of the 
covered stent.  The overhang membrane on one edge was clamped, and the EDC/NHS 
cross-linker using a syringe.  The protocol was described in Chapter 5. 
 
Stage 8 involves the introduction of anti-CD34 antibodies. The protocol was 
described in Chapter 5.     
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Figure 7.2. An overview of stages involved in construction of a nano-inspired multifunctional 
POSS-PCU covered stent.  Metal stents are chemically treated before being integrated between a 
biofunctionalized version of POSS-PCU.       
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Figure 7.3. The 8 main stages of construction.  The resultant stent contains anti-CD34 antibodies in 
the luminal area, and liposomes in the abluminal area.   
 
7.2.7. Tensile Test (Film) 
 
An Instron 5565 Tensile Tester (Instron Ltd., UK) was used to measure the tensile 
strength of samples, in accordance with ISO 37.  Samples were cut into dumbbell-
shaped specimens (Type 3), measuring 4 mm in width, 16 mm in gauge length, and 
20 mm of initial grid distance.  Parameters were set as follows: an initial distance of 
20 mm, and a displacement rate of 200 mm/min. 6 measurements were taken for each 
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sample (n = 6), and test were carried out until break point.  Stress-strain curves were 
obtained by plotting engineering stress (σeng) against engineering strain (εeng). The 
Young’s modulus (E) was obtained by calculating the gradient of the linear part of the 
initial point (from 0 to 2 N/mm2) of the stress-strain curve (E = σ / ε).     
 
7.2.8. Puncture Resistance (Film)  
 
Puncture resistance was measured using the Instron 5565 Tensile Tester (Instron Ltd., 
UK), with a needle (0.02 mm in diameter) placed between the top gripping arm.  Rate 
of descent was set at 3 mm/min, and the amount of force required for the needle to 
puncture the polymer film was recorded.          
 
7.2.9. Tear Resistance (Film)  
 
Tear resistance was conducted using the Instron 5565 Tensile Tester (Instron Ltd., 
UK), in accordance with ISO 34 Type B Method. An Angle-shaped specimen was 
made for all polymer samples, with a small cut at the edge.  The displacement rate 
was set at 500 mm/min, and six measurements were recorded for each sample (n = 6).        
 
7.2.10. Viscoelasticity /Compliance Measurements (Tube)  
 
A flow circuit was set up to mimic physiological conditions (Figure 7.4). Polymer 
tube samples were connected with a 10% longitudinal stretch to a Harvard Apparatus 
Model 1421 Pulse Generator.  Pulse pressure was maintained at 60 mmHg, and 
frequency was maintained at 1 Hz. Human blood was obtained from the Blood Bank 
at the Royal Free Hospital, and placed in a reservoir at 37 °C. The mean pressure of 
the flow circuit was determined by the height of the reservoir.  A 2F Millar Mikro-tip 
catheter and a SPC-320 Transducer (Millar Instruments Inc., USA) was placed within 
the polymer tube and connected to the pressure transducer.  A 50 mm 7.5 linear array 
probe with a Doppler Ultrasound System (Pye Medical, UK) was clamped at a 90° 
angle with respect to the tube. Wall Tracking Software (Pye Medical Wall Track 
System II, UK) was used to measure the distension of the luminal area of the tube at 
20 mmHg increments of mean pressure, ranging from 30 to 100 mmHg.  This 
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approximates to physiological ranges.  Maintenance of pressure was achieved by 
detecting the radiofrequency signal produced by the vessel wall over a 4 s time frame. 
This allows the recording of wall distension and pressure in real-time simultaneously.  
Results were recorded using MATLAB® and analyzed using an algorithm developed 
by Mr. Ryan Dee in our lab (unpublished results). Generation of actionable data was 
assisted by Dr. Yasmin Farhatnia in our lab. 3 parameters were obtained for 
viscoelasticity/compliance measurements: diametric compliance (DC), Peterson 
Elastic Modulus (Ep), and Beta Stiffness Index (β). 
 
         
Figure 7.4. A home-built flow circuit.  This is used to measure the viscoelasticity/compliance of a 
material. The ultrasound device probe measures changes in diameter in response to pressure changes 
generated by the pump. 
 
7.2.11. Maximum Burst Pressure (Tube) 
 
A custom-made home-built burst pressure circuit assembled using water as a pressure 
builder.  A 1000 ml conical flask was used as a reservoir, and kept on a hot plate to 
maintain the temperature at 37 °C.  A tube was placed inside the reservoir, which 
enabled water to flow through a Flow Inducer (Watson-Marlow Ltd., UK).  POSS-
PCU polymer tubes were connected to the flow inducer, and water was pumped 
through the polymer tube samples.  The sample tubes were connected to a 3-way 
valve, which fed into a Universal Biometer Pressure Gauge (Pullman Instruments, 
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UK). Water was pumped at a rate of 100 ml/min to the point where polymer tube 
samples burst. The pressure at which the burst occur was recorded.   
 
 
Figure 7.5. A home-built burst pressure system.  The flow inducer pumps water, while the three-way 
valve facilitates pressure build-up to the point where the membrane ruptures.    
 
7.2.12. Radial Strength (Covered Stent) 
 
Radial strength of covered stent samples were measured using the Instron 5556 
Tensile Tester (Instron Ltd., UK).  Covered stent samples were expanded and placed 
between two flat stoppers attached to the mechanical arm.  The speed of descent of 
the mechanical arm was set to 0.065 mm/s.  The force (N) and distance travelled 
(mm) was recorded.  The amount of force per unit length required to radially collapse 
the sent was calculated by the formula: 
 
Force per unit length = N / mm 
 
7.2.13. Viscoelasticity / Compliance Measurements (Covered Stent) 
 
Viscoelasticity/compliance measurements of covered stent samples were similar to 
the set-up for film samples mentioned above. 
 
7.2.14. 3-Point Bending Test (Covered Stent) 
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3-point bending test was conducted using the Instron 5565 Tensile Tester (Instron 
Ltd., UK).  Covered stent samples were placed on two supporting columns, and force 
was applied on the middle portion of the sample using the mechanical arm.  The force 
applied (N) and distance travelled (m) by the mechanical arm was recorded when the 
middle portion makes contact with the base.  The amount of work required to bend 
the stent was calculated by multiplying force with distance: 
 
Work = N × m 
 
7.2.15. Raman Spectroscopy 
 
As described in Chapter 5. 
 
7.2.16. Physiological Flow Circuit  
 
EPC capture was conducted in a flow circuit set-up, described above in the 
viscoelasticity measurement. The flow circuit was left to run for 24 h before 
conducting immunofluorescence under confocal microscopy, with green quantum 
dots used as fluorophores (details of which have been described in Chapter 5).    
 
7.2.17. Statistical Analyses 
 
Parametric data is presented as ± standard deviation (SD) of the mean, and all 
experiments were performed in triplicates (n = 3), unless otherwise stated.  Curve 
fitting and statistical analysis was done using GraphPad Prism® (GraphPad Software 
Inc., USA).  One-way analysis of variance (ANOVA) with post-hoc Tukey’s range 
test was performed at a 95% confidence interval.  p < 0.05 was considered statistically 
significant.    
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7.3. Results 
 
7.3.1. Tensile Test (Film) 
 
POSS-PCU-Lipo-Ab had a lower tensile strength (45.0 ± 2.1 MPa) compared to 
POSS-PCU (46.2 ± 3.0 MPa) (Figure 7.6). However, the difference between tensile 
strength was not statistically significant (p > 0.05).  After 1 year elution, the sample 
also had a slightly lower tensile strength.  Similarly, the results were not statistically 
significant (p > 0.05) from both POSS-PCU and POSS-PCU-Lipo-Ab in the 
percentage elongation break (Figure 7.7).  A small decrease in percentage elongation 
break was observed after 1 year elution.  However, this small decrease in percentage 
elongation break was not statistically significant (p > 0.05) from POSS-PCU and 
POSS-PCU-Lipo-Ab.  Similarly, a small decrease in Young’s modulus at 10% strain 
was observed after 1 year elution (Figure 7.8).  However, this difference in value was 
too small to be statistically significant (p > 0.05) when compared to both POSS-PCU 
and POSS-PCU-Lipo-Ab. Overall, it was observed that the tensile properties of 
biofunctionalized POSS-PCU was not statistically significantly different from non-
biofunctionalized POSS-PCU.  This indicates that integration of antibodies and 
liposomes onto POSS-PCU did not adversely affect its mechanical properties. 
Furthermore, although there was a small decrease in tensile strength after immersing 
the biofunctionalized polymer film in aqueous medium for 1 year, the difference post-
elution was not statistically significant (p > 0.05) from pre-elution.       
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Figure 7.6. Tensile strength.  A small decrease in tensile strength for POSS-PCU-Lipo-Ab and after 1 
year elution was observed.  However, the difference was not statistically significant (p > 0.05) from 
POSS-PCU. 
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Figure 7.7. Percentage elongation break. A small decrease in percentage elongation break was 
observed after 1 year elution.  However, the difference was not statistically (p > 0.05) significant 
compared to POSS-PCU and POSS-PCU-Lipo-Ab.  
 
 
Figure 7.8. Young’s modulus at 10% strain. A small decrease in Young’s modulus was observed 
after 1 year elution.  However, this difference was not statistically significant (p > 0.05) from POSS-
PCU and POSS-PCU-Lipo-Ab. 
 
7.3.2. Puncture Resistance (Film)  
 
The push-through load for POSS-PCU-Lipo-Ab was slightly higher (0.099 ± 0.007 N) 
than POSS-PCU (0.0954 ± 0.007 N) (Figure 7.9).  However, this difference was not 
statistically significant (p > 0.05).  After 1 year elution, it was observed that the push-
through load for POSS-PCU-Lipo-Ab was lower (0.091 ± 0.007 N) compared to its 
pre-elution form, with the difference being statistically significant (p < 0.05).  
Interestingly enough, when compared to POSS-PCU, the difference becomes non-
statistically significant (p > 0.05). Push-through displacement also had a similar trend 
to push-though load, whereby POSS-PCU-Lipo-Ab had a slightly higher value 
compared to POSS-PCU, and the value decreased after 1 year elution (Figure 7.10).  
Overall, it can be seen that even after 1 year elution, the biofunctionalized version of 
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POSS-PCU retained similar mechanical characteristics when compared to POSS-
PCU.     
 
 
Figure 7.9. Push-through load.  POSS-PCU-Lipo-Ab displayed a higher push-through load compared 
to POSS-PCU.  After 1 year elution, a slight decrease in push-through load was observed.  
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Figure 7.10. Push-through displacement.  A similar trend to push-through load was observed 
whereby POSS-PCU-Lipo-Ab had a slightly higher value compared to POSS-PCU, and values 
decreased after 1 year elution.   
 
7.3.3. Tear Resistance (Film)  
 
Tear resistance displayed a trend that was consistent with tensile strength; POSS-
PCU-Lipo-Ab had a higher value (57.2 ± 4.2) compared to POSS-PCU (55.0 ± 3.0), 
with the difference being non-statistically significant (p > 0.05) (Figure 7.11).  After 1 
year elution, although there was a decrease in value, there difference was also not 
statistically significant (p > 0.05) to POSS-PCU. 
  
 
Figure 7.11. Tear resistance. POSS-PCU-Lipo-Ab had a slightly higher tear resistance compared to 
POSS-PCU, but the difference was not statistically significant (p > 0.05).  After 1 year elution, a small 
decrease in value as observed, but this decrease was not statistically significant (p > 0.05) to POSS-
PCU. 
 
7.3.4. Viscoelasticity /Compliance Measurements (Tube)  
 
Polymer tube samples (without the metal stent structure) was subject to viscoelasticity 
testing.  This would provide information on the behavior of the polymer itself.  
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Measurements of viscoelasticity were taken four different pressure points: 35 mmHg, 
55 mmHg, 75 mmHg, and 95 mmHg.  These 4 pressure points were deemed most 
appropriate and approximates to physiological conditions, taking into consideration 
the constraints of the experimental set-up (Farhatnia, unpublished data).  All polymer 
tube samples displayed almost identical DC values at all pressure points, with their 
differenced being non-statistically significant (p > 0.05) (Figure 7.12, Figure 7.13, 
Figure 7.14, Figure 7.15). The same trend was also observed Peterson elastic modulus 
(Ep), whereby all polymer tube samples displayed similar Ep values, with their 
differences being non-statistically significant (p > 0.05) (Figure 7.16, Figure 7.17, 
Figure 7.18, Figure 7.19).  This was also true for beta stiffness index (β), where all 
polymer tube samples had similar β value, with their differences being non-
statistically significant (p > 0.05) (Figure 7.20, Figure 7.21, Figure 7.22, Figure 7.23). 
Taken together, it can be seen that POSS-PCU-Lipo-Ab displayed similar viscoelastic 
behavior as (non-biofunctionalized )POSS-PCU.  Furthermore, even after a 1-year 
elution period, POSS-PCU-Lipo-Ab retained the same viscoelasticity as pre-elution 
samples.  In summary, results here clearly indicate that the viscoelastic behavior of 
POSS-PCU was preserved after biofunctionalization, and was also robust enough to 
withstand 1-year elution without any significant deviations. 
 
 
	   335	  
Figure 7.12. Diametric compliance (DC) at 35 mmHg. All samples displayed very similar DC values, 
with differences being non-statistically significant (p > 0.05).  
 
 
Figure 7.13. Diametric compliance (DC) at 55 mmHg. All samples displayed very similar DC values, 
with differences being non-statistically significant (p > 0.05). 
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Figure 7.14. Diametric compliance (DC) at 75 mmHg. All samples displayed very similar DC values, 
with differences being non-statistically significant (p > 0.05). 
 
 
Figure 7.15. Diametric compliance (DC) at 95 mmHg. All samples displayed very similar DC values, 
with differences being non-statistically significant (p > 0.05). 
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Figure 7.16. Peterson elastic modulus (Ep) at 35 mmHg.  All samples displayed very similar Ep 
values, with the differences being non-statistically significant (p > 0.05). 
 
 
Figure 7.17. Peterson elastic modulus (Ep) at 55 mmHg.  All samples displayed very similar Ep 
values, with the differences being non-statistically significant (p > 0.05). 
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Figure 7.18. Peterson elastic modulus (Ep) at 75 mmHg.  All samples displayed very similar Ep 
values, with the differences being non-statistically significant (p > 0.05). 
 
 
Figure 7.19. Peterson elastic modulus (Ep) at 95 mmHg.  All samples displayed very similar Ep 
values, with the differences being non-statistically significant (p > 0.05). 
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Figure 7.20. Beta stiffness index (β) at 35 mmHg.  All samples displayed very similar β, with 
differences between them being non-statistically significant (p > 0.05). 
    
 
Figure 7.21. Beta stiffness index (β) at 55 mmHg.  All samples displayed very similar β, with 
differences between them being non-statistically significant (p > 0.05). 
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Figure 7.22. Beta stiffness index (β) at 75 mmHg.  All samples displayed very similar β, with 
differences between them being non-statistically significant (p > 0.05). 
 
 
Figure 7.23. Beta stiffness index (β) at 95 mmHg.  All samples displayed very similar β, with 
differences between them being non-statistically significant (p > 0.05). 
 
7.3.5. Maximum Burst Pressure (Tube) 
 
There was a small increase in burst pressure for POSS-PCU-Lipo-Ab (450 ± 35 
mmHg) compared to POSS-PCU (438 ± 29 mmHg).  However, this difference was 
not statistically significant (p > 0.05) (Figure 7.24).  The difference in burst pressure 
value after 1 year elution was also not statistically significant from its pre-eluted 
version and POSS-PCU.  Overall, it can be seen that the maximum pressure at which 
the membrane can withstand without rupturing was essentially the same for all 
samples.   
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Figure 7.24. Burst pressure.  A small increase in burst pressure was observed for POSS-PCU-Lipo-
Ab, but the difference was not statistically significant (p > 0.05) to POSS-PCU. The burst pressure 
after 1 year elution was not statistically significant (p > 0.05) to both pre-elution sample as well as 
POSS-PCU. 
 
7.3.6. Viscoelasticity / Compliance Measurements (Covered Stent) 
 
Covered stent samples (polymer with metal stent structure) were also subjected to 
viscoelasticity measurements.  This would provide information on the viscoelastic 
behavior of the covered stent system as a whole. All covered stent samples displayed 
almost identical DC values at all pressure points, with their differenced being non-
statistically significant (p > 0.05) (Figure 7.25, Figure 7.26, Figure 7.27, Figure 7.28). 
The same trend was also observed Peterson elastic modulus (Ep), whereby all covered 
stent samples displayed similar Ep values, with their differences being non-
statistically significant (p > 0.05) (Figure 7.29, Figure 7.30, Figure 7.31, Figure 7.32).  
This was also true for beta stiffness index (β), where all covered stent samples had 
similar β value, with their differences being non-statistically significant (p > 0.05) 
(Figure 7.33, Figure 7.34, Figure 7.35, Figure 7.36). Taken together, it can be seen 
that POSS-PCU-Lipo-Ab displayed similar viscoelastic behavior as (non-
biofunctionalized )POSS-PCU, even with the presence of a metal stent structure.  
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Furthermore, even after the 1-year elution period, POSS-PCU-Lipo-Ab retained the 
same viscoelasticity as pre-elution samples.  Due to the fact that the viscoelasticity of 
non-biofunctionalized POSS-PCU covered stents have been extensively tested and 
optimized by Farhatnia in our lab (unpublished results), the main objective of this test 
was to assess the viscoelastic behavior of the POSS-PCU-Lipo-Ab covered stents (the 
biofunctionalized version of POSS-PCU covered stents), and whether there would be 
any significant changes in its viscoelasticity.  Results here clearly indicate that POSS-
PCU-Lipo-Ab covered stents had the same viscoelastic behavior has POSS-PCU 
covered stents.  This viscoelasticity was also preserved even after being subject to 1-
year elution.      
 
 
Figure 7.25. Diametric compliance (DC) of covered stent samples at 35 mmHg.  DC of all covered 
stent samples had similar DC values, with the difference being non-statistically significant (p > 0.05).   
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Figure 7.26. Diametric compliance (DC) of covered stent samples at 55 mmHg.  DC of all covered 
stent samples had similar DC values, with the difference being non-statistically significant (p > 0.05).   
 
 
Figure 7.27. Diametric compliance (DC) of covered stent samples at 75 mmHg.  DC of all covered 
stent samples had similar DC values, with the difference being non-statistically significant (p > 0.05).   
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Figure 7.28. Diametric compliance (DC) of covered stent samples at 95 mmHg.  DC of all covered 
stent samples had similar DC values, with the difference being non-statistically significant (p > 0.05).   
 
 
Figure 7.29. Peterson elastic modulus (Ep) of covered stent samples at 35 mmHg.  All covered 
stent samples displayed closely similar Ep values, and the differences between them were not 
statistically significant (p > 0.05). 
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Figure 7.30. Peterson elastic modulus (Ep) of covered stent samples at 55 mmHg.  All covered 
stent samples displayed closely similar Ep values, and the differences between them were not 
statistically significant (p > 0.05). 
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Figure 7.31. Peterson elastic modulus (Ep) of covered stent samples at 75 mmHg.  All covered 
stent samples displayed closely similar Ep values, and the differences between them were not 
statistically significant (p > 0.05). 
 
 
Figure 7.32. Peterson elastic modulus (Ep) of covered stent samples at 95 mmHg.  All covered 
stent samples displayed closely similar Ep values, and the differences between them were not 
statistically significant (p > 0.05). 
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Figure 7.33. Beta stiffness index (β) of covered stent samples at 35 mmHg.  All covered stent 
samples at similar β values, with the differences between them being non-statistically significant (p > 
0.05). 
 
 
Figure 7.34. Beta stiffness index (β) of covered stent samples at 55 mmHg.  All covered stent 
samples at similar β values, with the differences between them being non-statistically significant (p > 
0.05). 
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Figure 7.35. Beta stiffness index (β) of covered stent samples at 75 mmHg.  All covered stent 
samples at similar β values, with the differences between them being non-statistically significant (p > 
0.05). 
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Figure 7.36. Beta stiffness index (β) of covered stent samples at 95 mmHg.  All covered stent 
samples at similar β values, with the differences between them being non-statistically significant (p > 
0.05). 
 
7.3.7. 3-Point Bending Test 
 
3-point bending test revealed that although POSS-PCU-Lipo-Ab had a slightly higher 
value compared to POSS-PCU, the difference in value was not statistically significant 
(p > 0.05) (Figure 7.37).  A small decrease in value was observed after 1-year elution, 
but the difference was not statistically significant.  In summary, covered stent samples 
had similar 3-point bending test results, indicating that biofunctionalization did not 
adversely affect polymer-stent mechanics.   
 
 
Figure 7.37. Three-point bending test.  POSS-PCU-Lipo-Ab covered stents had a slightly higher 
value compared to POSS-PCU covered stents.  A small decrease in value was observed after 1 year 
elution.  Values between samples were not statistically significant from each other (p > 0.05). 
 
7.3.8. Radial Strength 
 
Radial strength of covered stent samples revealed that both POSS-PCU and POSS-
PCU-Lipo-Ab had similar radial strength values (p > 0.05) (Figure 7.38).  The same 
	   350	  
level of radial strength was preserved even after being subjected to 1-year elution (p > 
0.05).      
 
 
Figure 7.38. Radial strength of covered stent samples.  All covered stent samples displayed similar 
radial strength, with the differences between them being non-statistically significant (p > 0.05).  
 
7.3.9. Liposome Integration on Abluminal Area 
 
Liposomes on the abluminal area of POSS-PCU-Lipo-Ab covered stents were 
detected using Raman, with results indicating a strong signal at 2900 cm-1 (Figure 
7.39).  This represents the C-H stretching region of liposomes, in agreement with 
previous studies[11].  Raman integration maps were also constructed showing the 
liposome-rich areas.  This indicates that liposomes remained present on the abluminal 
area of the POSS-PCU stent, further supporting the feasibility of the manufacturing 
process. 
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Figure 7.39. Raman spectra and integration maps of liposomes on the abluminal area of covered 
stent samples. Liposomes were detected on the abluminal area of POSS-PCU-Lipo-Ab covered stent 
samples, indicating successful liposomal integration after the manufacturing process. 
 
7.3.10. Endothelial Progenitor Cell Capture on Luminal Area 
 
After placing the covered stent in a physiological flow circuit for 24 hours, 
endothelial progenitor cells (EPCs) were detected on POSS-PCU-CD34-Ab, but not 
on POSS-PCU (Figure 7.40).  This indicates that POSS-PCU-CD34-Ab was able to 
capture circulating EPCs as early as within 24 hours after exposure.     
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Figure 7.40. Endothelial progenitor cell (EPC) capture in physiological flow circuit.  POSS-PCU-
CD34-Ab covered stents were able to capture EPCs, but not POSS-PCU covered stents. Scale bar 
represents 10 µm.  
 
7.3.11. Prototype of Nano-Inspired Multifunctional POSS-PCU Covered 
Stent  
 
The finished product consists of a metal stent that is sandwiched between 
biofunctionalized POSS-PCU (Figure 7.41).  This biofunctionalization consists of 
anti-CD34 antibodies in the luminal area for the capture of EPCs, and liposomal 
paclitaxel on the abluminal area for sustained and controlled drug release to inhibit 
VSMC (Figure 7.42).  Furthermore, the biofunctionalized membrane also serves as a 
physical barrier, preventing plaque dislodgement during stent deployment, and can 
also function as a “fail-safe” measure that prevents haemorrhage in the event of vessel 
perforation.  The smooth luminal area also minimizes the possibility of turbulent flow 
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(when compared to bare metal stent struts without a covering membrane), thereby 
closely approximating to the haemodynamic flow conditions of native vessels.     
 
 
Figure 7.41. Photographs of the finished product.  The POSS-PCU-Lipo-Ab covered stent consists 
of a metal stent strut sandwiched between biofunctionalized POSS-PCU membranes. Scale bar 
represents 100 µm.  
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Figure 7.42. Prototype of the nano-inspired multifunctional POSS-PCU covered stent. The luminal 
area harbours EPC capture potential to increase endothelialization, while the abluminal area consists of 
liposomal paclitaxel for inhibition of VSMC proliferation.   
 
7.4. Discussion 
 
A polymer that is integrated onto a metal stent must fulfill two basic criteria. Firstly, it 
must be robust enough to withstand mechanical forces experienced during and after 
implantation, and secondly, it must be flexible and viscoelastic enough to mimic 
vessel biomechanics.  Due to the fact that a covered stent is considered a hybrid stent-
graft that would be integrated within the vessel wall, a description of the function of 
vessel biomechanics is necessitated.  Apart from serving as conduits for the 
distribution of blood, blood vessels are viscoelastic in nature, thereby allowing them 
to serve as pressure dampers during pressure fluctuations.  This facilitates the 
conversion of pulsatile flow into a continuous flow within the blood circulation.  
Viscoelasticity thus allows instantaneous reversion the original shape upon the 
removal of applied pressure. During systole, potential energy is stored in the vessel 
wall, and is responsible for the elastic recoil during diastole.  This mechanical 
phenomenon ensures unidirectional blood flow, and prevents backflow to a certain 
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extent.  Under normal physiological circumstances, the artery wall is viscoelastic in 
nature.  The elastic component serves to minimize arterial systolic pressure and 
increases diastolic pressure, thereby maintaining a mean arterial pressure and low 
pulsatility.  This viscoelastic characteristic also guards against wall stress and strain 
during times of sudden pressure increases[12, 13].  It is known that the tunica media 
of arteries regulates vasomotor tone in response to blood pressure.  Elastin confers a 
degree of elasticity to the vessel wall, allowing it to stretch during systole and revert 
back to its original dimensions during diastole.  Thus it can be seen that elastin 
functions as the primary load bearer at low pressures.  In situations of high pressure, 
collagen serves as the primary load bearer, conferring stiffness and a degree of non-
linearity to the vessel.  This loading and unloading effect in response to changes in 
pressure is collectively termed compliance. 
 
In the previous Chapters, efforts were made to study the biophysical characteristics of 
biofunctionalized POSS-PCU.  This Chapter would mainly focus on the mechanical 
characteristics of POSS-PCU and its implications of functioning as a hybrid-stent 
graft. Results have revealed that, across all mechanical parameters, biofunctionalized 
(liposome and antibody) POSS-PCU was not statistically significant (p > 0.05) from 
non-biofunctionalized POSS-PCU. Considering that the mechanical properties of a 
polymer on a stent would determine its long-term patency and behavior under flow 
conditions, it is pertinent to conduct robust mechanical assessment on both the 
polymer itself as well as the final product.  Due to the fact that implanted stents is 
analogous to being part of the vessel wall, its mechanical behavior would have a 
bearing on vascular haemodynamics and the potential to alter flow patterns.  Indeed, 
deployment of a stent within a vessel wall would inadvertently modify its mechanical 
properties, especially if the device in question is non-viscoelastic.  It has been 
demonstrated that stent-vessel mismatch can have a significant effect on flow 
patterns[14, 15].  It is also reported that abnormal flow patterns, such as low shear 
stress, pulsatile mechanical stress, and turbulent flow can have detrimental effects on 
the vessel[16].  The impairment of normal flow patterns (possibly via flow stagnation) 
would increase the resistance time of chemotactic factors and platelets[17, 18], 
thereby increasing the risk of neointimal hyperplasia[19, 20] and thrombosis[21].  
POSS-PCU has been previously demonstrated to be highly viscoelastic, thereby 
suitable for being implanted in a vessel[22].  It is pertinent for material to exhibit 
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viscoelastic properties, because an excessively stiff membrane can damage 
endothelial cells and increase vascular smooth muscle cell (VSMC) proliferation, 
thereby causing restenosis[23].  Compliance mismatch can result in a alteration of 
physiological cyclic stretching forces, which in turn causes modification of VSMC 
phenotype via upregulation of growth rate by almost five-fold, and deposition of 
extracellular matrix (ECM) in the tunica intima[24].  Furthermore, there is also 
evidence to suggest that non-compliant membranes can lead to fluctuations in wall 
shear stress, vortex formation, and flow reversal, ultimately increasing the risk of 
intimal hyperplasia[25, 26].  These effects are further magnified when we consider 
small-diameter covered stents to be used in coronary arteries.  This can be explained 
by Poiseuille’s law: 
 
Q = [(P0 – P1) πr4] / 8nl 
 
Where Q is the volumetric flow rate (m3/s), P0 and P1 are the pressures at the entrance 
and the exit of the tube respectively (perfusion pressure), r is the radius of the tube, l 
is the length of the tube, and n is the viscosity of the liquid.  Due to the fact that flow 
is the function of the fourth power of the radius, it is evident that halving the diameter 
of the tube would lead to a 16-fold reduction in the flow rate. 
 
The concept of viscoelasticity can be broken down into two main components: the 
viscous component, and the elastic component.  The viscous component can be 
expressed mathematically as: 
 
ηω = Esinφ 
 
Where η is the coefficient of viscosity, ω is the angular velocity, and E is the elastic 
modulus.  The viscous component is responsible for the dissipation of energy from 
the incident and reflected pressure waves. If one were to consider a situation of a 
liquid flowing through a tubular structure, increase in pressure would result in an 
increase in the diameter of the tube.  However, this change in diameter (strain) lags 
behind the change in pressure (force).  This lag can be graphically explained by a 
hysteresis loop, when pressure is plotted against diameter.  The relationship between 
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the change in pressure and the change in diameter can defined mathematically by the 
equation:  
 
sinφ = a / ΔF 
 
Where φ is the phase angle, a is the ratio of the ascending and descending segments at 
mid-cycle, and ΔF is the total excursion. 
 
The elastic component of the system can be described by three parameters, due to the 
non-linearity and anisotropy of a three-dimensional (tubular) system: diametric 
compliance (DC), Peterson elasticity (Ep), and beta stiffness index (β).  DC can be 
defined as the absolute change in volume for a given pressure change, and can be 
expressed as: 
 
DC = Ds – Dd / [Dd (Ps – Pd) × 104] 
 
Where P is pressure, D is diameter, and the d and s subscripts are systolic phase and 
diastolic phase respectively.   
 
Peterson elastic modulus is the inverse of compliance, and is expressed as: 
 
Ep = [Dd (Ps – Pd)] / (Ds – Dd) 
 
Due to the fact that compliance is a function of blood pressure, a method of 
calculating compliance independent of blood pressure is the beta stiffness index, 
which is written as: 
 
β =  [Dd ln(Ps/Pd)] / [Ds – Dd] 
    
This method uses the logarithmic conversion of the ratio of systolic phase to diastolic 
phase. 
 
Indeed, results presented in this Chapter pertaining to viscoelasticity clearly showed 
that the biofunctionalized version of POSS-PCU had similar performance to the non-
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biofunctionalized version that had been optimized for covered stent applications.  
This lends credence to the hypothesis that biofunctionalizing POSS-PCU with 
antibodies and liposomes did not adversely alter the viscoelasticity of the polymer and 
the entire covered stent system as a whole.  Hence, the feasibility of developing a 
biofunctionalized POSS-PCU for covered stent that is highly compliant for 
implantation into a vessel wall has been robustly demonstrated.   
 
Another important aspect that is closely related to viscoelasticity / compliance is the 
burst pressure.  This can be viewed as an extreme case of compliance, as the 
experiment requires a pressure build-up to the point of membrane rupture. Our results 
reveal that biofunctionalized POSS-PCU had a burst pressure of 450 mmHg (± 35 
mmHg), and was not statistically significantly different (p > 0.05) from the non-
biofunctionalized version of POSS-PCU. This indicates that biofunctionalization with 
liposomes and antibodies do not adversely affect the mechanical performance of 
POSS-PCU.  Although blood pressure of 400 mmHg is not usually seen under 
physiological circumstances, the purpose of this over-compensation underscores the 
mechanical robustness of the polymer.  
 
POSS-PCU is a segmented polyurethane, consisting of a crystalline hard segment, and 
an amorphous soft segment.  The hard segments are formed via the reaction of 
diisocyanate with a short chain diol (1,4 butanediol) or diamine (ethylenediamine).  
The soft segments are formed via the reaction of diisocyanate with high molecular 
weight polyols (e.g. polyether, polycarbonate, polyester).  It is known that 
nanocomposite materials consisting of two or more constituent elements would 
significantly improve the overall performance of the final resultant product.  The two 
main parts of a nanocomposite polymer is the reinforcement and the matrix.  In the 
case of POSS-PCU, the reinforcement is POSS, and the matrix is PCU.  In 
incorporation of POSS nanoparticles into PCU has a synergistic effect on the 
polymer, rendering the resultant product mechanically superior to its constituent 
components[27].  The mechanical strength of a nanocomposite polymer is highly 
dependent on three-dimensional configuration of the reinforcements in the matrix.  
The reinforcement provides enhanced tensile strength, while the matrix facilitates 
efficient load transfer.  This symbiotic relationship is possibly due to the increased 
surface area-to-volume ratio and chemical reactivity via covalent cross-linking, 
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electrostatic interactions, and hydrogen bonding.  This is seen in POSS-PCU, 
whereby the alternation of hard and soft segments allows the modification of polymer 
chemistry to potentiate both flexibility and enhanced mechanical strength[28].  The 
crystallization and aggregation of POSS is a requirement for the interaction with the 
matrix, as the crystallization and aggregation process creates a supramolecular entity 
with a lower symmetry.  The integration of POSS into the matrix also introduces 
strong Si-O bonds into the polymer system, thereby conferring more stability and 
mechanical strength, compared to the C-O bond in PCU. Indeed, our group had 
previously demonstrated that superior mechanical properties of POSS-PCU is 
dependent on the alignment, cross-linking, hydrogen bonding, and van der Waal’s 
forces between the crystalline hard segment and the amorphous soft segment[29].  It 
is highly likely that the interactions between these two segments are attributed to the 
branching of the hard segment, thereby increasing the surface area-to-volume ratio for 
chemical reactions to occur. 
 
Whilst the emphasis on the two previous chapters were concerned with flat sheets of 
polymers, the fact that this chapter revolves around the concept of the construction of 
a hybrid stent-graft system creates the need for tests that would adequately address 
mechanical issues seen in such a system.  
 
Prior to the ultrasonic atomization spray process, the metal stent has to be chemically 
treated via covalent modification with organosilane precursors.  This salinization 
process creates an amino-propyl functional layer on the stent surface upon reaction of 
the hydroxyl groups on the metal oxide layer with triethoxysilane groups.  This 
charged layer facilitates cross-linking between the pre-polymer and the metal surface.  
The pre-polymer can be considered a primer, where the amine-group from the 
salinization process reacts with the isocyanate group from the pre-polymer, forming a 
urea group via covalent modification.  Excess isocyanate react with atmospheric 
moisture to form a high molecular weight polyurethane.  Hence, it can be seen that the 
pre-polymer is analogous to an adhesive layer which facilitates the bonding process.  
Actual POSS-PCU polymer is then sprayed onto the pre-polymer, creating an ultra-
thin polymer layer (2.5 µm), before the dip coating process to form the covering 
membrane.  This ultra-thin sprayed polymer prior to the dip coating has been shown 
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to provide a better integration between the base substrate and the subsequent 
formation of the POSS-PCU covering membrane (Farhatnia 2013, unpublished data).   
 
We advocate the use of a non-biodegradable biofunctionalized POSS-PCU polymer 
on the surface of a metal stent, as evidence has shown that a covalent bonding 
between the metal stent strut and polymer extends its in vivo durability[30, 31] by 
reducing the risk of thrombosis, as well as preventing the leaching of metal ions into 
the bloodstream, which can lead to inflammation[32].  While the presence of a 
permanent metal stent strut in the abluminal area holds the vessel open and maintains 
patency, the protrusion of stent struts within the luminal area of the vessel can lead to 
unintended consequences, such as restenosis.  Efforts have been made in the 
development of new and improved metal alloys that allow thinner strut profiles while 
maintaining its radial strength[33].  A randomized controlled trial (RCT) 
demonstrated that for two stents with similar design, the one with a thinner profile 
resulted in a 42% reduction in restenosis rates, compared to the one with a thicker 
profile[34].  Another RCT also showed that even with two stents with different 
designs, the one with a thinner profile still had lower rates of restenosis compared to 
the thicker one[35].  Furthermore, it has also been reported that a more rounded and 
streamlined stent strut has a lower tendency for thrombotic events, compared to stent 
struts with angular profiles[4].  Therefore, our method of creating a covering 
membrane can be seen as an effort to normalize and indeed neutralize the effect of 
stent strut profiles, and to re-establish a smooth and uniform luminal area.  A smooth 
and uniform luminal area, as seen in native arteries under physiological conditions, 
facilitates laminar flow patterns with a relatively high level of shear stress.  Laminar 
shear stress regulates vessel homeostasis, as opposed to turbulent shear stress, which 
can potentiate pathological conditions.  Anti-coagulant factors such as nitric oxide 
(NO), prostacyclin (PGI2) tissue plasminogen activator (TPA), tissue factor pathway 
inhibitor (TFPI), heparin, and thrombomodulin (TM) inhibit the coagulation cascade 
and reduce the risk of thrombosis[4].  In the deployment of a (non-covered) metal 
stent, the protruding stent struts disrupts the smoothness and uniformity of the luminal 
area, which can adversely affect haemodynamic flow, and would prove detrimental to 
an already injured vessel[36].  The presence of non-uniform stent struts would cause 
flow re-circulation, flow separation, and eddy currents, magnifying the effects of low 
and turbulent fluid shear stress, which trap platelets in a localized area of flow 
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separation.  In these zones of fluid re-circulation, pro-coagulant factors (such as 
prothrombin, fibrinogen, TF, and vWF) would rise to critical levels, activating 
platelets and triggering the coagulation cascade and the consequent formation of a 
thrombus[37].  Furthermore, turbulent flow would also upregulate the proliferation of 
VSMC.  Endothelial denudation during the stent deployment would remove anti-
coagulant molecules which endothelial cells normally produce, further exacerbating 
VSMC proliferation.  The very act of stenting also carries a risk of dislodging the 
atherosclerotic plaque, which can introduce thrombogenic molecules into the 
bloodstream, increasing the risk of thromboembolism in downstream arteries.  Thus, 
having a covering membrane on stent struts would serve to neutralize the effects of 
strut protrusion as well as functioning as a physical barrier to guard against plaque 
dislodgement.  Conceptually, the presence of smooth covering membrane (rather than 
stent struts) is analogous to reducing the thickness of the strut profile to almost zero.  
This dramatic reduction of stent profile would re-establish laminar flow patterns, 
effectively removing areas of fluid re-circulation and the probability of platelet 
deposition and activation in these zones of flow stagnation[38].                           
 
Blood vessels are subject to a variety of pressures and loads, for example during the 
cardiac cycle and vessel spasms.  The application of pressure on a cylindrical / tubular 
structure (artery, or a covered stent) would cause a hoop, or circumferential loading of 
the vessel.  Both the pressure applied and the consequent hoop stress is described as 
force per unit area, although they have different vectors.  In this instance, pressure is 
considered the perpendicular force applied against the vessel wall, divided by the 
luminal surface area.  Hoop stress is defined as the circumferential loading in the 
vessel wall divided by the cross-sectional area.  Hoop stress (σ) and pressure (p) is 
related via the equation: 
 
σ = pφ / 2t 
 
Where φ is the diameter of the vessel, and t is the wall thickness.  Hoop force (Fθ) can 
be written as: 
 
Fθ = σtL = pφL / 2 
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Where L is the vessel length.  It can also be written in terms of hoop force per unit 
length (fθ): 
 
fθ = Fθ / L = σt = pφ / 2 
 
Although forces acting on a cylindrical / tubular structure can be described by 
pressure, hoop force and hoop stress (all three being closely related), it is 
hypothesized that hoop force (fθ) is the most appropriate measure when we are 
considering the radial strength of a stent[39]. This is due to the observation that fθ 
describes radial strength, and specifically the maximum hoop load that the stent can 
resist without failure.  However, it must be noted that the term “failure” connotes 
different meanings in different situations.  In the case of a cylindrical structure or a 
tube, the term failure is used when the structure bursts or ruptures. Therefore in this 
case, failure is defined as the point at which hoop stress exceeds the ultimate tensile 
strength of the material.  On the other hand, when we are considering a stent that is 
implanted within an artery, the definition of failure would confer a different meaning.  
Since the main purpose of a stent is to maintain vessel patency, failure would be the 
point at which permanent plastic deformation occurs, with the stent being no longer 
able to hold the vessel open.  Taken together, it can be seen that the radial strength of 
a stent in preventing failure hinges on its ability to withstand external forces without 
collapsing in on itself.  The stiffness of a covered stent can also be deduced in terms 
of hoop stiffness, or radial stiffness.  It is postulated that hoops stiffness would be a 
more appropriate measure, as it has a closer correlation to stent design.  We can 
therefore infer that hoop stiffness of a covered stent is the hoop force per unit length 
needed to elastically change its diameter: 
 
kθ = fθ / Δφ 
 
Where kθ is hoop stiffness, fθ is hoop force per unit length, and Δφ is the change in 
diameter.  It must also be stated that stiffness is inversely related to compliance; the 
stiffer the material, the less compliant it is.  Considering the compliance is defined as 
the change in diameter for a given pressure, hoop stiffness can also be related to 
compliance via the equation: 
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kθ = P0 / 2C0 
 
Where P0 is pressure, C0 is the compliance.  Flexibility of the covered stent can also 
be assessed using a three-point bending test.  This can be analyzed using the Euler-
Bernoulli equation: 
 
σ = My / Ixx 
 
Where σ is the bending stress, M is the moment about the neutral axis, y is the 
perpendicular distance to the neutral axis, and Ixx is the area moment of inertia about 
the neutral axis x. 
 
For all mechanical testing parameters presented in this chapter, results revealed that 
the biofunctionalization with antibody and liposome did not significantly alter the 
mechanical properties of POSS-PCU.  This has important implications as it indicates 
that the biofunctionalization process is indeed a feasible technique, not just in terms 
of creating a platform for EPC capture and sustained drug release, but it also 
preserves the optimal mechanical properties of POSS-PCU.  Due to the fact that 
extensive mechanical testing of POSS-PCU film and POSS-PCU covered stent has 
already been investigated by Farhatnia in our lab (unpublished results), results here in 
this chapter further strengthens the case for the utilization of a biofunctionalized 
version of POSS-PCU to be used as a covering membrane for coronary stents. 
 
Although mechanical testing was the main parameter that was assessed in this 
Chapter, detection of liposomes and antibodies were also conducted as an additional 
parameter.  Results revealed that, when a physiological flow circuit using whole 
blood was used, successful capture of EPCs were attained.  Furthermore, Raman 
integration maps also detected the presence of liposomes on the abluminal area, 
indicating the feasibility of the manufacturing technique on a covered stent system. 
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7.5. Conclusion 
 
In this Chapter, we have successfully demonstrated a facile technique of constructing 
a nano-inspired multifunctional POSS-PCU covered stent, with anti-CD34 antibodies 
in the luminal area, and liposomes in the abluminal area. Mechanical testing revealed 
that the biofunctionalized version of POSS-PCU did not deviate significantly from its 
non-biofunctionalized counterpart.  Due to the fact that POSS-PCU covered stents 
have already been extensively tested and optimized mechanically, results in this 
Chapter suggests that this biofunctionalized version has the same superior mechanical 
properties of the non-biofunctionalized version.  Taken together, it can be seen that 
POSS-PCU-Lipo-Ab could form the cornerstone of a new breed of covered stent for 
cardiovascular applications with EPC capture potential and liposomal drug release.      
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Effects of Sterilization 
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8.1. Introduction 
 
In terms of biomaterials, the definition of it being “sterile” connotes the absence of 
living organisms such as bacteria, viruses, moulds, and yeasts.  Having even a single 
strain of living bacterium on a material makes it non-sterile.  However, it is important 
to note that the term “sterility” should not be confused with the term “clean”.  For 
example, metal surface that is polished shiny might be non-sterile, as it might be 
contaminated with living organisms, while a rusty nail can be rendered sterile after 
being treated with proper sterilization techniques.  Sterility can be measured by 
incubating the samples into a container of sterile liquid microbiological culture 
medium.  Sterile samples would display no microbial growth, and the culture medium 
would remain clear.  In contrast, non-sterile samples would make the culture medium 
cloudy or turbid, due to microbial proliferation. 
 
Depending on the intended application, steam sterilization (autoclave), gamma 
irradiation, and ethylene oxide (EO) are the 3 most common sterilization techniques 
that are approved by the FDA for medical applications[1]. 
 
Steam sterilization was the first sterilization method that was employed for medical 
implants for human use[2].  This method involved placing the sample in a pressure-
rated chamber, and exposed to saturated steam at either 121 °C or 125 °C.  It must be 
ensured that all surfaces of the sample must be in contact with the steam and reach at 
least 121 °C.  This high temperature would destroy microorganisms by disrupting the 
structural and metabolic components in them that are essential for the replication.  
The destruction of enzymes, proteins, and lipids are the main events that are lethal to 
the microorganisms.   
 
EO sterilization involves placing the sample in a chamber, which is then exposed to 
EO gas.  The mechanism of action of EO sterilization is the alkylation of the amine 
groups on nucleic acids in microorganisms.  EO is used to sterilize a wide range of 
medical implants, such as stents, grafts, heart valves, ligament and tendon repair 
devices, neurosurgery devices, and surgical sutures.  It is important to note that all 
FDA-approved drug-eluting stents (DES) are sterilized using EO. 
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Gamma irradiation involves the exposure of the sample to ionizing radiation from a 
radioactive isotope.  Gamma irradiation is highly penetrating and is suitable for 
sterilizing products that are heat-sensitive and unable to tolerate autoclaving.  The 
decay of radioactive isotope would produce gamma rays, which causes the ionization 
of nucleic acids and other cellular components, which would ultimately result in the 
death of the organism.  Gamma irradiation is used in a wide range of medical devices 
such as surgical drapes, bone implants, and syringes.                         
 
Considering the harsh environment that the samples would be exposed to during the 
sterilization process, any changes in the biophysical characteristics of the sample 
would affect its behavior when implanted into biological systems.  This Chapter aims 
to investigate the effects of sterilization on the performance of biofunctionalized 
POSS-PCU against non-sterilized samples. Samples would be treated to different 
sterilization techniques, and a selection of tests derived from the previous chapters 
would be conducted to assess its endothelial progenitor cell (EPC) capture potential, 
drug elution kinetics, and mechanical behavior.     
 
8.2. Materials and Methods 
 
All experiments were done in triplicates (n=3) unless otherwise stated.   
 
8.2.1. POSS-PCU-Lipo-Ab Film Samples 
 
The manufacture of POSS-PCU-Lipo-Ab film was described in the previous Chapter.    
 
8.2.2. POSS-PCU-Lipo-Ab Covered Stent Samples 
 
The manufacture of POSS-PCU-Lipo-Ab covered stent was described in the previous 
Chapter.    
 
8.2.3. Steam Sterilization (Autoclave) 
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Samples were placed in an autoclave (Rodwell Scientific Instruments, UK) at 121 °C 
and 19 psi for 30 min, with 15 min of drying.     
 
8.2.4. Ethylene Oxide (EO) 
 
Samples were placed in a Seal and Peel® waterproof bag, and placed in an Anprolene 
AN74ix System (Andersen Products Inc., USA), and set at the automated 12 h cycle.  
After 12 h, samples were left to de-gas under ambient conditions for 24 h.       
 
8.2.5. Gamma Irradiation 
 
Samples were sealed in a water-tight container, and placed in a cup with ice to 
prevent over-heating during the irradiation process.  This was then placed in a 
Gammacell 1000 Caesium-137 Irradiator (Best Theratronics, Canada).  Irradiation 
was administered at 25 kGy for 2 h to achieve FDA-approved level of sterilization[3].   
 
8.2.6. Gel Permeation Chromatography (GPC) 
 
15 ml of dimethylformamide (DMF) was added to 30 mg of samples, and left to 
dissolve on a roller mixer (Stuart Equipment, UK) for 24 h.  The samples were then 
analyzed using a PL-GPC 50 system (Agilent Technologies, UK) with a PLGel 
column guard and 3 PLGel 5 µm mixed bed-C columns (300 × 7.5 mm).  
Temperature was set at 50 °C in DMF, and the eluent was pumped at a constant flow 
rate of 1.0 ml/min.  The system was calibrated using a polystyrene standard of known 
molecular weight (12-point calibration curve in the nominal range of 162-6000 
g/mol).  The detection conducted using a PL-BV 400 RT viscometer and a PL-RI 
differential refractometer. Results were presented as a percentage of untreated control.  
 
8.2.7. Growth Medium  
 
The efficacy of sterilization techniques was assessed using Tryptone soya broth (TSB) 
and Fluid Thioglycollate medium (THY) assay (Wickham Laboratories, UK).  
Samples were placed in the culture medium for 14 days at 23 °C for the TSB assay, 
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and 33 °C for the THY assay.  Sterile broth was used as negative control, and non-
sterile samples were used as positive controls.  The broth was examined 
macroscopically everyday.  Clear medium indicated the lack of microorganism 
growth, while cloudy medium indicated the growth of microorganism.     
 
8.2.8. Endothelial Progenitor Cell (EPC) Capture  
 
As described in Chapter 5. 
 
8.2.9. High Performance Liquid Chromatography (HPLC) 
 
As described in Chapter 6. 
 
8.2.10. Tensile Strength 
 
As described in Chapter 7. 
 
8.2.11. Viscoelasticity / Compliance 
 
As described in Chapter 7.  
 
8.2.12. Statistical Analyses 
 
Parametric data is presented as ± standard deviation (SD) of the mean, and all 
experiments were performed in triplicates (n = 3), unless otherwise stated.  Curve 
fitting and statistical analysis was done using GraphPad Prism® (GraphPad Software 
Inc., USA).  One-way analysis of variance (ANOVA) with post-hoc Tukey’s range 
test was performed at a 95% confidence interval.  p < 0.05 was considered statistically 
significant.    
 
8.3. Results 
 
8.3.1. Sterilization Efficacy 
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Results revealed that all sterilization techniques performed (autoclave, EO, gamma) 
were effective in inhibiting the growth of microorganisms (Figure 8.1).  This indicates 
that these established techniques were indeed efficacious in terms of sterilizing the 
material.   
 
 
Figure 8.1. Sterilization efficacy. All sterilization techniques performed were able to inhibit 
microorganism growth.    
 
8.3.2. Polymer Integrity Assessment via GPC 
 
Gel permeation chromatography (GPC) revealed a small decrease in molecular weight 
of the sample that was exposed to steam sterilization (autoclave), with statistical 
significance (p < 0.05) (Figure 8.2).  However, the values of all other samples that 
were exposed to EO and gamma were not statistically significantly different (p > 
0.05) from control.      
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Figure 8.2. Percentage change in molecular weight of polymer. A small reduction (10%) of 
molecular weight (Mw) was observed in autoclaved samples.  Changes in Mw for samples exposed to 
EO and gamma were not statistically significant (p > 0.05) from control.  
 
8.3.3. EPC Capture Assay 
 
Due to the fact that the basis of EPC capture relies on antibodies which are protein in 
nature, it was expected that heat treatment would affect its functionality.  Results were 
in agreement with this, as samples that were exposed to autoclave had a drastically 
reduced EPC capture potential, compared to samples that were exposed to EO and 
gamma (Figure 8.3).  Samples that were exposed to EO and gamma were somewhat 
lower than control, possibly due to the inherent harshness of the treatment that might 
have affected antibody structure and orientation on the surface, thereby reducing its 
ability to bind antigens.   
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Figure 8.3. Effects of sterilization on EPC capture potential. Autoclaved samples had a dramatically 
lower efficacy in capturing EPCs compared to EO and gamma exposed samples.  EO and gamma 
exposed samples had a slightly lower EPC capture efficacy compared to control, possibly due to the 
inherent harshness of the sterilization treatment that affected the antibody structure.    
 
8.3.4. Drug Elution Kinetics via HPLC 
 
It was observed that autoclaving had a detrimental effect on drug elution, with results 
showing that it was statistically significantly lower (p < 0.05) than that of controls, 
and those exposed to EO and gamma (Figure 8.4).  Samples exposed to gamma had a 
slightly lower drug elution curve, compared to controls, although the reduction was 
not as great as that of autoclaved samples.  In contrast, samples exposed to EO did not 
display a statistically significantly different (p > 0.05) drug elution curve, indicating 
that EO might be most appropriate in preserving sustained and controlled drug 
release.     
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Figure 8.4. Effects of sterilization on drug elution. Autoclaved samples had a statistically 
significantly (p > 0.05) lower drug elution curve compared to controls.  In contrast, EO and gamma 
exposed samples were not statistically significant (p > 0.05) from controls.    
 
8.3.5. Tensile Strength 
 
Tensile testing demonstrated that autoclaved samples had a statistically significantly 
lower (p < 0.05) tensile strength compared to controls (Figure 8.5).  In contrast, 
samples exposed to EO and gamma did not display a statistically significantly 
different value (p > 0.05) compared to controls.     
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Figure 8.5. Effects of sterilization on tensile strength. Autoclaved samples displayed a statistically 
significantly lower (p < 0.05) tensile strength compared to EO and gamma samples.  EO and gamma 
samples were not statistically significant from controls.  
 
8.3.6. Preservation of Viscoelasticity   
 
Diametric compliance (DC) measurements revealed that at 35 mmHg (Figure 8.6), 55 
mmHg (Figure 8.7), 75 mmHg (Figure 8.8), and 95 mmHg (Figure 8.9), 
viscoelasticity was preserved, as all samples (autoclave, EO, and gamma) had values 
that were not statistically significant from controls.  This has important implications, 
as it demonstrates that the polymer is resistant to changes in compliance even when 
exposed to different sterilization techniques.   
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Figure 8.6. Effects of sterilization on DC at 35 mmHg.  Viscoelasticity was preserved even after 
sterilization, as all samples were not statistically significant (p > 0.05) from controls.   
 
 
Figure 8.7. Effects of sterilization on DC at 55 mmHg. Viscoelasticity was preserved even after 
sterilization, as all samples were not statistically significant (p > 0.05) from controls.   
 
 
	   380	  
 
Figure 8.8. Effects of sterilization on DC at 75 mmHg.  Viscoelasticity was preserved even after 
sterilization, as all samples were not statistically significant (p > 0.05) from controls.   
 
 
 
 
Figure 8.9. Effects of sterilization on DC at 95 mmHg.  Viscoelasticity was preserved even after 
sterilization, as all samples were not statistically significant (p > 0.05) from controls.   
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8.4. Discussion 
 
The risk of infection is a perennial problem associated with medical implants.  This 
issue is further complicated by the observation that microorganisms that are usually of 
low virulence would often revert to a state of being highly pathogenic when they 
contaminate implantable devices.  The pertinence of achieving an understanding of 
the causes of infection is further underscored by the fact that almost 500,000 stenting 
procedures are done annually in the USA[4].   
 
However, the mechanisms by which an implanted device increases the risk of 
infection are not completely understood[5-7].  The association between an implanted 
foreign object and an increased incidence of infection has been clearly demonstrated 
in many clinical studies.  For instance, it has been estimated that more than 30,000 
patients a year in the USA develop bacteraemia from the use of intravenous catheters, 
with the case fatality ratio being 20% to 40%[8, 9].  Staphylococci and Gram-negative 
bacilli are most often implicated, and treatment generally entails removal of the 
device and additional medication. 
 
The pathogenesis of implant-related infections, and the rate at which they progress is 
dependent upon a myriad of factors, including the material of the device, the location 
at which it is implanted, the length of time in place, and the underlying medical 
condition of the patient[10-12].  Although the use of antibiotics might limit the 
infection, removal of the device is often necessitated, as its very presence within 
biological tissue is a nidus for the proliferation of microorganisms. Sterilization of 
medical devices is conducted to eliminate the presence of microorganisms, as the 
contaminating flora determines the outcome of surgical infection.  However, it is 
interesting to note that the type of flora present can also have a bearing on the 
pathogenesis of the infection. Indeed, the same medical device that is implanted in 
different parts of the body would come into contact with different flora and different 
host defence mechanisms, which may ultimately alter the progression of prosthesis-
associated infection.  Furthermore, special phenomena are usually observed, often 
unique to biomaterial implants.  For instance, the adherence of bacteria to implant 
materials can sequester them from elimination by host secretions, and the flow of 
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blood can also prevent their removal by defence mechanisms such as 
phagocytosis[13].  Certain sub-groups of coagulase-negative staphylococci 
(particularly the S2 Baird Parker sub-group) have been shown that in vitro, they 
develop a mucoid layer that facilitates their adherence to cerebral spinal fluid 
shunts[14].  The host immune response can also be altered by biomaterial implants, 
via modulation in immunoglobulin synthesis, inflammatory response, and phagocytic 
activity[15-17].  Tissue damage during the implantation procedure can also 
exacerbate prosthesis-associated infection[18].  In addition, metal surfaces provide a 
platform on which bacteria readily adhere and proliferate on[13].  Apart from metals, 
polymers can also form a breeding ground for microorganisms.  Studies have been 
conducted pertaining to the ability of Marlex® and Prolene® in preventing 
prosthesis-associated infections, and also between Teflon® and silicon-based 
polymers[19, 20].  Indeed, the adherence of various microorganisms on different 
biomaterial surfaces, such as Gore-Tex®, Dacron®, Teflon® -coated rubber, and 
silicon-based rubber, have been investigated[21, 22].  However, the absence of 
uniformity among the various published studies makes it difficult for data 
comparison. 
 
It is worth mentioning that infections associated with biomaterial implants are a 
subset of more general surgical infections.  Correctly classifying the source of 
infection is important, as it allows a more effective method of control.  Broadly 
speaking, the source of infection can be classified as operating room-based, surgical 
procedure-based, or other hospital-based infections termed as nosocomial infections.  
Nosocomial infection is attributed to microbial invasion of the body, usually by 
virulent and antibiotic-resistant microorganisms within the hospital environment.  
Infection control can be properly managed using a complex interplay of several 
factors: pre-operative preparation of the patient, preparation of the operating room 
team, maintenance of the operating room equipment and environment, and the use of 
antimicrobial agents and sterilized instruments[23, 24]. 
 
Although it has often been assumed that infection begins at the time of device 
implantation, graft infections may in fact remain dormant for years before manifesting 
itself.  The anatomic location of the implant and the use of prophylactic antibiotics are 
known to affect the progression of infection[25].  Lapses in sterile techniques and 
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inadequate sterilization of the implant can be a source of infection, and wound 
infection in close proximity to the implant can also result in infection via direct 
extension.  On the other hand, if the implant comes into contact with skin, adsorption 
of microorganisms onto the implant might occur.  In fact, this route of infection 
occurs most commonly in grafting sites in the femoral area[26].  The high percentage 
of staphylococcal graft infections is indicative of the patient’s skin being a source of 
contamination.  Although secondary infection by haematogenous transmission is less 
common, there is evidence that it can be caused by bacteraemia[27].  In addition, it 
has been reported that the incidence of secondary infection by bacteraemia can be 
directly due to the type of biomaterial that has been implanted[28].  Given the fact 
that a lower bacterial count is needed to elicit an infection when there is an implant in 
question, it is pertinent to minimize the likelihood of bacteria reaching the wound[29, 
30].  Although the most common microorganism associated with infection of vascular 
implants is Staphylococus aureus, Gram-negative bacteria has also been implicated.  
Therefore prophylactic antibiotics have been used to reduce the probability of 
infection in procedures involving vascular implants.   
 
The efficacy of steam sterilization is dependent upon 3 main factors: penetration, heat 
content, and moisture content[31].  The process of steam sterilization penetrates 
materials, while dry heat sterilization, although slower, will penetrate materials that 
are not permeable to steam.  In order for steam sterilization to be effective, 
temperatures must reach above 100 °C, usually around 121 °C to 134 °C[31].  
Saturated steam consists of vaporized water in equilibrium with liquid water.  
Evaporation and condensation happens at equal rates at the boundary between the 
vapour and liquid phases of water, making the relative humidity of the vapour at 
100%.  Hence, 100% saturated steam at 121 °C to 134 °C are the defined parameters 
that bacterial spores are least resistant to.  Latent heat is released upon the 
condensation of steam on a surface.  Effective penetration is achieved via the removal 
of air from the sterilization chamber.  When the temperature of steam is above that of 
its corresponding pressure at the phase boundary, it is said to be in a super-heated 
state.  In this scenario, however, the relative humidity is below 100%, and unless the 
temperature is reduced to the phase boundary, condensation would not take place.  In 
this case, release of latent heat and moisture deposition would not occur, which 
increases the risk of microorganisms remaining viable.  Factors like an overheated 
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steam jacket, contact with a dehydration load, and a pressure reduction in the supply 
line can steam conditions in a sterilization chamber.  Excess water would impair the 
sterilization process as it soaks porous materials, thereby creating a barrier to air 
removal and delays drying after sterilization.  To avoid this, a steam separator is 
placed in the supply line; this is crucial as the mixture of air and steam would 
adversely affect the relative humidity, and residual air can interfere with penetration.   
 
Sterilization using ionization includes methods like accelerated electrons, x-rays, and 
gamma rays.  For gamma irradiation, caesium-137 and cobalt-60 are often used. 
Caesium-137 emits gamma rays at 0.662 eV, and cobalt-60 emits at 1.333 and 1.73 
eV.  Compared to gamma rays, accelerated electrons (which can be produced using a 
linear accelerator) have a lower penetration depth.  The efficacy of ionizing radiation 
is due to its interactions with the DNA of microorganisms[32, 33]. Upon exposure to 
ionizing radiation, aqueous free radicals are formed, which are highly reactive and it 
is postulated that DNA is damaged via the radiolysis of the water.  However, the exact 
mechanism of how ionizing radiation actually destroys microorganism is not 
completely understood.  Indeed, there is a large variation in the number of breaks in 
DNA strand required to cause cell death, and some microorganisms are known to be 
efficient at repairing DNA damage, with some vegetative organisms appearing more 
resistant than bacterial spores[34-37]. Respiration and motility of bacteria may last for 
several hours even after ionization.  Considering that death of the microorganism 
would only commence during the first DNA replication, conditions like low 
temperature would actually delay this process and aid the repair process. Sterilization 
using ionizing radiation is normally conducted at room temperature, but increases of 
10 °C can significantly reduce decimal reduction time (D value)[38].  Although 
oxygen and moisture can influence sensitivity, only a small amount of oxygen is 
needed to ensure maximum sensitivity[39].    
 
Heat-sensitive biomaterials can be sterilized using ethylene oxide (EO) gas.  EO is a 
colourless gas, with a boiling point of 10.4 °C at 760 mmHg.  EO can polymerize 
under catalytic influence in 3% to 100% in mixture with air in a highly exothermic 
and explosive reaction. However, this does not happen in mixtures of less than 20% 
with an inert gas.  The biocidal activity and alkylating power of EO can be attributed 
to its unstable 3-membered ring structure[40].  Alkylation involves the addition of 
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saturated hydrocarbon groups other reactive groups such as carboxyl (COOH), 
hydroxyl (OH), sulphydryl (SH), and amino (NH2) found on protein molecules and 
nucleic acid bases within cells[41, 42].  There is less variation in the resistance of 
vegetative cells and bacterial spores to EO sterilization, compared to conventional 
heat sterilization, where the variation in resistance can be several orders of magnitude.  
The efficacy of EO sterilization is dependent upon the gas contact time, the 
concentration of the gas, relative humidity, and temperature.  The efficacy of EO 
sterilization would be compromised if the microorganism in question has been 
previously desiccated or is protected by organic material. At lower temperatures, 
assuming gas concentration and relative humidity are kept constant, the rate of 
bacterial spore destruction would double for every 10 °C rise in temperature[43, 44].  
At temperatures above 45 °C, there is little increase in biocidal activity once gas 
concentrations exceed 450 mg/l.  Since water is needed to act as a reactive medium 
for the mobilization of hydrogen ions, optimum humidity is set at around 30%, to 
ensure maximum alkylating power.  Efficacy would decrease at low humidity levels, 
even if gas concentration and contact time were increased. The kill rate would be 
linear at humidity levels above 33%[43, 45].  It has been suggested that moisture is 
necessary for the combination of EO gas with reactive groups on the bacterial 
surface[40].  It is also thought that EO gas would dissolve in the thin film of water 
formed on the bacterial surface, forming a concentrated solution which functions as a 
medium for the ionization of reactive groups.  Furthermore, it has also been proposed 
that organic materials that might otherwise protect bacteria would dissolve within the 
thin film of water, thereby facilitating the biocidal potency. 
 
Given the ubiquitous nature of sterilization in the field of medical implants, it must 
also be noted that the process of sterilization itself can also affect the properties and 
subsequent performance of the biomaterial in question.   
 
It is known that autoclaving or steam sterilization can significantly change the 
properties of polymers used in biomaterials.  If the temperature in steam sterilization 
exceeds the glass transition temperature (Tg) of the polymer, changes in physical and 
chemical properties can occur, which could affect biological and mechanical 
performance of the implant.  Hydrophilic materials can also be adversely affected 
when exposed to steam sterilization.  Results in this chapter showed that drug elution 
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was impaired after steam sterilization.  This would be due to the temperature being 
above the Tg of the liposomes, thereby rendering them less effective in terms of 
functioning as a controlled and sustained release agent.  Absorption of water into the 
polymer can happen during the sterilization process, and this can impair the 
mechanical properties of the polymer during to a microcavitation process.  
Condensation polymers, such as polyesters, are particularly vulnerable as they are 
susceptible to hydrolytic cleavage[46].  The denaturation of proteins under high 
temperature is also well-documented.  In fact, this is in agreement with results 
presented here in this chapter showing that the EPC capture potential was almost non-
existent after exposure to steam sterilization.  This is because their tertiary structure 
and three-dimensional configuration would be lost due to the denaturation of proteins 
under high temperature.  Hence it can be seen that biofunctionalized polymers, 
especially those that are reliant on proteins, are not suitable for steam sterilization.  In 
the case of polyurethane (PU)-based biomaterials, there is evidence that PU 
degradation can cause the release of carcinogenic agent, 4,4’-methylenedianiline 
(MDA)[47].  It has been proposed by Hirata et al that this was due to cleavage at the 
urethane linkage successive to the terminal amino group[48].  It was also speculated 
that the probability of MDA production increases when larger molecular weight 
polyols are used in the manufacture of PU.  Furthermore, a study by Shintani also 
found that autoclaving PUs released more hydrophilic compounds, and this effect was 
magnified with PUs that were synthesized with smaller molecular weight polyols[47].  
It has been widely reported that the high pressure, temperature, and humidity can 
during steam sterilization can result in softening, hydrolysis, and degradation of 
biomedical polymers[49].  The high temperature and humidity conditions during 
steam sterilization promote chain scission, which could explain the apparent decrease 
in tensile strength and molecular weight profile of POSS-PCU.          
 
Sterilizing biomaterials with ionizing radiation can also engender several unintended 
consequences.  This is especially true in the case of polymers, as they might undergo 
degradation and/or cross-linking (depending on their chemical structure) when 
exposed to high-energy ionizing radiation[50].  In general, polymers that display high 
heats of polymerization tend to undergo cross-linking, while polymers that display 
low heats of polymerization tend to undergo degradation.  If the process were 
predominantly cross-linking, the polymer would exhibit increasing molecular weight 
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with increasing dosage of ionizing radiation.  In contrast, if the process were 
predominantly degradation, the polymer would undergo chain scission and decreasing 
molecular weight[51].  High-energy ionizing radiation may also cause gas release and 
the generation of free radicals[52].  This can potentially be a serious problem, as free 
radicals can cause further oxidation to an already weakened polymer, thereby 
accelerating its degradation.  There are various reports documenting the effects of 
gamma irradiation on PUs.  Shintani and Nakamura showed that degradation in PU 
occurred mainly at the soft segment, with a degree of cleavage of urethane bonds in 
the hard segments[53].  Simmons et al demonstrated that PU degradation occurs in 
both the urethane bonds and ether soft segments, and implantation of a gamma-
irradiated PU into an in vivo animal model further increased the degradative and 
oxidative effects[49].  Polymers that the highly vulnerable to ionizing radiation 
include polytetrafluoroethylene (PTFE), which can be adversely affected by as little 
as 100 Gy, while others like poly(methyl methacrylate) (PMMA) require slightly 
higher doses of 10000 Gy.  Indeed, it is important to note that biomaterials are, for all 
intents and purposes, not “pure” materials as they contain small amounts of additives 
such as catalysts and antioxidants that may be affected by ionizing radiation.  
Furthermore, radiation might also cause the additives to react with the polymer itself.  
Also, given the fact that most additives tend to be industrial trade secrets, it is difficult 
to ascertain the reactivity of the biomaterial in question to ionizing radiation.  
Nevertheless, results in this chapter revealed that gamma irradiation did not 
significantly alter the properties of biofunctionalized POSS-PCU covered stent.  For 
all parameters tested, gamma irradiation appeared to have less of an effect on product 
viability and functionality, compared to steam sterilization.   
 
On its own, ethylene oxide (EO) is a toxic gas, with concerns relating to its 
mutagenicity, and carcinogenicity[54-56].  Stringent occupational safety protocols are 
in place to protect workers who operate the EO sterilization system.  EO residues left 
behind on the surface of biomaterials after the sterilization process could potentially 
be harmful to patients.  Earlier reports have described EO residues in tubings used in 
extracorporeal circulation that have resultant in patient death[57].  Plastics that are 
sterilized by EO have also been linked to severe tissue reactions such as haemolysis in 
blood administration sets and pump oxygenators, tracheal necrosis during intubation, 
and even burns from surgical gloves, gowns and masks[58-60].  There are also reports 
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documenting anaphylactic reactions in dialysis patients after exposure to EO-
sterilized dialysis machines.  Although EO is one of the most widely employed 
sterilization techniques in the medical device and healthcare industry[61], its 
alkylating power has also been reported to interact with the functional groups of some 
polymers[49].  Although EO does not affect siloxanes, the urethane linkages within 
PUs might be affected.  However, our results revealed that EO does not affect POSS-
PCU as much as autoclaving and gamma irradiation.  Indeed, it must be noted that all 
FDA-approved drug eluting stents are sterilized via EO.  Hence, EO sterilization can 
be considered as an “industry standard” with regards to drug-eluting/biofunctionalized 
polymers for stent applications.      
 
 
8.5. Conclusion 
 
Sterilization of medical devices is often the penultimate step before packaging and 
available for clinical use.  Although the main purpose of sterilization is to prevent the 
devices from causing infection after implantation, the sterilization process itself can 
alter the both the properties and functionality of the device.  In this chapter, three 
most commonly used sterilization techniques were employed in order to assess their 
effects on biofunctionalized POSS-PCU covered stents.  Given the fact that antibodies 
would be denatured at high temperatures, steam sterilization can thus be said to be 
inappropriate for our biofunctionalized POSS-PCU.  Performance of our biomaterial 
was almost similar when exposed to EO and gamma, thereby indicating that these two 
techniques might be viable for sterilizing our product.     
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Chapter 9.  
_________________ 
 
 
 
 
 
Summary and Future 
Work: An Epilogue  	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With the increasing emphasis on the development of multifunctional 
biomaterials for medical applications, it is envisioned that the next generation 
biomedical devices would incorporate elements of nanotechnology and bio-
inspiration.  In this thesis, we seek to address the two main unresolved problems 
encountered in stenting: in-stent restenosis due to VSMC proliferation, and stent 
thrombosis due to sub-optimal drug release and impaired endothelialization.  The 
proposed solution was to develop a novel POSS-PCU-based nanocomposite polymer 
with EPC capture moieties in the luminal area, and controlled and sustained liposomal 
drug release in the abluminal area.  This would fulfill the dual criteria of increasing 
endothelialization in the luminal area whilst limiting VSMC proliferation in the 
abluminal area.  Furthermore, having a covering membrane on the stent itself would 
serve as a physical barrier to prevent plaque dislodgement during stent deployment, as 
well as functioning a safety feature in the event of vessel perforation. 
 
We have attempted to increase endothelialization on POSS-PCU by covalently 
immobilizing anti-CD34 antibodies on its surface.  Antibody attachment was 
characterized using various biophysical methods such as Raman, SEM, AFM, XPS, 
and water contact angle which clearly showed surface modifications, indicating 
successful surface immobilization. The use of the EDC/NHS crosslinker was also 
shown to be crucial for ensuring the correct orientation of antibodies on the surfaces 
of POSS-PCU for antigen (EPC) capture, as opposed to merely relying on physical 
adsorption.  The presence of anti-CD34 antibodies rendered POSS-PCU more 
hydrophilic, and also created a more ridge-like topography, as opposed to a bulbous 
topography seen on unmodified POSS-PCU.  Furthermore, POSS-PCU-CD34 was 
seen to be haemocompatible and non-immunogenic. We have also demonstrated that 
POSS-PCU-CD34 was able to support a higher level of EPC growth on its surface, 
compared to unmodified POSS-PCU.  However, one limitation of this study is the fact 
that anti-CD34 antibodies alone, although necessary, might not be sufficient to 
increase endothelialization to physiological levels. Perhaps future studies could 
include the use of anti-CD34 antibodies in tandem with other functional peptide 
motifs or indeed other antibodies such as anti-VEGFR-2, which may increase the 
specificity of EPC capture.   
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We advocated the encapsulation of paclitaxel into PEGylated (stealth) liposomes as a 
means of increasing the levels of sustained and controlled release.  Results revealed 
that liposomal paclitaxel integrated onto POSS-PCU were able to facilitate drug 
release in a sustained and controlled manner over 1 year.  In contrast, integrating 
paclitaxel alone (without liposomes) onto POSS-PCU resulted in a burst release, with 
100% of it being depleted in 4 months.  Interestingly enough, liposomal paclitaxel 
was observed to be more haemocompatible and less immunogenic compared to 
paclitaxel.  Liposomes were able to protect paclitaxel from pre-mature degradation, 
and it was able to achieve a higher level of VSMC inhibition in a 28-day in vitro cell 
culture.  The mechanism of cellular uptake of liposomes was also investigated, with 
results suggesting a caveolae-mediated endocytosis.  However, given the fact that the 
liposomes were not targeted specifically for VSMC, there is a risk of potentially 
inhibiting endothelial cell growth as well, especially at the edges of the stent.  Hence, 
future studies could include the use of peptides or functional biomolecules on the 
surfaces of liposomes that can be specifically targeted to VSMCs, although this would 
require the elucidation of specific cell receptors that can differentiate VSMCs from 
endothelial cells.        
 
Mechanical engineering tests were also performed on POSS-PCU-Lipo-Ab (POSS-
PCU with liposomes on one side, and anti-CD34 antibodies on the other), and tested 
against unmodified POSS-PCU.  Considering that extensive mechanical studies have 
already been performed (and indeed optimized) on POSS-PCU for stent applications, 
the purpose was to ascertain if POSS-PCU-Lipo-Ab could yield similar mechanical 
test results to POSS-PCU.  Results revealed that the difference in mechanical test 
values between that of POSS-PCU-Lipo-Ab and POSS-PCU were not statistically 
significant, thereby indicating that it had retained its favourable mechanical 
characteristics, with particular emphasis on its compliance/viscoelasticity and tensile 
strength.  A physiological flow circuit that was set up confirmed that EPCs could 
readily adhere onto POSS-PCU-CD34 as quickly as 24 hours after initial exposure. 
Perhaps a limiting factor in our mechanical tests was that most of the experimental 
set-up was home-built and custom-made, and therefore susceptible to experimental 
and operator variability.  Future work in this aspect could involve having multiple 
operators obtaining separate readings, and then calculating the average value. For 
more advanced mechanical testing, one possibility is to collaborate closely with 
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industrial test centres that have specialized tools and equipment that are tailor-made 
for stent testing, and are able replicate tests to a high degree of fidelity. 
 
Sterilization techniques performed on the finished product showed that EO and 
gamma irradiation appeared most promising in terms of maintaining biomaterial 
functionality.  This was because performance and functionality of the finished product 
remained virtually unchanged (particularly its EPC capture potential, drug elution 
kinetics, and compliance/viscoelasticity) after exposure to EO and gamma.  Although 
autoclave (steam sterilization) is widely employed in sterilizing medical and lab 
equipment, this was not a viable technique for our material because the high 
temperatures denatured the anti-CD34 antibodies, thereby rendering it incapable of 
capturing EPCs.  It must be noted that all FDA-approved DES are sterilized using EO, 
lending credence to the notion that EO should perhaps remain the standard 
sterilization technique for drug-eluting biomaterials for stent applications.  One 
limitation in this study is that we unable to adequately characterize residues and by-
products left on the material after sterilization.  Several reports have indicated that 
carcinogenic substances (such as 4,4’-Methylenedianiline (MDA)) could potentially 
be produced after sterilizing polyurethane-based materials due to polymer 
degradation.  Therefore, future work could include identifying the various by-
products that could have been left behind on the material either as a by-product from 
the sterilization process, or from degradation of the polymer itself.                 
 
Although several limitations have been mentioned, we have nonetheless successfully 
demonstrated the ability of the biofunctionalized POSS-PCU polymer to increase 
endothelialization and inhibit VSMC with statistical significance when compared to 
controls.  Furthermore, we have described a facile method for the construction of a 
nano-inspired multifunctional POSS-PCU covered stent with EPC capture technology 
simultaneously with controlled and sustained drug release.  Various mechanical 
engineering tests performed also indicated both its robustness as well as its 
viscoelasticity – two important considerations in terms of stent design.  The final part 
of the thesis explored various FDA-recommended sterilization methods for medical 
devices, and tested its effects and functionality thereafter.     
 
	   398	  
We had initially planned to carry out in vivo studies in a swine model, but 
experimental and time constraints meant that this had to be postponed to a later date.  
Nevertheless, we have demonstrated the in vitro biosafety profile of the product in 
terms of its haemocompatibility and non-immunogenicity in this thesis.  It has often 
been postulated that the future of stents would be one that is fully bioabsorbable.  
Indeed, the most promising bioabsorbable stent with drug-eluting capabilities at the 
moment is the Absorb Bioresorbable Vascular Scaffold (Abbott Vascular).  This is the 
only model in the market that has attained the Conformité Européene (CE) mark (at 
time of writing), and we predict that it would be the first fully bioabsorbable drug-
eluting stent to gain FDA approval in the coming years. However, given the 
complexities of designing a clinically functional stent with drug-eluting capabilities, 
and the various regulatory bodies that govern medical devices before it can be safe for 
routine clinical use, we expect that the paradigm shift towards a fully bioabsorbable 
stent with nanotechnology and bio-inspired elements would be evolutionary rather 
than revolutionary.  Hence, it can be reasonably argued that metal stents with polymer 
coatings would still form the bulk of devices for clinical use in the foreseeable future.  
Given the ubiquitous nature of metal stents in the market, the technique described and 
demonstrated here in this thesis provides a facile and yet effective method of 
fabricating a multi-functional covered stent with both nano-drug formulation and 
cellular regenerative capacity, with the potential to address perennial problems seen in 
current stents.  This could well serve as a bridge between the current range of stents, 
and nanotechnology-based polymeric stents of the future.     
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Addendum 
_______________________ 
 
Given the multi-faceted and multi-disciplinary nature of the studies presented in the 
thesis, several experimental limitations were identified.  Although they did not 
significantly alter the conclusions that had been established, the issues raised were of 
substantial relevance that warranted mention.  
 
A noteworthy observation made regarding the surface modification of POSS-PCU, 
was that it was highly unlikely that the anti-CD34 antibodies themselves were 
responsible for the changes seen in the Raman integration maps (Figure 5.9 and 
Figure 5.10).  It was pointed out that it was more likely that the EDC/NHS 
crosslinker, which was dissolved in succinic acid, had some form of surface-
modifying effect on POSS-PCU.  This is evident as the distribution of POSS on the 
surface was seen to change after conjugation with antibodies.  Hence, a separate 
control was proposed, whereby POSS-PCU is modified with the EDC/NHS 
crosslinker only, without the anti-CD34 antibodies.  This would allow us to study the 
effect of the EDC/NHS crosslinker has on the POSS-PCU surface.  In fact there has 
been a study conducted by Chong et al which demonstrated that having the EDC/NHS 
crosslinker on the surface of a polycaprolactone (PCL) polymer does indeed result in 
chemical and topographical modifications[1]. It is also acknowledged that the changes 
to surface properties (e.g. chemical and topographical) could affect protein binding 
and cell behavior independently of anti-CD34.  Indeed, the acidic nature of the 
medium that the anti-CD34 antibodies were dissolved in could have had an impact on 
the surface properties, thereby acting as a confounding factor.  Therefore, this limit 
has to be addressed in future, whereby in-depth studies on how the acidic agent 
(EDC/NHS crosslinker) in which anti-CD34 antibodies affect the surface 
characteristics of POSS-PCU, and consequently the cell behavior on such a surface.       
 
Another point that was raised was the effect of inter- and intra-operator variability. 
This means that the observed results could theoretically be different when the test is 
	   400	  
repeated by the same person, and when a different person repeats the same test.  
Although significant efforts were made to ensure that experimental protocols were as 
precise as possible, variability in observed results could still occur. This correlation 
could be diagrammatically represented by the Bland-Altman plot, which analyzes the 
agreement between the results of inter- and intra-operator variability. The Bland-
Altman plot allows one to evaluate the existence of systematic differences between 
the measurements (fixed bias) and to identify possible outliers.  Furthermore, 
proportional bias can also be measured by identifying any possible relationship of the 
discrepancies between the measurements and the true value. 
 
A limitation in this study was that only a small sample size (n=3) was used, and 
would therefore limit the power of the study.  This was mainly due to the limited 
number of materials that were available for use, and also experimental constraints 
which meant that the bare minimal number (n=3) was used.   
 
Considering the fact that the stents would be implanted in a human body, the 
temperature at which it would be exposed to would be 37 °C.  However, due to 
experimental constraints, test parameters on stents in this thesis were conducted at 
room temperature.  Although it would be technically challenging to conduct every 
single test parameter at 37 °C, perhaps a more feasible way would be to select a few 
significant tests that are imperative to stent functionality, and test it at 37 °C.  For 
instance, drug elution kinetics would be monitored at both room temperature and 37 
°C in order to better ascertain the effect of temperature on drug release.  It is known 
that temperature can affect the mechanical properties of polymers, hence mechanical 
tests such as tensile strength and radial strength tests could also be conducted at 37 
°C. Another issue was the fact that phosphate-buffered saline (PBS) was used as an 
immersion medium in most of the drug release studies.  This is because PBS is 
isotonic and therefore mimics the ionic concentration of the human body.  A 
suggestion was made that perhaps a more representative effect of the human body 
would be to use human serum.  Since serum contain proteins, electrolytes, antibodies, 
antigens, and hormones, it was postulated that this would be more appropriate as we 
can study the interactions (if any) between these serum components and the implanted 
biomaterial.  Furthermore, using human serum at 37 °C would therefore provide an 
insight on the degradation of the material at physiological conditions.   
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In thromboelastography (TEG), the r-time for POSS-PCU in this thesis was 15.2±2 
min.  A slightly higher value was seen in a previous study by Farhatnia[2], which 
showed 17.7±0.4 min. A slightly lower value of 12±1 min was observed in work done 
by Ghanbari[3], and a value of 11±1 min was observed in a study done by de Mel[4].  
Although there were differences in values, the normal range depicting 
haemocompatibility, according to the manufacturer’s manual, is 9 to 27 min.  In all 
three studies, the values were well within this range.  However, a point of contention 
is that having a value that is within this range does not necessarily mean that the 
material is question is haemocompatible.  Rather it merely suggests that the material 
does not affect normal clotting tendencies to such a large extent that renders it 
inappropriate for biological systems.  Interestingly, there is a study done by 
Chevallier et al[5], which showed the r-time for an ePTFE graft that is used clinically 
to be 6 min.  Therefore, this suggests that the manufacturer’s guidelines on the 
“haemocompatible” range might not be accurate.  Nevertheless, another study done 
by Chong et al[6] showed that the r-time for PCL (which had already been used in 
patients by that group) was 17.5±3.6 min, thereby suggesting a degree of 
haemocompatibility within the manufacturer’s range.  Therefore, this highly 
contentious issue of haemocompatibility using TEG is one that needs to be addressed 
in future.  The observed differences in values could be due to the blood taken from 
different patients, and therefore a small difference in clotting times were observed.  
Furthermore, the technique that was used in TEG was different. In this thesis, POSS-
PCU was sprayed directly onto the TEG cups and blood was pipetted into the TEG 
cups and placed in the TEG machine.  However, in both Farhatnia[2] and 
Ghanbari[3], blood was first incubated for 5 minutes with POSS-PCU, and then the 
blood was transferred to the TEG cups.  It must be noted that TEG cups are made of 
polypropylene. In this thesis, the TEG cups were spray-coated with POSS-PCU as 
was therefore not exposed to polypropylene.  Therefore, technically, blood was 
exposed to 2 different materials during the measurement process in both studies by 
Farhatnia and Ghanbari, which could have explained the observed differences in 
values between this thesis and work done by Farhatnia and Ghanbari.  This was also 
highlighted in a paper by Roche et al which describes the variation in in clotting times 
depending on the types of TEG cups used[7].   
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In the platelet retention index study of POSS-PCU, results in this thesis was 0.35±0.1.  
In previous studies, the values were different, with Ahmed et al having 0.25±0.05[8, 
9], Farhatnia having 0.1±0.02[2], and Ghanbari having 0.075±0.01[3].  The 
differences in the platelet retention index could be due to the blood samples being 
different, and therefore differences in clotting tendencies in different patients could be 
reasonable expected.  Furthermore, in the study by Ahmed[9], a coagulated form of 
POSS-PCU was used, rather than casted.  Thus this difference in casted and 
coagulated could have an effect on platelet behavior on the surface, due to the fact 
that a there is a higher level of porosity on coagulated POSS-PCU compared to casted 
POSS-PCU.   
 
In the water contact angle study of POSS-PCU, results in this thesis showed a value 
of 100±1°.  This was in agreement with previous study by Farhatnia[2], showing a 
value of 101±1°. It must be noted that the POSS-PCU that was used in this thesis, as 
well as in the work by Farhatnia[2] was the casted version of POSS-PCU.  In contrast, 
de Mel[10] demonstrated a water contact angle of 110±2°.  The POSS-PCU in de 
Mel’s work was coagulated, which lends credence to the observation that surface 
properties of casted and coagulated forms of POSS-PCU could be different.  
Furthermore, there is also a batch-to-batch variability of POSS-PCU prepared in our 
lab, as a version called Prep 9 was used a few years ago, whereas Prep 10 was the 
newer version that was used recently. The difference is due to the fact that the raw 
materials were obtained from different suppliers, therefore undermining the 
consistency of POSS-PCU. It must be noted that throughout this thesis, Prep 10 was 
used. Therefore, the differences in batch numbers could have had an effect on the 
observed differences in values. 
 
In the compliance study, diameteric compliance (DC) of POSS-PCU in this thesis was 
4.1±0.01.  This was in agreement with previous work done by Farhatnia[2], which 
had a value of 4.2±0.04.  In both this thesis and work done by Farhatnia, both forms 
of POSS-PCU were casted.  However, work done by Ahmed et al[11], which is the 
coagulated form of POSS-PCU, showed a DC of 6±0.4.  This apparent difference 
could be due to the effects of porosity, as coagulated POSS-PCU has a higher porosity 
compared to casted POSS-PCU. 
 
	   403	  
The tensile strength of POSS-PCU in this thesis was 45±2 MPa.  This correlated well 
with previous study performed by Farhatnia[2], which showed a value of 46.5±0.8 
MPa.  However, a study done by Kidane et al[12] showed a tensile strength of 
33.8±2.1 MPa.  This observed difference could be due to the different batch of POSS-
PCU that was used; the one used in this thesis as well as in Farhatnia’s work was Prep 
10, whereas the one in Kidane’s work was Prep 9.  Operator variability could also be 
a factor, although this seems less likely as results in this thesis was in agreement with 
work done by Farhatnia.  This trend was also seen in the Young’s modulus of POSS-
PCU.  In this thesis, the Young’s modulus was 5±0.2 MPa.  This was in agreement 
with work done by Farhatnia, which showed a Young’s modulus of 5.1±1.01 MPa.  In 
contrast, Kidane et al[12] observed the Young’s modulus of POSS-PCU to be 9.1±0.9 
MPa.  Therefore, this observed difference could have come from the different batch of 
POSS-PCU that was used (Prep 9 in Kidane vs. Prep 10 in Farhatnia as well as in this 
thesis). 
 
A limitation in this thesis was that experiments were conducted at room temperature 
(25 °C). In terms of mechanical properties, there were observed differences in tensile 
strength and Young’s modulus, that was previously established by Ghanbari[3] and 
Kidane[12].  In Ghanbari’s work, the tensile strength of POSS-PCU at 25 °C was 
observed to be 33.8±2.1 MPa, while the tensile strength at 37 °C was observed to be 
24.8±3.4 MPa.  It was also observed that the Young’s modulus was 9.1±0.9 MPa at 
25 °C, while the Young’s modulus was observed to be 8.4±0.5 at 37 °C.  Although 
there have been no published reports by our group on why this change in temperature 
might have affected the mechanical performance of POSS-PCU, it was postulated that 
this could be due in part to the chain relaxation in POSS-PCU.  However, previous 
experiments done by Ghanbari[3] using differential scanning calorimetry (DSC) 
showed the glass transition temperature (Tg) of POSS-PCU to be -29.95 °C.  This 
suggests that the change in mechanical properties that was seen in the temperature 
increase from 25 °C to 37 °C is unlikely due to any effects from the glass transition 
temperature of POSS-PCU.  Hence, this is an interesting aspect of research regarding 
POSS-PCU that could be undertaken in future.                        
 
Taking these factors into consideration, it is clear that there is room for improvement, 
and the highlighted points should be undertaken as future work.    
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